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Animals are such agreeable friends - they ask no questions, they pass no criticisms 
Mr. Gifil's Love Story George Eliot 1819-1880
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O f seeming wise Francis Bacon 1561-1626
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Summary
Penicillin G was detected in plasma (>0.01 Jig/ml) for up to 8 h in horses and 6 h in ponies 
and donkeys following intravenous administration at a dose rate of 10 mg/kg bwt. The 
elimination half-life (harmonic mean) of penicillin G was similar in horses, ponies and 
donkeys (38.95, 27.25 and 31.52 min, respectively). The short elimination half-life was 
reflected by a high mean CLb of 514.46, 505.36 and 462.86 ml/h.kg, respectively. There 
was an increase in the mean number of coliforms (10^-10^/g) isolated from faeces following 
intravenous administration of penicillin G to ponies and donkeys. There was an increase in 
the mean number of Clostridium spp. (10^/g) isolated from donkey faeces following 
intravenous administration of penicillin G. There were no marked alterations in the viable 
number of bacteria isolated from caecal liquor, or in caecal liquor pH following intravenous 
administration of penicillin G; however there was an increase in caecal liquor lactic acid 
concentrations to 59.5 mmol/1 in 1/2 ponies only. Penicillin G was absorbed rapidly 
following administration by nasogastric tube to ponies at a dose rate of 10 mg/kg bwt, and 
peak concentrations of 0.09-0.19 |ig/ml were reached at 0.5 h, but the systemic availability 
was low (0.12-0.34%). Peak concentrations of penicillin G in caecal liquor were high (4.96- 
157.12 |Lig/ml), and there were increases in the number of viable coliforms (10^-10^/ml), 
streptococci (lO^-lO^O/ml) and Clostridium spp. (10^-10^/ml) isolated from caecal liquor. 
In addition there was an increase in caecal pH from 6.8-7.2 to 7.3-8.3. There were 
alterations in SCFA concentrations in caecal liquor following oral administration of penicillin 
G. Namely, an increase in lactic acid concentrations to 5.1-38.7 mmol/1, and a reduction in 
propionic acid concentrations to 0.0-3.7 mmol/1 and butyric acid concentrations to 0.0-3.5 
mmol/1, and a reduction in the proportions of propionic and butyric acids to 0.0% and 0.0- 
7.1%, respectively. The increase in lactic acid concentrations in caecal liquor was reflected 
by a slight increase in lactic acid concentrations in faeces to 6.5 mmol/kg. Incubation of 
penicillin G in vitro at 37 °C in an anaerobic environment for 3 and 24 h resulted in the 
destruction of 19.8 and 64.5%, respectively. Incubation of penicillin G at pH 1.9 for 1 h at 
room temperature resulted in the destruction of 84.7%. It appeared, from a single replicate, 
that around 90% of penicillin G was bound to hay at pH 1.9 and pH 7.0 in vitro.
Ampicillin was detected (>0.02 fig/ml) in plasma for 8 h in horses and 6 h in ponies and 
donkeys following intravenous administration at a dose rate of 10 mg/kg bwt. The 
elimination half-life (harmonic mean) was 60.88, 52.34 and 42.80 min in horses, ponies 
and donkeys, respectively. There was a statistically significant difference between the AUC 
and CLb in horses and donkeys. The mean AUCs were 44.17 Jig.h/ml and 24.70 pg.h/ml 
and the CLbs were 229.67 ml/h.kg and 418.80 ml/h.kg in horses and donkeys, 
respectively. There were no marked alterations in the number of viable bacteria isolated from
faeces following intravenous administration of ampicillin to horses, ponies and donkeys. 
There was an apparent increase in the concentrations of lactic acid in caecal liquor, up to a 
maximum of 44.4 mmol/1, following intravenous administration of ampicillin to ponies. 
Ampicillin was absorbed rapidly following administration by nasogastric tube to ponies at a 
dose rate of 10 mg/kg bwt. Maximum plasma concentrations of 0.74-2.30 |ig/ml were 
measured at 0.5-0.75 h, but the systemic availability was low (1.20-5.54%). There were 
high concentrations (3.63-144.53 p.g/ml) of ampicillin measured in caecal liquor following 
oral administration to ponies with cannulated caecal fistulas and consequently there were 
increases in the number of viable coliforms (10^-10^/m l), streptococci (10^-10^/m l), 
lactobacilli (10^-10^/ml) and Clostridium spp. (10^-10^/ml) isolated. The most marked 
trend in SCFA concentrations in caecal liquor following oral administration of ampicillin was 
an increase in lactic acid concentrations to a maximum of 51.6 mmol/1, a reduction in 
propionic acid concentrations to 0.0-3.8 mmol/1, and a reduction in the proportion of 
propionic acid to 0.0-3.8%. In addition, there was an increase in lactic acid concentrations in 
faeces to 35.6-64.2 mmol/kg. There were no marked alterations in the faecal dry matter 
content or consistency. Approximately 64% of ampicillin was inactivated by anaerobic 
incubation in caecal liquor for 24 h at 37 #C. Little or no ampicillin was destroyed by 
incubation at pH 1.9 for 1 h at room temperature. Incubation of ampicillin with hay at 37 *C 
for 3 h resulted in inactivation of around 59% at pH 7.0.
Amikacin was measured (>0.02 fig/ml) in plasma for 12 h in horses and donkeys and 8 h in 
ponies following intravenous administration at a dose rate of 6 mg/kg bwt. The elimination 
half-life (harmonic mean) of amikacin was similar in horses, ponies and donkeys (2.84, 
1.60 and 1.93 h, respectively), and the CLb (mean) was quite slow (45.19, 82.37 and 
57.98 ml/h.kg, respectively). There were no marked alterations in the number of viable 
bacteria isolated, caecal liquor pH or caecal liquor and faecal SCFA concentrations. 
Amikacin was not detected (<0.02 }ig/ml) in plasma following administration by nasogastric 
tube to ponies with cannulated caecal fistulas, however there were high concentrations of 
amikacin measured in caecal liquor (maximum 16.19-99.37 |!g/ml). Despite the high 
concentrations of amikacin in caecal liquor, there were no marked alterations in the number 
of viable bacteria isolated from caecal liquor, however there was a reduction in caecal liquor 
pH to <6.6, and there was an increase in caecal liquor lactic acid concentrations to a 
maximum of 24.4 mmol/1. The increase in caecal liquor lactic acid concentrations were 
reflected by a maximum lactic acid concentration of 15.4 mmol/kg in faeces. There were no 
marked alterations in the faecal dry matter content or consistency. Incubation of amikacin in 
caecal liquor in vitro resulted in little loss in activity; 90.8% and 85.0% remained following 
3 and 24 h incubation, respectively. There was little loss of activity (14.4%) of amikacin 
following incubation in vitro at pH 1.9 for 1 h at room temperature. There appeared to be a
high percentage of activity of amikacin lost (around 95%) following incubation in vitro with 
hay at 37 #C for 3 h at pH 1.9 and pH 7.0.
Oxytetracycline was detected (>0.08 |ig/ml) in plasma for 96 h in horses, 72 h in ponies and 
48 h in donkeys following intravenous administration at a dose rate of 10 mg/kg bwt. The 
elimination half-life (harmonic mean) of oxytetracycline was 11.69, 11.77 and 5.40 h. There 
were statistically significant (P<0.05) differences in AUC, AUMC and CLb between horses, 
ponies and donkeys following intravenous administration at a dose rate of 10 mg/kg bw t 
The mean AUC and AUMC in horses (253.53 pg.h/ml and 3949.47 pg.h^/ml) were larger 
than in donkeys (109.45 |ig.h/ml and 780.41 p.g.h^/ml), and the mean CLb in horses 
(39.31 ml/h.kg) was lower than in donkeys (91.37 ml/h.kg). There were increases in the 
mean number of viable streptococci (10^/g), lactobacilli (lO^-lO* Vg) and Clostridium spp. 
(107/g) isolated from faeces following intravenous administration of oxytetracycline to 
horses, and there was an increase in the mean number of coliforms (lOfyg) isolated from 
donkey faeces. There were increases in the mean lactic acid concentrations in faeces to 25.1 
and 6.4 mmol/kg in horses and ponies, respectively and there was a reduction in the mean 
dry matter content of faeces to <17% in all three groups. There was a maximum 
concentration of oxytetracycline of 2.41 |ig/ml in caecal liquor following intravenous 
administration to ponies with cannulated caecal fistulas at a dose rate of 10 mg/kg bwt which 
was usually less than 17% of the administered dose. There were no marked alterations in the 
number of viable bacteria isolated from caecal liquor following intravenous administration of 
oxytetracycline to ponies with cannulated caecal fistulas although there were increases in 
caecal liquor lactic acid concentrations to a maximum of 40.2 mmol/1, and faecal lactic acid 
concentrations to a maximum of 25.7 mmol/kg. The ponies were depressed and anorectic 
following oral administration of oxytetracycline at a dose rate of 10 mg/kg bwt. 
Oxytetracycline was absorbed quite rapidly, but the systemic availability was low (0.43- 
1.04%). Peak plasma concentrations of 0.38-0.84 |ig/ml were measured at 0.5-1.5 h after 
administration, and there were high concentrations of oxytetracycline measured in caecal 
liquor (18.40-80.50 (ig/ml). Salmonella typhimurium  phage type 204c, which was 
susceptible in vitro to furazolidone, was isolated from one pony on two separate occasions 
following oral administration of oxytetracycline. There were increases in the number of 
viable coliforms (lO^-lO^/ml), streptococci (lO^-lO* tyml), lactobacilli (10^-10^/ml) and 
Clostridium spp. (lO^-lO^/ml) isolated from caecal liquor following oral administration of 
oxytetracycline. There was an increase in lactic acid concentrations up to a maximum of 53.9 
mmol/1, which was reflected by an increase in lactic acid concentrations in faeces up to a 
maximum of 65.4 mmol/kg. There were no marked alterations in the faecal dry matter 
content although the faecal consistency was reported as soft following oral administration of 
oxytetracycline. There was little alteration (17% reduction) in oxytetracycline activity
following anaerobic incubation of oxytetracycline in caecal liquor at 37 *C for 3 and 24 h and 
following incubation of oxytetracycline at pH 1.9 for 1 h at room temperature (4% 
reduction). There was an increase in the number of coliforms (lO^O/ml) and Clostridium 
spp. (lOfyml) isolated from caecal liquor following in vitro incubation with 80 p.g/ml 
oxytetracycline for 24 h.
A bbreviations
A acetic acid
ALT alanine transaminase
AST aspartate transaminase
ATCC American Type Culture Collection
aufs absorbance units full scale
B butyric acid
B. Bacteroides
Bas basophils
bwt bodyweight
C. Clostridium
cfu colony forming units
cm centimetres
D- dextro-rotatory
dl decilitres
E. Escherichia
e. g . for example
Eos eosinophils
etal. and others
F systemic availability
fl femtolitres
FW formula weight
g grams
g gravity, 10"^ N.m/s^
GGT gamma glutamyl transferase
GLC gas-liquid chromatography
h hours
Hb haemoglobin concentration
Hct haematocrit
Hg mercury
HPLC high performance liquid chromatography
i. e. that is
IB isobutyric acid
id internal diameter
iu international units
IV isovaleric acid
kg kilogram
L lactic acid
1 litre
X wavelength
Lr /aevo-rotatory
L. Lactobacillus
lb pound (weight)
log 10 logarithm base 10
Lym lymphocytes
M molar
m metres
MCH mean cell haemoglobin
MCHC mean cell haemoglobin concentration
MCV mean cell volume
mg milligram
MIC minimum inhibitory concentration
min minutes
ml millilitre
mM millimolar
mm millimetres
mmol millimoles
Mon monocytes
mV millivolts
Neu neutrophils
nm nanometres
No. number
NS no sample
NVFA non-volatile fatty acids
obs observed values
p probability
P propionic acid
P+B propionic plus butyric acids
PCT plateletcrit
PDW platelet distribution width
pg picograms
pH negative logarithm of hydrogen ion concentration
ppm parts per million
r Pearson linear correlation coefficient
RCC red cell count
s seconds
S. Salmonella
SAP alkaline phosphatase
SCFA short-chain fatty acids
SD standard deviation
SEM standard error of mean
spp. bacterial species
TSI triple sugar iron
U units
uv ultraviolet
V valeric acid
VFA volatile fatty acid
w/v weight/volume
wcc white cell count
Hg micrograms
Hi microlitres
Jim micrometres
|imol micromoles
•c degrees Centigrade
XV
Pharmacokinetic terms
A l, A2 Zero-time plasma drug concentration intercepts (jig/ml) of a bi-
phasic disposition curve where Al is based on the terminal exponential slope.
A3 Zero-time plasma concentration (|ig/ml) intercept of initial exponent
of a tri-phasic disposition curve.
AUC Total area under the drug concentration versus time or zero moment
curve (|ig.h/ml) from time 0 to time <*> after administration of a single dose calculated using 
the trapezoidal rule (obs) and from A3/B3 + ^ /B 2  + ^ V b I-
AUMC Total area under the drug concentration time versus time or first
moment curve (jig.h^/ml) from time 0 to time <» after administration of a single dose 
calculated using the trapezoidal rule (obs) and from A3/B3^ + A2/g 22 + A l/g  j2.
B l, B2 Hybrid rate constants (exponents) (/h) of a bi-phasic disposition
plasma concentration versus time curve related to the slopes of the distribution and 
elimination phases of a bi-exponential drug disposition curve, where B2 is the overall 
elimination rate constant.
B3 Hybrid rate constant (/h) of the initial exponent of a tri-exponential
disposition curve.
CLb Body clearance (ml/h.kg) of a drug which represents the sum of all
clearance processes in the body calculated from ^ose/AUC-
Cmax Maximum plasma concentration (|ig/ml) following oral drug
administration.
CpO Initial concentration of a drug in plasma (p.g/ml) following
administration of an intravenous bolus administration calculated from the sum of the 
coefficients.
F Systemic availability calculated as the fraction of the dose that enters
the systemic circulation intact following oral administration by dividing AUCobs following 
oral administration by AUCobs following intravenous administration and expressing it as a 
percentage.
x v i
kl2» k21, k i3 , k3i First-order transfer rate constants calculated for drug distribution
between the central and peripheral compartments of a multi-compartment model, 
kel First-order elimination rate constant (/h) for the disappearance of a
drug from the apparent central compartment calculated from the ratio of body clearance to the 
apparent volume of the central compartment.
MAT mean absorption time (h) calculated from the difference between the
MRT following a single oral administration and MRT following a single intravenous 
administration.
MRT Mean residence time (h), quantitative estimate of the persistence of a
drug in the body, or the time for 63.2% of a drug to be eliminated. Calculated from 
AUMCobs/AUCobs
11/2 B1 Elimination (biological) half-life (h or min) following intravenous
administration or time taken for 50% of a drug to be eliminated, or apparent half-life 
following oral administration, calculated from 0.693/ b  i  .
tty2 B2 and B3 Distribution half-lives (h or min) following intravenous
administration or apparent half-life (B2) following oral administration, calculated from 
0.693/B2 and °*693/B3-
Vc Apparent volume of the central compartment (ml/kg) calculated from
dose/CP0.
Vdarea Apparent volume of distribution (ml/kg) based on the AUC,
proportionality constant relating the plasma drug concentration to the amount of drug in the 
body calculated from dose/AUC.Bl •
Vdss Apparent volume of distribution (ml/kg) at steady state concentration
calculated from dose(intravenous)-AUMC/AUC2-
11 Introduction
1.1 Antimicrobial agents
An antibiotic is defined as a substance which kills or inhibits the growth of microorganisms. 
The original antibiotics were produced as the by-products of fermentation of 
microorganisms, however some antibiotic compounds are synthesized and this has led to the 
use of the more general term of antimicrobial agent to describe substances which, at low 
concentrations, antagonize the growth of microorganisms.
Antimicrobial agents can be allocated to different groups according to a variety of factors. 
The classification of antimicrobial agents into those which result in cell death in vitro, 
bactericidal antimicrobial agents, and those which cause stasis of bacterial growth in vitro 
and those which rely on competent host defence mechanisms in vivo, bacteriostatic 
antimicrobial agents, is ambiguous. Classification as bactericidal and bacteriostatic requires 
specific organisms and growth conditions to be defined, and therefore is inapplicable to a 
clinical situation. Classification of antimicrobial agents according to their mechanism of 
action is less confusing. Antimicrobial agents can be allocated to groups such as compounds 
which inhibit cell wall synthesis (bacitracin, penicillins, cephalosporins, isoniazid, 
vancomycin), inhibit plasma membrane function (polymyxins), irreversibly inhibit protein 
synthesis (aminoglycosides, aminocyclitols), reversibly inhibit protein synthesis 
(chloramphenicol, lincosamides, macrolides, tetracyclines), inhibit nucleic acid synthesis 
(metronidazole, nitrofurans, rifamycins), inhibit intermediary metabolism (trimethoprim, 
sulphonamides, ionophores), and interfere with deoxyribonucleic acid packaging and 
transcription (quinolones).
The spectrum of activity of an antimicrobial agent can be described as either narrow or 
broad. An antimicrobial agent with a narrow spectrum of activity affects a relatively narrow 
range of organisms. A broad spectrum antimicrobial agent affects a wide variety of Gram 
positive and Gram negative bacteria, and may affect other organisms, such as rickettsias. 
Penicillin G affects Gram positive and a limited range of Gram negative (e . g. Pasteurella 
spp.) bacteria. Aminoglycosides affect aerobic Gram negative bacteria, in the main, and are 
of no value in an anaerobic environment. Penicillins with an extended spectrum of activity, 
such as ampicillin and amoxicillin, are active against Gram positive bacteria and some Gram 
negative bacteria but are not active against bacteria that produce 6-lactamase enzymes. The 
tetracyclines affect many Gram positive and Gram negative bacteria, and rickettsia, 
mycoplasma and ehrlichia.
21.2 Antimicrobial therapy
Antimicrobial agents have been used commonly for veterinary therapy, prophylaxis and as 
low level feed additives for growth promotion (Powers and Mercer, 1980). A number of 
factors should be considered prior to the selection of an antimicrobial agent (Brumbaugh, 
1987, Baggot and Prescott, 1987, Sandford, 1976, Spurlock and Hanie, 1989). Firstly, the 
organism must be susceptible to the action of the antimicrobial agent. Secondly, an 
appropriate drug concentration must be present at the site of infection for sufficient time and 
the drug must retain its activity at the site of infection. Finally, safety and cost should be 
taken into consideration.
Information on the susceptibility of bacterial pathogens to different antimicrobial agents is 
available in the literature (Hirsh and Jang, 1987). Bacterial isolation and antimicrobial 
susceptibility testing of bacterial isolates from individual cases allows therapy to be tailored 
to suit the individual. There are a number of different tests used to quantify the susceptibility 
of bacterial isolates to antimicrobial agents, such as minimum inhibitory concentrations. This 
type of test provides useful information on the appropriate concentrations of an antimicrobial 
agent required to affect susceptible bacteria. However, care should be taken in the 
interpretation of the results of this type of in vitro diagnostic technique, since it is carried out 
under standardized, controlled laboratory conditions, including the use of specific growth 
media and optimal conditions for bacterial growth, and may not reflect the clinical situation 
(Brumbaugh, 1987, Prescott and Baggot, 1985).
Pharmacokinetics is a mathematical description of drug disposition, usually in plasma, with 
time in the body of an animal. There are a number of computer software programmes 
available for the analysis of plasma concentration versus time data. Studies of plasma 
disposition of a drug, usually following a single intravenous, intramuscular or oral 
administration, are used to calculate the optimal frequency of drug administration required to 
attain and maintain desired therapeutic plasma concentrations (English and Roberts, 1979). 
In addition, studies that examine drug excretion (e . g. renal or biliary) and tissue 
concentrations provide additional useful information on the absorption, distribution and 
clearance of a drug. The majority of pharmacokinetic data is collected in normal animals and 
there is little information on the effects of clinical or subclinical disease on drug disposition.
1.3 Adverse reactions to antimicrobial agents
An adverse reaction is defined as any response to a drug, excluding therapeutic failures, 
which is noxious and unintended and which occurs following administration, for 
prophylaxis, diagnosis or therapy, of an appropriate dose of a drug and within a reasonable
3time frame of administration (Baggot, 1989, Davis, 1987, Ruckebusch, 1983). These 
effects can be direct or indirect, and include acute immune-mediated reactions (e . g. 
hypersensitivity), acute non-immune mediated drug reactions (e. g. cardiovascular and 
haematologic reactions, drug fever), and toxic reactions (e. g. nephrotoxicity, 
hepatotoxicity) (Baggot, 1989, Davis, 1987, English and Roberts, 1983, Powers and 
Mercer, 1980, Ruckebusch, 1983). Toxic drug reactions are, by definition, drug-induced 
reactions that result in damage to an organ due to an alteration in its structure or function. 
Biological or metabolic effects, such as alterations in the gastrointestinal microflora, should 
be included in this category. Although, the complex mechanisms of some toxic drug 
reactions are recognized (e. g. the nephrotoxicity of the aminoglycoside antimicrobial agents) 
many mechanisms of drug toxicity remain obscure (Davis, 1987). In addition, interpretation 
of an adverse drug reaction is made more complex by the presence of more than one drug, 
and by reaction to components of the dosage form other than the active agent.
The adverse effects of antimicrobial agents on the alimentary tract have been well recognized 
as a complication of modern antimicrobial therapy in several species (Mackellar eta l., 1973, 
Owen, 1975, Ricketts and Hopes, 1984, Roberts and English, 1979, White and Prior, 
1982). Gastrointestinal side effects can range from mild diarrhoea to severe and potentially 
life-threatening antimicrobial-associated colitis (Baggot, 1989, Butzler, 1982, Cheymol et 
al., 1986, Ewe, 1988).
The development of antimicrobial-associated colitis due to C. difficile infection may be due 
to inappropriate antimicrobial therapy. In one survey, only 25% of patients who developed 
C. difficile toxin positive stool had been treated with a suitable antimicrobial agent for their 
primary infection, and a further 25% had an appropriate diagnosis but were treated 
incorrectly (Yarinsky and Wheeler, 1990). In addition, fatal pseudomembranous colitis has 
been related to the dosage and duration of antimicrobial therapy (Ramirez-Ronda and 
Sandford, 1975). Hence the importance of isolating bacterial pathogens, testing the 
susceptibility of bacterial isolates to antimicrobial agents, and selecting and administering an 
antimicrobial agent.
Any antimicrobial agent which remains in the gastrointestinal lumen, following oral 
administration, or which is excreted in bile or through the intestinal mucosa, following 
parenteral or oral administration, may alter or destroy the normal gastrointestinal microflora, 
and allow overgrowth of non-susceptible or pathogenic microorganisms and the 
development of diarrhoea (Bell eta l., 1978, Butzler, 1982, Jusko, 1975, Larson et al., 
1978, Levine and Lamont, 1982, Mittermayer, 1989, Nord, 1991, Powers and Mercer, 
1980, Swerczek, 1979). Alteration in the commensal microflora may result in the 
exacerbation of existing disease or the development of a secondary infection, thus the value
4of antimicrobial agents in the treatment of intestinal disease is questionable (Powers and 
Mercer, 1980, Swerczek, 1979). The development of ulcerative colitis, as a sequel to 
dysbiosis of the colonic bacteria, is due to bacterial enteroadhesion, the release of bacterial 
peptides and the formation of bacterial secondary metabolites (Roediger, 1980).
Adverse reactions to antimicrobial agents have been reported in the horse but either occur 
infrequently or are not observed or reported (English and Roberts, 1983). In France, around 
0.8% of antimicrobial treatments in horses are reported as adverse reactions (Puyt, 1989).
The horse may be particularly susceptible to adverse reactions to antimicrobial agents due to 
its digestive physiology and to the limited number of antimicrobial agents indicated 
specifically for use in this species (Puyt, 1989). This may result in the use of inappropriate 
antimicrobial agents in the equine. Surprisingly, gastrointestinal adverse reactions have 
received scant attention despite the value of individual horses and the problems of litigation 
(Roberts and English, 1979).
Antimicrobial agents which undergo enterohepatic circulation, e. g. ampicillin and 
oxytetracycline, may affect the microorganisms of the caecum and colon following parenteral 
or oral administration, and this may limit their clinical usefulness in adult horses (Baggot and 
Prescott, 1987, Cook, 1973, Owen, 1975, Roberts and English, 1979). Oral administration 
of antimicrobial agents has been uncommon in the horse due to the low systemic availability 
of antimicrobial agents. Systemic availability may be poor even when the physicochemical 
properties of an antimicrobial agent are suitable for absorption due to poor dissolution 
performance, hepatic or bacterial metabolism, or drug instability (e. g. penicillin G and 
erythromycin) (Baggot, 1984). Following oral administration, any antimicrobial agent 
remaining in the gastrointestinal lumen may alter the commensal microflora and produce 
changes in SCFA concentrations, and unabsorbed SCFA may precipitate or exacerbate 
osmotic diarrhoea (Baggot, 1984, Clark and Becht, 1987, Ensink et al., 1992, Owen, 1975, 
Roberts and English, 1979). The hazard of inducing dysbacteriosis is smallest when the 
concentration of active antimicrobial agent reaching the caecum and colon is low (Ensink et 
al.y 1992). This occurs following the complete absorption of an antimicrobial agent in the 
jejunum, in the absence of biliary elimination, or following the administration of an inactive 
prodrug.
1.4 Pseudom em branous colitis
In man, the most severe gastrointestinal adverse reaction to antimicrobial agents is 
pseudomembranous colitis which was first documented in 1893 which preceded the 
discovery of antimicrobial agents. Pseudomembranous colitis is a reasonably common side 
effect of antimicrobial administration caused by overgrowth of the toxin producing, spore
5forming, Gram positive, anaerobic rod, C. difficile (Meyer-Kawohl and Bockemuhl, 1986, 
O'Connor, 1981, Trnka and Lamont, 1984). In fact, C. difficile is one of the commonest 
pathogens of the lower intestinal tract with infection almost always occurring during or after 
antimicrobial treatment (Guandalini et al., 1988, Kager et al., 1979, Meyer-Kawohl and 
Bockemuhl, 1986, Trnka and Lamont, 1984). Bacteria other than C. difficile have been 
involved in the development of pseudomembranous colitis. Aronsson et al. (1981) isolated 5 
strains of Clostridium spp. that were not C. difficile, and Borriello et al. (1984) and Machida 
et al. (1989) isolated C. perfringens. In addition, colitis may be due to infection with 
Citrobacter spp. (Barbulescu, 1972), Campylobacter jejuni (Butzler, 1982), toxin-producing 
E. coli (0157:H7) (Griffin et al., 1990) or staphylococci (including methicillin-resistant 
staphylococci) (Chovancova and Lucansky, 1970, Chubachi et al., 1989, Hori et al., 1989, 
Klimek etal., 1976).
Clostridium difficile does not colonize the normal healthy adult gastrointestinal tract. 
Antimicrobial therapy alters the normal gastrointestinal microflora and allows C. difficile 
colonization to take place (Borriello et al., 1987, Meyer-Kawohl and Bockemuhl, 1986). In 
the normal gastrointestinal lumen, some component of the commensal microflora may 
prevent C. difficile colonization (Aronsson et al., 1982, Trnka and Lamont, 1984).
Clostridium difficile produces two toxins (toxin A or enterotoxin and toxin B or cytotoxin) 
(Aronsson et al., 1982, Lima et al., 1988, Lima et al., 1989, Tucker et al., 1990). 
Clostridium difficile toxin produces cytotoxic damage to the colonic mucosa, which can lead 
to the development of diarrhoea (Mittermayer, 1989, Trnka and Lamont, 1984). One test of 
the cytotoxic effect of the these toxins is the oral inoculation of hamsters with an isolate of 
C. difficile. High virulence of C. difficile isolates has been defined as the ability of the 
organism to colonize the gastrointestinal lumen in the hamster, to produce disease, and to 
generate high concentrations of enterotoxin rapidly (Borriello et al., 1987). There is wide 
variation in the virulence of different isolates of C. difficile. Strains of C. difficile isolated 
from domestic pets may be of low virulence for the hamster, although C. difficile is present 
after oral inoculation, caecal concentrations of enterotoxin and cytotoxin are low (Borriello et 
al., 1987).
Clostridium difficile is an infectious organism and human cases of pseudomembranous 
colitis have occurred in groups or clusters (Cannon et al., 1988). The major mode of spread 
of C. difficile infection is via the environment (Delmee etal., 1988, Kaatzetal., 1988, Kim 
et al., 1981, Levine and Lamont, 1982, Meyer-Kawohl and Bockemuhl, 1986), but 
infection may occur after contact with an infected individual (Cerquetti et al., 1989, Kim et 
al., 1981, Meyer-Kawohl and Bockemuhl, 1986, Mollby et al., 1985, Wilson et al., 1982, 
Wust et al., 1982).
6In Sweden (1980-1982), C. difficile or toxin was present in 2% of the general population, in 
3% of diarrhoea cases unrelated to antimicrobial administration, and in 18% of patients with 
antimicrobial-associated diarrhoea (Mollby et al., 1985). However, C. difficile colitis was 
recorded as an infrequent occurrence in adults in Peru (Sanchez et al., 1990). Although, C. 
difficile appears to be an unusual infection in adults it has been reported as being endemic in 
longterm care facilities, particularly where there are geriatric patients (Rybolt et al., 1989). 
Pseudomembranous colitis usually occurs in hospitalized patients. However, it has been 
reported in outpatients, where the number of unreported cases may be very high, since only 
severe cases of diarrhoea are investigated thoroughly (Jaeger et al., 1981, Mittermayer, 
1989).
The demonstration of C. difficile toxin is not associated exclusively with antimicrobial 
administration or the development of diarrhoea. In one study, Clostridium difficile toxin 
positive stool samples were recorded from 33% and cytotoxin from 50% of patients without 
diarrhoea, and similar results were obtained from patients with diarrhoea (Surawicz et al., 
1989). However, C. difficile was cultured, or toxin demonstrated, from stool samples of 
90% of patients with pseudomembranous colitis, but neither were demonstrated in healthy 
human adults or in other intestinal diseases, except for cases of inflammatory colitis (Saco et 
al., 1981). Thomas et al. (1990) reported that C. difficile infection was responsible for 20- 
25% of cases of antimicrobial-associated diarrhoea. Similarly, Trnka and Lamont (1984) 
noted that C. difficile toxin was demonstrable in stool filtrates of 33-50% of mild cases and 
nearly all severe cases of pseudomembranous colitis but Mogg et al. (1982) reported that 
only 44.7% (17/38) of patients with severe antimicrobial-associated post-operative diarrhoea 
had demonstrable faecal C. difficile or toxin.
The incidence of pseudomembranous colitis has ranged from 0.2% (Cheymol etal., 1986) 
and 0.75% (Cannon et al., 1988) to 1% (Cheymol et al., 1986) of hospital patients treated 
with antimicrobial agents, 0.55% of surgical cases (Barile et al., 1978) and 4% of patients 
that have undergone orthopaedic surgery (Cannon et al., 1988). Colonic complications, 
including pseudomembranous colitis, occur in 1.9% of renal transplant cases (Flanigan et 
al., 1988). Complications occurred in 5-10% of cases following colorectal surgery, due to a 
failure to prevent post-operative infections by antimicrobial prophylaxis (Alexander and 
Becker, 1988). It has been suggested that the incidence of post-operative colitis is increasing 
(Barzilai et al., 1985, Hori et al., 1989).
1.5 Colitis and C. difficile infection in human neonates
An abnormal flora may result if there is a delay in the normal bacterial colonization of the 
gastrointestinal tract. An abnormal gastrointestinal microflora may occur as a result of a
7number of factors such as antimicrobial treatment (Lawrence et al., 1982). In the human 
neonate, necrotizing colitis is thought to be caused by toxin production by an abnormal 
gastrointestinal microflora (George etal., 1979, Lawrence etal., 1982).
Commonly, neonates are asymptomatic carriers of C. difficile infection (Viscidi et al., 
1981). Colonization of the gastrointestinal tract of human neonates with C. difficile has 
ranged from 2-52% (Wilson et al., 1982), and 25-60% of healthy human infants have been 
shown to carry C. difficile as part of their normal gastrointestinal microflora (Meyer-Kawohl 
and Bockemuhl, 1986, Mittermayer, 1989, Zweiner et al., 1989). Thus, the isolation of the 
C. difficile or the demonstration of toxin cannot be linked exclusively to clinical signs of 
colitis in children (Meyer-Kawohl and Bockemuhl, 1986, Mittermayer, 1989). Moreover, 
C. difficile infection in children is not associated exclusively with antimicrobial therapy. 
Children with inflammatory bowel disease (e. g. Crohn's disease) can develop toxin 
negative C. difficile infection in the absence of exposure to antimicrobial agents (Hyams and 
McLaughlin, 1985). In one study, C. difficile was isolated from and toxin was detected in 
28.9% (13/45) and 26.7% (12/45), respectively, of human neonates not exposed to 
antimicrobial agents but only 8.7% (2/23) and 4.4% (1/23), respectively, of older children 
(Viscidi et al., 1981).
1.6 Antimicrobial agents associated with colitis in man
In humans, administration of nearly all antimicrobial preparations has triggered the 
development of C. difficile colitis (Ewe, 1988, Hecht and Olinger, 1989, Ledger and 
Puttier, 1975, Mittermayer, 1989). The risk of developing C. difficile colitis is increased 
when broad spectrum antimicrobial preparations are administered (Colatutto et al., 1989, 
McKinley et al., 1982, Mittermayer, 1989, Slagle and Boggs, 1976). Antimicrobial- 
associated colitis is associated more commonly with therapy using a combination of 
antimicrobial agents. Pseudomembranous colitis has been recorded as a complication of 
multiple antimicrobial therapy (Chua and Jackson, 1979, Church and Fazio, 1986). In one 
retrospective study, only 32.3% of patients with demonstrable C. difficile infection had been 
treated with a single antimicrobial agent (Church and Fazio, 1986).
Treatment with narrow or broad spectrum antimicrobial agents that inhibit bacterial cell wall 
synthesis has resulted in the development of colitis. Mild gastrointestinal side effects, such 
as nausea, diarrhoea or vomiting, occurred in 3.6-6.8% of patients following oral treatment 
with B-lactam antimicrobial agents (Buchi and Casey, 1988, Newman et al., 1985). 
Pseudomembranous colitis has been recorded following the administration of the penicillins 
(Aronsson et al., 1982, Cheymol et al., 1986, Chua and Jackson, 1979, Leung et al., 
1985). This has included both narrow spectrum penicillins, such as penicillin G (Borriello et 
al., 1984, Buts et al., 1977, McKinley et al., 1982, Zweiner et al., 1989), penicillin V
8(Drapkin et al., 1985), and flucloxacillin (Borriello et al., 1984, Cannon et al., 1988), and 
extended spectrum, semisynthetic penicillins, such as ampicillin (Buts et al., 1977, Jaeger et 
al., 1981, Jusko, 1975, Keshavarzian et al., 1984, Leung et al., 1985, McKinley et al., 
1982, Zweiner et al., 1989) and amoxicillin (Zweiner et al., 1989). In addition, treatment 
with the cephalosporins has resulted in the development of pseudomembranous colitis 
(Church and Fazio, 1986, Drapkin et al., 1985, Hori et al., 1989, Leung et al., 1985, 
Marsh, 1984, McKinley et al., 1982, Pierce et al., 1982, Surawicz et al., 1989, Zweiner et 
al., 1989). This has included a variety of different first generation cephalosporins, such as 
cefazolin (Clarke et al., 1990a), cephradine (Cannon etal., 1988) and cefuroxime (Adams et 
al., 1985, Borriello et al., 1984, Cannon et al., 1988, Morris et al., 1984). Treatment with 
the cephalosporins, in particular the third generation cephalosporins (e.g. cefotaxine, 
moxalactam), is around 37 times more likely to result in the development of C. difficile 
colitis than penicillin V, and patients treated with the B-lactamase resistant penicillins (e. g. 
methicillin, nafcillin, cloxacillin, flucloxacillin) proved to be at an even greater risk 
(Aronsson et al., 1982). Intravenous administration of vancomycin resulted in the 
development of C. difficile colitis in a patient undergoing chronic haemodialysis, possibly 
due to the prolonged elevation of serum concentrations of vancomycin in patients with renal 
failure (Hecht and Olinger, 1989).
The development of C. difficile colitis has been associated with the administration of 
antimicrobial agents that inhibit bacterial protein synthesis. Pseudomembranous colitis has 
been recorded following administration of the aminoglycosides (Ewe, 1988, Leung et al., 
1985, Pierce etal., 1982), including streptomycin (Chua and Jackson, 1979) and gentamicin 
(Borriello et al., 1984, Boyd and Den Besten, 1976, Clarke et al., 1990a, Leung et al., 
1985). The development of pseudomembranous colitis has been reported following 
administration of the macrolides spiramycin (Di Febo et al., 1982) and erythromycin 
(McKinley et al., 1982). The passage of watery stools, with or without an increased 
frequency of bowel action, occurs commonly in association with clindamycin therapy 
(Spiller et al., 1984) and antimicrobial-associated colitis has been reported following 
administration of lincomycin or clindamycin (Boyd and Den Besten, 1976, Burdon et al., 
1981, Buts et al., 1977, Cheymol et al., 1986, Clarke et al., 1990a, Dhawan and 
Thadepalli, 1982, Ewe, 1988, McKinley et al., 1982, Pierce et al., 1982, Ramirez-Ronda 
and Sandford, 1975, Surawicz et al., 1989, Zweiner et al., 1989). The risk of developing 
C. difficile colitis after lincosamide treatment was reported to be around 63 times greater than 
after treatment with penicillin V (Aronsson et al., 1982), moreover colitis was 3-4 times 
more likely to develop following oral, compared with parenteral, lincosamide therapy 
(Dhawan and Thadepalli, 1982). The tetracyclines, including tetracycline (Boyd and Den 
Besten, 1976) and doxycycline (Chua and Jackson, 1979), have been reported to result in 
the development of pseudomembranous colitis.
9Leung et al. (1985) reported the development of colitis following treatment with 
metronidazole, an inhibitor of bacterial nucleic acid synthesis.
Antimicrobial agents which inhibit bacterial intermediate metabolism have been associated 
with the development of colitis. Pseudomembranous colitis has been reported to develop 
following administration of the sulphonamides (Ewe, 1988) and the potentiated 
sulphonamides (trimethoprim/sulphonamide combinations) (Borriello et al., 1984, Ewe, 
1988, McKinley et al., 1982, Surawicz et al., 1989).
In patients with antimicrobial-associated colitis, the duration of diarrhoea and the presence of 
rectal pseudomembranes have not been associated with the administration of a specific 
antimicrobial agent (Burdon et al., 1981). Moreover, it has been impossible to correlate the 
antimicrobial agents involved in the development of pseudomembranous colitis with 
increased resistance of C. difficile to antimicrobial agents (Aronsson et al., 1981). Clinical 
isolates of C. difficile did not show any increased resistance to the penicillins or clindamycin 
(Aronsson et al., 1982). This suggests that factors other than antimicrobial susceptibility, 
such as antimicrobial concentrations in the gastrointestinal tract or alterations in the normal 
gastrointestinal microflora, may play a role in the development of colitis.
1.7 O ther factors associated with colitis in man
Antimicrobial administration may result in the development of colitis but there are a number 
of other important factors involved. Firstly, impaired host resistance due to severe 
underlying disease, e. g. acute promyelocytic leukaemia, is common in patients that develop 
colitis following antimicrobial therapy (Borriello et al., 1984, Chubachi et al., 1989, 
Dhawan and Thadepalli, 1982, Leung et al., 1985, Meyer-Kawohl and Bockemuhl, 1986, 
Nord, 1991). Similarly, ovarian cancer chemotherapy (Satin et al., 1989), and treatment 
involving enemas (Pierce et al., 1982), nasogastric intubation (Pierce et al., 1982, Surawicz 
et al., 1989) or surgery (Clarke et al., 1990a, Hori et al., 1989, Ledger and Puttier, 1975, 
McKinley et al., 1982, Meyer-Kawohl and Bockemuhl, 1986, Pesce etal., 1984, Pierce et 
al., 1982) have been associated with the development of antimicrobial-associated colitis. The 
length of the surgery and inadequate antimicrobial prophylaxis in the peri-operative period 
predispose patients to a high rate of post-operative infections (Alexander and Becker, 1988).
There is circumstantial evidence to support the role of faecal stasis in the pathogenesis of C. 
difficile related disease (Aubia et al., 1981, Church and Fazio, 1986, Levine and Lamont, 
1982, Percy and Christensen, 1985, Zweiner et al., 1989). Many patients who developed 
pseudomembranous colitis were receiving treatment with medicines which produce faecal 
stasis (Church and Fazio, 1986) or had an underlying disease associated with faecal stasis,
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e. g. Hirschsprung's disease or uraemia. In patients with Hirschsprung's disease, non­
specific inflammatory colitis may develop into pseudomembranous colitis in the absence of 
exposure to antimicrobial agents (Brearly etal., 1987). Antimicrobial-associated depression 
of gastrointestinal motility, which is most pronounced with the lipid soluble lincosamides, 
may contribute to the development of antimicrobial-associated colitis (Lees and Percy, 1981, 
Percy and Christensen, 1985).
1.8 Clinical signs and m ortality rate of pseudomembranous colitis
Antimicrobial-associated colitis has been defined as a severe, infectious disease, which has 
symptoms ranging from self-limiting diarrhoea to severe colitis, with or without the 
formation of intestinal pseudomembranes, which occurs 4-10 days after the commencement 
of antimicrobial therapy (Aronsson et al., 1982, Clarke et al., 1990a, Dhawan and 
Thadepalli, 1982, Leung et al., 1985, Levine and Lamont, 1982, Guandalini et al., 1988, 
Meyer-Kawohl and Bockemuhl, 1986, Mittermayer, 1989, Mollby etal., 1985, Ramirez- 
Ronda and Sandford, 1975, Trnka and Lamont, 1984). Pseudomembranous colitis is 
characterized by the development of whitish exudative lymphoid plaques 
(pseudomembranes) attached to the large intestinal mucosa (Pesce et al., 1984, Saco et al., 
1981, Trnka and Lamont, 1984).
A wide variety of clinical signs have been associated with colitis due to C. difficile infection. 
The clinical signs of colitis include abdominal pain (Clarke et al., 1990a, Dhawan and 
Thadepalli, 1982, Griffin et al., 1990, Leung et al., 1985, McKinley et al., 1982, Machida 
et al., 1989, Mittermayer, 1989, Mueller and Benowitz, 1989, Ramirez-Ronda and 
Sandford, 1975), acute onset watery diarrhoea with or without fever (Dhawan and 
Thadepalli, 1982, Griffin et al., 1990, Hori et al., 1989, Leung et al., 1985, Mittermayer, 
1989), pseudomembrane formation (Slagle and Boggs, 1976), intestinal inflammation 
(Slagle and Boggs, 1976), loss of appetite (Machida et al., 1989), leucocytosis (McKinley et 
al., 1982, Mittermayer, 1989) and hypoproteinaemia (Buts et al., 1977, Leung etal., 1985). 
Rybolt etal. (1989) demonstrated high concentrations of the serum protein a - 1-antitrypsin 
in stool samples from patients with C. difficile infection, and correlated serum protein loss 
into the gastrointestinal tract with the severity of C. difficile infection. The possibility of C. 
difficile colitis should be considered in patients with signs similar to those of intestinal 
obstruction (Clarke et al., 1990a) or with atypical symptoms of food poisoning (Borriello et 
al., 1984). Moreover, Drapkin et al. (1985) concluded that 5.2% of patients that presented 
with signs of acute abdominal disease (e . g. acute peritonitis, peritoneal irritation and 
leucocytosis) had C. difficile colitis.
The mortality rate of C. difficile colitis has ranged from 20% (Zweiner et al., 1989), 23% 
(Church and Fazio, 1986), or 24% (Hori et al., 1989), to around 30% (Guandalini et al.,
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1988).
Antimicrobial-associated pseudomembranous colitis should be included in the differential 
diagnosis when there is a clinical history of recent antimicrobial therapy (Hakkal, 1976, 
McKinley et al., 1982, Trnka and Lamont, 1984, O'Connor, 1981).
1.9 Diagnosis of pseudomembranous colitis and C. difficile infection
A diagnosis of C. difficile colitis is made by the endoscopic/sigmoidoscopic demonstration 
of intestinal pseudomembrane formation (Meyer-Kawohl and Bockemuhl, 1986, McKinley 
et al., 1982, Mittermayer, 1989, Ramirez-Ronda and Sandford, 1975, Trnka and Lamont, 
1984), isolation of the organism (Borriello et al., 1984, Clarke et al., 1990a, Meyer-Kawohl 
and Bockemuhl, 1986, Mittermayer, 1989) and demonstration of toxin production (Borriello 
etal., 1984, Meyer-Kawohl and Bockemuhl, 1986, McKinley eta l., 1982, Mittermayer,
1989).
Diagnostic imaging techniques, other than endoscopy, have been used to demonstrate the 
pathognomonic intestinal pseudomembranes. However, the positive contrast radiographic 
findings of ulceration, mucosal oedema and excessive mucous excretion are insufficient to 
differentiate antimicrobial-associated pseudomembranous colitis from other inflammatory 
diseases of the gastrointestinal tract (Hakkal, 1976).
There are a variety of techniques, of varying sensitivity and specificity, available for the 
demonstration of C. difficile infection. Isolation of C. difficile using selective media and 
stringent anaerobic environmental conditions is a sensitive (89%) means of demonstrating 
the presence of C. difficile however it is only 74% specific (Walker et al., 1986). 
Clostridium difficile colitis cannot be diagnosed by the demonstration of the organism alone, 
since there are strains of low virulence and the development of the disease depends on toxin 
production. Enzyme-linked immunosorbent assay (ELISA) is a sensitive way of detecting 
cytotoxin and enterotoxin production. The specificity of the cytotoxin ELISA is low (56%), 
compared to the enterotoxin ELISA (100%), due to cross-reaction with cytotoxins produced 
by other Clostridium spp., such as C. sordelli (Walker et al., 1986). The microtitre 
cytotoxicity assay provides a sensitive (78%) and specific (95%) means of demonstrating the 
presence of C. difficile, whereas the tube cytotoxin assay is less specific (79%) (Walker et 
al., 1986). In 93% of cases of pseudomembranous colitis, a fluorescent antibody test agreed 
with culture and toxin demonstration for C. difficile (Larson et al., 1982).
1.10 Prevention and treatment of pseudomembranous colitis in man
The development of diarrhoea, following the administration of clindamycin, should not 
prevent the use of this reliable and well tested antimicrobial agent in the treatment of
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anaerobic infections since, in a significant number of patients, diarrhoea ceases as soon as 
drug therapy is discontinued (Dhawan and Thadepalli, 1982, Spiller et al., 1984). The 
judicious selection and use of antimicrobial agents may reduce the incidence of antimicrobial- 
associated colitis (Yarinsky and Wheeler, 1990). The importance of appropriate dose rates 
and regimes have been emphasized. In addition, it has been shown that the duration of 
antimicrobial prophylaxis should be minimized to reduce the risk of developing C. difficile 
colitis (Clarke etal., 1990a).
Clostridium difficile is an infectious organism therefore patients with C. difficile colitis 
should be isolated to reduce the risk of cross-infection (Leung et al., 1985). The 
environment is an important source of C. difficile infection. Hypochlorite (1600 ppm 
available chlorine, pH 7.6) was effective in eliminating C. difficile from a hospital 
environment (Kaatz et al., 1988).
Generally, C. difficile colitis is cured easily, but it is important to determine patients at high 
risk, such as those with severe underlying disease or primary or secondary faecal stasis 
(Colatutto et al., 1989). In addition, some cases of pseudomembranous colitis resolve 
rapidly following the discontinuation of treatment with the causative antimicrobial agent 
(Burbige and Radigan, 1987, Church and Fazio, 1986, Hecht and Olinger, 1989, 
Keshavarzian et al., 1984, Meyer-Kawohl and Bockemuhl, 1986, Ramirez-Ronda and 
Sandford, 1975, Saco etal., 1981). Generally, patients with culture positive, toxin negative 
C. difficile infection recover without specific treatment (McKinley et al., 1982).
A number of antimicrobial agents have been used to treat C. difficile infection. Vancomycin, 
a narrow spectrum (Gram positive) antimicrobial agent which inhibits bacterial cell wall 
formation, has been used to treat methicillin-resistant staphylococcal infections and 
antimicrobial-associated colitis due to C. difficile infection (Cheung and Di Piro, 1986, 
Griffith, 1981, Hermans and Wilhelm, 1987, Levine and Lamont, 1982, McKinley etal., 
1982, Saco et al., 1981, Silva et al., 1981). Treatment of pseudomembranous colitis with 
vancomycin is effective but 10-15% of cases may relapse (Levine and Lamont, 1982). The 
antibacterial spectrum of metronidazole is limited to microaerophilic and anaerobic bacteria. 
Oral administration of metronidazole has been used to treat antimicrobial-associated colitis 
and, in addition, therapy with metronidazole is much cheaper than the standard treatment 
with oral vancomycin (Bolton and Culshaw, 1986, Briceland et al., 1988, Hecht and 
Olinger, 1989). The rifamycins, which inhibit bacterial nucleic acid synthesis, are active 
against Gram positive and some Gram negative bacteria and Mycobacterium tuberculosis. 
The administration of the rifamycin, rifaximin, by nasogastric tube to patients with severe 
colitis and bacterial superinfection, was highly effective clinically, and there were no reports 
of local or systemic side effects (Alvisi et al., 1987). In addition, other agents which inhibit
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bacterial cell wall synthesis and have activity against Gram positive bacteria have been used 
to treat antimicrobial-associated colitis due to C. difficile infection. These include the 
cephalosporin ceftizoxime (Iwai et al., 1982), fusidic acid (Canzi et al., 1987), and 
bacitracin (Trnka and Lamont, 1984).
A range of other agents and supportive measures have been used in the treatment of 
antimicrobial-associated colitis. Cholestyramine and colestipol are strongly basic anion- 
exchange resins which have been used in the treatment of antimicrobial-associated colitis. 
Cholestyramine and colestipol are lipid regulating agents which exchange chloride ions for 
the anions of bile salts within the gastrointestinal lumen, prevent their absorption from the 
gastrointestinal tract, and lead to an overall reduction in serum cholesterol, and in particular 
low density lipoprotein, concentrations. The advantage of cholestyramine and colestipol in 
the treatment of antimicrobial-associated colitis have been attributed to the fact that they bind 
to C. difficile toxins (Chang et al., 1978, Mogg et al., 1982). Fluid and electrolyte 
replacement therapy have been used to restore a proper fluid and electrolyte balance (Meyer- 
Kawohl and Bockemuhl, 1986, Saco et al., 1981). Surawicz et al. (1989) noted that the 
administration of the non-pathogenic yeast Saccharomyces boulardii reduced the incidence of 
antimicrobial-associated diarrhoea in hospitalized patients. In some refractory cases of 
pseudomembranous colitis, medical treatment is insufficient, and surgical intervention, e. g. 
colectomy, has been of benefit in some of these cases (Boyd and Den Besten, 1976, 
Eriksson etal., 1982, McKinley et al., 1982).
1.11 Animal models of antimicrobial-associated colitis
A number of different animal models have been used in the diagnosis and evaluation of 
treatment of antimicrobial-associated colitis. The majority of antimicrobial agents, which 
result in the development of antimicrobial-associated colitis in man, produce disease in 
hamsters (Boon and Beale, 1985). The hamster model has been regarded as a sensitive 
indicator of the antimicrobial agents likely to cause antimicrobial-associated colitis in treated 
patients since C. difficile infection is common in the hamster (Boon and Beale, 1985). 
Hawkins et al. (1984) reported that 13% of hamsters had demonstrable C. difficile infection 
prior to antimicrobial administration. Uninfected and untreated hamsters may acquire C. 
difficile infection either by cross-infection or from the environment (Hawkins etal., 1984, 
O'Connor et al., 1981). Rehg and Lu (1982) reported C. difficile typhilitis in the hamster 
that was not associated with antimicrobial administration. The B-lactam antimicrobial agents 
vary in their ability to cause colitis and death in the hamster-model of C. difficile colitis 
(Weinberg et al., 1986). For example, azotreonam is quite safe following intraperitoneal or 
oral administration, whereas ceftazidine is only safe to use parenterally, and cefoperazone 
and latamoxef result in caecitis and death following parenteral administration (Weinberg et
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al., 1986). Fatal C. difficile colitis occurs within a few days of treating hamsters with other 
6-lactam antimicrobial agents, including ampicillin (Larson and Borriello, 1990), 
flucloxacillin (Larson and Borriello, 1990), cefoxitin (Boon and Beale, 1985, Dubini, 1988) 
ceftazidine (Weinberg et al., 1986), and cefuroxime (Larson and Borriello, 1990). Parenteral 
administration of latamoxef and cefaperazone to hamsters resulted in marked changes in the 
anaerobic caecal microflora and the growth of C. difficile (Weinberg et al., 1986). 
Administration of the macrolide N-formimidoyl thienamycin to hamsters resulted in the 
development of colitis with a mortality rate of 75% (Hawkins et al., 1984). Clindamycin 
treatment of hamsters resulted in the development of rapidly fatal colitis (Boon and Beale, 
1985, Dubini, 1988, Larson and Borriello, 1990, Weinberg et al., 1986). Moreover, a 
persistent loss of resistance to C. difficile colonization, a type of post-antibiotic effect, was 
reported in hamsters which developed non-fatal colitis following administration of 
clindamycin. O'Connor et al. (1981) reproduced the typical clinical and morphological 
changes associated with colitis following administration of arifamycin antimicrobial agent, 
rifampicin, to hamsters.
Fekety et al. (1979) prevented clindamycin-induced C. difficile colitis in hamsters by the oral 
administration of either vancomycin or metronidazole. The acidic lipopeptide antimicrobial 
agent LY146032, which inhibits the biosynthesis of bacterial cell wall peptidoglycan, 
delayed death in the hamster model of pseudomembranous colitis at a dose rate of 0.05 
mg/day; equivalent protection with vancomycin would require administration at 100 times 
the dose rate, i. e. 5 mg/day (Dong et al., 1987). The survival of hamsters was prolonged 
significantly by the administration of cholestyramine but the development of colitis and death 
were not prevented (Fekety et al., 1979). Treatment with corticosteroids or an 
atropine/diphenoxylate combination did not alter the course of clindamycin-induced colitis in 
the hamster (Fekety et al., 1979).
A similar phenomenon occurs in other species. Guinea pigs are susceptible to C. difficile 
infection and the high incidence of antimicrobial-associated colitis restricts the use of many 
antimicrobial agents in this species (Fritz et al., 1987). George et al. (1979) and Lowe et al. 
(1980) reported C. difficile associated caecitis in guinea pigs exposed to penicillin, and 
caecal filtrates from penicillin treated guinea pigs which developed colitis contained C. 
difficile toxin (George et al., 1979, Rothman, 1981). Vancomycin treatment of guinea pigs, 
with penicillin-induced C. difficile colitis, increased the survival time and decreased the 
number of deaths (Rothman, 1981). Similarly, antimicrobial-associated colitis has been 
reported in the rabbit. Guandalini et al. (1988) reported the development of C. difficile colitis 
in rabbits following oral administration of ampicillin. In addition, administration of 
clindamycin to rabbits has been shown to alter the quantitative and qualitative composition of 
the obligate anaerobic microflora (Poliak et al., 1983).
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1.12 Colitis in the equine
In the horse, colitis has been described using a variety of different names, such as equine 
non-parasitic diarrhoea (Nielsen and Vibe-Petersen, 1979), acute diarrhoea (Wierup and Di 
Pietro, 1981), acute equine colitis (Roberts, 1990, Whitlock, 1986), colitis 'X' (Harries and 
Strother, 1969, Kelly, 1972, Onderdonk, 1985, Prescott et al., 1988, Vaughan, 1973, 
Wierup and Di Pietro, 1981), exhaustion shock (Harries and Strother, 1969, Rooney et al., 
1963, Onderdonk, 1985), or fatal idiopathic colitis (Prescott et al., 1988). Proudman (1992) 
found that 1% of equine colic cases were due to colitis and that in general these cases were 
fatal.
The cause of equine colitis is unknown, but specific causes have been demonstrated. 
Recently, equine intestinal clostridiosis was described as an enterotoxaemia caused by high 
numbers of C. perfringens in the gastrointestinal tract (Pearson etal., 1986, Schiefer, 1981, 
Sims et al., 1985, Wierup and DiPietro, 1981). The colitis 'X' syndrome was believed to be 
related to a toxaemia brought on by the absorption of endotoxins from autolysing Gram 
negative bacteria in the gastrointestinal tract (Harries and Strother, 1969, Kelly, 1972).
In the equine a diagnosis of colitis describes a syndrome with a wide range of different 
causative agents. Colitis-associated diarrhoea has been reported as a sequel to a number of 
well recognized infections in the horse, including parasitic infections such as migrating 
strongyle larvae (Blackwell, 1973, Breider et al., 1985, Jasko and Roth, 1984), and 
bacterial infections such as Salmonella spp., including Salmonella typhimurium (Dorn et al., 
1975, Goetz and Coffman, 1984, Manahan, 1970, Slocombe and Slauson, 1988, Whitlock, 
1986), and Ehrlichia risticii infection (Cordes et al., 1986, Palmer et al., 1986, Van Der 
Kolk and De Groot, 1991). In addition, equine colitis-associated diarrhoea has been 
recorded following infection with bacteria isolated less commonly, including E. coli (Kelly, 
1972, Manahan, 1970), Staphylococcus spp. (Manahan, 1970), Mycobacterium avium 
(Buergelt et al., 1988, Cline et al., 1991), Clostridium spp., including C. difficile (Jones et 
al., 1987, Jones et al., 1988) and C. cadaveris (Prescott et al., 1988) and Acinetobacter 
calcoaceticus (Dickie and Regnier, 1978). In addition, other organisms, such as 
Trichomonas-type protozoa (Manahan, 1970), Giardia-type protozoa (Manahan, 1970), 
Geotrichum-type fungi (Manahan, 1970), Histoplasma spp. (Dade et al., 1973, Goetz and 
Coffman, 1984), and the ciliate Polymorphella ampulla (Gregory et al., 1986), have been 
reported as a cause of colitis-associated diarrhoea in the equine.
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1.13 Antimicrobial agents associated with colitis in the equine
In the equine the development of colitis has been associated with the administration of 
antimicrobial agents. Diarrhoea has developed following the administration of the penicillins 
(Baggot et al., 1990, English and Roberts, 1983, Roberts, 1990), including penicillin V 
(Baggot etal., 1990, Ducharme et al., 1983), chloramphenicol (Nielsen and Vibe-Petersen, 
1979), the macrolides spiramycin (Nielsen and Vibe-Petersen, 1979), erythromycin (Baggot 
and Prescott, 1987, Roberts, 1990) and tylosin (Roberts, 1990), lincomycin and 
clindamycin (Raisbeck et al., 1981, Prescott et al., 1988), metronidazole (Sweeney et al., 
1991), and the potentiated sulphonamides (Murray, 1988b, Roberts, 1990) The adverse 
reaction to the tetracyclines should be familiar to all equine clinicians (Roberts and English, 
1979, Whitlock, 1990). Diarrhoea has been reported following administration of 
oxytetracycline (Andersson et al., 1971, Baker and Leyland, 1973, Cook, 1973, Kuiperand 
Franken, 1980, Mackellar et al., 1973, Nielsen and Vibe-Petersen 1979, Owen, 1975, 
Swerczek, 1979) and chlortetracycline (Cook, 1973).
One of the most common causes of adverse gastrointestinal reactions to antimicrobial agents 
in the equine appears to be the feeding of contaminated or inappropriate feedstuffs. 
Diarrhoea was reported following the oral administration of a premix containing 
oxytetracycline, sulphadimethoxine and furazolidone and following oral administration of an 
oxytetracycline and sulphadiazine premix (Ruckebusch, 1983). Rollinson eta l. (1987) 
reported salinomycin poisoning, in horses fed contaminated feed, similar to that seen 
following administration of another ionophore antimicrobial agent, monensin.
1.14 Other factors involved in the development of equine colitis
The administration of other therapeutic agents, including anthelmintics and non-steroidal 
anti-inflammatory drugs, has resulted in the development of diarrhoea in horses (Karcher et 
al., 1990, Nielsen and Vibe-Petersen, 1979, Simmons et al., 1990).
Stress, such as a change of diet, strenuous work, abdominal pain, transport, hospitalization, 
general anaesthesia and abdominal surgery, has initiated clinical enteritis possibly due to an 
increased susceptibility to intestinal infections (Baker and Leyland, 1973, Clarke et al., 
1990b, Cook, 1973, Harries and Strother, 1969, Mackellar et al., 1973, Manahan, 1970, 
Nielsen and Vibe-Petersen, 1979, Owen, 1975, Palmer et al., 1985, Rooney et al., 1963, 
Schiefer, 1981, Swerczek, 1979, Vaughan, 1973, Wierup and DiPietro, 1981, Wilson, 
1979). Proudman (1992) found that 43% of cases of spasmodic colic were associated with 
stress, such as drug administration, transportation, a management or weather change, 
surgery and an unusual feed intake.
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The alterations in the gastrointestinal tract that occur as a result of so-called stress may be 
due to exposure to different organisms, or to a reduction in feed and water intake, even if 
this is only temporary. In the pig, the coliform flora is complex and a turnover of biotypes 
has been associated with changes in pen occupancy and diet (Hedges and Linton, 1988). In 
the pony, an abrupt change in diet from hay to concentrates resulted in an increase in the total 
number of viable anaerobic bacteria and an alteration in the luminal pH in the caecum, similar 
to those seen in the bovine rumen under similar feeding conditions (Goodson etal., 1988).
Hird et al. (1986) reported that 38.8% (83/214) of cases of equine salmonellosis were 
primary infections whereas 61.2% (131/214) were hospital acquired infections. The odds 
for developing salmonellosis were higher if the animal was admitted as an emergency, or if 
treatment involved nasogastric intubation, intravenous catheterization, rectal examination, 
surgery especially invasive abdominal surgery or enterotomy, inhalational anaesthesia and 
parenteral or oral antimicrobial administration. It was suggested that horses with intestinal 
disturbances were more susceptible to Salmonella spp. infection than other horses, although 
there was a slight bias in that it was more likely for samples to be submitted for 
bacteriological examination from these animals.
1.15 Clinical signs and mortality rate o f  colitis in the equine
Profuse watery diarrhoea is the commonest sign of colitis in the equine (Roberts, 1990). 
However, there are a wide spectrum of clinical signs associated with the build up of fluid in 
the intestinal lumen. Consequently, equine colitis presents with clinical signs ranging from 
peracute, acute or subacute colic to chronic mild diarrhoea which usually occur within 
approximately 3 days of commencing drug administration (Andersson et al., 1971, Baker 
and Leyland, 1973, Cook, 1973, English and Roberts, 1983, Harries and Strother, 1969, 
Karcher et al., 1990, Kuiper and Franken, 1980, Manahan, 1970, Nielsen and Vibe- 
Petersen, 1979, Parry, 1983, Rooney et al., 1963, Schiefer, 1981, Whitlock, 1986, Wierup 
and DiPietro, 1981, Wilson, 1979). However, the onset of diarrhoea may be delayed for 
some weeks after the cessation of antimicrobial treatment (Cook, 1973, Ruckebusch, 1983). 
Thus the clinical picture can be of sudden onset explosive diarrhoea resulting in dehydration 
which, in the absence of appropriate treatment, may lead to the development of shock, 
disseminated intravascular coagulation and death within a few days. At the opposite end of 
the spectrum, depression, anorexia and mild diarrhoea and, in chronic cases, 
hypoproteinaemia and weight loss may be the only clinical signs.
A guarded prognosis should be given to horses with colitis (Nielsen and Vibe-Petersen, 
1979). The mortality rate of horses with acute colitis was 83% (Nielsen and Vibe-Petersen,
1979), although the longer the animals live the greater the survival rate (subacute cases of
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colitis had a mortality rate of 45%).
Acute oxytetracycline-induced diarrhoea, intestinal clostridiosis and the colitis 'X' syndrome 
are not dissimilar clinically or at necropsy (English and Roberts, 1983). At post mortem 
examination there are a wide range of pathological findings and not surprisingly the most 
striking findings are in the gastrointestinal tract. Pathological findings may be restricted to 
the large intestine, e. g. typhlocolitis (inflammation of the caecum and colon) (Harries and 
Strother, 1969, Prescott et al., 1988, Rooney et al., 1963), or may extend from the 
duodenum to the colon (Schiefer, 1981). Generally, the intestinal lumen is filled with watery 
contents, and there is mucosal oedema, and mucosal necrosis with or without ulcers (Harries 
and Strother, 1969, Prescott et al., 1988, Rooney et al., 1963, Schiefer et al., 1981).
1.16 Diagnosis of colitis in the equine
A diagnosis of colitis has been applied to a wide variety of infections with similar clinical 
signs, such as salmonellosis, intestinal clostridiosis, and strongyle larval migrans. 
Consequently, there is no definitive technique for diagnosing of colitis in the equine. In 
many cases, the clinical course can be so rapid that a diagnosis is made at post mortem 
examination only. In more protracted cases, standard techniques of bacterial isolation can be 
used. However, there are a wide range of causative organisms many of which are present in 
normal faeces and, in addition, repeated sampling may be required to demonstrate 
pathogenic organisms, such as Salmonella spp..
There is a paucity of information on the microbial population that inhabits the gastrointestinal 
tract of the horse (Mackie and Wilkins, 1988). It has been suggested that a diagnosis of 
equine intestinal clostridiosis can be based upon the isolation and enumeration of C. 
perfringens from intestinal contents or faeces (Wierup and Di Pietro, 1981). However, 
studies of the faecal flora in man and animals, after antimicrobial therapy, have suffered 
from a lack of quantitative techniques to cope with the enormous variations in the number 
and the type of organism present in the gastrointestinal microflora (Trnka and Lamont, 
1984). In addition, there can be differences in the flora of animals managed under different 
conditions (Wierup and Di Pietro, 1981). It may be that, given sufficient information on the 
number of bacteria in the normal gastrointestinal tract, techniques that enumerate bacteria 
could be used in the diagnosis of colitis in the equine. It should be remembered that these 
techniques reflect luminal and not mucosal bacterial populations, although it has been shown 
that, in the horse, there is a close relationship between the number of viable luminal and 
mucosal bacteria in the gastrointestinal tract (Mackie and Wilkins, 1988).
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1.17 Prevention and treatment of colitis in the equine
It would be prudent to avoid the administration of antimicrobial agents which have been 
associated with the development of potentially life-threatening diarrhoea in other species, 
particularly where there is not specific information on their use in the equine. Nielsen and 
Vibe-Petersen (1979) recommended that the administration of chloramphenicol, the 
lincosamides and the tetracyclines should be avoided in horses. In addition, all cases of 
colitis should be treated with care, even where a specific pathogen has been isolated, since 
antimicrobial therapy may exacerbate the condition (Schiefer, 1981).
Obviously, if antimicrobial-associated colitis is suspected, the administration of the causal 
antimicrobial agent should be stopped immediately. Fluid and electrolyte loss into the 
gastrointestinal lumen, and absorption of enterotoxin or endotoxin through the intestinal 
mucosa, produce systemic fluid and electrolyte imbalances and lead to the development of 
life-threatening hypovolaemic or endotoxic shock. Therefore, the treatment of equine colitis 
aims to correct the body fluid and electrolyte balances by vigorous fluid and electrolyte 
replacement therapy (Harries and Strother, 1969, Manahan, 1970, Nielsen and Vibe- 
Petersen, 1979, Roberts, 1990, Vaughan, 1973). In addition, a variety of different agents 
have been recommended for administration to horses with colitis-associated diarrhoea. These 
include intestinal protectants, antimicrobial agents, analgesics, anti-diarrhoeal agents, 
sodium bicarbonate and dietary changes (Harries and Strother, 1969, Nielsen and Vibe- 
Petersen, 1979, Roberts, 1990).
1.18 The commensal gastrointestinal microflora and toxins
Monogastric animals have a modification of the lower intestinal tract, inhabited by symbiotic 
microorganisms, whose function is to breakdown some of the fibrous feed components 
since, in general, the animals lack the enzymes that degrade cellulose. In the horse, the 
caecum and colon have been enlarged to accommodate microbial colonization and 
fermentation.
At birth the large intestine is sterile and it acquires an anaerobic microflora gradually (Murray 
et al., 1987). A wide variety of potentially pathogenic bacteria are found in the 
gastrointestinal tract (Strachan, 1983, White and Prior, 1982), including coliforms, 
streptococci and Clostridium spp., and these occur in varying numbers in the faeces from 
pigs, chickens, sheep, calves, dogs, cows, horses and man (Havelaar et al.y 1986). 
Multiplication of bacteria in the gastrointestinal lumen can occur when an obstruction or 
blood are present, and when the animal's immune defences are lowered (Strachan, 1983). 
Moreover, stress results in an increase in the number of viable coliforms and reduction in the
20
number of viable lactobacilli in the gastrointestinal tract, and may reduce VFA concentrations 
due to a depression of the anaerobic microflora (Sogaard, 1986).
A number of different bacterial species produce disease by the production of enterotoxins, 
cytotoxins or endotoxins. Enterotoxins and cytotoxins are preformed toxins produced by a 
number of Gram positive and Gram negative bacteria including Clostridium spp., toxin- 
producing staphylococci and enterotoxigenic E. coli. Clostridium difficile produces both 
enterotoxin and cytotoxin which damage the intestinal mucosa and result in the development 
of pseudomembranous colitis in man. An enterotoxaemia produced by the overgrowth of 
toxin producing C. perfringens in the gastrointestinal tract has been described in the horse 
and in foals (Pearson et al., 1986, Wierup and Di Pietro, 1981). In addition, diarrhoea due 
to C. difficile infection has been reported in foals (Jones et al., 1987, Jones et al., 1988).
Endotoxin is the lipopolysaccharide outer cell wall of Gram negative bacteria, such as E. 
coli, and Salmonella, Klebsiella, Proteus and Pseudomonas spp.. Endotoxin has been 
implicated in the pathogenesis of a variety of diseases in the equine, including laminitis, 
septic shock, colitis ’X’ and colic (Burrows, 1981c, King and Gerring, 1988, Muir, 1987). 
Endotoxin is present in the normal gastrointestinal lumen and the intestinal mucosa generally 
represents an effective barrier (King and Gerring, 1988, Moore and Morris, 1992). Hence, 
there is a concentration gradient of endotoxin from the gastrointestinal lumen via the 
peritoneal cavity to the systemic circulation, and there are low concentrations of endotoxin in 
the peritoneal cavity and systemic circulation of normal horses. However, the absorption of 
large quantities of endotoxin into the peritoneal cavity, and hence into the systemic 
circulation, may occur when the gastrointestinal wall is damaged, e. g. in intestinal 
ischaemia as a sequel to intestinal volvulus or incarceration. An experimental increase in 
circulating endotoxin concentrations produced a variety of clinical signs in the pony, 
including colic, lactic acidosis and diarrhoea (Moore et a l, 1981). In addition, experimental 
acute E. coli endotoxaemia in ponies resulted in a variety of blood biochemical and 
haematological alterations, including an increase in the packed cell volume, blood glucose 
and blood lactate concentrations and a reduction in the plasma bicarbonate ion concentration, 
pH and white blood cell count (Burrows, 1981a, b, c, Green and Adams, 1992, Moore and 
Morris, 1992, Morris et a l, 1986, Stadler and Van Amstel, 1989, Ward et al., 1987). In 
clinical cases, an increase in the plasma endotoxin concentration has been correlated with an 
increase in heart rate and packed cell volume, and with death by King and Gerring (1988).
1.19 Microbial fermentation in the gastrointestinal tract
The extensive fermentation of polysaccharides and the production of SCFA in the hind gut is 
a common feature of all mammals, although the hindgut volume varies considerably between 
carnivores, omnivores and herbivores (Alexander, 1971, Argenzio et a l, 1974, Bruorton et
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al., 1991, Bugaut, 1987, Cummings et al., 1976, Hintz, 1975, Stevens et al., 1986, 
Weaver et al., 1988). The role of SCFA in the nutrition and health of the large intestine is 
well recognized in man (Fleming and Arce, 1986) and in ruminants (Czerkawski, 1986).
The metabolic products of bacterial fermentation, SCFA, make a major contribution to the 
energy metabolism in animals (Rechkemmer et al., 1988, Tisserand, 1989). The highest 
SCFA concentrations have been recorded in the forestomachs of ruminants and in the large 
intestine of all mammals (Bugaut, 1987). The biochemical activities and microbial 
composition of the micro flora reflect the anaerobic environment of the gastrointestinal tract 
(Mackie and Wilkins, 1988) and the microbial metabolism in the lower intestine of 
monogastric animals resembles the reactions that occur in the rumen (Miller and Wolin, 
1979, Prins, 1987).
Most non-sporing anaerobes in the gastrointestinal tract ferment carbohydrates according to 
the Embden-Meyerhof-Parnas scheme (Miller and Wolin, 1979). Non-sporing anaerobic 
bacteria in the gastrointestinal tract decarboxylate pyruvate to acetyl coenzyme A (the 2 
carbon radical of acetate) and carbon dioxide, with the concomitant reduction of a low- 
potential electron acceptor or the reduced form of nicotinamide adenine dinucleotide 
(NADH), and the formation of hydrogen (Coffman, 1975a, b, Miller and Wolin, 1979). 
Lactate is produced by the oxidation of the NADH formed during glycolysis (Miller and 
Wolin, 1979). Acetate, ethanol or butyrate are formed from acetyl coenzyme A, and the 
carboxylation of pyruvate or phosphoenolpyruvate produces oxaloacetate which is reduced, 
eventually, to succinate, a precursor of propionate. Isobutyrate, isovalerate, valerate and 
hexanoate are produced by valine, leucine and polypeptide degradation, respectively 
(Mortensen etal., 1988, Zarling and Ruchim, 1987).
1.20 Lactic acid
Gastrointestinal bacteria produce both D- and L-lactic acid, the latter being the endogenous 
molecular species in mammals, in a process which is dependent, partially, on thiamine 
(Coffman, 1975a, b). Faecal coliform bacteria in cattle, horses and red pandas produced D- 
lactate, acetate and ethanol in 1% glucose broth in vitro (Slyter and Rumsey, 1991). Lactic 
acid in the intestinal contents of ruminants is derived from lactate in feed and from readily 
fermentable carbohydrate (Wolffram et al., 1988). Substantial amounts of lactic acid are 
produced by bacterial fermentation in the stomach of the adult horse and these are either 
absorbed in the small intestine or fermented in the colon (Alexander, 1971, Argenzio etal., 
1974). Sodium ions stimulate L-lactate uptake, in isolated bovine brush border membrane 
vesicles, whereas acetate, propionate and butyrate inhibit sodium ion dependent L-lactate 
uptake (Wolffram et al., 1988).
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Lactic acid metabolism can be affected by feeding. Dietary protein content did not affect the 
blood lactate concentrations in horses, but the lactate to pyruvate concentration ratio was 
higher when a low protein (9%) diet was fed compared with a high (18.5%) protein diet 
(Miller-Graber et al., 1991). As a result Miller-Graber et al. (1991) suggested that the 
conversion of lactate to pyruvate may be influenced by the composition of the diet in the 
horse.
In the bovine rumen and in the equine caecum, the lactic acid concentrations increase 
following the fermentation of starch and soluble sugars, e. g. following carbohydrate 
overload (Coffman, 1975a, b, Wernery and Wensvoort, 1992). Experimentally induced 
lactic acidosis (by intraruminal glucose administration) resulted in a typical reduction in 
ruminal pH and a concurrent increase in L- and D-lactic acid concentrations (Muir et al., 
1980, Nagaraja et al., 1982). Following carbohydrate overload in the horse, there was an 
increase in the number of viable lactate producing bacteria and a reduction in the number of 
viable Gram negative bacteria (Garner et al., 1978), an increase in the caecal endotoxin and 
lactic acid concentrations (Moore et al., 1979), and a reduction in the pH of caecal samples 
(Moore et al., 1979, Garner et al., 1978).
Systemic lactic acidosis is characterized by metabolic acidosis, due to hydrogen ion 
accumulation in blood, and a blood lactate concentration of at least 5 mM (Arieff et al., 
1982). An increase in blood D- and L-lactate concentrations resulted in the development of 
metabolic acidosis with a high anion gap and changes in the plasma potassium ion and serum 
inorganic phosphate concentrations in ponies (Gossett et al., 1987, Gossett et a l, 1990a, b). 
Moore et al. (1976) showed a correlation between increased blood lactate concentrations and 
a reduction in the percentage survival in horses with colic, and suggested that blood lactate 
concentrations were a good prognostic indicator in horses with colic.
1.21 Volatile fatty acids
The main end products of saccharide fermentation are the VFAs, acetate, propionate and 
butyrate, and these are the major anions in the large intestine (Argenzio, 1981, Czerkawski, 
1986, Mortensen et al., 1988, Weaver et al., 1988, Zarling and Ruchim, 1987). In the 
equine, 50% of the ingested soluble carbohydrate is fermented to produce VFAs in the 
caecum and colon (Argenzio, 1975, Murray, 1988a). Bonhomme-Florentin (1988) showed 
that components of the horse caecal contents break down plant structural polysaccharides 
(hemi-cellulose and pectin) via polysaccharide depolymerases and glycoside hydrolases.
Diet influences VFA production in the rumen and human colon (Mortensen et al., 1988, 
Prins, 1987). Addition of a yeast culture supplement to the diet of Holstein cows has been
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shown to reduce the ruminal pH, ammonia concentration, molar proportions of acetate and 
isovalerate and the acetate to propionate concentration ratio and to increase the molar 
proportions of propionate and valerate, but not to affect the proportions of isobutyrate, 
butyrate, or the total VFA or viable yeast concentrations in ruminal fluid (Harrison et al., 
1988). In the rat, the incorporation of fibre and crude potato starch in the diet resulted in a 
significant enlargement of the caecum and an increase in VFA concentrations and an increase 
in the pool of acetate, propionate and butyrate (Mazur et al., 1990). It has been suggested 
that, in the horse, the concentration ratio of acetate to propionate is influenced by the level of 
soluble carbohydrate in the diet (Hintz, 1975). However, Wolter et al. (1980) fed a complete 
pelleted diet to ponies and rabbits and found that there were no statistically significant 
differences in the dry matter content, starch digestion and the molar ratio of acetate, 
propionate and butyrate in the gastrointestinal tract.
In the rabbit, a daily meal was followed by an increase in the VFA concentrations and a 
reduction in the pH of caecal contents (Fioramonti and Ruckebusch, 1976). In the miniature 
swine, digesta entering the caecum produced an increase in SCFA concentrations and a 
reduction in pH (Fleming et al., 1989). Fluctuations in the VFA concentrations in rabbits 
and sheep are marked following once daily feeding, compared with ad libitum feeding and 
twice daily feeding, respectively (Parker and McMillan, 1976, Van der Walt and Briel, 
1976). Similarly, in the equine twice daily feeding of high energy, low carbohydrate forage 
rations resulted in an increase in the amount of fermentable carbohydrate in the caecum, due 
to an increase in the intestinal transit rate, and may produce changes in the gastrointestinal 
microflora and alterations in the intraluminal endotoxin pool (Clarke etal., 1990b).
In the equine, cyclic changes in VFA production and pH have been related to the cyclic 
changes in gastrointestinal volume which occur in association with cyclic periods of 
microbial digestion (Argenzio, 1975, Argenzio et al., 1974). Studies on the effect of 
episodic feeding on the microbial digestion within the equine large intestine have suggested 
that the fermentation cycle represents a subclinical carbohydrate overload (Clarke et al., 
1990b).
In the colon, VFAs mediate the symbiotic existence of the bacteria and the colonic mucosa 
and play an important role in the nutrition of colonocytes (Roediger, 1980, Sakata, 1987). 
VFAs are absorbed readily by the simple columnar epithelium of the intestine, but not all the 
absorbed VFAs reach the plasma due to metabolism in the gastrointestinal wall where they 
are an important energy source (Argenzio, 1975, Bugaut, 1987, Roediger, 1980). Both 
acetate and propionate are mitogenic to ovine rumen epithelial cells but are less so than 
butyrate (Sakata and Tamate, 1979). In the rat, there is a dose dependent, stimulatory effect 
of VFAs on ileal epithelial cell proliferation, with butyrate being the most active followed by
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propionate and then acetate (Sakata, 1987). This effect is independent of the presence of gut 
bacteria and low luminal pH. The major respiratory fuel in colonocytes is rt-butyrate (Kripke 
etal., 1989, Roediger, 1980, Roediger, 1982, Thomsen etal., 1984) and carbon dioxide 
production, due to butyrate utilization may provide a useful means of examining the 
functional activity of the colonic mucosa clinically and in vivo (Roediger, 1982).
1.22 Mechanisms of absorption and secretion in the large intestine
Transport mechanisms absorb VFAs from the large intestinal lumen to maintain the luminal 
pH. between 6.8 and 7.2, and the luminal osmolality at 300 milliosmoles/kg (Alexander, 
1971, Argenzio et al., 1974, Argenzio and Stevens, 1975, Bugaut, 1987, Murray, 1988a, 
Rechkemmer et al., 1988, Umesaki et al., 1979). The magnitude of colonic fermentation is 
dependent upon the load of rapidly fermentable substrate delivered to the resident microflora 
(Clarke etal., 1990b). Rapid fermentation requires transmural fluid movement, to buffer and 
dilute the organic acids produced, and, in addition, the induction of renal and humoural 
mechanisms to maintain systemic homoeostasis (Clarke et al., 1990b). In hindgut 
fermenting herbivores, the ileal outflow provides the fluid and buffering capacity essential 
for microbial metabolism (Rechkemmer et al., 1988). However, the buffering capacity of the 
ileal outflow of the horse is exhausted by the caecum, and the colon has developed an 
independent means of buffering during periods of rapid fermentation (Alexander, 1971, 
Argenzio, 1975).
In the equine caecum, during periods of rapid digestion, sodium/hydrogen ion exchange is 
interrupted, acetate is exchanged for the bicarbonate ion, and net water absorption is 
abolished (Argenzio, 1975, Argenzio et al., 1977). However, there are no changes in the 
osmolality of the caecal contents, suggesting that fluid retention and the neutralization of 
luminal contents may be controlled by neurotransmitters and gastrointestinal hormones. 
Between periods of rapid fermentation, VFA concentrations fall, water and sodium ions are 
absorbed, bicarbonate ions are buffered by sodium/hydrogen ion exchange and carbon 
dioxide is absorbed into the bloodstream (Argenzio and Stevens, 1975, Murray, 1988a).
Most VFAs are absorbed in an undissociated form, but at physiological pH circa 99% exist 
in an ionized form (Argenzio, 1981, Argenzio and Stevens, 1975, Argenzio et al., 1974, 
Argenzio et al., 1977, Bugaut, 1987, Engelhardt et al., 1989, Murray, 1988a, Umesaki et 
al., 1979). Carbon dioxide, a product of bacterial fermentation, combines with water to 
produce hydrogen and bicarbonate ions, and the dissociated VFAs combine with the 
hydrogen ions to produce undissociated, absorbable VFAs (Bugaut, 1987, Murray, 1988a, 
Roediger, 1989). In addition, there is a sodium/hydrogen ion exchange. There is an 
interdependency between VFA absorption and sodium ion absorption, and between VFA 
absorption and bicarbonate ion secretion in a variety of genera (Argenzio, 1975, Argenzio
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and Stevens, 1975, Stevens et al., 1986, Titus and Ahearn, 1988, Umesaki et al., 1979). 
The formation of undissociated VFAs results in the accumulation of bicarbonate ions in the 
colonic lumen, and a concomitant reduction in the luminal partial pressure of carbon dioxide 
(Argenzio, 1975, Stevens et al., 1986, Rechkemmer et al., 1988, Umesaki et al., 1979). In 
addition, bicarbonate ions are secreted in exchange for chloride ions and there is a net 
accumulation of bicarbonate ions in the gastrointestinal lumen (Argenzio et al., 1977, 
Edmonds, 1982, Rechkemmer et al., 1988, Umesaki et al., 1979). The ability of the large 
intestine to secrete bicarbonate ions in exchange for other anions, both chloride and VFAs, 
may control intraluminal pH by the alkalization of contents (McNeil et al., 1978, Umesaki et 
al., 1979). In addition, the poor absorption of bicarbonate ions by the colon restricts the 
absorption of sodium ions (Argenzio, 1975). Potassium and inorganic phosphate ions are 
absorbed poorly and are found in high concentrations in the distal colon of the horse 
(Argenzio, 1975).
The absorption of VFAs is rapid, passive, and independent of luminal pH (except at below 
pH 6.4), due to the constant pH microclimate at the mucosal surface (McNeil et al., 1978, 
Rechkemmer et al., 1988, Engelhardt et al., 1988). In the large intestine, sodium, 
bicarbonate and chloride ions are transported against electrochemical gradients (Argenzio, 
1975, Argenzio et al., 1977, Edmonds, 1982, Stevens et al., 1986). The energy for the 
active transport of sodium ions is provided by glucose and by the absorption of acetate 
(Argenzio, 1975). The human and equine colon absorb sodium ions more slowly than VFAs 
(Argenzio, 1975, McNeil et al., 1978, Stevens et al., 1986). There is a relationship between 
the net movement of water and the net production of VFAs, and between net movement of 
water and the osmolality of the intestinal contents (Argenzio, 1975, Cummings etal., 1976). 
In addition, there is a relationship between the net movement of water and solutes (Argenzio, 
1975, Murray, 1988a).
In the rat colon, absorption of VFAs, such as acetate, propionate, and butyrate, is much 
greater than absorption of NVFAs, such as succinate and lactate (Umesaki et al., 1979). In 
the human jejunum, acetate, propionate and butyrate are absorbed rapidly at equal rates in a 
linear fashion, but the absorption process reaches saturation at higher concentrations (40-50 
mM) (Schmitt et al., 1976). Different monocarboxylate anions (pyruvate, acetate, propionate 
and butyrate) may have different affinities for a common carrier (Lamers, 1975). Acetate, 
propionate, butyrate, and high concentrations of the bicarbonate ion, stimulate the efflux of 
pyruvate, probably due to an anionic counter transport mechanism, in intestinal epithelial 
cells, in vitro (Lamers and Hulsmann, 1975). Lamers and Hulsmann (1975) suggested that 
the lipophilicity and acidic dissociation constants of the monocarboxylic acids may determine 
the contribution of non-ionic diffusion to the overall transport of SCFAs. Pyruvate transport 
is likely to be carrier mediated as shown by saturation kinetics, competitive inhibition by
SCFAs and counter transport (Lamers and Hulsmann, 1975).
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The large intestine of the horse has a critical function in the storage and absorption of large 
volumes of water and in general the caecal contents are more fluid than those of the colon 
(Argenzio 1975, Frape 1983). Thus, the equine caecum is the primary site of net water 
absorption. Each day in the normal animal, a large volume of fluid, equivalent to the 
extracellular fluid volume of the animal, circulates between the intestinal lumen and the body 
(Argenzio, 1978, Argenzio and Stevens, 1975, Argenzio et al., 1974). Horse faeces usually 
contains 66-76% water (/. e. 24-34% dry matter), although ponies and donkeys may void 
faeces of a drier consistency (Frape 1983). Diet can affect faecal consistency. In man, an 
increase in dietary wheat fibre results in an increase in faecal weight largely due to a relative 
reduction in solid content and an increase in water content (Cummings et al., 1976). In the 
horse, a high grain diet decreases the faecal water content and pelleted foods tend to increase 
the faecal moisture content (Frape, 1983).
1.23 Abnormalities of the large intestine
Severe diarrhoea and conditions which affect the large intestine, e. g. colitis 'X', result in 
the development of metabolic acidosis due to a loss of sodium and bicarbonate ions into the 
intestinal lumen, and lactic acidosis and hypercarbia (an increased blood lactate and a base 
excess) due to anaerobic tissue metabolism (Manahan, 1970, Roberts, 1990, Svendsen et 
al., 1979, Vaughan, 1973).
The pathogenesis of colitis-associated diarrhoea, described by Argenzio (1975), Argenzio 
(1978), Murray (1988b) and Roberts (1990), includes the failure of colonic absorption and 
secretion processes due to abnormal mucosal permeability, abnormal motility, abnormal ion 
transport and abnormal microbial digestion. Interference with colonic absorption can be due 
to mucosal damage, a reduction in the fluid transit time, toxins or drugs which alter solute 
transport, interference with the intercellular hydrostatic pressure gradients due to junctional 
complex damage, or inhibition of the active transport mechanisms. An increase in net 
secretion results when there is an alteration in the capillary and tissue pressure dynamics, 
high luminal osmotic pressure or active electrolyte secretion. Damage to intercellular tight 
junctions, e. g. due to unabsorbed acid, reduces the pressure gradients and makes 
absorption difficult or impossible. Epithelial damage, such as inflammatory lesions of the 
colon, reduces mucosal permeability due to loss of specific entry systems. An increase in 
tissue pressure may increase hydrostatic pressure and result in net intestinal secretion. 
Primary causes of deranged intestinal motility are uncommon and a primary increase in 
activity does not increase luminal volume. A reduction in the intestinal transit time or an 
alteration in secretion or absorption in the small intestine may result in an increase in the load 
on the colon, a reduction in mucosal contact and malabsorption (Argenzio, 1978, Mohsen et
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a l , 1987).
Intestinal absorption may be affected by antimicrobial agents. In the human jejunum, the 
absorption of sodium ions and water was inhibited reversibly by therapeutic concentrations 
of clindamycin (Spiller et al., 1984). A significant impairment of the bicarbonate ion 
stimulated absorption of sodium ions and water would increase the volume of fluid entering 
the ileum, but the development of diarrhoea would not be expected unless both the ileal and 
colonic absorption were impaired. Dobbins et al. (1968) demonstrated a morphological 
brush border alteration associated with malabsorption, and the subsequent development of 
diarrhoea, following neomycin treatment.
Bacterial infections can affect mucosal transport mechanisms. Guandalini et al. (1988) 
demonstrated that C. difficile infection in the rabbit reduced both glucose and amino acid 
transport in the jejunum and ileum. In the ileum, C. difficile increased the conductance and 
enhanced the permeability to electrolytes with lesser shifts in sodium and chloride ion 
transport. In the caecum, C. difficile infection has profound effects on sodium and chloride 
ion transport resulting in a net secretion of the chloride ion. In another study, C. difficile 
toxin resulted in bicarbonate ion accumulation and an increase in the pH of the rabbit large 
intestine (Lima et al., 1988).
An infusion of SCFAs, at concentrations similar to those produced by bacterial fermentation, 
into rat ileum reduced the stomach to caecum transit time, particularly at high acid 
concentrations and with short chain lengths (e. g. acetic acid) (Richardson et al., 1991). 
Primary or secondary alterations in SCFA concentrations can produce intestinal disease. An 
increase in the luminal osmotic pressure may be secondary to luminal acidification or lactic 
acid production (Argenzio, 1978, Argenzio, 1981, Garner et al., 1978). In pathological and 
physiological states where there is diminished SCFA oxidation, e. g. ulcerative colitis, the 
absorption of sodium ions is reduced (Roediger, 1989). Either a suppression of or an 
abnormal increase in the gastrointestinal microbial fermentation may result in the 
development of diarrhoea (Argenzio, 1978). An over production of microbial endproducts, 
e. g. due to dietary problems or secondary to carbohydrate malabsorption in the small 
intestine, produces luminal acidification and hyperosmolarity, and may lead to the 
development of osmotic diarrhoea (Argenzio, 1978, Holtug and Mortensen, 1989, Schmitt 
et al., 1976). High faecal concentrations of SCFAs have been observed in diarrhoea 
associated with carbohydrate malabsorption (Schmitt etal., 1976). An intra-rectal instillation 
of acetic acid in rats and cats resulted in the development of diffuse colitis similar to the 
human disease (McCafferty and Zeitlin, 1989). Butyric acid instillation in mice produced a 
reproducible, concentration-dependent colitis at concentrations between 1 and 12%, but this 
could not be reproduced by either low pH or by the administration of the butyrate anion at
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neutral or alkaline pH (McCafferty and Zeitlin, 1989). Changes in SCFA production in 
patients with ulcerative colitis may be due to the bacterial fermentation of blood (Holtug et 
al., 1988). In vitro, the addition of blood to a faecal incubation system resulted in a change 
in the SCFA production from acetate and propionate production to butyrate, isobutyrate, 
isovalerate and valerate domination (Holtug et al., 1988). In man, increased SCFA (acetic, 
propionic and lactic) concentrations in non-strangulated intestinal obstruction have been 
related to the inhibition of water and electrolyte absorption, which leads to bowel distension 
(Fukushima et al., 1983).
1.24 Mechanisms of antimicrobial alteration of gastrointestinal microflora
Antimicrobial-associated depression or alteration of the normal gastrointestinal microflora 
may be due to either an overgrowth of pathogens or to to inhibition of the normal microbial 
activity and VFA production resulting in digestive upsets, inappetence and a reduction in 
gastrointestinal motility (Argenzio, 1975, Prins, 1987).
It is worth considering the effects of antimicrobial agents on the ruminal microflora since 
these have been studied extensively. The effects of antimicrobial agents in the equine caecum 
are likely to be similar. Antimicrobial agents may alter ruminal bacterial fermentation 
following oral administration. In sheep, ruminal function was depressed following oral 
administration of penicillin G, streptomycin, chloramphenicol, terramycin and aureomycin 
(Prins, 1987). In addition, some antimicrobial agents alter ruminal fermentation following 
parenteral administration, due to excretion through the rumen wall or in saliva (Prins, 1987). 
Several antimicrobial agents, including penicillin G, ampicillin, methicillin, erythromycin, 
oleandomycin and oxytetracycline, are effective inhibitors of rumen cellulolysis in vitro, and 
can be assumed to damage the rumen ecosystem in vivo, whereas the aminoglycosides 
streptomycin, kanamycin and neomycin have no effect on cellulose breakdown (Prins, 
1965, Wright, 1961). Penicillin G was inactivated rapidly in the rumen but despite this it 
reduced cellulolytic activity both in vitro and in vivo (Prins, 1987). In ruminal fluid in vitro, 
a penicillin/streptomycin combination reduced gas production, a measure of microbial 
activity, by a process that appeared to be dependent on the exposure time of the organisms to 
the antimicrobial agents (Klopfenstein et al., 1964).
Defaunation decreases the proportions of acetate, butyrate and methane and increases the 
proportions of propionate in fermentation end-products in ovine ruminal fluid in vitro 
(Demeyer and Van Nevel, 1987). Antimicrobial agents used as feed additives (e. g. 
lasalocid, monensin, narasin, salinomycin and lysocellin) improve weight gain and feed 
conversion efficiency, reduce acetate, butyrate and methane production, reduce the ratio of 
acetate to propionate and increase propionate production (Bagley et al., 1988, Chalupa etal., 
1980, Chirase et al., 1988, Prins, 1987, Spears et al., 1989). Chalupa et al. (1980) and
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Sauer and Teather (1987) showed that the addition of monensin to rumen fluid in vitro 
inhibited methanogenesis, reduced the ratio of acetate to propionate, reduced acetate and 
butyrate production and increased valerate production. Amicloral reduces acetate production, 
increases ruminal propionate and butyrate production and almost completely inhibits 
methanogenesis (Chalupa et al., 1980). In vitro all the antimicrobial agents tested 
(avoparcin, lasalocid, monensin, narasin, salinomycin, thiopeptin, tylosin, virginiamycin, 
lonomycin, nigericin, cationomycin and lysocellin) increased the molar proportion of 
propionate (Hillaire et al., 1989, Nagaraja et al., 1987) and reduced the final pH and L- 
lactate concentrations in ruminal fluid (avoparcin, lasalocid, monensin, narasin, 
salinomycin, thiopeptin, tylosin, virginiamycin) (Nagaraja et al., 1987). Antimicrobial 
treatment did not affect the total VFA concentrations in ruminal fluid, except at high 
concentrations of tylosin and virginiamycin when there was a reduction in the total VFA 
concentration (Nagaraja et al., 1987). In addition, there was an increase in the proportion of 
acetate at high concentrations (greater than 6 (ig/ml) of tylosin, monensin, virginiamycin and 
thiopeptin, in ruminal fluid in vitro (Nagaraja et al., 1987). Lasalocid, monensin and 
thiopeptin reduce lactate production and enhance lactate utilization in the rumen and are 
effective in treating ruminal lactic acidosis (Muir et al., 1980, Nagaraja et al., 1982). 
Nagaraja et al. (1987) reported that narasin and salinomycin were the most effective 
enhancers of propionate production in ruminal fluid in vitro, and that the ionophore 
compounds produced a greater inhibition of butyrate production than the non-ionophore 
compounds. In bovine ruminal fluid in vitro, administration of chloral hydrate, chloroform 
or triethanol reduced acetate, propionate and butyrate production and increased lactate 
production, and chloroform and chloral hydrate inhibited methane production (Amgarten et 
al., 1981). The reduction in total VFA production appeared to be due to inhibition of the 
reductive pathway leading from lactate to propionate, resulting in an accumulation of lactate 
and a reduction in propionate concentrations.
1.25 The effects o f  the gastrointestinal tract on drug absorption
Drugs, chemicals, food substances and other factors may prevent an antimicrobial agent 
from reaching the systemic circulation following oral administration (Powers and Mercer,
1980). Chemical and physical binding and interactions of drugs occur in the gastrointestinal 
lumen and these alter the rate of transport or rate of metabolism of inactive compounds. This 
may result in an increase or a reduction in drug transport.
In man, under controlled conditions, there was a range of drug absorption following oral 
administration due to variations in gastrointestinal factors, e. g. gastric pH, rate of gastric 
emptying, gastrointestinal motility, transit time and the area of mucosa available for 
absorption (Macleod et al., 1974). Following oral antimicrobial administration, the presence
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of food in the gastrointestinal tract affects drug absorption profoundly, due to either chemical 
interactions between the ingesta and the drug, or physiological alterations in the intestinal 
tract due to the presence of food (Bogan et al., 1984, Watson, 1986). Cellulose has a high 
capacity for drug binding and, in the horse feeding reduced the systemic availability of 
trimethoprim and phenylbutazone (Bogan et al., 1984, Bogan and Marriner, 1987). In 
addition, the pH of the gastrointestinal tract is affected by feeding and is less acid when the 
digesta volume is largest. The presence of gastric ingesta influences the absorption of 
penicillin V in man and the dog (Ducharme et al., 1983). In the equine, Wilson etal. (1985) 
noted that the absorption of cefadroxil monohydrate was poor and inconsistent. Ampicillin is 
absorbed poorly following oral administration to calves (Ziv and Horsey, 1979). Inefficient 
absorption and high concentrations of an antimicrobial agent remaining in the gastrointestinal 
lumen following oral administration may lead to disruption of the gastrointestinal microflora. 
However, the absorption of some agents is improved by the presence of food. The presence 
of bran strongly increased the intestinal absorption of chloramphenicol palmitate and it was 
suggested that the improved absorption may be due to more rapid intestinal hydrolysis of the 
drug by the increased activity of pancreatic lipase on bran (Bueno etal., 1984).
The microorganisms in the rumen and the intestine may metabolize and inactivate certain 
antimicrobial agents. For example, chloramphenicol is absorbed very well following oral 
administration to dogs, cats, horses and pigs, but it has no therapeutic activity in the 
ruminant due to breakdown by ruminal microorganisms (Powers and Mercer, 1980). 
Virginiamycin is metabolized extensively, resulting in a reduction in antimicrobial activity, in 
bovine ruminal fluid in vitro (Gottschall et al., 1988). In the horse, microbial activity in 
response to feeding could affect daig availability (Bogan et al., 1984). In addition, bacterial 
fermentation in the caecum may release drug bound to cellulose, or a drug may be destroyed 
by microbial metabolism (Bogan et al., 1984).
31
Aims
This project set out to examine the disposition of four antimicrobial agents in Equidae, with 
particular reference to the interactions with the gastrointestinal microflora. The plasma 
disposition and pharmacokinetics were studied following intravenous administration of 
penicillin G, ampicillin, amikacin and oxytetracycline to horses, ponies and donkeys and the 
caecal disposition was examined, in ponies with cannulated caecal fistulas, following 
intravenous and oral drug administration. Serial samples of caecal liquor or faecal material 
underwent bacteriological examinations to enumerate the commensal microflora and to detect 
the presence of pathogenic bacteria. Gastrointestinal fermentation was monitored, prior to 
and following antimicrobial administration, by measurement of caecal luminal pH and caecal 
and faecal SCFA concentrations. The presence or absence of diarrhoea was assessed by 
estimating faecal dry matter content and by observing and recording faecal consistency. The 
development of clinical signs, such as depression and anorexia, were recorded. Factors that 
may affect the systemic availability of an orally administered drug were studied in vitro. 
Antimicrobial agents were incubated in caecal contents in an anaerobic environment as a 
means of studying intra-caecal drug destruction or binding and in vitro alterations in SCFA 
concentrations. In addition, antimicrobial agents were incubated in buffer at gastric pH to 
determine the percentage of an agent remaining following passage through the stomach. In 
vitro studies of the binding of antimicrobial agents to hay at gastric and small intestinal pH 
were carried out.
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2 Materials and Methods
2.1 Animals
Six thoroughbred horses (5 geldings and 1 mare) (numbers 1-6), aged 7-22 years, and 
weighing 489-613 kg, were used. Seven ponies (2 geldings and 5 mares) (numbers 7-13), 
aged 5-20 years and weighing 161-386 kg, were used. Four donkeys, (1 stallion and 3 
mares) (numbers 14-17), aged 2-20 years, and weighing 161-213 kg, were used. In 
addition, 3 pony mares (numbers I-III), with caecal fistulas, aged 5-6 years and weighing 
198-260 kg were used.
M anagement
All animals were housed in stable accommodation for at least 3 days prior to and during the 
experimental procedures. Ponies with caecal fistulas were housed at all times. Animals were 
fed hay twice daily (0900 h and 1600 h approximately), no concentrate feed was given. 
Water was available ad libitum.
2.2 Antimicrobial agents
Penicillin G (benzylpenicillin sodium BP, Crystapen 600 mg, Glaxo Laboratories Limited, 
Greenford, U. K.) dissolved in 4 ml water (sterile pyrogen-free water for injections, 
Animalcare Limited, York, U. K.) was used for both intravenous and oral administration.
Ampicillin (ampicillin sodium B. P. (Vet.), Penbritin™ veterinary injectable 2 g, Beecham 
Animal Health, Brentford, U. K.) was dissolved in 20 ml water for injections and was used 
for intravenous and oral administration.
Amikacin (amikacin sulphate, 250 mg/ml, Amiglyde-V, Fort Dodge Laboratories Inc, Iowa, 
U. S. A., Willows Francis Limited, Crawley, U. K.) was used for both intravenous and 
oral administration.
Oxytetracycline (oxytetracycline hydrochloride Ph Eur, 100 mg/ml, Terramycin* Q-100 
injectable solution, Pfizer Limited, Sandwich, U. K.) was used for intravenous 
administration. Oxytetracycline (oxytetracycline hydrochloride, 200 g/kg, in a water soluble 
base, Terramycin* soluble powder concentrate 20%, Pfizer Limited, Sandwich, U. K.) 
dissolved in approximately 150 ml sterile water, was used for oral administration.
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2.3 Antimicrobial agent administration  
Intravenous drug administration
Slow (30-90 s depending on injection volume) intravenous injection was via a sterile needle 
(Microlance 25 mm long, 0.9 mm diameter, Becton-Dickinson, Dublin, Ireland) into a 
jugular vein. Prior to injection, some blood was drawn into the syringe containing the drug 
to check that the needle was lying in the lumen of the vein and not against the vessel wall. 
During injection, blood was drawn into the syringe 3-6 times (depending on injection 
volume) to check that the needle was still in a suitable position in the vein.
Penicillin G, ampicillin and oxytetracycline were administered at a dose rate of 10 mg/kg 
bwt. Amikacin was administered at a dose rate of 6 mg/kg bwt.
Oral drug administration
Oral drug administration was via a clean nasogastric tube (3 m long, 15 mm diameter, Vet 
Drug Company pic, Falkirk, U. K.). The nasogastric tube was warmed and softened by 
placing in a bucket of hot (40-50 °C) tap water for 5-10 min and the first 15 cm 
(approximately) of the end of the tube to be inserted into a nostril was lubricated (Lubrel, 
Arnolds Veterinary Products, Romford, U. K.). The lubricated end of the nasogastric tube 
was inserted into the medial aspect of the right nostril, taking care to avoid the false nostril, 
and pushed gently along the nasal passage with the animal's neck maintained in flexion. The 
progression of the tube was halted, in the region of the epiglottis, until swallowing occurred 
at which time the tube was fed gently down the oesophagus into the stomach. Prior to 
nasogastric intubation the tube was held on the outside of the animal to correspond with its 
direction of passage and the desired length was marked in indelible ink on the exterior of the 
nasogastric tube. Correct positioning of the tube was confirmed by blowing gently down the 
tube and listening for gurgling sounds, which indicated that tube was lying in the stomach. 
If nothing happened when the position of the nasogastric tube was checked then it was 
withdrawn slightly (5-10 cm) and the test repeated in case the tube had become kinked or the 
end blocked, e. g. by lying against the stomach wall. The drug solution was poured 
carefully into the rostral end of the tube and the tube end was held up at arm's length. The 
drug solution was followed by approximately 200 ml of cold tap water. Any fluid remaining 
in the tube was expelled into the stomach by gentle blowing. The tube was withdrawn 
slowly to allow any fluid remaining to trickle out into the oesophagus.
Penicillin G, ampicillin and oxytetracycline were administered at a dose rate of 10 mg/kg 
bwt. Amikacin was administered at a dose rate of 6 mg/kg bwt.
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2.4 Caecal fistulation technique  
A nim als
One pony mare, aged 5 years and weighing 260 kg was fistulated, prior to the 
commencement of the present studies, using a procedure similar to the one outlined below, 
and was acquired with the caecal fistula in situ. Two pony mares aged 5 years and weighing 
230 and 256 kg were selected for a two stage caecal fistulation procedure similar to that 
described by Boyd (1985). Prior to general anaesthesia, the animals were starved overnight 
(approximately 18 h ) to reduce the volume of the intestinal contents. In addition, the hair 
was clipped from an area between the spine and ventral midline, and between the femur and 
the thirteenth rib.
A naesthesia
Intravenous drug administration was via an intravenous cannula (Vygon Intraflon 2, 80 mm 
long, 2.1 mm diameter, Vet Drug Company pic, Falkirk, U. K.) placed in the right jugular 
vein. Prior to cannulation, the hair in the jugular groove region of the neck was clipped and 
the area cleaned. Local anaesthesia of the area was produced by subcutaneous injection of 
approximately 2 ml of lignocaine hydrochloride solution (30 mg/ml, Lignocaine-A Injection, 
Univet Limited, Bicester, U. K.) into the area where the cannula was to be inserted. A small 
skin incision (approximately 5 mm) was made with a sterile scalpel blade, and the 
intravenous cannula was inserted through the skin incision into the jugular vein, and a three- 
way tap (Vet Drug Company pic, Falkirk, U. K.) attached in the closed position. Prior to 
insertion, the cannula and three-way tap were flushed with a small volume (3-5 ml) of 
heparinized saline (4 units per ml, 0.25 ml heparin sodium injection BP (mucous) (1000 
units per ml, Evans, Langhurst, U. K.) diluted in 500 ml of sterile normal saline 
(Aquapharm 0.9% w/v sodium chloride intravenous infusion BP, Animalcare Limited, 
York, U. K.). The cannula and three-way tap were held in position by suturing to the skin 
of the neck.
In each instance, the animal was premedicated by intravenous administration of xylazine (20 
mg/ml, Rompun, Bayer UK Limited, Bury St Edmunds, U. K.) at a dose rate of 1.1 mg/kg 
bwt. Two minutes after xylazine administration, general anaesthesia was induced by 
intravenous administration of ketamine hydrochloride (100 mg/ml, Vetalar, Parke, Davis 
and Company, Pontypool, U. K.) at a dose rate of 2.2 mg/kg bwt. After induction of 
general anaesthesia, the animal was intubated with an endotracheal tube (18 or 20 mm 
diameter) and general anaesthesia was maintained using 2-4% halothane (Fluothane*,
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Coopers Pitman-Moore, Crewe, U. K.) in oxygen (BOC, Glasgow, U. K.) at a flow rate of 
4-6 1/min.
Postoperative analgesia was maintained by intramuscular administration of pethidine 
hydrochloride (50 mg/ml, Arnolds Veterinary Products, Romford, U. K.) at a dose rate of 2 
mg/kg bwt, intravenous administration of flunixin meglumine (Finadyne* solution, 50 
mg/ml, Schering-Plough Animal Health, Mildenhall, U. K.) at a dose rate of 1.1 mg/kg bwt 
or intravenous administration of butorphanol tartrate (Torbugesic, 10 mg/ml, C-Vet Limited, 
Bury St Edmunds, U. K.) at a dose rate of 1.1 mg/kg bwt.
Cannula design
The cannula was based on the design described by Simmons and Ford (1988). Unlike their 
design the cannula was T  shaped and split in two lengthwise, to allow the insertion of the 
2 'L' shaped halves (a semicylindrical limb (80 mm long, 25 mm diameter, 15 mm id) 
angled at approximately 120 ° to the threaded cannula stem (120 mm long, 25 mm diameter, 
15 mm id)) through a small incision in the caecal wall. The cannula was held in place by two 
rings (80 mm diameter with 25 mm diameter hole in centre) which were screwed onto the 
threaded stem of the cannula until secure against the flank of the animal. The flank was 
protected by a piece of rubber which was cut to the same size and shape as the securing 
rings. The cannula and rings were made out of solid plastic. The cannula design is shown in 
Figure 2-1.
Caecal fistulation
After induction of general anaesthesia, the animal was placed in left lateral recumbency with 
its hind limbs supported and tied in extension. After suitable preoperative preparation, a 
vertical incision, approximately 20 cm long, was made in the right flank midway between 
the spine and ventral midline and between the last rib and the ipsilateral hind limb. The 
caecum was localised within the abdomen by palpation of the characteristic four longitudinal 
muscular bands (Nickel et al., 1979) and was orientated so that part of the caecal wall could 
be sutured onto the abdominal wall. The caecum was attached to the abdominal musculature 
by a double ring (approximately 3 cm diameter) of non-absorbable sutures (simple 
interrupted pattern, Prolene 1, Vet Drug Company pic, Falkirk, U. K.). A similar pattern of 
absorbable sutures (Vicryl 0, Vet Drug Company pic, Falkirk, U. K.) was used to appose 
the muscular layers of the dorsal V2_^ /3 of the incision. The dorsal V2~^/3 of the skin 
incision was closed using non-absorbable sutures (Prolene 1, Vet Drug Company pic) in a 
simple interrupted pattern. The animal was allowed to recover from the anaesthetic and the 
flank wound was allowed to heal. The flank wound was bathed with sterile normal saline 
(Aquapharm 0.9% w/v sodium chloride intravenous infusion BP, Animalcare Limited,
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Figure 2-1. Caecal cannula design
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York, U. K.), and the skin stitches were removed after 7-10 days. Antimicrobial therapy 
was maintained for 7 days with ampicillin sodium (Penbritin, Beecham Animal Health, 
Tadworth, U. K.) at a dose rate of 10 mg/kg bwt every 12 h. Figure 2-2a shows an animal 
10 days after the first stage of the caecal fistulation procedure.
The second stage was carried out 4-6 weeks after the first stage. The animal was 
anaesthetized, and placed in left lateral recumbency. After suitable pre-operative preparation, 
approximately 5 cm of the ventral aspect of the original incision site was incised carefully 
until the caecal wall was located. A small (2-3 cm) 'X' shaped incision was made in the 
caecal wall and the 2 'L' shaped halves of the cannula inserted. The 2 halves of the cannula 
were held together and the end of the resultant cannula was plugged with a swab to prevent 
leakage of the caecal contents. The cannula was put under slight lateral tension and sutures 
(where required) were put in to appose the exposed abdominal muscle and skin layers. The 
rubber protective ring and the 2 plastic rings were screwed onto the cannula stem to hold it 
in place loosely against the animal's flank, the swab was removed, and the cap was screwed 
on. The animal was allowed to recover from the anaesthetic and the flank wound was 
allowed to heal. Post-operative care was the same as in the first stage of the procedure. On a 
daily basis, the flank skin proximal to the cannula was bathed to remove debris and was 
protected from damage, caused by the leakage of caecal fluid, by the liberal application of 
white soft paraffin BP (Vet Drug Company pic, Falkirk, U. K.) until healing was complete.
The flank wound healed by granulation until there was little or no leakage around the 
cannula. Once healing was complete, the area around the cannula was kept clean by washing 
with tap water, when required. Hair was clipped from the flank in the region of the cannula 
when necessary. The cannula was left in place for 4-6 weeks prior to the start of 
experimental procedures. Figure 2-2b shows an animal 8 weeks after the second stage of the 
caecal fistulation procedure.
2.5 Sam pling techniques and sample preparation 
Blood Sam pling Technique
Blood, for drug analysis and plasma biochemistry, was collected from a jugular vein into 10 
ml lithium heparin syringes (Li-Heparin LH/10 Monovette®, Sarstedt Limited, 
Loughborough, U. K.) using a sterile needle (Microlance, 25 mm long, 0.9 mm diameter, 
Becton-Dickinson, Dublin, Ireland). Blood, for haematological examinations, was collected 
in a similar manner into 5 ml potassium ethylenediaminetetracetic acid syringes (K-EDTA, 
Monovette®, Sarstedt Limited).
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Figure 2-2a. The flank of an animal 10 days after the first stage o f the caecal fistulation 
procedure
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Figure 2-2b. The flank of an animal 8 weeks after the second stage o f the caecal fistulation 
procedure
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Intestinal fluid sampling technique
Samples of caecal liquor were taken by removing the cap from a caecal cannula. The cannula 
was cleared and an aliquot of caecal liquor was removed using a piece of clean polythene 
tubing of approximately 1 cm in diameter. Caecal liquor was collected into a clean glass 
universal container with a screw top.
Faecal sampling technique
Faecal samples were taken from the rectum using adequate lubricant gel (Lubrel, Arnolds 
Veterinary Products, Romford, U. K.) applied to a gloved (Nublu Arm-length disposable 
gloves, Arnolds Veterinary Products, Romford, U. K.) hand. The samples were placed 
directly into faecal cartons with lids (Bettercater Limited, Edinburgh, U. K.).
Sample Preparation
After collection, blood samples in lithium heparin tubes were centrifuged at 1800 g for 10 
min in a cooled (5-15 °C) centrifuge (MSE Chilspin, M. S. E. Scientific Instruments, 
Crawley, U. K.). Plasma was decanted into 10 ml neutral tubes (Sarstedt Limited, 
Loughborough, U. K.) and stored at either 4 °C overnight until analysed by bioassay for 
penicillin G, ampicillin, amikacin or oxytetracycline, or at -20 *C until analysed by HPLC 
for oxytetracycline. The samples for plasma biochemistry were submitted for analysis on the 
day of collection. The samples for haematological examination were mixed well and 
submitted for analysis on the day of collection. Caecal liquor samples were decanted into 10 
ml neutral tubes and stored at 4 *C until drug analysis, and then at -20 °C until analysis for 
SCFA content. Faecal samples were stored in faecal cartons in a similar manner to caecal 
liquor.
The samples for the bioassay were analysed as soon as possible after the experiments took 
place (within approximately 2 days). Standard plasma, caecal liquor or faecal samples were 
made on the day of the experiment and stored along with the unknown samples. Other 
analyses were carried out as soon as possible (within 14 days of sampling where possible).
2.6 General solutions
All water, unless stated otherwise, was distilled in the presence of potassium permanganate.
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Hydrochloric acid solution (0.2 M)
The solution was made from 20 ml of a stock solution of 1 M hydrochloric acid (50 ml 10 M 
hydrochloric acid (Convol®, The British Drug House Chemicals Limited) in 500 ml water) 
diluted to 100 ml with water.
Potassium dihydrogen orthophosphate solution (0.2 M)
The solution was made from 27.22 g potassium dihydrogen orthophosphate (FW 136.09 g, 
The British Drug House Chemicals Limited, Poole, U. K.) dissolved in 1 1 water.
Sodium hydroxide solution (0.2 M)
The solution was made from 8 g of sodium hydroxide (FW 40 g, pellets pure analytical 
reagent, Koch-Light Limited, Haverhill, U. K.) dissolved in 11 water.
! Sodium hydroxide solution (1 M)
S The solution was made from 40 g of sodium hydroxide dissolved in 1 1 water.
t
Potassium hydroxide solution (10 M)
|
i
The solution was made from 56.11 g (FW 56.11 g, Analar®, The British Drug House
| Chemicals Limited) dissolved in 100 ml water.
|
Potassium chloride solution (0.2 M)
The solution was made from 14.91 g potassium chloride (FW 74.55 g, The British Drug 
House Chemicals Limited) dissolved in 1 1 water.
Phosphate buffer (0.05 M, pH 7.0)
Stock phosphate buffer solution (0.05 M, pH 7.0) was made from 250 ml of 0.2 M 
potassium dihydrogen orthophosphate and 148 ml of 0.2 M sodium hydroxide, made up to 
11 with water.
Phosphate buffer (0.05 M, pH 8.0)
Stock phosphate buffer solution (0.05 M, pH 8.0) was made from 250 ml of 0.2 M 
potassium dihydrogen orthophosphate and 234 ml of 0.2 M sodium hydroxide, made up to 
11 with water.
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Phosphate buffer (0.05 M, pH 4.5)
Stock phosphate buffer solution (0.05 M, pH 4.5) was made from 250 ml of 0.2 M 
potassium dihydrogen orthophosphate, made up to 1 1 with water and with the pH adjusted 
using 10 M potassium hydroxide.
Chloride buffer (0.02 M, pH 1.9)
Stock chloride buffer solution (0.02 M, pH 1.9) was made from 50 ml 0.2 M potassium 
chloride and 50 ml 0.2 M hydrochloric acid diluted in 1 1 with water.
The pH of the buffer solutions was checked using a digital pH/temperature meter (Fisons 
Scientific Equipment, Loughborough, U. K.). The pH meter was calibrated to pH 7.0 using 
pH 4.0 and pH 7.0 buffer (±0.01 at 20°C, The British Drug House Chemicals Limited, 
Poole, U. K.). The pH meter was calibrated between measurements, after washing with 
deionized water (Ionmiser, Model 2C, Houseman Hegro, Slough, U. K.) and blotting dry.
2.7 M easurement of antibiotics by agar gel diffusion assay
A bioassay similar to that described by Bennett et al. (1966) was used to measure penicillin 
G, amikacin, ampicillin and oxytetracycline in equine plasma, caecal liquor and faeces.
Spore preparation
Vials of ATCC spore cultures (1 ml per vial, Bacto®, Difco Laboratories Limited, East 
Molesey, U. K.) were stored at 4 °C until required. The contents of a vial of spore culture 
were diluted in approximately 19 ml of sterile normal saline (0.9% w/v sodium chloride 
dissolved in water) in a glass universal bottle. The resultant diluted spore suspension was 
stored at 4 °C until required.
Preparation of sterile growth medium
Agar, of a suitable pH for the antibiotic assay and for the growth of the chosen test 
organism, was dissolved in hot tap water at the recommended concentration in a 2 1 glass 
conical flask. The mixture was stirred with a glass stirring rod, the top of the flask covered 
with aluminium foil to prevent excessive evaporation and the flask placed in a steamer (100 
*C, Laboratory Thermal Equipment, Oldham, U. K.) for 90 min or until the mixture was 
clear, and the contents stirred occasionally. The agar was divided into aliquots of 
approximately 310 ml using a glass 500 ml measuring cylinder, and poured into 500 ml 
clean glass screw cap bottles. The bottles were capped loosely and sterilized in an autoclave 
(Autoclave 290EH, Harvard Apparatus and Instrument Services, Oldham, U. K.) for 15
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min at 121 *C and 825 mm Hg, allowed to cool, the caps tightened, and stored at 4 *C until 
required.
Test of spore suspension concentration
Test plates were used to assess the concentration of the spore suspension which was needed 
to obtain a suitable colony density after incubation. A known volume of diluted spore 
suspension was added to each of six aliquots of the desired growth medium (Table 2-1). 
The resultant seeded agar was poured immediately into clean plastic petri dishes (90 mm 
diameter, triple vent, Greiner Labortechnik Limited, Dursley, U. K.), the lids replaced and 
the agar allowed to set (around 30 min at room temperature (20 *C)). Once the agar had 
cooled and solidified, a single 9 mm well was made in the centre of each plate and filled with 
a suitable standard solution.
There was no growth of Bacillus spp. at 0% spore suspension showing that no bacterial 
contamination of sterile agar or pipette tips had occurred. At 0.05% and 0.1% spore 
suspension, separate colonies were evident after incubation, and a zone of inhibition was 
present around the standard filled well but the edge of the zone was indistinct. The most 
satisfactory percentage of diluted spore suspension was 0.33% (/. g. 1 ml diluted spore 
suspension per 300 ml agar). This concentration of diluted spore suspension produced a 
confluent lawn of colonies whilst still leaving a clear, well defined zone of inhibition around 
the well containing the antibiotic standard solution. At 0.5 and 1.0% spore suspension the 
growth of the bacterial lawn was thicker and, although the inhibition zone was defined 
clearly, there was some reduction in the diameter of the inhibition zone.
Stock sterile buffer solutions
Penicillin G and ampicillin were dissolved in phosphate buffer (0.05 M, pH 7.0). Amikacin 
was dissolved in phosphate buffer (0.05 M, pH 8.0). Oxytetracycline was dissolved in 
phosphate buffer (0.05 M, pH 4.5). Buffer was divided into aliquots of approximately 500 
ml, poured into clean 500 ml glass screw cap bottles, capped loosely, and sterilized in an 
autoclave for 15 min at 121 *C and 825 mm Hg (Autoclave 290EH, Harvard Apparatus and 
Instrument Services, Oldham, U. K.). After sterilizing, the screw caps were tightened and 
the buffer stored at 4 °C until required.
Standard solutions
On the day of assay, a 200 p.g/ml standard solution was made by weighing 0.02 g of 
standard compound and dissolving it in a suitable sterile stock buffer solution, in a clean 100 
ml glass volumetric flask, to a produce a final volume of 100 ml. A 20 ^g/ml standard was
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% diluted spore 
suspension
Agar
(ml)
Volume diluted spore 
suspension (|il)
0 20 0
0.05 20 10
0.1 20 20
0.33 20 66
0.5 20 100
1.0 20 200
Table 2-1. Test of diluted spore suspension concentration used for agar gel diffusion assay
Plasma/caecal liquor 
concentration (pg/ml)
Stock standard solution 
(volume and concentration)
Plasma or caecal liquor 
volume (pi) (or 1 g faeces)
0 0 1
0.25 12.5 pi of 20 pg/ml 987.5
0.5 25 pi of 20 pg/ml 975
1 50 pi of 20 pg/ml 950
2 100 pi of 20 pg/ml 900
4 20 pi of 200 pg/ml 980
5 25 pi of 200 pg/ml 975
8 40 pi of 200 pg/ml 960
10 50 pi of 200 pg/ml 950
20 100 pi of 200 pg/ml 900
25 125 pi of 200 pg/ml 875
40 200 pi of 200 pg/ml 800
50 250 pi of 200 pg/ml 750
80 400 pi of 200 pg/ml 600
100 500 pi of 200 pg/ml 500
Table 2-2. Standard plasma, caecal liquor and faecal concentrations of antimicrobial drugs 
for agar gel diffusion assay
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made by taking 10 ml, by glass bulb pipette, of the 200 |ig/ml standard and diluting it to 100 
ml with a suitable volume of sterile stock buffer solution in a clean glass volumetric flask.
Standards for the assay of unknown equine plasma and equine caecal liquor samples were 
prepared in drug-free equine plasma or drug-free equine caecal liquor using the 200 and 20 
|ig/ml stock standards described above. A range of plasma or caecal liquor standards was 
constructed to encompass the range of likely plasma or caecal liquor concentrations (Table 2- 
2). Plasma or caecal liquor was measured into 10 ml clean neutral tubes (Sarstedt Limited, 
Loughborough, U. K.), the required volumes of stock standard solution was added to each 
tube, a plastic push-in stopper (Sarstedt Limited) put in each tube and the plasma or caecal 
liquor and stock standard solutions mixed for approximately 10 s using a Griffin vortex 
shaker/stirrer (Griffin and George Limited, Loughborough, U. K.). Standards for assay of 
equine faecal samples were prepared in drug-free equine faeces using the 200 and 20 fig/ml 
stock standards. A range of faecal standards were constructed to encompass the range of 
likely faecal concentrations (Table 2-2). Faecal material was weighed into aliquots of 1 g and 
put into 10 ml clean neutral tubes. The required volume of stock standard solution was 
added to each tube and 3 ml of sterile phosphate buffer (0.05 M, pH 7.0) was added to each 
sample and a plastic push-in stopper put into each tube. The samples were then mixed using 
a Griffin vortex shaker/stiiTer for 30 s and centrifuged for 15 min at 1800 g. The supernatant 
from each sample was put into the appropriate wells on agar plates.
Preparation of assay plates
The plates for the bioassays consisted of a 30 cm x 30 cm aluminium frame, an aluminium 
lid, a glass plate and 8 spring clips. Clean, dry, cool glass plates were held onto the 
aluminium frames using the spring clips, sterilized by flaming with a Bunsen burner and 
placed on a pre-levelled triangular levelling stand until the agar was poured.
On the day of an analysis the required number of bottles of agar were placed in a water bath 
(Laboratory Thermal Equipment, Oldham, U. K.) at 54 °C until warm (around 1 h) and 
placed in a steamer until liquid (around 1 h) before being allowed to cool. Once the liquid 
agar had cooled to a suitable temperature (around 1 h in a water bath at 54 °C), the required 
amount of diluted spore suspension (1 ml per 300 ml agar) was added. The seeded agar was 
mixed using a gentle swirling motion, i. e. sufficient to mix in the diluted spore suspension 
whilst avoiding air bubble formation, and poured onto the prepared plates in a circular 
pattern. The seeded agar was poured rapidly to avoid too much cooling, and gently enough 
to avoid spilling, and to cover the plate evenly. Any air bubbles formed during the 
mixing/pouring process were removed by piercing with a sterile needle. The lid of the plate
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was replaced as soon as possible. The plates were left at room temperature (20 #C) until the 
agar had cooled and solidified (approximately 45 min).
Holes were punched in the solidified agar using a 9 mm diameter circular metal punch (C. P. 
Instrument Company Limited, Bishops' Stortford, U. K.) in a quasi latin square pattern. A 
64 well plate (8 rows of 8 wells) design was used and this was arranged so that each sample 
only appeared once in each row or column. There were four replicates of each sample. This 
meant that samples were spread randomly over the area of the plate thus allowing for any 
variation in agar depth, pH or temperature. In general, there were 6 standard concentrations 
(/. e. 4 replicates of 6 standard concentrations), and 4 replicates of 10 samples of unknown 
concentration, per plate. A cardboard template, marked with the well pattern for the quasi 
latin square design, was placed directly under the plate. The loosened agar was removed 
using the blunt end of a disposable Pasteur micropipette (Bilbate Limited, Daventry, U. K.) 
attached by rubber tubing to a vacuum pump (Millipore U. K., Watford, U. K.). Waste agar 
was collected in a conical flask placed between the disposable Pasteur micropipette and the 
vacuum pump.
Assay preparation and incubation
A known volume (170 |il) of each standard or sample solution was measured into 4 wells 
using the cardboard quasi latin square template as a guide. A fresh pipette tip was used for 
each standard or sample. Once all the wells on a plate were filled, the lid of the plate was 
replaced gently and the plate placed carefully in an incubator at 30 #C (Gallenkamp Size 3 
Economy incubator with fan, Fisons Scientific Equipment, Loughborough, U. K.) 
overnight (18-21 h).
Reading plates
The plates were removed from the incubator, the lids removed and the plates placed on the 
quasi latin square template. The zones of inhibition were measured using an electronic digital 
calliper (Fowler and NSK Max-cal, C. P. Instrument Company Limited, Bishops' 
Stortford, U. K.) and recorded using a printer (Fowler QC EDP-100, C. P. Instrument 
Company Limited). After reading and recording the 4 zone diameters for each sample, the 
statistics facility on the printer was used to calculate and record the arithmetic mean, 
maximum, minimum, range and SD of each sample.
Calculation of results
A programmable calculator (TI Programmable 59, Texas Instruments, Texas, U. S. A.) was 
used to calculate the concentration of each unknown sample from the mean zone diameter of 
that sample. The zone diameter (mm) was related to the lo g io  of the standard
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concentrations. By entering the logio of the concentration and the mean zone diameter (mm) 
for each standard concentration, a regression line (line of best fit for logio concentration 
versus zone diameter plot) and r was calculated for each plate. The log io  of the 
concentration of an unknown sample was calculated from the regression line, from the 
relevant plate, using the mean zone diameter of that sample, and the concentration was 
calculated by taking the antilogarithm of this number (2 decimal places).
Precision
The precision of each agar gel diffusion assay was assessed using the coefficients of 
variation of the mean zone diameter (mm) of each replicate plate (4 wells per plate), that is 
the sample SD expressed as a percentage of sample mean, of equine plasma, caecal liquor or 
faeces standard samples to which antimicrobial preparation had been added and analysed in a 
single assay (within-day or intra-assay variation) and on different days (between-day or 
inter-assay variation).
Linearity and Sensitivity
A computer programme (Cricket graph version 1.3, Cricket software, Pennsylvania, U. S. 
A.) was used to plot a graph of zone diameter (mm) (mean±SD) versus logio concentration 
(|ig/ml) and to calculate the line of best fit, r and the limit of detection for the replicate plates 
of standard equine plasma, caecal liquor and faecal concentrations used for the method 
validation. The sensitivity of each assay was calculated, from the equation of the line of best 
fit, using a minimum zone diameter of 10 mm.
2.8 Agar gel diffusion assay of penicillin G sodium
A spore suspension of Bacillus subtilis (ATCC 6633) was used as the test organism. The 
test agar used was antibiotic medium 2 (pH 6.6, Bacto®, Difco Laboratories Limited, East 
Molesey, U. K.) at a concentration of 2.55% w/v agar base dissolved in water. Penicillin G 
(benzylpenicillin G sodium salt, Sigma Chemical Company Limited, Poole, U. K.) for 
standard solutions was dissolved in stock sterile phosphate buffer solution (0.05 M, pH 
7.0). Plasma, caecal liquor or faecal standards were made on the day of the experiment.
Precision
The precision of the agar gel diffusion assay of penicillin G sodium in equine plasma was 
good as shown by the low (<6%) values of the within-day and between-day coefficients of 
variation of the zone diameter (mean±SD) of 3 plates analysed in a single assay and 8 plates 
analysed on different days (Table 2-3).
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Concentration
(pg/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n= ll) 0.00 (n=3) 0.00 (n=8)
0.25 23.36±1.22 (n= ll) 1.70 (n=3) 5.94 (n=8)
1 30.17±0.96 (n= ll) 1.79 (n=3) 3.51 (n=8)
5 36.55±1.05 (n= ll) 1.81 (n=3) 3.06 (n=8)
10 39.03±1.24 (n= ll) 2.06 (n=3) 3.55 (n=8)
20 41.01±1.03 (n= ll) 2.30 (n=3) 2.54 (n=8)
40 43.84±0.71 (n= ll) 1.33 (n=3) 1.73 (n=8)
80 46.58±0.95 (n= ll) 0.42 (n=3) 2.36 (n=8)
Table 2-3. Zone diameters and coefficients of variation of penicillin G sodium in equine 
plasma
Concentration
(pg/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n= ll) 0.00 (n=3) 0.00 (n=8)
0.25 22.96±1.06 (n= ll) 5.68 (n=3) 4.24 (n=8)
1 30.40±1.18 (n= ll) 3.42(n=3) 3.65 (n=8)
5 36.52±0.71 (n= ll) 1.91 (n=3) 1.96 (n=8)
10 39.46±0.98 (n= ll) 0.92 (n=3) 2.68 (n=8)
20 42.13±0.98 (n= ll) 1.36 (n=3) 2.48 (n=8)
40 44.24±1.03 (n=8) NS 2.34 (n=8)
80 45.88±1.39 (n=8) NS 3.03 (n=8)
Table 2-4. Zone diameters and coefficients of variation of penicillin G sodium in equine
caecal liquor
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The precision of the agar gel diffusion assay of penicillin G sodium in equine caecal liquor 
was good as shown by the low (<6%) values of the within-day and between-day 
coefficients of variation of the zone diameter (mean±SD) of 3 plates analysed in a single 
assay and 8 plates analysed on different days (Table 2-4).
The precision of the agar gel diffusion assay for penicillin G sodium in equine faeces was 
good as shown by the reasonably low (<13%) values of the between-day coefficients of 
variation of the zone diameter (mean±SD) of 5 plates analysed on different days (Table 2-5).
Linearity and Sensitivity
The linearity of the zone diameters of penicillin G sodium was evaluated from the 11 
replicate plates of standard equine plasma samples and was found to be good (r = 0.996) 
over the concentration range studied (0.25-80 fig/ml) (Figure 2-3). The overall limit of 
detection, 0.01 fig/ml, was calculated from the equation of the line of best-fit, y = 29.59 + 
9.05(logiox).
The linearity of the zone diameters of penicillin G sodium was evaluated from the 11 
replicate plates of standard equine caecal liquor samples and this was found to be good (r = 
0.989) over the concentration range studied (0.25-80 (ig/ml)) (Figure 2-3). The overall limit 
of detection, 0.01 pg/ml, was calculated from the equation of the line of best-fit, y = 29.64 
+ 9.16(logiox).
The linearity of the zone diameters of penicillin G sodium was evaluated from the 5 replicate 
plates of standard equine faecal samples and this was found to be good (r = 0.994) over the 
concentration range studied (0.25-10 pg/ml)) (Figure 2-3). The overall limit of detection, 
0.07 pg/ml, was calculated from the equation of the line of best-fit, y = 23.81 + 
11.83(logiox).
2.9 Agar gel diffusion assay of ampicillin sodium
The agar and test organism used for the bioassay of ampicillin sodium were the same as 
described for penicillin G. Ampicillin (ampicillin sodium salt, Sigma Chemical Company 
Limited, Poole, U. K.) for standard solutions was dissolved in sterile phosphate buffer 
(0.05 M, pH 7.0). Plasma, caecal liquor or faecal standards were made on the day of the 
experiment and stored with the unknown samples at 4 #C.
Precision
The precision of the agar gel diffusion assay of ampicillin sodium in equine plasma was 
good as shown by the low (<8%) values of the within-day and between-day coefficients of
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Concentration Zone diameter (mm) Coefficient of variation (%)
(M-g/ml) (mean±SD) Between-day
0 0.00±0.00 (n=5) 0.00 (n=5)
0.25 16.12±2.04 (n=2) 12.64 (n=2)
1 24.74±1.59 (n=5) 6.41 (n=5)
5 32.04±2.52 (n=5) 7.87 (n=5)
10 35.33±1.85 (n=5) 5.22 (n=5)
Table 2-5. Zone diameters and coefficients of variation of penicillin G sodium G in equine 
faeces
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Figure 2-3. Zone diameters (mean±SD) of penicillin G sodium in equine
plasma, caecal liquor and faeces
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variation of the zone diameter (mean±SD) of 6 plates analysed in a single assay and 8 plates 
analysed on different days (Table 2-6).
The precision of the agar gel diffusion assay of ampicillin sodium in equine caecal liquor 
was good as shown by the low (<10%) values of the within-day and between-day 
coefficients of variation of the zone diameter (mean±SD) of 3 plates analysed in a single 
assay and 8 plates analysed on different days (Table 2-7).
The precision of the agar gel diffusion assay of ampicillin sodium in equine faeces was good 
as shown by the low (<9%) values of between-day coefficients of variation of the zone 
diameter (mean±SD) of 3 plates analysed on different days (Table 2-8).
The precision of the agar gel diffusion assay of ampicillin sodium in phosphate buffer (0.05 
M, pH 7.0) was good as shown by the low (<8%) values of between-day coefficients of 
variation of the zone diameter (mean±SD) of 12 plates analysed on different days (Table 2- 
9).
L inearity  and Sensitivity
The linearity of the zone diameters of ampicillin sodium was evaluated from the 14 replicate 
plates of standard equine plasma samples and this was found to be good (r = 0.992) over the 
concentration range studied (0.25-80 pg/ml) (Figure 2-4). The overall limit of detection, 
0.02 pg/ml, was calculated from the equation of the line of best-fit, y = 25.88 + 
9.01(logiox).
The linearity of the zone diameters of ampicillin sodium was evaluated from the 11 replicate 
plates of standard equine caecal liquor samples and this was found to be good (r = 0.980) 
over the concentration range studied (0.25-80 pg/ml) (Figure 2-4). The overall limit of 
detection, 0.12 pg/ml, was calculated from the equation of the line of best-fit, y = 20.92 + 
11.89(logiox).
The linearity of the zone diameters of ampicillin sodium was evaluated from the 3 replicate 
plates of standard equine faecal samples and this was found to be good (r = 0.993) over the 
concentration range studied (0.5-20 pg/ml) (Figure 2-4). The overall limit of detection, 0.31 
pg/ml, was calculated from the equation of the line of best-fit, y = 16.10 + 12.17(logiox).
The linearity of zone diameters of ampicillin sodium was evaluated from the 12 replicate 
plates of standard phosphate buffer (0.05 M, pH 7.0) samples and this was found to be 
good (r = 0.987) over the concentration range studied (0.25-100 pg/ml) (Figure 2-4). The
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Concentration
(lig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n=14) 0.00 (n=6) 0.00 (n=8)
0.5 22.22±1.31 (n= ll) 2.99 (n=6) 7.10 (n=5)
2 29.31±1.69 (n= ll) 2.84 (n=6) 7.28 (n=5)
5 32.49±1.87 (n=14) 1.81 (n=6) 6.93 (n=8)
10 35.51±1.77 (n=14) 1.53 (n=6) 5.94 (n=8)
20 37.75±1.78 (n=14) 1.44 (n=6) 5.71 (n=8)
40 40.06±1.64 (n=14) 1.97 (n=6) 4.59 (n=8)
80 42.44±1.82 (n= ll) 2.10 (n=6) 5.07 (n=5)
Table 2-6. Zone diameters and coefficients of variation of ampicillin sodium in equine 
plasma
Concentration
(tig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n= ll) 0.00 (n=3) 0.00 (n=8)
0.5 15.57±1.31 (n=7) 5.62 (n=3) 9.04 (n=4)
1 21.10±1.20 (n= ll) 3.13 (n=3) 5.36 (n=8)
5 31.29±1.98 (n= ll) 4.37 (n=3) 6.95 (n=8)
10 33.81±1.60 (n= ll) 3.15 (n=3) 5.24 (n=8)
20 36.93±1.77 (n= ll) 3.47 (n=3) 5.24 (n=8)
40 39.40±0.94 (n=4) NS 2.38 (n=4)
80 42.07±1.07 (n=7) 2.18 (n=3) 2.61 (n=4)
Table 2-7. Zone diameters and coefficients of variation of ampicillin sodium in equine caecal
liquor
53
Concentration
(lig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of variation (%) 
Between-day
0 0.00±0.00 (n=3) 0.00 (n=3)
0.5 11.9510.97 (n=3) 8.15 (n=3)
1 16.4211.20 (n=3) 7.34 (n=3)
5 24.7711.31 (n=3) 5.30 (n=3)
10 29.1011.37 (n=3) 4.71 (n=3)
20 31.0910.96 (n=3) 3.09 (n=3)
Table 2-8. Zone diameters and coefficients of variation of ampicillin sodium in equine faeces
Concentration
(tig/ml)
Zone diameter (mm) 
(meaniSD)
Coefficient of Variation (%) 
Between-day
0 0.0010.00 (n=12) 0.00 (n=12)
0.5 18.3811.44 (n=4) 7.82 (n=4)
2 25.6010.75 (n=4) 2.93 (n=4)
5 28.7611.06 (n=4) 3.67 (n=4)
10 32.9011.74 (n=9) 5.30 (n=9)
20 33.5710.81 (n=4) 2.40 (n=4)
25 37.0911.60 (n=8) 4.31 (n=8)
50 39.5810.27 (n=8) 3.22 (n=8)
100 41.5911.36 (n=8) 3.26 (n=8)
Table 2-9. Zone diameters and coefficients of variation of ampicillin sodium in phosphate 
buffer
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Figure 2-4. Zone diameters (mean±SD) of ampicillin sodium in equine 
plasma, caecal liquor, faeces and phosphate buffer
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overall limit of detection, 0.07 pg/ml, was calculated from the equation of the line of best- 
fit, y = 21.95 + 10.11 (log i ox).
2.10 Agar gel diffusion assay of amikacin sulphate
The agar used was the same as for penicillin G and ampicillin except that the pH of the agar 
was increased, from 6.6 to 7.9, by adding 5 ml of 1 M sodium hydroxide per 1 prior to 
sterilization. The test organism used was Bacillus subtilis (ATCC 6633). Amikacin 
(amikacin sulphate, Fort Dodge Laboratories Inc., Iowa, U. S. A., Willows Francis 
Limited, Crawley, U. K.) for standard solutions was dissolved in sterile phosphate buffer 
(0.05 M, pH 8.0). Plasma, caecal liquor or faecal standards were made on the day of the 
experiment.
Precision
The precision of the agar gel diffusion assay of amikacin sulphate in equine plasma was 
good as shown by the low (<9%) values of the within-day and between-day coefficients of 
variation of the zone diameter (mean±SD) of 4 plates analysed in a single assay and 8 plates 
analysed on different days (Table 2-10).
The precision of the agar gel diffusion assay of amikacin sulphate in equine caecal liquor 
was good as shown by the low (<10%) values of the within-day and between-day 
coefficients of variation of the zone diameter (mean±SD) of 4 plates analysed in a single 
assay and 6 or 8 plates analysed on different days (Table 2-11).
The precision of the agar gel diffusion assay of amikacin sulphate in equine faeces was good 
as shown by the low (<10%) values of the between-day coefficients of variation of the zone 
diameter (mean±SD) of 3 or 4 plates analysed on different days (Table 2-12).
Linearity and Sensitivity
The linearity of the zone diameters of amikacin sulphate was evaluated from the 12 replicate 
plates of standard equine plasma samples and this was found to be reasonably good (r = 
0.982) over the range of concentrations studied (0.25-80 pg/ml) (Figure 2-5). The overall 
limit of detection, 0.02 pg/ml, was calculated from the equation of the line of best-fit, y = 
22.73 + 7.09(logiox).
The linearity of the zone diameters of amikacin sulphate was evaluated from the 12 replicate 
plates of standard equine caecal liquor samples and this was found to be reasonably good (r 
= 0.970) over the concentration range studied (0.25-80 pg/ml)) (Figure 2-5). The overall
c
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Concentration
(tig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n=12) 0.00 (n=4) 0.00 (n=8)
0.25 17.16±1.23 (n=12) 3.33 (n=4) 8.58 (n=8)
1 23.71±1.06 (n=12) 3.72 (n=4) 4.71 (n=8)
5 28.44±1.67 (n=12) 3.53 (n=4) 6.17 (n=8)
10 30.46±1.83 (n=12) 4.58 (n=4) 5.86 (n=8)
20 31.92±1.80 (n=12) 3.56 (n=4) 5.63 (n=8)
40 33.91±2.17 (n=8) 4.49 (n=3) 6.20 (n=5)
80 35.38±2.46 (n=8) 2.76 (n=3) 6.72 (n=5)
Table 2-10. Zone diameters and coefficients of variation of amikacin sulphate in equine 
plasma
Concentration
(tig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n=12) 0.00 (n=4) 0.00 (n=8)
0.25 16.08±1.64 (n=12) 4.33 (n=4) 9.56 (n=8)
1 22.68±1.29 (n=12) 3.78 (n=4) 6.25 (n=8)
5 29.52±1.85 (n=12) 1.74 (n=4) 6.47 (n=8)
10 31.00±1.63 (n=12) 3.82 (n=4) 5.37 (n=8)
20 33.03±1.59 (n=12) 2.25 (n=4) 5.81 (n=8)
40 34.76±2.01 (n=10) 1.56 (n=4) 6.83 (n=6)
80 35.61±1.74 (n=10) 1.12 (n=4) 5.78 (n=6)
Table 2-11. Zone diameters and coefficients of variation of amikacin sulphate in equine 
caecal liquor
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Concentration Zone diameter (mm) Coefficient of variation
(M-g/ml) (mean±SD) Between-day
0 0.00±0.00 (n=4) 0.00 (n=4)
1 15.90±1.11 (n=3) 6.98 (n=3)
5 18.87±1.47 (n=4) 7.78 (n=4)
10 21.99±2.10 (n=4) 9.56 (n=4)
20 23.64±1.57 (n=4) 6.63 (n=4)
Table 2-12. Zone diameters and coefficients of variation of amikacin sulphate in equine 
faeces
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Figure 2-5. Zone diameters (mean±SD) of amikacin sulphate in equine 
plasma, caecal liquor and faeces
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limit of detection, 0.03 |ig/ml, was calculated from the equation of the line of best-fit, y =
22.31 + 7.88(logiox).
The linearity of the zone diameters of amikacin sulphate was evaluated from the 4 replicate 
plates of standard equine faecal samples and this was found to be reasonably good (r = 
0.968) over the concentration range studied (0.25-20 fig/ml)) (Figure 2-5). The overall limit 
of detection, 0.12 ng/ml, was calculated from the equation of the line of best-fit, y = 15.56 
+ 6.05(logiox).
2.11 Agar gel diffusion assay of oxytetracycline hydrochloride
The test organism was Bacillus cereus (ATCC 11778). The test agar was 4% w/v Diagnostic 
Sensitivity Test agar (CM261, Oxoid, Unipath Limited, Basingstoke, U. K.) dissolved in 
water. Plasma, caecal liquor or faecal standards were made on the day of the experiment. 
Oxytetracycline (oxytetracycline hydrochloride, Sigma Chemical Company Limited, Poole, 
U. K.) for making standard solutions was dissolved in stock sterile phosphate buffer 
solution (0.05 M, pH 4.5).
iI
Precision
The precision of the agar gel diffusion assay of oxytetracycline hydrochloride in equine 
plasma was good as shown by the low (<7%) within-day and between-day coefficients of 
variation of the zone diameter (mean±SD) of the 3 plates analysed in a single assay and 2 
plates analysed on different days (Table 2-13).
The precision of the agar gel diffusion assay of oxytetracycline hydrochloride in equine 
caecal liquor was good as shown by the low (<9%) within-day and between-day coefficients 
of variation of the zone diameter (mean±SD) of the 4 plates analysed in a single assay and 8 
plates analysed on different days (Table 2-14).
The precision of the agar gel diffusion assay of oxytetracycline hydrochloride in equine 
faeces was good as shown by the low (<6%) within-day and between-day coefficients of 
variation of the zone diameter (mean±SD) of the 4 plates analysed in a single assay and 5 
plates analysed on different days (Table 2-15).
Linearity and Sensitivity
The linearity of the zone diameters of oxytetracycline hydrochloride was evaluated on the 5 
replicate plates of standard equine plasma samples and this was found to be good (r = 
0.987) over the concentration range studied (1-80 fig/ml) (Figure 2-6). The overall limit of
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Concentration
(Lig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 0.00 (n=3) 0.00 (n=2)
1 17.17±0.89 (n=5) 5.00 (n=3) 5.72 (n=2)
5 25.83±1.76 (n=5) 6.99 (n=3) 6.96 (n=2)
10 28.71±1.01 (n=5) 2.98 (n=3) 4.17 (n=2)
20 31.27±1.14 (n=5) 4.71 (n=3) 1.38 (n=2)
40 33.77±1.01 (n=5) 3.10 (n=3) 3.09 (n=2)
80 36.06±1.61 (n=5) 4.48 (n=3) 4.79 (n=2)
Table 2-13. Zone diameters and coefficients of variation of oxytetracycline hydrochloride in 
equine plasma
Concentration
(jig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of Variation (%) 
Within-day Between-day
0 0.00±0.00 (n=12) 0.00 (n=4) 0.00 (n=8)
1 18.56±1.50 (n=12) 4.72 (n=4) 8.79 (n=8)
5 26.24±1.19 (n=12) 1.94 (n=4) 5.34 (n=8)
10 29.30±1.31 (n=12) 4.03 (n=4) 4.74 (n=8)
20 31.65±0.95 (n=12) 3.00 (n=4) 3.03 (n=8)
40 33.71±1.18 (n=9) 2.69 (n=3) 3.40 (n=6)
80 36.11±1.12 (n=9) 2.64 (n=3) 3.07 (n=6)
Table 2-14. Zone diameters and coefficients of variation of oxytetracycline hydrochloride in 
equine caecal liquor
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Concentration
(tig/ml)
Zone diameter (mm) 
(mean±SD)
Coefficient of variation (%) 
Within-day Between-day
0 O.OOtO.OO (n=9) 0.00 (n=4) 0.00 (n=5)
1 10.33±0.50 (n=6) 3.84 (n=4) 5.79 (n=2)
4 17.07±0.72 (n=4) 4.23 (n=4) NS
5 18.63±1.02 (n=5) NS 1.02 (n=5)
8 20.90±0.75 (n=4) 3.60 (n=4) NS
10 23.12±1.17 (n=5) NS 5.06 (n=5)
20 24.82±1.13 (n=9) 3.05 (n=4) 4.00 (n=5)
Table 2-15. Zone diameters and coefficients of variation of oxytetracycline hydrochloride in 
equine faeces
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Figure 2-6. Zone diameters (mean±SD) of oxytetracycline hydrochloride in 
equine plasma, caecal liquor and faeces
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detection, 0.15 Jig/ml, was calculated from the equation of the line of best-fit, y = 18.12 + 
9.85(logiox).
The linearity of the zone diameters of oxytetracycline hydrochloride was evaluated on the 12 
replicate plates of standard equine caecal liquor samples and this was found to be good (r = 
0.989) over the concentration range studied (1-80 pg/ml) (Figure 2-6). The overall limit of 
detection, 0.10 fig/ml, was calculated from the equation of the line of best-fit, y = 19.33 + 
9.15(logiox).
The linearity of the zone diameters of oxytetracycline hydrochloride was evaluated on the 9 
replicate plates of standard equine faecal samples and this was found to be good (r = 0.986) 
over the concentration range studied (1-20 |ig/ml) (Figure 2-6). The overall limit of 
detection, 0.92 |ig/ml, was calculated from the equation of the line of best-fit, y = 10.43 + 
11.61(logiox).
2.12 High performance liquid chromatography - General 
HPLC System
A solvent delivery pump and manometric module (Gilson Model 302 and 802, Scotlab, 
Coatbridge, U. K.) were used to pump the solvent at an appropriate flow rate through a 
suitable column and a variable X uv detector (Model CE2112, Cecil Instruments Limited, 
Cambridge, U. K.) set at the required X and absorbance. The samples or standards were 
injected using a glass syringe into an injection port with a valve attached. The valve had a 
loop of similar size to the injection volume. The uv detector was connected to a variable 
chart recorder (Vitatron, M. S. E. Scientific Instruments, Crawley, U. K.) set at a speed of 
5 mm/min and a voltage of 10 mV.
The solvent was degassed thoroughly using a sonic bath (Sonicleaner, Dawe Instruments 
Limited, Scotlab, Coatbridge, U. K.) and vacuum pump (Millipore U. K., Watford, U. K.) 
before use.
Chromatograms
The capacity factor was used to measure the time that the sample component spent in the 
mobile phase. The capacity factor was calculated by adjusting the retention time of the 
sample (sample retention time minus solvent retention time) and dividing it by the unretained 
peak (solvent) time. The retention time (min) of both the sample component and the 
unretained peak were measured (mm) from the chromatogram.
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Recovery and precision
The precision of the extraction and the chromatographic procedures was assessed by the 
coefficients of variation of the replicate plasma samples to which the desired compounds had 
been added and analysed in a single assay (within-day or intra-assay variation) and on 
different days (between-day or inter-assay variation).
Linearity and Sensitivity
A computer programme (Cricket graph version 1.3, Cricket software, Pennsylvania, U. S, 
A.) was used to plot a graph of peak height (units) versus concentration ()ig/ml) and was 
used to calculate the line of best fit and r of the replicates used for the method validation. The 
overall limit of detection was calculated as the concentration corresponding to a peak height 
of 1 unit, using the average standard peak height from the replicate analyses used in the 
method validation.
2.13 Estimation of oxytetracycline hydrochloride in plasma 
Sample preparation
Plasma (3 ml) and 2 ml of a 10% w/v aqueous solution of trichloroacetic acid (Analar®, The 
British Drug House Chemicals Limited, Poole, U. K.) were added to a clean 10 ml neutral 
tube with a push in stopper (Sarstedt Limited, Loughborough, U. K.). The mixture was 
mixed well using a Griffin vortex shaker/stirrer (Griffin and George Limited, 
Loughborough, U. K.) and centrifuged for 15 min at 1800 g in a cooled centrifuge (5-15 
°C) (MSE Chilspin, M. S. E. Scientific Instruments, Crawley, U. K.). The supernatant was 
collected for injection into a reverse phase HPLC system.
Standard solutions
Unknown concentrations of oxytetracycline hydrochloride in plasma were calculated from a 
standard curve of known concentrations. A standard solution of 200 Mg/ml was prepared by 
dissolving 0.02 g of oxytetracycline (oxytetracycline hydrochloride, Sigma Chemical 
Company Limited, Poole, U. K.) in 100 ml of oxytetracycline eluting solution (6.12 ml 
orthophosphoric acid (Analar®, The British Drug House Chemicals Limited, Poole, U. K.), 
2.08 g potassium dihydrogen orthophosphate (Analar®, The British Drug House Chemicals 
Limited) and 1.36 g 1-heptane sulphonic acid (sodium salt, Sigma Chemical Company 
Limited, Poole, U. K.) dissolved in 11 of water) in a clean 100 ml glass volumetric flask. A 
20 fig/ml solution was prepared by diluting 10 ml of the 200 (ig/ml solution to 100 ml with 
oxytetracycline eluting solution. A 2 |!g/ml standard solution was made by diluting 10 ml of
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the 20 pg/ml solution to 100 ml in 50:50 oxytetracycline eluting solution: 10% w/v aqueous 
solution of trichloroacetic acid (Analar®, The British Drug House Chemicals Limited). A 
series of standard solutions were made, to encompass the range of likely plasma 
concentrations, from the standard solutions and drug-free equine plasma and put through the 
extraction procedure for calibration of the method and the determination of recoveries (Table 
2-16).
Solvent
The solvent used contained 0.564 g 1-heptane sulfonic acid (sodium salt, Sigma Chemical 
Company Limited, Poole, U. K.), 5.12 ml orthophosphoric acid (Analar®, The British 
Drug House Chemicals Limited, Poole, U. K.), 1.72 g potassium dihydrogen phosphate 
(Analar®, The British Drug House Chemicals Limited) and 257 ml of acetonitrile (HPLC 
Grade, Rathbum Chemicals Limited, Walkerbum, U. K.) made up to 1 1 with water.
Samples requiring dilution were diluted in 50:50 oxytetracycline eluting solution: 10% w/v 
aqueous solution of trichloroacetic acid (Analar®, The British Drug House Chemicals 
Limited, Poole, U. K.) following extraction.
HPLC Conditions
The flow rate was set at 1 ml/min, the loop size was 20 pi and the injection volume was 15 
pi. The column used was a Partisil 5 pm octadecylsilica column (125 mm long, 4.6 mm id, 
HPLC Technology, Macclesfield, U. K.). The uv X was set at 354 nm and the absorbance 
was set at 0.02 aufs.
Chromatograms
The chromatograms of oxytetracycline hydrochloride were clearly deliniated from the 
solvent with a retention time of 2 min and a capacity factor of 0.57. Typical chromatograms 
are presented in Figure 2-7 and as can be seen, no coextracted endogenous compounds from 
equine plasma interfered with the oxytetracycline hydrochloride peak.
Recovery and precision
The recovery of oxytetracycline hydrochloride from equine plasma was evaluated by 
reference to the peak heights resulting from the direct injection of the standard solution. 
Twelve sets of oxytetracycline hydrochloride standards in equine plasma were extracted and 
chromatographed; 6 in one day and 6 on 6 different days. The recovery of oxytetracycline 
hydrochloride from the 12 equine plasma replicates was good and was 73.26% on average. 
The precision of the extraction procedure was good, as can be seen from the low values of
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Concentration
(pg/ml)
Standard 
(volume and concentration)
Plasma
(ml)
0 0 3
0.25 37.5 pi of 20 pg/ml 3
1 150 pi of 20 pg/ml 3
5 75 pi of 200 pg/ml 3
10 150 pi of 200 pg/ml 3
20 300 pi of 200 pg/ml 3
Table 2-16. Standard plasma concentrations for HPLC analysis of oxytetracycline in equine 
plasma
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i
Figure 2-7. Typical chromatograms of oxytetracycline hydrochloride in equine plasma
Key: a drug-free plasma; b 1 |ig/ml oxytetracycline hydrochloride in equine plasma; c 2 
|ig/ml standard solution; d unknown equine plasma sample (4 h after intravenous 
administration of oxytetracycline hydrochloride at a dose rate of 10 mg/kg bwt); I  injection 
of sample; direction of flow; 1 oxytetracycline.
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within-day and between-day coefficients of variation which averaged 8.84 and 8.14%, 
respectively (Table 2-17). No oxytetracycline hydrochloride was recovered from drug-free 
plasma.
Linearity and Sensitivity
The linearity of the plot of peak height (units) versus concentration of oxytetracycline 
hydrochloride (pg/ml) was evaluated on the 12 replicates of the standard equine plasma 
samples and this was found to be good (r = 1.000) over the concentration range studied 
(0.25-20 pg/ml) (Figure 2-8). The overall limit of detection of oxytetracycline hydrochloride 
in equine plasma, for the 12 replicate analyses, was 0.08 pg/ml.
2.14 Estimation of SCFA in equine caecal liquor and faeces
An HPLC method, using an ion-exchange column similar to the one used by Guerrant et al. 
(1982), was used to measure SCFA in equine caecal liquor and faeces.
Sample preparation
Caecal liquor (1 ml) was passed through a Sep-pak C l8 cartridge (Waters, Millipore U. K., 
Dagenham, U. K.) which had been pre-conditioned with 5 ml methanol (HPLC Grade, 
Rathbum Chemicals Limited, Walkerburn, U. K.) and 5 ml 0.02 M chloride buffer (pH 
1.9). Excess fluid was shaken out of the Sep-pak cartridge prior to elution. The eluent was 
3.5 ml of phosphate buffer (0.05 M, pH 7.0). After elution, 3.5 ml was collected and 
filtered through a 0.22 pm prefilter (AP25, Millipore U. K.) and a 0.45 pm white cellulose 
nitrate membrane filter (25 mm diameter, Whatman Labsales Limited, Maidstone, U. K.) in 
a reusable filter holder (25 mm diameter, Swinnex, Millipore U. K.). The filter was pre­
conditioned with 3 ml phosphate buffer (0.05 M, pH 7.0) and washed with 2 ml phosphate 
buffer (0.05 M, pH 7.0). 20 pi of the resultant solution (total volume 5.5 ml) was injected 
into an ion exchange chromatograph.
A 1-2 g aliquot of each faecal was weighed into a 10 ml neutral tube with a push in stopper 
(Sarstedt Limited, Loughborough, U. K.) and 3 times the mass of phosphate buffer (0.05 
M, pH 7.0) was added. The sample/phosphate buffer was mixed thoroughly for 20-30 s 
using a Griffin vortex shaker/stirrer (Griffin and George Limited, Loughborough, U. K.), 
centrifuged for 15 min at 1800 g in a cooled centrifuge (5-15 °C) (MSE Chilspin, M. S. E. 
Scientific Instruments, Crawley, U. K.), and the resultant supernatant passed through the 
extraction procedure.
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Concentration Recovery Coefficient of Variation (%)
(pg/ml) (%) Within-day Between-day
0.25 77.33 (n=l 1) 5.97 (n=5) 8.65 (n=6)
1 65.08 (n=12) 9.15 (n=6) 7.44 (n=6)
5 73.97 (n=12) 1.91 (n=6) 2.55 (n=6)
10 78.03 (n=12) 1.75 (n=6) 7.93 (n=6)
20 72.21 (n=12) 2.54 (n=6) 5.52 (n=6)
Mean 73.26 (n=59) 8.84 (n=29) 8.14 (n=30)
Table 2-17. Mean recovery and coefficients of variation of oxytetracycline hydrochloride in 
equine plasma
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Figure 2-8. Peak heights (mean±SD) of oxytetracycline hydrochloride in 
equine plasma
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S tandard  solutions
Stock solutions of 0.5 M lactic (Analar®, not less than 88%, The British Drug House 
Chemicals Limited, Poole, U. K.), acetic (HPLC Grade, The British Drug House 
Chemicals Limited), propionic (approximately 98%, Sigma Chemical Company Limited, 
Poole, U. K.), isobutyric (2-methyl propionic acid, approximately 98%, Sigma Chemical 
Company Limited) and butyric (approximately 98%, Sigma Chemical Company Limited) 
acids were prepared by diluting 0.75, 0.57, 0.75, 0.93 and 0.92 ml, respectively, in 20 ml 
water. Similarly 0.1 M stock solutions of isovaleric (3-methyl butyric acid, approximately 
98%, Sigma Chemical Company Limited) and valeric (approximately 98%, Sigma Chemical 
Company Limited) acids were prepared by diluting 0.22 ml of each in 20 ml of water. A 
composite standard, containing all 7 SCFA, was prepared from the stock solutions diluted in 
phosphate buffer (0.05 M, pH 7.0) to a concentration 0.001 M. A series of standard 
samples (Table 2-18) was made from the standard solutions and phosphate buffer (0.05 M, 
pH 7.0), to encompass the range of likely caecal liquor or faecal concentrations, and put 
through the extraction procedure for calibration and determination of recovery.
Solvent
The mobile phase was 0.05 M sulphuric acid (1.35 ml diluted to 11 with water, apparent pH 
2.0, Pronalys*AR, analytical grade, May and Baker Limited, Dagenham, U. K.).
HPLC Conditions
The pump flow rate was set at 0.5 ml/min and the loop size and injection volume were 50 
pi. A Brownlee Polypor H (10 pm) column (250 mm long, 4.6 mm id, Anachem Limited, 
Luton, U. K.) for the separation of weak organic acids was used. The uv X was set at 210 
nm and the absorbance at 0.02 aufs.
Chrom atogram s
All seven SCFA formed well delineated, distinct peaks with retention times of 4.8 (L), 6.0 
(A), 6.9 (P), 7.6 (IB), 8.6 (B), 9.9 (IV), and 12.8 (V) min and capacity factors of 0.85 (L),
1.31 (A), 1.65 (P), 1.92 (IB), 2.31 (B), 2.81 (IV), and 3.92 (V). Typical chromatograms 
are presented in Figure 2-9 and, as can be seen, no coextracted endogenous compounds 
from caecal liquor interfered with the acid peaks.
Recovery and precision
The recovery of the 7 SCFAs from phosphate buffer, to which the 7 SCFAs had been 
added, was calculated by reference to the peak heights resulting from direct injection of the
Concentration
(mmol/1)
Standard 
(volume and concentration)
Phosphate 
buffer (ml)
0.0 0 10.00
0.5 10 pi of 0.5 M; 50 pi of 0.1 M 9.85
1.0 20 pi of 0.5 M; 100 pi of 0.1 M 9.70
2.5 50 pi of 0.5 M; 250 pi of 0.1 M 9.25
5.0 100 pi of 0.5 M; 500 pi of 0.1 M 4.25
10.0 200 pi of 0.5 M; 1 ml of 0.1 M 3.50
50.0 1ml of 0.5 M; no 0.1 M 2.50
Table 2-18. Standard phosphate buffer concentrations for HPLC analyses of SCFA
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Figure 2-9. Typical chromatograms of 7 SCFA in phosphate buffer and equine caecal liquor
Key: a 1.0 mmol/1 standard; b SCFA-free phosphate buffer; c 10.0 mmol/1 SCFA in 
phosphate buffer; d SCFA in equine caecal liquor 6 h after oral administration of ampicillin 
sodium at a dose rate of 10 mg/kg bwt; I  injection of sample; direction of flow; 1 L; 2 
A; 3 P; 4 IB; 5 B; 6 IV; 7 V.
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composite standard solution. Recovery of the 7 SCFA from phosphate buffer was good and 
was 74.30 (L), 76.76 (A), 84.48 (P), 84.42 (IB), 82.55 (B), 79.43 (IV), and 72.56 (V) % 
on average (Tables 2-19a and 2-19b). No SCFA were recovered from SCFA-free phosphate 
buffer.
The precision of the extraction method was reasonable, as shown by the good to moderate 
values of the within-day (6 replicates) coefficients of variation which averaged 11.07 (L), 
10.41 (A), 7.63 (P), 16.58 (IB), 18.67 (B), 15.06 (IV) and 20.90 (V) and the between-day 
(6 replicates) coefficients of variation which averaged 12.02 (L), 12.14 (A), 10.75 (P), 
16.25 (IB), 14.79 (B), 15.56 (IV) and 17.80 (V) (Tables 2-19a and 2-19b).
Linearity and Sensitivity
The linearity of peak height versus concentration of the 7 SCFA was evaluated from the 12 
replicates of the standard phosphate buffer samples and this was found to be good (r = 
0.996 (L), r = 0.992 (A), r = 0.996 (P), r = 1.000 (IB), r = 1.000 (B), r = 0.990 (IV) and r 
= 0.982 (V)) over the concentration range studied (0.5-10.0 mmol/1) (Figure 2-10). The 50 
mmol/1 phosphate buffer standard was validated at a later date and was not included here. 
The overall limit of detection of the seven acids in phosphate buffer, i. e. the concentration 
corresponding to a peak height of 1 unit, was calculated using the average standard peak 
height for the 12 replicate analyses and was 0.1 mmol/1 (L, A, P and IB) and 0.2 mmol/1 (B, 
IV and V).
2.15 Bacteriological examinations 
Smear preparation and staining technique
An air dried heat fixed smear was made from each sample and stained by Gram's method. 
The smear was covered with 0.5% w/v aqueous solution of crystal violet (The British Drug 
House Chemicals Limited, Poole, U. K.) for 30 s then rinsed off with tap water, this was 
replaced by Gram's iodine (1 g iodine resublimed GPR (The British Drug House Chemicals 
Limited) and 2 g potassium iodide (The British Drug House Chemicals Limited) dissolved in 
300 ml water) for 30 s then rinsed off with tap water, decolourized with acetone (technical 
grade, The British Drug House Chemicals Limited) for 1-2 s, washed with tap water, 
counterstained for 30 s with dilute carbol fuschin (1:10 with water, fuschin basic, The 
British Drug House Chemicals Limited), washed with water and blotted dry. Examination of 
stained smears was by oil immersion (Lenzol immersion oil, The British Drug House 
Chemicals Limited) light microscopy at 1000 times magnification (SM Lux, Ernst Leitz 
GmBH, Wetzlar, Germany) and organisms were identified by their Gram stain reaction 
(positive purple; negative pink) and morphology (coccus or bacillus).
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Acid Concentration Recovery Coefficient of Variation (%)
(mmol/1) (%) Within-day Between-day
L 0.5 82.97 (n=12) 7.11 (n=6) 12.88 (n=6)
1.0 71.30 (n=12) 10.87 (n=6) 8.21 (n=6)
2.5 72.65 (n=12) 7.42 (n=6) 11.36 (n=6)
5.0 69.82 (n=12) 8.87 (n=6) 15.70 (n=6)
10.0 77.69 (n=12) 5.48 (n=6) 8.22 (n=6)
50.0 71.14 (n= ll) 7.63 (n=5) 7.17 (n=6)
Mean 74.30 (n=71) 11.07 (n=35) 12.02 (n=36)
A 0.5 76.25 (n=12) 9.45 (n=6) 17.68 (n=6)
1.0 74.44 (n=12) 8.81 (n=6) 7.94 (n=6)
2.5 73.86 (n=12) 9.13 (n=6) 8.87 (n=6)
5.0 74.90 (n=12) 7.63 (n=6) 13.17 (n=6)
10.0 86.56 (n=12) 5.55 (n=6) 2.51 (n=6)
50.0 74.38 (n= ll) 6.96 (n=5) 11.86 (n=6)
Mean 76.76 (n=71) 10.41 (n=35) 12.14 (n=36)
P 0.5 80.23 (n= ll) 9.67 (n=6) 15.16 (n=5)
1.0 83.37 (n=12) 6.74 (n=6) 12.21 (n=6)
2.5 79.92 (n=12) 5.05 (n=6) 8.42 (n=6)
5.0 85.79 (n=12) 5.93 (n=6) 10.30 (n=6)
10.0 93.06 (n= ll) 4.10 (n=5) 2.07 (n=6)
50.0 84.93 (n= ll) 7.20 (n=5) 7.02 (n=6)
Mean 84.48 (n=69) 7.63 (n=34) 10.75 (n=35)
Table 2-19a. Mean recovery and coefficients of variation of 7 SCFA in phosphate buffer
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Acid Concentration Recovery Coefficient of Variation (%)
(mmol/1) (%) Within-day Between-day
IB 0.5 87.01 (n=12) 7.83 (n=6) 12.22 (n=6)
1.0 87.60 (n=12) 12.38 (n=6) 11.99 (n=6)
2.5 91.59 (n=12) 6.88 (n=6) 10.49 (n=6)
5.0 91.98 (n=12) 6.61 (n=6) 10.14 (n=6)
10.0 88.36 (n=12) 6.69 (n=6) 4.45 (n=6)
50.0 57.75 (n= ll) 11.22 (n=5) 5.02 (n=6)
Mean 84.42 (n=71) 16.58 (n=35) 16.25 (n=36)
B 0.5 82.31 (n= ll) 10.10 (n=6) 17.08 (n=6)
1.0 87.35 (n=12) 10.20 (n=6) 8.29 (n=6)
2.5 90.09 (n=12) 5.78 (n=6) 9.68 (n=6)
5.0 88.30 (n=ll) 9.93 (n=5) 13.75 (n=6)
10.0 87.82 (n=12) 5.21 (n=6) 3.11 (n=6)
50.0 57.82 (n= ll) 14.07 (n=5) 8.51 (n=6)
Mean 82.55 (n=69) 18.67 (n=34) 14.79 (n=35)
IV 0.5 86.52 (n=10) 15.14 (n=5) 15.77 (n=5)
1.0 86.02 (n= ll) 5.01 (n=5) 12.33 (n=6)
2.5 87.54 (n=12) 5.43 (n=6) 9.41 (n=6)
5.0 74.49 (n=12) 8.99 (n=6) 12.46 (n=6)
10.0 64.82 (n=12) 6.12 (n=6) 4.63 (n=6)
Mean 79.43 (n=57) 15.06 (n=28) 15.56 (n=29)
V 0.5 84.91 (n= ll) 4.28 (n=5) 16.72 (n=6)
1.0 72.19 (n= ll) 17.41 (n=5) 16.52 (n=6)
2.5 83.89 (n=12) 14.47 (n=6) 9.40 (n=6)
5.0 67.14 (n=12) 6.56 (n=6) 10.16 (n=6)
10.0 56.08 (n=12) 13.57 (n=6) 1.88 (n=6)
Mean 72.56 (n=58) 20.90 (n=28) 17.80 (n=30)
Table 2-19b. Mean recovery and coefficients of variation of 7 SCFA in phosphate buffer
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Figure 2-10. Peak heights (mean±SD) of 7 SCFA in phosphate buffer
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Technique for counting of viable cfu
Eight ten-fold dilutions of 1.0 ml of caecal liquor or 1.0 g of faecal material were prepared in 
sterile phosphate buffered saline (pH 7.3, Dulbecco 'A', BR14a, Oxoid, Unipath, 
Basingstoke, U. K.). A 10 pi drop of each dilution was placed onto agar plates, which had 
been marked out as a template of 8 segments, and allowed to dry. The limit of detection was 
103 viable cfu/ml or /g, /. e. 1 viable colony in the first dilution. In Appendices A, B, C and 
D the counts are expressed in scientific notation, where 1.00E+03 equals 1x10^.
Material obtained from each sample was used to inoculate a 7% sheep blood (210101, 
Becton-Dickinson, Dublin, Ireland) agar plate (CM271, Oxoid, Unipath, Basingstoke, U. 
K.) to detect coliforms, a MacConkey agar plate (CM7, Oxoid, Unipath) to detect non­
lactose fermenting aerobic bacteria and a 7% horse blood (SR50, Oxoid, Unipath) agar plate 
(CM271, Oxoid, Unipath) to detect Bacteroides spp.. Slanetz and Bartley (S&B) agar 
(CM377, Oxoid, Unipath) was inoculated to detect faecal streptococci and Mann, Sharpe 
and deRogosa (MRS) agar (CM361, Oxoid, Unipath) was inoculated to detect lactobacilli. 
Perfringens agar base (CM587, Oxoid, Unipath) supplemented with TSC supplement 
(SR88, Oxoid, Unipath) was inoculated to detect C. perfringens. Clostridium difficile agar 
base (CM601, Oxoid, Unipath) supplemented with selenium (SR96, Oxoid, Unipath) and 
7% horse blood was inoculated to detect the presence of C. difficile.
The inoculated sheep blood agar, MacConkey agar and S&B agar plates were incubated 
aerobically (LTE Qualitemp 80, Laboratory Thermal Equipment, Oldham, U. K.) at 37 °C 
and the MRS agar plates were incubated microaerophilically in an atmosphere of 5% carbon 
dioxide and 95% hydrogen (BOC, Glasgow, U. K.) at 37 °C in a McIntosh and Fildes' 
anaerobic jar (Don Whitley Scientific Limited, Shipley, U. K.) with no cold catalyst added. 
In the initial experiments, anaerobic plates were incubated at 37 °C in an atmosphere of 5% 
carbon dioxide and 95% hydrogen (BOC) in a McIntosh and Fildes' anaerobic jar, with 2 
cold catalysts (D catalyst, Engelhard, Cinderford, U. K.) added. The remaining plates were 
incubated anaerobically in an environment containing 10% hydrogen (BOC), 10% carbon 
dioxide (BOC) and 80% nitrogen (BOC) in a MK3 Anaerobic Workstation (Don Whitley 
Scientific Limited) at 37 °C. Air was removed from the McIntosh and Fildes' anaerobic jars 
using an oil free vacuum pump and compressor (Edwards, Crawley, U. K.) with air 
removal stopped at 500 mm Hg for the microaerophilic jars and 600 mm Hg for the 
anaerobic jars. Plates that were incubated aerobically were examined after 24 h incubation, 
microaerophilic plates after 48 h incubation and anaerobic plates after 72 h incubation at 37 
°C. The anaerobic media were incubated for up to 72 h because some of the organisms were 
slow growing, and pigment producing organisms (such as some Bacteroides spp.) took 
longer than 24-48 h to produce pigment. The bacterial colonies present on each medium
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were recorded, identified presumptively by their colonial morphology and Gram stain 
reaction, and subcultured for subsequent identification. The resultant colonies on the 
segmented plates were counted, recorded and the numbers of each organism calculated. An 
example of a typical plate is shown in Figure 2-11.
A single colony of an anaerobic bacterium for identification was subcultured onto horse 
blood agar and incubated anaerobically for 24-72 h at 37 *C. A rapid biochemical 
identification was carried out using a system for the identification of anaerobes (API20A, 
bioMerieux UK Limited, Basingstoke, U. K.) and used along with other tests, such as 
colonial and microscopic morphology and Gram stain reaction, to confirm the identification. 
The test system contains 20 microtubules of dehydrated test substances. Bacterial 
suspension is dispensed into the microtubules and the bacterial metabolites produced by 
anaerobic incubation result in an alteration in the colour of the reconstituted substrates, due 
to either a change in pH or the addition of specific reagents. The substrates are tryptophan, 
urea, glucose, mannitol, lactose, saccharose, maltose, salicin, xylose, arabinose, gelatin, 
esculin/ferric citrate, glycerol, cellobiose, mannose, melezitose, raffinose, sorbitol, 
rhamnose and trehalose.
The growth from a subculture plate was harvested using a plain sterile swab (Medical Wire 
and Equipment Company (Bath) Limited, Corsham, U. K.) and emulsified in a freshly 
opened ampoule of API20A medium (bioMerieux UK Limited), taking care to avoid 
dissolving air in the inoculation medium, to produce a final turbidity of greater than or equal 
to tube 3 on the McFarland scale. An individual incubation box was moistened with 5 ml 
sterile water and an individual API20A strip (bioMerieux UK Limited) inserted. Each tube 
on the strip was filled with the inoculated API20A medium (bioMdrieux UK Limited) using 
a sterile Pasteur micropipette. Care was taken to avoid air bubble formation in the tubes by 
tilting the strip during inoculation. The tube and cupule were filled with the test suspension 
to detect hydrolysis of gelatin or protease production. The cupule of the test for indole 
formation (tryptophan) was filled with mineral oil (bioMerieux UK Limited) to prevent 
evaporation of any indole produced. After inoculation, the incubation box was closed and 
the test strip incubated for 24-48 h in the MK3 anaerobic workstation at 37 "C.
After 24 h incubation, reactions which do not require the addition of reagents, namely, the 
production of urease (positive red; negative yellow-orange), the acidification of sugars 
(positive yellow/green-yellow; negative purple), and the hydrolysis of gelatin (positive 
diffusion of black pigment; negative no pigment diffusion) and esculin (positive brown- 
black; negative yellow) were read, and if reactions were observed reagents were added to the 
remaining tubes. If only a few or no reactions were observed the strip was incubated for a 
further 24 h. Indole formation was detected by adding a drop of XYL reagent (xylene,
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Figure 2-11. A typical example of a plate showing a count of viable coliforms using serial 
dilutions
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bioMdrieux UK Limited) to the mineral oil in the tryptophan cupule, mixing it and leaving it 
for 2-3 min then adding a drop of EHR reagent (8.75% w/v solution of p - 
dimethylaminobenzaldehyde in 82.5:17.5 ethanol:37% hydrochloric acid, bioMdrieux UK 
Limited). The reagent floated on the surface of the mineral oil and a reaction (positive red; 
negative yellow) took place within 5 min. A drop of BCP reagent (0.02% w/v aqueous 
solution of bromocresol purple, bioMdrieux UK Limited) was added to the sugar containing 
tubes if they were difficult to interpret due to discolouration caused by reduction; 
discoloured tests were recorded as a negative reaction. Organisms that produce hydrogen 
sulphide produced a black precipitate of ferric sulphide at the base of the esculin/ferric citrate 
tube, whereas esculin hydrolysis resulted in a brown-black area at the top of the tube. In 
cases where the esculin/ferric citrate tube was entirely brown-black, the strip was placed 
under a uv lamp at X 365 nm (Wood's lamp) to detect hydrogen sulphide production 
(positive no fluorescence; negative fluorescence). Production of catalase (positive gas 
bubble production; negative no gas production) was tested by adding 2 drops of a 30% 
aqueous solution of hydrogen peroxide (100 volumes, Fisons Limited, Loughborough, U. 
K.) to the mannitol tube after the strip had been in an aerobic environment for 30 min. In 
addition, Gram stain reaction, microscopic morphology and presence or absence of spores 
were recorded. Positive and negative reactions were recorded on a report sheet (bioM&ieux 
UK Limited) and compared with the results in the Analytical Profile Index (bioMerieux UK 
Limited). A typical example of a biochemical identification strip is shown in Figure 2-12.
Selective isolation of Salmonella spp. was by inoculation of 10 ml of tetrathionate broth 
(CM29, Oxoid, Unipath, Basingstoke, U. K.) with either 1 ml of caecal liquor or a sterile 
loop of faecal material, addition of 200 p.1 of aqueous iodine solution (30 g iodine 
resublimed GPR (The British Drug House Chemicals Limited) and 25 g potassium iodide 
(The British Drug House Chemicals Limited) dissolved in 100 ml water), mixing by gentle 
rotation and aerobic incubation. After 24 h incubation, both Salmonella!Shigella modified 
agar (CM533, Oxoid, Unipath) and desoxycholate citrate (Hynes modification) agar 
(CM227, Oxoid, Unipath) were inoculated from the tetrathionate broth and incubated 
aerobically for 24 h. A 1 ml aliquot of urea broth (urea broth base, CM271, supplemented 
with 40% urea, SR020K, Oxoid, Unipath) was inoculated with a single suspect colony 
(yellow/translucent) from the agar plates and any urease negative organisms (positive pink; 
negative yellow/translucent), after 24 h aerobic incubation, were inoculated onto a TSI agar 
slant (CM 277, Oxoid, Unipath) for subsequent identification. Reactions of organisms on 
TSI slant were interpreted using a table of the reaction of Gram negative bacteria on TSI 
slants (Carter, 1979) after 24 h aerobic incubation (Figure 2-13).
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Figure 2-12. A typical example of a rapid biochemical identification strip of C. perfringens
Key: positive reaction (+), negative reaction (-); IND (+) indole, URE (-) urease, GLU (+) 
glucose, MAN (-) mannitol, LAC (+) lactose, SAC (+) saccharose, MAL (+) maltose, 
SAL (+) salicin, XYL (-) xylose, ARA (-) arabinose, GEL (+) gelatin, ESC (-) esculin, 
GLY (-) glycerol, CEL (-) cellobiose, MNE (+) mannose, MLZ (-) melezitose, RAF (-) 
raffinose, SOR (-) sorbitol, RHA (-) rhamnose, TRE (+) trehalose.
Figure 2-13. A typical TSI slant from an isolate of Salmonella typhimurium phage type 204c 
Key: red alkaline slant; black hydrogen sulphide production
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Any suspect Salmonella spp. were tested serologically for both somatic (O) and flagellar (H) 
antigens using polyvalent O (groups A-G), polyvalent H (phase 1 and 2) and subgroups B, 
C and D Salmonella agglutinating sera (Wellcome Diagnostics, Dartford, U. K.). A suspect 
colony was emulsified in two drops of sterile water on a clean glass slide. A drop of 
agglutinating serum was added to one and the drops mixed by gentle rotation of the slide. A 
positive agglutination (appearance of clumps of material in drop) occurred rapidly (within 2 
min). The drop with no agglutinating serum added was used as a control for 
autoagglutination.
Where positive agglutinations occurred a standardized biochemical identification system for 
the identification of Enterobacteria and other Gram negative rods (API20E, bioMerieux UK 
Limited, Basingstoke, U. K.) was used for further identification. Bacterial metabolism was 
indicated by either a pH indicator in the substrate microtubules or by the addition of specific 
reagents after a suitable period of incubation.
A single colony subcultured onto a 7% sheep blood (210101, Becton-Dickinson, Dublin, 
Ireland) agar plate (CM271, Oxoid, Unipath, Basingstoke, U. K.) was harvested using a 
sterile wire loop and emulsified in a 5 ml of sterile water to produce a homogeneous 
suspension. An individual incubation box was moistened with 5 ml of sterile water and an 
individual API20E strip (bioMerieux UK Limited) inserted. Each tube on the strip was filled 
with the inoculated sterile water using a sterile Pasteur micropipette. Care was taken to avoid 
air bubble formation in the tubes by tilting the strip during inoculation. The tube and cupule 
were filled with the test suspension to detect citrate utilization (sodium citrate, positive blue- 
green/green; negative pale green/yellow), hydrolysis of gelatin (Kohn's gelatin, positive 
diffusion of black pigment; negative no pigment diffusion) or acetoin production (sodium 
pyruvate). Only the tube was filled for the tests for production of fi-galactosidase (o- 
nitrophenylgalactoside, positive yellow; negative colourless), arginine dihydrolase (arginine, 
positive red/orange; negative yellow), lysine decarboxylase (lysine, positive orange; 
negative yellow), ornithine decarboxylase (ornithine, positive red/orange; negative yellow), 
sodium thiosulphate (hydrogen sulphide production, positive black deposit/thin line; 
negative colourless/greyish), tryptophan desaminase and indole (tryptophan) and for 
fermentation or oxidation sugars (positive yellow; negative blue/blue green) glucose, 
mannitol, inositol, sorbitol, rhamnose, sucrose, melibiose, amygdalin and arabinose. In 
addition, the cupules of the tubes of arginine, lysine, ornithine, urea and hydrogen sulphide 
production were filled with mineral oil (bioMerieux UK Limited) to create an anaerobic 
environment. After inoculation, the incubation box was closed and the test strip incubated 
aerobically at 37 °C for 18-24 h. After 18-24 h incubation, if glucose (positive yellow; 
negative blue/blue-green) was fermented or 3 or more tests were positive, the reagents were
81
added to the remaining tests. The Voges Proskauer (VP) test (positive pink/red; negative 
colourless) for acetoin was performed by adding a drop of reagents VP1 (40% w/v aqueous 
solution of potassium hydroxide, bioMerieux UK Limited) and VP2 (6% a  naphthol in 
ethanol, bioMerieux UK Limited) and waiting for at least 10 min. The tryptophan deaminase 
(TDA) test (positive dark brown; negative yellow) was carried out by adding a drop of TDA 
reagent (3.4% w/v aqueous solution of ferric chloride, bioMerieux UK Limited) to the 
tryptophan tube. Indole (IND) formation (positive red ring; negative yellow ring) was 
detected by adding a drop of IND reagent (5% p-dimethylaminobenzaldehyde dissolved in a 
75:25 isoamyl alcohol:37% hydrochloric acid, bioMerieux UK Limited). A nitrite (NIT) test 
(positive red; negative yellow) was performed by adding 1 drop of NIT1 (0.8% sulfanilic 
acid in acetic acid, bioMerieux UK Limited) and NIT2 (0.6% N-N-dimethyl-1- 
naphthylamine in 5 M acetic acid, bioMerieux UK Limited) to the glucose tube and waiting 
for 2-3 min. A negative reaction occurred if reduction occurred in the tube. In addition, the 
results of an oxidase reaction and a Gram stain reaction, and the microscopic morphology 
were recorded. The oxidase test (positive purple; negative colourless) was carried out by 
wetting a piece of filter paper with 0.5% w/v aqueous solution of N-tetramethyl-p- 
phenylene-diamine dihydrochloride (The British Drug House Chemicals Limited, Poole, U. 
K.) and emulsifying a single colony on the strip of paper. Positive and negative reactions 
were recorded on a report sheet (bioMerieux UK Limited) and compared with the results in 
the Analytical Profile Index (bioMerieux UK Limited). Salmonella spp. were sent to a 
reference laboratory (National Health Service (Scotland) Salmonella Reference Laboratory, 
Stobhill General Hospital, Glasgow, U. K.) for antigenic analysis to identify the species 
and phage type.
The susceptibility of any Salmonella spp. isolated, to a series of standard antimicrobial 
agents, was examined in vitro. A plate of diagnostic sensitivity test agar (CM261, Oxoid, 
Unipath Limited, Basingstoke, U. K.) with 7% horse blood (SR50, Oxoid, Unipath) added 
was inoculated with the test organism. A series of 8 paper susceptibility discs (Oxoid, 
Unipath Limited, Basingstoke, U. K.) containing antimicrobial agents (10 |ig ampicillin, 30 
fig chloramphenicol, 50 fig furazolidone, 10 fig neomycin, 30 fig oxytetracycline, 10 |lg 
streptom ycin, 100 jig sulfafurazole and 1.25 fig/23.75 |ig trim ethoprim / 
sulphamethoxazole) were spaced evenly on the surface of the agar and the plate was 
incubated aerobically for 24 h. Disks with a clear zone of inhibition of bacterial growth were 
read as positive and where there was no zone of growth inhibition the bacterium was 
considered to be resistant to that antimicrobial agent.
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Screening for Salmonella species
Selective isolation of Salmonella species from 12 ponies at slaughter was carried out by 
inoculating 10 ml of tetrathionate broth with either a plain sterile swab (Medical Wire and 
Equipment Company (Bath) Limited, Corsham, U. K.) taken from the terminal ileal or 
caecal mucosa, or a portion of mesenteric lymph node. After 24 h incubation, both 
Salmonella/Shigella modified agar (CM533, Oxoid, Unipath) and desoxycholate citrate 
(Hynes modification) agar (CM227, Oxoid, Unipath) were inoculated from the tetrathionate 
broth and incubated aerobically for 24 h.
2.16 Caecal pH
The pH of serial samples of caecal liquor was measured using a hand held Whatman® pH 
psensor (Whatman Labsales Limited, Maidstone, U. K.). The pH meter was calibrated to 
pH 7.0 using pH 7.0 buffer (±0.01 at 20°C, The British Drug House Chemicals Limited, 
Poole, U. K.). The pH meter was calibrated between measurements, after washing with 
deionized water (Ionmiser, Model 2C, Houseman Hegro, Slough, U. K.) and blotting dry.
2.17 Faecal dry matter
Faecal dry matter content was estimated as a means of monitoring the development of 
diarrhoea.
An aliquot of 1-2 g of faeces was weighed from each sample and put into a 5 ml neutral tube 
(Sarstedt Limited, Loughborough, U. K.), the mass of the tube and the tube plus sample 
were recorded. Each aliquot was taken from the middle of a faecal ball. Uncovered tubes 
were placed in a polystyrene rack and the whole was covered with aluminium foil and placed 
in an oven (Laboratory Thermal Equipment, Oldham, U. K.) at 50-60 *C. Drying was 
monitored by weighing the tubes after 48, 72 and 120 h. The initial mass of each sample 
was calculated by subtracting the mass of the tube (g) from the mass of the tube plus sample 
(g). After drying the mass of faeces remaining was calculated as a percentage of the initial 
mass of each aliquot.
2.18 Plasma biochemistry
Estimation of plasma sodium and potassium ion concentrations was carried out using atomic 
emission spectrophotometry (Flame Photometer 543, Instrumentation Laboratories, 
Massachusetts, U. S. A.). Analysis for calcium and magnesium ions was by atomic 
absorption spectrophotometry (AA/AE spectrophotometer 257, Instrumentation 
Laboratories). Plasma chloride ion concentrations were measured using a Coming Chloride
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Analyser 925 (Corning, New York, U. S. A.). Total protein and albumin concentrations 
were measured using a Technicon® autoanalyser II (Technicon Instrument Company 
Limited, Basingstoke, U. K.) and globulin concentrations were calculated by subtracting the 
albumin concentration from the total protein concentration for each sample. The remainder of 
the analyses (phosphate ion, urea, creatinine, bilirubin, SAP, AST, ALT and GGT) were 
measured in a Cobas Mira Analyser (Roche Products Limited, Welwyn Garden City, U. 
K.). Values were compared to tables of normal ranges for the equine (Department of 
Veterinary Clinical Biochemistry, University of Glasgow Veterinary School; Kaneko, 
1989).
2.19 Haematology
Haematological examinations were carried out using a Minos®Vet automatic cell counter 
(Minos, Montpellier, France). In addition an air-dried blood smear was stained with May 
Grunwald's Giemsa stain (The British Drug House Chemicals Limited, Poole, U. K.) and 
examined under a light microscope (SM Lux, Ernst Leitz GmBH, Wetzlar, Germany) for 
red and white blood cell morphology and differential white blood cell counts. Values were 
compared to tables of normal ranges for the equine (Department of Veterinary Pathology, 
University of Glasgow Veterinary School; Kaneko, 1989).
2.20 Bromsulphalein retention test of liver function
A sterile aqueous solution of 10% w/v bromsulphalein (sulphobromophthalein sodium salt, 
Sigma Chemical Company Limited, Poole, U. K.) was administered by intravenous bolus 
injection. Blood samples were taken into 10 ml lithium heparin syringes (Li-Heparin LH/10 
Monovette®, Sarstedt Limited, Loughborough, U. K.) 6, 9 and 11 min after intravenous 
administration. The plasma concentration of bromsulphalein was analysed by absorbance 
spectrophotometry (Cecil Instruments Limited, Cambridge, U. K.) at a X of 565 nm. The 
plasma concentrations were calculated from a plot of standard bromsulphalein concentrations 
(p.g/ml) versus absorbance (Department of Veterinary Medicine, University of Glasgow 
Veterinary School). The elimination half-life of bromsulphalein in each animal was 
calculated from a plot of the bromsulphalein concentrations versus time (Cricket Graph 
version 1.3, Cricket software, Pennsylvania, U. S. A.).
2.21 Statistical analysis
All statistical analyses were performed using a standard statistical computer software 
package (Minitab Release 8 Macintosh® version, Clecom, Birmingham, U. K.). A non- 
parametric analysis of variance (Kruskal Wallis test) was used to compare pharmacokinetic 
parameters in horses, ponies and donkeys, and where statistically significant differences
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were apparent, a Mann Whitney U test was used to compare the data between groups. The 
results of the analyses were considered to be significantly different when p <0.05, highly 
significantly different when p <0.01 and very highly significantly different when p <0.001. 
Statistical analysis was not carried out, unless stated, on other data due to the low numbers 
of animals involved in the present study. In particular, the majority of studies were carried 
out in two ponies on two separate occasions. Also, there was a wide range in normal counts 
of viable bacteria and the development of clinical signs was considered more important than 
a statistically significant difference.
2.22 Pharm acokinetic analysis
The equations described in this section can be found in standard pharmacokinetic texts. The 
information used here was obtained from Baggot (1977a), Gibaldi (1991), Gibaldi and 
Perrier (1982), Rowland and Tozer (1989) and Sams (1987).
The disposition characteristics of each drug were calculated by analysing the changes in 
plasma drug concentrations versus time following a single intravenous bolus administration. 
All the pharmacokinetic analyses, of concentration versus time data for each animal on each 
occasion, were performed using a nonlinear regression Fortran IV curve stripping computer 
programme, CSTRIP (Sedman and Wagner, 1976). The programme generates up to 3 y- 
axis intercepts (Al, A2 and A3) and exponents (Bl, B2 and B3) (last to first) for the 
equations best describing the data, and a linear correlation coefficient. The number of 
exponents best describing each data set was confirmed using Akaike's information criterion 
(Yamaoka etal., 1978).
The y-axis intercepts and exponents for each data set were used to calculate the disposition 
kinetics of a drug in plasma. The elimination half-life or the time taken for 50% of the dose 
to be eliminated, in h or min, was estimated as 0.693/BI; where Bl is the hybrid rate 
constant for the terminal phase of disappearance of drug from the plasma. Similarly, the 
half-life of each distribution phase, in h or min, was calculated using 0.693/B2 and 
0.693/B3. The initial plasma concentration (CpO), in |!g/ml, is the sum of the 0 time 
intercepts of the coefficients (A 1, A2 and A3). The volume of the central compartment (Vc), 
in ml/kg, was calculated using the equation Vc = dose/CpO, where the dose was in mg/kg 
bwt. The area under the zero moment curve or AUC, in |ig.h/ml, was calculated by the sum 
of the ratio of each y-axis intercept and exponent, i. e. A3/B3 + A2/B2 + A l/B l. The area 
under the first moment curve (AUMC), i. e. the plasma concentration time versus time 
curve, in pg.h^/ml, was calculated using the equation AUMC = A3/(B3)2 + A2/(B2)2 + 
A1/(B1)2. The apparent volume of distribution (Vdarea) is the concentration of drug 
achieved after distribution is complete and is affected by both the dose and the extent of 
distribution of drug into the tissues. The Vdarea> *n rnl/kg, was calculated using the equation
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Vdarea = dose/AUC.Bl. The apparent volume of distribution at steady state (VdssX in 
ml/kg, was calculated using the equation Vdss = dose.AUMC/(AUC)2. The body clearance 
(CLb), in ml/h.kg, was calculated using the equation CLb = dose/AUC. The elimination rate 
constant (kel), in h, was calculated from the ratio of the CLb to the Vc.
The area under the plasma concentration versus time curve for observed values (AUCobs)» 
in jig.h/ml, from time 0 to infinity was determined for observed concentrations using the 
trapezoidal rule. The area of the triangle between time 0 and the first sample was calculated 
by taking the average of the CpO and the first observed concentration multiplied by the first 
time point, and the area of the triangle between the last sample and 0 concentration was 
calculated by dividing the final concentration by the terminal slope, B l. The area under the 
first moment curve for observed values (AUMC0bs) from time 0 to infinity, i. e. the plasma 
concentration time versus time curve, in )ig.h /ml, and the area of the triangle between time 
0 and the first sample were calculated in a similar fashion. The area (AUMC) of the triangle 
between the last sample and concentration 0 was calculated using the product of time and the 
last plasma concentration divided by B l, plus the last concentration divided by Bl squared. 
The ratio of the AUMC to the AUC for any drug is a measure of its mean residence time 
(MRT), in h or min, which is a quantitative estimate of the persistence of a drug in the body 
and the time it takes for 63.2% of the dose to be eliminated.
A bi-exponential equation was related to a two-compartment model with first-order rate 
constants kl2 and k21, in h or min, describing drug transfer between the compartments of 
the pharmacokinetic model. The rate constants were calculated using the equations B l -1- B2 
= k l2  + k21 + kel and B1.B2 = k21.kel. A tri-exponential equation was related to a three- 
compartment model with rate constants kl2, k21, kl3 and k31 were calculated using the 
equations described by Gibaldi and Perrier (1982).
The exponents (Bl and B2), describing the plasma concentration versus time data following 
oral administration, were used to calculate the apparent half-lives (tl/2 Bl and tl/2  B2). 
Following oral drug administration, the lag time, in h or min, was calculated as the time 
between drug administration and the start of absorption, i. e. the point where extrapolated 
and residual curves intersected. An alteration in the rate of absorption produces changes in 
the time profile and plasma concentrations of a drug in the body however other factors (e. g. 
CLb, apparent Vd, elimination half-life) remain constant. The availability (F), as a %, 
assuming CLb remains constant, was calculated as the ratio of the total AUC0bs following 
oral administration to the AUCobs following intravenous bolus administration, appropriately 
correcting for dose. The mean absorption time (MAT), in h or min, was calculated as the 
difference between the MRT following extravascular administration and the MRT following 
intravenous bolus administration.
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2.23 Baseline SCFA concentrations in vivo
Samples of caecal liquor were taken at specific times (approximately 1030, 1330, 1730 and 
2130 h), over two non-consecutive periods of 5 days from ponies I and II, prior to any drug 
administration. Samples were stored at -20 °C until analysis for SCFA concentrations. The 
results for each SCFA were expressed as a median (sample midpoint), lower and upper 
quartiles (Q1-Q3, range of 50% of the data points) and range (minimum to maximum), and, 
in addition, the VFA concentrations were expressed as a total, and the proportions of the 
main VFA (A, P and B) were expressed as a % of the total VFA concentrations (Table 2- 
20).
2.24 In vitro s tu d ie s
An attempt was made to mimic the fate of the antimicrobial agents and the microbial 
fermentation patterns which appeared to occur in the gastrointestinal lumen in vivo.
Drug concentrations, bacteriological examinations and SCFA concentrations
Drug-free caecal liquor (pooled samples from animals I and II) was taken, on 4 separate 
occasions for each of the 4 antimicrobial drugs, and divided into aliquots in 15 ml glass 
tubes. In addition a known quantity of each drug (Table 2-21) and a magnetic stirring rod 
were added to each tube. The tubes were held in a wooden rack, covered with plastic film to 
prevent significant evaporation, and placed on a stirring plate (Corning hot plate PC101, 
Coming, New York, U. S. A.) in a MK3 Anaerobic Workstation (Don Whitley Scientific 
Limited, Shipley, U. K.) at 37 °C.
Changes in the number of viable bacteria were assessed for oxytetracycline only. 
Bacteriological examinations were carried out prior to incubation (no drug) and after 3 and 
24 h incubation at concentrations of 0 and 80 pg/ml oxytetracycline on 4 separate occasions.
After 3 h incubation 3 ml of caecal liquor was removed from each tube and the incubation 
was continued for a total of 24 h. The destruction of antimicrobial drugs in caecal liquor was 
examined for by analysing the antimicrobial activity of the aliquots removed after 3 and 24 h 
incubation, using an agar gel diffusion assay immediately after collection. The remainder of 
each aliquot was stored at -20 °C until analysis for SCFA concentrations was performed. 
Allowance for the dilution of SCFA (by addition of drug standard) was made when 
calculating the SCFA concentrations.
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Acid n Median Q1-Q3 Range
SCFA concentration (mmol/I)
L 57 1.5 0.0-4.8 0 .0 -2 4 .4
A 57 34.4 28.5-39.3 1 2 .6 -6 4 .5
P 57 10.9 8.5-14.6 4 .7 -2 4 .5
IB 57 0 .0 0.0 0 .0 -2 .9
B 57 12.2 9.4-20.2 4 .8 -6 7 .3
IV 57 0 .0 0.0-1.2 0 .0 -3 .8
V 57 0 .0 0.0 0 .0 -9 .2
Total VFA 57 65 .0 52.3-78.2 2 4 .4 -1 0 9 .2
VFA concentration (%)
A 57 53.1 48.9-58.9 2 7 .9 -6 7 .0
P 57 18.7 13.8-24.4 4 .9 -3 8 .5
B 57 21 .3 16.9-32.4 8 .7 -6 6 .7
P+B 57 43 .3 37.1-50.0 2 7 .1 -7 2 .1
Table 2-20. Baseline values of SCFA in equine caecal liquor
Concentration
(Hg/ml)
Standard 
(volume and concentration)
Caecal liquor 
(ml)
0 0 10.00
0.25 12.5 Jill of 200 |ig/ml 9.99
1 50 i^l of 200 |J.g/ml 9.95
5 250 |il of 200 |ig/ml 9.75
10 500 |il of 200 (ig/ml 9.50
20 1000 |il of 200 [ig/ml 9.00
40 2000 |il of 200 |ig/ml 8.00
80 4000 M.1 of 200 |ig/ml 6.00
Table 2-21. Standard antimicrobial agent concentrations for studies in equine caecal liquor in 
vitro
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Acid pH
Antimicrobial agents were incubated in chloride buffer (0.02 M, pH 1.9) to mimic the 
effects of the equine gastric pH (pH 1.63-1.97, Sangiah et al., 1989) on antimicrobial 
activity. A series of standard concentrations of each drug were made from a 10 mg/ml 
standard solution (0.01 g standard compound dissolved in 10 ml stock sterile buffer 
solution) (Table 2-22). The acid samples were mixed for approximately 20 s using a Griffin 
vortex shaker/stirrer (Griffin and George Limited, Loughborough, U. K.) and samples were 
incubated at room temperature (20 °C) for 1 h. An aliquot of 100 fil of each sample was 
diluted with 900 p.1 of the appropriate stock sterile buffer solution and mixed for 
approximately 20 s using a Griffin vortex shaker/stirrer. The standard samples were 
analysed immediately after incubation by agar gel diffusion assay. The experiment was 
repeated on 4 occasions for each drug.
Binding to hay
The binding of antimicrobial agents to hay was examined by incubating a series of standard 
drug concentrations with hay at a pH similar to that found in the equine stomach (pH 1.63- 
1.97, Sangiah et al., 1989) and small intestine (pH 6.32-7.47, Mackie and Wilkins, 1988). 
A sample of hay was cut into lengths of approximately 10 mm and 1 g was added to a series 
of 50 ml screw cap plastic tubes (Greiner labortechnik Limited, Dursley, U. K.) containing 
phosphate buffer (0.05 M, pH 7.0) and standard concentrations of the antimicrobial agent 
(Table 2-22). Control tubes of standard drug concentrations without hay were incubated 
alongside the test tubes on a rotary mixer (Eschmann Brothers and Walsh Limited, 
Shoreham-By-Sea, U. K.) at 37 °C in a hot room for 3 h. Following incubation the 
concentrations of the antimicrobial agent in the supernatant of the tubes containing hay were 
compared with control concentrations, by agar gel diffusion assay. The experiment was 
carried out on one occasion for penicillin G, six occasions for ampicillin and one occasion 
for amikacin.
Stability of 7 SCFA in equine caecal liquor in vitro
Stability of SCFAs in equine caecal liquor was assessed by the repeated analysis of a series 
of samples of pooled caecal liquor. A fresh pooled sample of caecal liquor was divided into 
a series aliquots in glass universal bottles which were subjected to a variety of different 
conditions. One set of four aliquots was analysed on the same day for SCFA concentrations; 
one set of aliquots was sterilized by radiation (50 kiloGray in 40 h, 60q > source, Scottish 
Universities Reactor and Research Centre, East Kilbride, U. K.); one set of aliquots was 
stored at room temperature (20 °C); one set at 4 °C; and one set at -20 °C. After 2 days,
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Concentration
(pg/ml)
Standard 
(volume and concentration)
Buffer volume 
(ml)
0 0 10.00
10 10 pi of 10 mg/ml 9.99
20 25 pi of 10 mg/ml 9.98
50 50 pi of 10 mg/ml 9.95
100 100 pi of 10 mg/ml 9.90
Table 2-22. Standard antimicrobial drug concentrations for studies at acid (pH 1.9) and 
neutral (pH 7.0) pH
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SCFA concentrations were analysed in all 16 samples. The irradiated and 20 °C samples had 
magnetic stirring rods added and were placed on a stirring plate (Corning hot plate PC101, 
Coming, New York, U. S. A.) in a MK3 Anaerobic Workstation (Don Whitley Scientific 
Limited, Shipley, U. K.) at 37 °C for 24 h. The SCFA concentrations were measured after 
24 h incubation. In addition, the SCFA concentrations were measured after 14 days storage 
of samples at 4 and -20 °C.
A bacteriological examination was carried out following irradiation of one set of aliquots. A 
volume of 1 ml of each aliquot was inoculated onto a 7% sheep blood (210101, Becton- 
Dickinson, Dublin, Ireland) agar plate (CM271, Oxoid, Unipath, Basingstoke, U. K.) for 
the detection of coliforms, a 7% horse blood (SR50, Oxoid, Unipath) agar plate (CM271, 
Oxoid, Unipath) for the detection of Bacteroides spp. and MRS agar (CM361, Oxoid, 
Unipath) for detection of lactobacilli. After suitable incubation, there was only 1 sheep blood 
plate with a single coliform colony on it (which may have been a contaminant), therefore the 
samples were considered to be bacteria free following the irradiation procedure.
SCFA concentrations following storage were compared with initial SCFA concentrations 
using a Mann Whitney U test. There were no statistically significant changes in lactic, 
isobutyric, isovaleric or valeric acid concentrations following incubation, irradiation or 
storage. There was a statistically significant decrease in the concentration of acetic acid 
(median) from 28.8 mmol/1 to 19.5 mmol/1 and 19.6 mmol/1, respectively, following 
irradiation plus incubation and after 14 days at 4 °C (p <0.05). There was a statistically 
significant increase in the concentration of propionic acid from 8.2 mmol/1 to 10.8 mmol/1 
after 2 days storage at 20 °C and a decrease to 6.5 mmol/1 after 14 days storage at 4°C (p 
<0.05). There was a statistically significant increase in the median concentration of butyric 
acid from 5.7 mmol/1 to 14.6 mmol/1 after irradiation plus incubation and a decrease to 2.9 
mmol/1 after 14 days storage at 4 °C (p <0.05). Thus, SCFA concentrations were considered 
to be stable if stored at 4° C for 2 days and at -20 °C for 14 days, /. e. in the manner that 
unknown samples were treated. There were few alterations in SCFA concentrations 
following irradiation /. e. in the absence of bacteria.
2.25 Caecal volume
The volume of caecal contents was measured in 12 ponies at slaughter. After each animal 
was euthanised, the caecum was tied off and removed from the small intestine and colon. 
The contents of the caecum were emptied into a graduated plastic bucket and the volume (1) 
estimated. A computer programme (Cricket graph version 1.3, Cricket software, 
Pennsylvania, U.S. A.) was used to plot the volume of the caecal contents (1) versus the 
bwt (kg) and to calculate the line of best fit and r (Figure 2-14). The relationship between
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caecal volume (1) and bwt (kg) was reasonably linear (r = 0.748), and the line of best fit, y = 
-0.157 + 0.0293x, was used to calculate the approximate caecal volume in live animals. 
Two of the ponies with caecal fistulas (I and II) were weighed on 12 occasions over a period 
of 11 months. The bwt (mean±SD) for each pony was 233±16 and 216±14 kg and the 
calculated caecal volume (mean±SD) was 6.67±0.47 and 6.17±0.40 1, respectively. The 
volume of caecal contents in pony III (260 kg bwt) was estimated as 7.46 1.
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3 Studies with penicillin G
3.1 Introduction
The penicillins remain the most popular group of antimicrobial agents used in equine practice 
due to the suitable bacterial susceptibilities//? vitro, good general tolerance, satisfactory 
clinical responses and cost (Ricketts and Hopes, 1984). Procaine penicillin is used widely to 
treat equine infections caused by Gram positive bacteria. However, there are a number of 
factors which diminish the usefulness of penicillin G (benzylpenicillin). Penicillin G is 
inactivated rapidly in the gastrointestinal tract, by 6-lactamase enzymes, by protein binding 
and by acid (De Louvois and Hurley, 1977, Prins, 1987). The destruction of penicillin G by 
gastric acid means that it must be administered parenterally to attain suitable therapeutic 
plasma or serum concentrations.
Plasma and serum concentrations of penicillin G have been reported following intravenous 
and intramuscular administration to horses at a variety of different dose rates. The 
pharmacokinetics of sodium penicillin G were studied by Durr (1976) following intravenous 
administration at dose rates of 21 and 36.3 mg/kg bwt (35,000 or 60,500 iu/kg bwt). Knight 
(1975) suggested that in the horse dose rates of 12.5, 18 or 37.6 mg/kg (20,000, 30,000 or 
60,000 iu/kg) bwt, similar to those used in man, were appropriate for the intravenous 
administration of penicillin G potassium. Prescott and Baggot (1985) and Baggot and 
Prescott (1987) recommended a regime of either intravenous or intramuscular administration 
of penicillin G sodium at the lower dose rate of 9-12 mg/kg (15,000-20,000 iu/kg) bwt four 
times daily.
The procaine salt of penicillin G has been administered to horses at dose rates of 9-17.5 
mg/kg bwt by the intramuscular route (Brown et al., 1984a, Knight, 1975, Stover et al.> 
1981, Prescott and Baggot, 1985). Administration of procaine penicillin G at a dose rate of 
17.5 mg/kg bwt every 12-24 h has been recommended for clinical use (Prescott and Baggot, 
1985).
Penicillin V (phenoxymethylpenicillin) is stable in the presence of gastric acid. 
Consequently, penicillin V should have a higher systemic availability than penicillin G 
following oral administration, and should produce suitable therapeutic plasma or serum 
concentrations, and provide an alternative for long-term penicillin therapy. Schwark et al. 
(1983) examined the absorption and distribution patterns of penicillin V potassium following 
oral administration to horses at a dose rate of 73 mg/kg (110,000 iu/kg) bwt. Similarly, 
Ducharme et al. (1983) reported that oral administration of penicillin V at a dose rate of 44 or 
73 mg/kg (66,000 or 110,000 iu/kg) would provide a suitable alternative to parenteral
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administration of penicillin G. However, Baggot et al. (1990) reported that the systemic 
availability of penicillin V was low in adult horses compared with foals (1.65% and 
16.04%, respectively), and that it was lower than the systemic availability of penicillin G in 
adult horses (2.87%).
There have been reports of adverse reactions occurring in horses following the 
administration of the penicillins but host toxicity has not limited their use (Prescott and 
Baggot, 1985). Roberts and English (1979) reviewed adverse reactions to antimicrobial 
agents and noted that hypersensitivity was by far the most common adverse reaction to the 
penicillins. This type of reaction, along with muscle tenderness and localised oedema, was 
much more common following intramuscular administration compared with intravenous 
administration of the penicillins (Aronson and Brownie, 1978). Nielsen et al. (1988) 
reported 11 cases of acute procaine toxicity following intramuscular administration of 
penicillin G. In addition, the use of procaine salts has to be avoided in competition animals. 
Penicillin-induced anaemia (Step et al., 1991) is rare in the horse and in man but in the horse 
the percentage of individuals with anti-penicillin antibodies is high (Blue et al., 1987). 
Baggot et al. (1990) reported that five out of six horses developed clinical signs of lethargy, 
increased heart rate, increased respiratory rate and abdominal pain approximately 6 h after 
oral administration of penicillin V or penicillin G at a dose rate of 90 mg/kg bwt.
The purpose of the present study was to determine the plasma disposition and 
pharmacokinetics of penicillin G sodium following intravenous administration at the dose 
rate of 10 mg/kg bwt to horses, ponies and donkeys. Alterations in the gastrointestinal 
microflora were studied by bacteriological examination of serial faecal samples and large 
intestinal fermentation was studied using faecal SCFA concentrations. Faecal dry matter 
content and faecal consistency were used as an indicator of the presence or absence of 
diarrhoea. Similar studies were carried out in ponies with cannulated caecal fistulas 
following a single intravenous or oral administration of penicillin G at a dose rate of 10 
mg/kg bwt. In addition, drug and bacteriological analyses were carried out on caecal liquor, 
and plasma biochemistry and haematology were monitored.
3.2 Materials and Methods
3.2.1 Intravenous adm inistration  o f  penicillin  G to horses, ponies and  
d on k eys
Three thoroughbred geldings (No. 3-5), 3 ponies (No. 7, 8 and 10) and three donkeys (No. 
14-16) were used as outlined in the general Materials and Methods. Penicillin G sodium was 
administered by intravenous bolus injection at a dose rate of 10 mg/kg bwt. Plasma samples 
were taken prior to drug administration and at 0.033, 0.083, 0.25, 0.5 0.75, 1, 1.5, 2, 4, 6,
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8, 12 and 24 h, except in horse 3 there was a 0.33 h sample not a 0.25 h sample, and in 
horse 4 there was a 0.1 h sample not a 0.083 h sample, and in donkey 14 there was a 0.117 
h sample and no 0.033 or 0.083 h samples. Faecal samples were taken at 0, 24, and 48 h 
after drug administration for drug analysis, bacteriological examination, SCFA analysis and 
the measurement of dry matter content.
3.2.2 Intravenous administration of penicillin G to ponies with cannulated  
caecal fistulas
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 2 occasions (1 and 2). Penicillin G sodium was 
administered by intravenous bolus injection at a dose rate of 10 mg/kg bwt. Plasma samples 
for drug analysis and caecal liquor samples for drug analysis, measurement of pH and 
SCFA analysis were taken at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 and 24 h, with 
additional plasma samples at 0.033 and 0.083 h, and an additional caecal liquor sample at 48 
h. Bacteriological examination of caecal liquor was carried out at 0, 24 and 48 h. Faecal 
samples were taken for drug analysis, SCFA analysis and the measurement of dry matter 
content at 0, 24 and 48 h. Plasma biochemistry and haematological examinations were 
carried out at 0, 24 and 48 h.
3.2.3 Oral administration o f  penicillin G to ponies with cannulated caecal 
f is tu la s
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 2 occasions (1 and 2) at least 6 days after intravenous 
administration of penicillin G sodium. Penicillin G sodium was administered via nasogastric 
tube at a dose rate of 10 mg/kg bwt. Plasma samples for drug analysis and caecal liquor 
samples for drug analysis, pH measurement and SCFA analysis were taken at 0,0.25, 0.75, 
1, 1.5, 2, 4, 6, 8, 12 and 24 h, with further caecal liquor samples taken at 28, 32, 48, 52, 
56, 72, 96 and 168 h. Bacteriological examinations of caecal liquor were carried out at 0, 
24, 48, 72, 96 and 168 h. Faecal samples were taken for the measurement of drug 
concentrations, SCFA concentrations and dry matter content at 0,24, 48,72, 96 and 168 h. 
Samples were taken for plasma biochemistry and for haematological examinations at 0, 24, 
48 on occasions 1 and 2, and at 168 h on occasion 2.
3.2.4 In vitro studies with penicillin G
A range of concentrations of penicillin G sodium were incubated for 3 and 24 h in caecal 
liquor at body temperature in an anaerobic environment, and drug and SCFA concentrations 
were measured following incubation as described in the general Materials and Methods. A
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range of concentrations of penicillin G sodium were incubated at acid pH for 1 h at room 
temperature as outlined in the general Materials and Methods. A range of concentrations of 
penicillin G sodium were incubated in the presence of chopped hay at body temperature for 3 
h at gastric and small intestinal pH as outlined in the general Materials and Methods.
3.3 Results of intravenous adm inistration of penicillin G to horses, ponies 
and donkeys
3.3.1 Plasma disposition and pharm acokinetics
A semilogarithmic plot of plasma concentrations (mean±SEM), following intravenous 
administration of penicillin G to horses, ponies and donkeys, is shown in Figure 3-1. 
Individual and mean plasma concentrations are given in Appendix A (Tables A1-A3). In all 3 
groups, the initial plasma concentration versus time plots were similar, however the decline 
phase of the plasma concentration versus time plot was less steep in horses than it was in 
ponies and donkeys. Penicillin G was detected in plasma (>0.01 Jig/ml) for up to 8 h in 
horses, and 6 h in ponies and donkeys.
The pharmacokinetic parameters calculated from the bi-exponential equations used to 
describe the plasma concentration versus time data are given in Table 3-1 and in Appendix A 
(Tables A4-A6). The harmonic mean of the elimination half-life calculated for horses, ponies 
and donkeys was similar and quite short. The elimination half-life was longest in horses 
followed by donkeys and then ponies, whereas the MRT was longest in horses, followed by 
ponies and then donkeys. There were no statistically significant differences, calculated using 
a Kruskal Wallis test, between the pharmacokinetic parameters calculated for the three 
groups. The CLb was very high (circa 500 ml/h.kg).
3.3.2 Faecal concentrations
No penicillin G was detected in faeces following intravenous administration to horses, 
ponies and donkeys.
3.3.3 Bacteriological exam inations
Counts of viable bacteria in faeces (mean±SEM) following intravenous administration of 
penicillin G are shown in Figures 3-2, 3-3 and 3-4, and the individual and mean data are 
given in Appendix A (Tables A7-A9).
Salmonella spp. and C. difficile were selected for but not isolated.
In the 3 horses there were no marked changes in the number of coliforms, Bacteroides spp. 
or Clostridium spp. isolated (Figure 3-2). There was an apparent reduction in the mean
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Figure 3-1 Plasma concentrations (mean±SEM) of penicillin G following intravenous 
administration to horses, ponies and donkeys
Parameter Horses (n=3) Ponies (n=3) Donkeys (n=3)
tl/2 B2 (min)* 5.85 2.52 4.28
tl/2 B1 (min)* 38.95 27.25 31.52
CpO (Hg/ml) 62.90±8.87 74.52114.65 126.42143.13
Vc (ml/kg) 165.98±25.01 145.14128.38 95.91124.75
AUCobs (pg.h/ml) 23.03±5.07 21.1912.00 23.6612.51
AUMCobs (Hg.h2/ml) 15.0714.90 12.0012.96 9.7911.66
AUC (ng.h/ml) 22.4115.35 20.1511.95 21.9110.55
AUMC (|ig.h2/ml) 16.5315.86 12.2412.77 9.9011.40
MRT (min) 38.0715.29 34.3518.94 24.4611.83
Vdarea (ml/kg) 537.251205.21 368.42186.87 357.25130.67
Vdss (ml/kg) 362.321106.47 314.05191.85 204.5313.00
CLb (ml/h.kg) 514.461145.60 505.36147.46 462.86140.04
kel(/h) 3.0310.49 3.7210.73 5.7111.78
k21 (/h) 2.6210.83 6.5112.07 2.2610.32
kl2 (/h) 2.5210.40 7.7213.81 3.1411.40
Table 3-1. Disposition kinetics of penicillin G in plasma following intravenous 
administration to horses, ponies and donkeys 
Key: data as mean ±SEM; * harmonic mean
0 24 48
Time (h)
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Figure 3-2. Counts of viable bacteria in faeces (mean±SEM) following intravenous
administration of penicillin G to horses
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number of streptococci and lactobacilli isolated at 24 h after drug administration, but this 
appears to have been due to high initial counts of streptococci in horses 3 and 5 (10^- 
lOltyg), and lactobacilli in horse 4 (lO^/g).
In ponies, there was an increase in the mean number of coliforms, up to lO^/g, isolated at 24 
and 48 h after drug administration (Figure 3-3). There was an increase in the viable number 
of coliforms isolated from all 3 ponies but it was most marked in ponies 8 and 10 (10^/g). 
In the 3 ponies there were no marked changes in the number of streptococci, lactobacilli or 
Clostridium spp. isolated. There was an apparent increase in the mean number of 
Bacteroides spp. (109/g) isolated at 24 h after intravenous administration of penicillin G to 
ponies. This was due to the isolation of a low number of Bacteroides spp. (105-108/g) from 
all samples, except at 24 h after drug administration to pony 10 (lO^O/g). The low numbers 
of Bacteroides spp. isolated may have been due to exposure of the organisms to oxygen 
(air). There was a relatively high number of Clostridium spp. (lOfyg) isolated from pony 10 
prior to drug administration.
There was a slight increase in the mean number of coliforms isolated from donkey faeces at 
48 h after penicillin G administration (Figure 3-4). This was due to an increase in the 
number of coliforms (108/g) isolated from donkey 14 at 48 h after drug administration. 
There were no marked changes in the mean number of streptococci, lactobacilli or 
Bacteroides spp. isolated. The mean number of Clostridium spp. isolated at 48 h after drug 
administration was high (107/g) due to high numbers of Clostridium spp. isolated from 
donkeys 14 and 15 (lO^-lofyg) at this time. The numbers of Bacteroides spp. isolated from 
donkeys faeces was low (105-108/g) throughout the study.
Lactobacilli identified using the API system were L. acidophilus and L. fermentum. 
Bacteroides spp. identified using the API system were B. asaccharolyticus, B. eggerthii, B. 
ovatus, and B. thetaiotaomicron. Clostridium spp. identified using the API system were C. 
butyricum, C. clostridiiforme and C. tertium. Other bacteria identified using the API system 
were Actinomyces israelii, Actinomyces meyeri, Bifidobacter adolescentisf Eubacterium 
lentum, Peptococcus spp. and Streptococcus spp..
3.3.4 Faecal SCFA concentrations
Faecal lactic acid and total VFA concentrations (mean ±SEM), following intravenous 
administration of penicillin G to horses, ponies and donkeys are shown in Figures 3-5 and 
3-6, and the individual and mean data are given in Appendix A (Tables A10-A19).
The faecal SCFA concentrations in horses, ponies and donkeys were very variable following 
the intravenous administration of penicillin G. Lactic acid concentrations in faeces remained
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Figure 3-3. Counts of viable bacteria in faeces (mean±SEM) following intravenous 
administration of penicillin G to ponies
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Figure 3-4. Counts of viable bacteria in faeces (mean±SEM) following intravenous
administration of penicillin G to donkeys
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low following intravenous administration of penicillin G to horses, ponies and donkeys and 
were all within the normal range of 0.0-24.4 mmol/1 (Figure 3-5). In horses, ponies and 
donkeys, mean total VFA concentrations were within the normal range of 24.4-109.2 
mmol/1 at 0, 24 and 48 h after intravenous administration of penicillin G (Figure 3-6). In 
individual horses, ponies and donkeys, there were considerable fluctuations in the total and 
individual VFA concentrations. However, there did not appear to be any trend in the 
observed concentrations that was associated with antimicrobial administration.
3.3.5 Faecal dry m atter content and consistency
A plot of faecal dry matter content (mean±SEM) following intravenous administration of 
penicillin G to horses, ponies and donkeys is shown in Figure 3-7, and individual and mean 
data are given in Appendix A (Tables A20-A22).
There were no marked alterations in the mean faecal dry matter content following 
intravenous administration of penicillin to horses and donkeys. There was a reduction in the 
faecal dry matter content at 24 h in horse 4 (15.44%). In ponies, the mean faecal dry matter 
content was reduced at 48 h after drug administration (<17%) and this reflected a reduction 
in the faecal dry matter content in ponies 7 and 8 (15.86 and 14.98%, respectively). In 
addition, there appeared to be an increase in the faecal dry matter content in donkey 15 at 24 
and 48 h after intravenous administration of penicillin G (>30%).
No alterations in faecal consistency were observed following intravenous administration of 
penicillin G to horses, ponies and donkeys.
3.4 Results of in travenous adm in istration  of penicillin G to ponies with 
cannulated caecal fistulas
3.4.1 Plasm a disposition and pharm acokinetics
The plasma concentrations of penicillin G following intravenous administration to ponies I 
and II on occasions 1 and 2 are given in Appendix A (Table A23).
The plasma concentration versus time data from pony II could not be described using a bi­
exponential equation, therefore the parameters were calculated from a mono-exponential 
equation. A bi-exponential equation best described the data from ponies 12, III and 112. The 
pharmacokinetic parameters calculated from the plasma concentration versus time data of 
each animal on each occasion are given in Table 3-2. The pharmacokinetic parameters that 
were calculated for ponies 12 and III were similar to those obtained from ponies 7, 8 and 10 
in the previous study (3.3.1). However, the elimination half-life and MRT calculated for
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Figure 3-5. Lactic acid concentrations (mean±SEM) in faeces following 
intravenous administration of penicillin G to horses, ponies and donkeys
200:
.2 150:
100:
0 4824
Time (h)
O Horses □ Ponies— A—  Donkeys
Figure 3-6. Total VFA concentrations (mean±SEM) in faeces following intravenous
administration of penicillin G to horses, ponies and donkeys
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Figure 3-7. Faecal dry matter content (mean±SEM) following intravenous administration of 
penicillin G to horses, ponies and donkeys
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Parameter 11* I2§ II1§ II2§
tl/2 B2 (min) - 1.32 7.26 2.40
tl/2 B l (min) 69.60 38.82 36.78 62.70
CpO (|ig/ml) 15.86 132.50 59.43 32.40
Vc (ml/kg) 630.36 75.47 168.26 308.65
AUCobs (M-g.h/ml) 29.13 22.19 21.29 20.52
AUMCobs (Hg-h2/ml) 49.88 16.49 11.97 26.57
AUC (ng.h/ml) 26.53 20.32 20.76 19.82
AUMC (ng.h2/ml) 44.36 15.76 12.79 28.21
MRT (min) 102.74 44.59 33.73 77.69
Vdarea (ml/kg) 630.36 459.82 425.77 760.63
VdSs (ml/kg) 630.36 381.70 296.79 717.94
CLb (ml/h.kg) 376.98 492.15 481.71 504.53
kel(/h) 0.60 6.52 2.86 1.64
k21 (/h) - 5.27 2.26 7.02
kl2 (/h) - 21.37 1.73 9.31
Table 3-2. Disposition kinetics of penicillin G in plasma following intravenous 
administration to ponies
Key: * calculated from a mono-exponential equation; § calculated from a bi-exponential 
equation
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ponies II and 112 were very long.
3.4.2 Caecal liquor and faecal concentrations
The caecal concentrations of penicillin G following intravenous administration to ponies I 
and II on occasions 1 and 2 are given in Appendix A (Table A24). No penicillin G was 
detected in the caecal liquor samples from ponies II, III or 112 following intravenous 
administration. The caecal liquor concentrations of penicillin G in pony 12 are shown in 
Figure 3-8. A maximum caecal liquor concentration of 0.60 pg/ml was measured at 0.5 h 
after drug administration.
Drug disposition within the caecum was described using AUC and AUMC for observed 
values and the ratio of these (MRT). The AUC was 0.77 pg.h/ml, the AUMC was 0.93 
pg.h2/ml and the MRT was 72.40 min.
There was no penicillin G detected in the faecal samples from the ponies following 
intravenous administration.
3.4.3 Bacteriological exam inations
Counts of viable bacteria in caecal liquor following intravenous administration of penicillin 
G are shown in Figures 3-9 to 3-13, and the individual data is given in Appendix A (Table 
A25).
Salmonella spp. and C. difficile were selected for but not isolated.
There were no marked changes in the number of coliforms isolated from ponies II, HI and 
112 (Figure 3-9). The number of coliforms isolated from pony 12 was high (lO^/ml) prior to 
drug administration and fell to a normal value of lO^-lO^/ml at 24 and 48 h after drug 
administration.
There were no marked alterations in the number of streptococci isolated following 
intravenous administration of penicillin G to ponies II, 12, III and 112 (Figure 3-10). The 
number of streptococci isolated from pony III increased to lOfyml at 24 h after intravenous 
administration of penicillin G.
There were no marked alterations in the number of viable lactobacilli isolated following the 
intravenous administration of penicillin G to ponies II, 12, III and 112 (Figure 3-11). 
Lactobacilli identified using the API system were L. acidophilus and L. jensenii.
There were no marked alterations in the number of Bacteroides spp. isolated following 
intravenous administration of penicillin G to ponies II, 12, III and 112 (Figure 3-12).
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Figure 3-9. Counts of viable coliforms in caecal liquor following 
intravenous administration of penicillin G to ponies
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Figure 3-10. Counts of viable streptococci in caecal liquor following
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Figure 3-11. Counts of viable lactobacilli in caecal liquor following 
intravenous administration of penicillin G to ponies
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Figure 3-12. Counts of viable Bacteroides spp. in caecal liquor following intravenous
administration of penicillin G to ponies
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However, the number of Bacteroides spp. isolated was low (108/ml) prior to drug 
administration to pony III, and at 48 h after drug administration to pony II. Bacteroides 
spp. identified using the API system wereB. capillosus, B. oralis and#, uniforms.
There were no marked alterations in the number of Clostridium spp. (Figure 3-13) isolated 
from any of the ponies at any of the sampling times prior to or following intravenous 
administration of penicillin G. However, there were quite high numbers of Clostridium spp. 
(lOfyml) isolated from ponies II and 12 prior to drug administration, and from pony 12 at 24 
h after drug administration. Clostridium spp. identified using the API system were C. 
clostridiiforme and C. ramosum.
Other bacteria identified using the API system were Eubacterium lentum, Actinomyces 
naeslundiiy Peptococcus spp. and Streptococcus spp..
3.4.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
Caecal liquor pH values following intravenous administration of penicillin G are shown in 
Figure 3-14, and the individual data is given in Appendix A (Table A26). The caecal pH was 
slightly high (7.4) at 0.25 h after drug administration to pony II. In ponies 12 and 112 the 
caecal liquor pH was slightly lower than normal (<6.8) at 0.75, 1, 4 and 8 h and at 0, 0.25, 
0.75, 2, 4, and 8 h, respectively, following intravenous administration of penicillin G. At 
other sampling times the pH of caecal liquor was normal (6.8-7.2).
Caecal liquor lactic acid concentrations, following intravenous administration of penicillin G 
to ponies are shown in Figure 3-15, and the individual data is given in Appendix A (Tables 
A27a-A30a). In pony II, lactic acid concentrations were increased to 7.1-10.1 mmol/1 at 
0.5,0.75 and 1 h, but these concentrations were all within the normal concentration range of 
0.0-24.4 mmol/1. In pony 12, lactic acid concentrations were increased to 6.2-59.5 mmol/1 at 
0.5, 1.5, 2, 4, 6, 8, 12 and 48 h after drug administration, and were outside the normal 
range at 4, 6 and 8 h after drug administration. However, in ponies III and 112, lactic acid 
concentrations in caecal liquor did not increase and were within the normal range of 0.0-24.4 
mmol/1 at all times sampled.
Caecal liquor total VFA concentrations are shown in Figure 3-16, and total VFA and 
individual acid concentrations are given in Appendix A (Tables A27a-A30a). There were 
fluctuations in total and individual VFA concentrations about the normal ranges. Prior to 
drug administration to pony II, the propionic acid concentration of 3.0 mmol/1 was lower 
than the normal range of 4.7-24.5 mmol/1. In pony 12, the propionic acid concentrations of 
27.4-33.1 mmol/1 were higher than normal at 6 and 8 h after drug administration, and the
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Figure 3-13. Counts of viable Clostridium spp. in caecal liquor following intravenous 
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Figure 3-15. Lactic acid concentrations in caecal liquor following 
intravenous administration of penicillin G to ponies
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Figure 3-16. Total VFA concentrations in caecal liquor following 
intravenous administration of penicillin G to ponies
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butyric acid concentrations of 0.0-3.0 mmol/1 were below the normal range of 4.8-67.3 
mmol/1 at 0.5, 1.5, 2, 4 and 48 h. In ponies 12 and 112, the isovaleric acid concentrations of
7.5 and 6.3 mmol/1 at 0 and 12 h, respectively, were higher than the normal range of 0.0-3.8 
mmol/1.
The proportions of acetic, propionic and butyric acids, as a percentage of the total VFA 
concentrations, are given in Appendix A (Tables A27b, A28b, A29b and A30b). In pony 12, 
the ratios of acetic and propionic acid were 74.3% at 48 h, and 42.2-58.0% at 1.5, 2, 4, 6, 
and 8 h, respectively, and were elevated above the normal ranges of 27.9-67.0 % and 4.9-
38.5 %, respectively. In pony 12, the ratio of butyric acid of 0.0-5.2% at 2, 4 and 48 h was 
below the normal range of 8.7-66.7%.
Faecal SCFA concentrations following intravenous administration of penicillin G to ponies 
are shown in Figure 3-17, and the individual data is given in Appendix A (Tables A31-A34). 
Lactic acid concentrations were within the normal range of 0.0-24.4 mmol/1 at all sample 
times in all ponies. There was considerable variation in the total and individual VFA 
concentrations however, there were no trends in VFA concentrations that were considered to 
be associated with penicillin G administration. The total VFA concentrations were lower than 
the normal range of 24.4-109.2 mmol/1 at 24 and 48 h after drug administration to pony II, 
and throughout the study in ponies 12, III and 112.
3.4.5 Faecal dry matter content and consistency
Faecal dry matter content versus time following intravenous administration of penicillin G to 
ponies is shown in Figure 3-18, and the individual data is given in Appendix A (Table A35). 
There were no marked alterations in faecal dry matter content following intravenous 
administration of penicillin G. No changes in faecal consistency were observed.
3.4.6 Plasma biochemistry and haematological examinations
The plasma biochemistry results are given in Appendix A (Tables A36 and A37). The results 
of the haematological examinations are given in Appendix A (Tables A38 and A39). There 
were no alterations in plasma biochemistry or haematological parameters that were 
considered to be associated with the intravenous administration of penicillin G.
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Figure 3-17. Total VFA concentrations in faeces following intravenous 
administration of penicillin G to ponies
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Figure 3-18. Faecal dry matter content following intravenous administration 
of penicillin G to ponies
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3.5 Results of oral administration of penicillin G to ponies with cannulated 
caecal fistulas
3.5.1 Plasma disposition and pharmacokinetics
The plasma concentrations of penicillin G following oral administration to ponies are shown 
in Figure 3-19, and the individual data is given Appendix A (Table A40). Maximum plasma 
concentrations of 0.19, 0.09, 0.14 and 0.16 p.g/ml were measured at 0.5 h after nasogastric 
administration of penicillin G to ponies II, 12, III and 112.
The pharmacokinetic parameters calculated following oral administration of penicillin G to 
ponies are given in Table 3-3. The plasma concentration versus time data from pony 12 could 
not be described using a bi-exponential equation. No lag time was required to describe the 
plasma concentration versus time data following oral administration of penicillin G. The 
MAT was calculated as the difference between the mean MRT following intravenous 
administration for each animal and the MRT following oral administration on each occasion. 
The MAT was quite short in all the animals. The bioavailability of penicillin G, calculated 
from the AUC0ral and the mean AUCjntravenouS) was low (0.12-0.34%) following oral
administration.
3.5.2 Caecal liquor and faecal drug concentrations
The caecal liquor concentrations following oral administration of penicillin G to ponies are 
shown in Figure 3-20, and the individual data is given in Appendix A (Table A41). A 
maximum caecal liquor concentration of 157.12, 89.73, 118.98 and 4.96 Jig/ml was 
measured at 1.5 h in pony II, 1 h in pony 12, and 6 h in ponies III and 112, respectively. 
The caecal concentrations were much higher than the plasma concentrations of penicillin G 
following oral administration.
The disposition of penicillin G in the caecal liquor was described using observed AUC and 
AUMC to calculate MRT (Table 3-4). The AUC and AUMC were much larger than those 
calculated for penicillin G in plasma as was the MRT. There was a marked difference in 
MRT between the 2 animals, a fact that was also reflected in the difference in the time to 
maximum caecal liquor concentrations.
Faecal penicillin G concentrations following oral administration of penicillin G to ponies are
given in Appendix A (Table A42). Faecal drug concentrations were measured at 24 h after
oral administration of penicillin G to pony 12 (0.65 |ig/g), only.
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Figure 3-19. Plasma concentrations of penicillin G following oral 
administration to ponies
Parameter 11 12 III 112
tl/2 B2 (min) 7.74 - 10.80 11.46
tl/2 B1 (min) 13.32 - 16.62 21.18
Cmax (M-g/ml) 0.19 0.09 0.14 0.16
tmax (min) 30 30 30 30
AUCobs (M-g.h/ml) 0.13 0.04 0.09 0.11
AUMCobs (Ug.h2/ml) 0.07 0.03 0.05 0.07
AUC (ng.h/ml) 0.12 - 0.07 0.10
AUMC (ng.h2/ml) 0.06 - 0.05 0.08
MRT (min) 32.31 45.00 33.33 38.18
MAT (min) -41.36 -28.67 -22.38 -17.53
F (%) 0.27 0.12 0.24 0.34
Table 3-3. Disposition kinetics of penicillin G in plasma following oral administration to 
ponies
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Figure 3-20. Caecal liquor concentrations of penicillin G following oral 
administration to ponies
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Parameter 11 12 m 112
AUCobs (|ig.h/ml) 
AUMCobs (|ig.h2/ml) 
MRT (h)
746.24
2702.93
3.62
230.73
567.19
2.46
702.73
4356.80
6.20
24.15
161.47
6.69
Table 3-4. Disposition kinetics of penicillin G in caecal liquor following oral administration 
to ponies
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3.5.3 Bacteriological exam inations
Salmonella spp. and C. difficile were selected for but not isolated.
Counts of viable bacteria in caecal liquor following oral administration of penicillin G are 
shown in Figures 3-25 to 3-29, and the individual data is given in Appendix A (Table A43).
The viable number of coliforms isolated following oral administration of penicillin G to 
ponies increased to 108-10l0/ml (Figure 3-21). This was most marked at 24, 48 and 72 h 
after drug administration to ponies II, III and 112. There was a slight increase in the viable 
number of coliforms isolated from pony 12 (up to 107/ml) at 24 and 48 h after drug 
administration.
There was an increase in the number of viable caecal streptococci (up to 10$-1010/ml) 
isolated following oral administration of penicillin G (Figure 3-22). There was a slight 
increase in the number of streptococci isolated (to lO^/ml) at 24 h after drug administration 
to ponies II and 12, and a marked increase in the number of viable faecal streptococci 
isolated (10l0/ml) at 48 h after drug administration to pony III. There was a very small 
increase in the number of streptococci isolated (10^/ml) at 48 h after drug administration to 
pony 112.
There were no marked alterations in the number of viable lactobacilli isolated from caecal 
liquor, although there was an increase in the number of lactobacilli isolated (to lO^/ml) at 48 
h after oral administration of penicillin G to pony III (Figure 3-23). In ponies 12 and III, 
there were no lactobacilli counted at 72 h after drug administration due to mould overgrowth 
on the microaerophilic plates. Lactobacilli identified using the API system were L. 
acidophilus, L. fermentum and L. jensenii.
There were no alterations in the number of viable Bacteroides spp. isolated from ponies II, 
III and 112 after drug administration (Figure 3-24). Bacteroides spp. were isolated at 48 h 
after drug administration to pony 12, but they could not be counted due to the drops of 
diluted caecal liquor having run together on the agar plate. Bacteroides spp. counts were 
reduced slightly (to 108/ml) at 72 and 168 h after drug administration to pony 12. 
Bacteroides spp. identified using the API system were B. eggerthii, B.fragilis, B. ovatus, 
B. thetaiotaomicron, B. uniformis, and B. vulgatus.
There was an increase (10^-108/ml) in the number of Clostridium spp. isolated following 
oral administration of penicillin G to ponies (Figure 3-25). There were high numbers of 
Clostridium spp. isolated (lO^-lO^/ml) from caecal liquor at 24, 48 and 168 h in pony II, at 
0 ,24,48, 72 and 96 h in pony 12, at 24, 48 and 72 h in pony III, and at 48, 72 and 96 h in
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Figure 3-21. Counts of viable coliforms in caecal liquor following oral 
administration of penicillin G to ponies
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Figure 3-22. Counts of viable streptococci in caecal liquor following oral
administration of penicillin G to ponies
119
£
a<y
—BCG
0 24 48 72 96 120 144 168
Time (h)
I 2 HI  112
Figure 3-23. Counts of viable lactobacilli in caecal liquor following oral 
administration of penicillin G to ponies
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Figure 3-24. Counts of viable Bacteroides spp. in caecal liquor following oral
administration of penicillin G to ponies
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Figure 3-25. Counts of viable Clostridium spp. in caecal liquor following oral
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pony 112. Clostridium spp. identified using the API system were C. butyricum , C. 
clostridiiformey and C. perfringens. The latter was identified from pony III (lOfyml) at 24 h 
after oral administration of penicillin G.
Other bacteria identified using the API system were Actinomyces israelii, Bifidobacter 
adolescentis, Eubacterium lentumy and Peptococcus spp..
3.5.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
The luminal pH measurements are shown in Figure 3-26, and the individual data is given 
Appendix A (Table A44). In pony II the caecal liquor pH was increased (>7.2), up to a 
maximum of pH 8.3, at 2, 4, 6, 8, 12 and 24 h after drug administration. In pony 12, the 
caecal liquor pH was increased (>7.2), up to a maximum of pH 7.6, at 0.75, 1, 1.5, 4, 6, 
and 72 h after drug administration. There was an increase in the caecal liquor pH in pony E l 
at 4 and 6 h after drug administration up to 7.3 and 7.5, respectively. There was a slight 
increase in the caecal liquor pH (7.3) at 6 h after drug administration to pony E2.
Caecal liquor SCFA concentrations are shown in Figures 3-27 and 3-28, and the individual 
data is given in Appendix A (Tables A45a-A48a).
In pony II, caecal liquor lactic acid concentrations were increased to 10.1-38.7 mmol/1 at 4, 
6, 8, 12, 24, 28 and 32 h, and were above the normal range of 0.0-24.4 mmol/1 at 8 h after 
drug administration (Figure 3-27). In ponies 12, III and 112, caecal liquor lactic acid 
concentrations were elevated to 5.1-11.1 mmol/1 at 4, 8, 12 and 24 h, at 12, 24, 28 and 48 
h, and at 12, 24, 28 and 32 h, respectively, after drug administration but remained within the 
established normal range.
The total and individual VFA concentrations fluctuated around the normal ranges (Figure 3- 
28). In ponies II and 12, total VFA concentrations of 17.2-19.9 mmol/1 at 24 h and at 12, 28 
and 72 h, respectively, were lower than the normal range of 24.4-109.2 mmol/1. There was 
a reduction in acetic acid concentrations, below the normal range of 12.6-64.5 mmol/1, to 
4.3-10.9 mmol/1 at 8, 12 and 24 h in pony II and at 4, 6 and 8 h in pony 12. Propionic acid 
concentrations, compared with the normal range of 4.7-24.5 mmol/1, increased to 36.4-60.7 
mmol/1 at 4, 6 and 8 h in ponies II and 12. The concentration of propionic acid fell to 0.0- 
3.7 mmol/1 at 24 h in pony II, at 0.25, 0.5, 0.75, 1, 1.5, 12, 24, 28 and 72 h in pony 12, at 
24 h in pony III, and at 12 h in pony 112. Butyric acid concentrations fell, below the normal 
range of 4.8-67.3 mmol/1, to 0.0-3.5 mmol/1 at 6, 8, 12 and 168 h in pony II, a t , 6, 8, 12, 
28 and 72 h in pony 12, at 8, 12, and 32 h in pony III, and at 28 h in pony 112.
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Figure 3-26. Caecal liquor pH following oral administration of penicillin G 
to ponies
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Figure 3-27. Lactic acid concentrations in caecal liquor following oral administration of
penicillin G to ponies
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Figure 3-28. Total VFA concentrations in caecal liquor following oral 
administration of penicillin G to ponies
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The proportions of acetic, propionic and butyric acids, as a percentage of the total VFA 
concentrations are given in Appendix A (Tables A45b, A46b, A47b and A48b). There was a 
reduction in the ratio of acetic acid to 6.6-16.1%, compared with the normal range of 27.9- 
67.0%, at 6 and 8 h in pony II and at 4, 6 and 8 h in pony 12. The ratio of acetic acid 
increased to 71.1-86.7% at 28 h in pony 12, at 8, 12 and 24 h in pony III, and at 8, 12 and 
28 h in pony 112. The ratio of propionic acid was increased to 56.0-93.4%, compared with 
the normal range of 4.9-38.5%, at 4, 6, 8 and 12 h in pony II and at 4, 6 and 8 h in pony 
12. There was no propionic acid at 12 h in ponies 12 and 112 and at 24 h in pony HI. There 
was a reduction in the ratio of butyric acid to 0.0-7.1%, compared with the normal range of 
8.7-66.7%, at 6, 8 and 12 h in pony II, at 6 and 8 h in pony 12, at 8, 12 and 32 h in pony 
III, and at 28 and 72 h in pony 112. There was an increase in the percentage of propionic 
plus butyric acid to 77.7-93.4%, compared with the normal range of 27.1-72.1%, at 4, 6 
and 8 h in pony II and at 4, 6 and 8 h in pony 12. The ratio of propionic plus butyric acid 
fell to 13.3-19.9%, compared with the normal range of 27.1-72.1%, at 12 h in pony 12, at 
8, 24, 28 and 32 h in pony III, and at 8 h in pony III.
Faecal SCFA concentrations are shown in Figures 3-29 and 3-30, and the individual data is 
given in Appendix A (Tables A49-A52). Faecal lactic acid concentrations were increased to 
6.2-6.5 mmol/kg at 0 and 72 h after drug administration to pony II, but there were no lactic 
acid concentrations outside the normal range of 0.0-24.4 mmol/1 following oral 
administration of penicillin G to ponies II, 12, III and 112 (Figure 3.29). There were 
considerable variations in the faecal total and individual VFA concentrations following oral 
administration of penicillin G (Figure 3.30). In pony II, the faecal total VFA concentrations 
were lower than the normal range of 24.4-109.2 mmol/1 throughout the study. In pony 12, 
the total VFA concentrations were lower than normal at 0, 24, 72, 96 and 168 h after drug 
administration. In pony III, the faecal total VFA concentrations were lower than normal at 0, 
24 and 168 h after oral administration of penicillin G. In pony 112, the faecal total VFA 
concentrations were lower than normal at all sampling times except 168 h.
3.5.5 Faecal dry m atter content and consistency
The faecal dry matter content following oral administration of penicillin G is shown in 
Figure 3-31, and the individual data is given in Appendix A (Table A53). There were slight 
changes in faecal dry matter content, and no alterations in faecal consistency were observed.
3.5.6 Plasma biochemistry and haematological exam inations
The plasma biochemistry results are given in Appendix A (Tables A54-A57). There was an 
increase in plasma urea concentrations up to 7.1 mmol/1 following oral administration of
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Figure 3-31. Faecal dry matter content following oral administration of 
penicillin G to ponies
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penicillin G to pony I on occasions 1 and 2. The plasma bilirubin concentration was elevated 
to 30 |imol/l at 24 h in pony III. The results of the haematological examinations are given in 
Appendix A (Tables A58-A61). Other variations in plasma biochemistry and in the 
haematological parameters were not considered to be associated with the administration of 
penicillin G.
3.6 Results of in vitro studies with penicillin G
3.6.1 Caecal liquor concentrations
Penicillin G concentrations (mean±SEM) in caecal liquor following incubation in vitro are 
shown in Figure 3-32, and the individual and mean data are given in Appendix A (Tables 
A62a and b). After 3 h incubation, there was an average of 80.2 % of drug remaining. 
However, the largest reductions in concentration (zone diameter) were seen at either end of 
the concentration range due to limitations of the assay technique (zone diameter, limit of 
detection). That is, around 50-60% of penicillin G remaining at initial concentrations of 0.25 
and 1 pg/ml, whilst around 100% the drug activity remained at 5, 10 and 20 |ig/ml, and 70- 
80% of the drug activity remained at 40 and 80 pg/ml. There was an average of 35.5% 
(excluding 0.25 and 1 pg/ml samples) of drug remaining following 24 h incubation. 
Following 24 h incubation, there was a similar percentage reduction in concentration in all 
the samples (25-50%), except there was no inhibition zone for the 0.25 pg/ml sample, and 
there was only 1% of the 1 fig/ml sample remaining.
3.6.2 SCFA concentrations
Caecal lactic acid and total VFA concentrations (mean±SEM) following in vitro incubation 
are shown in Figure 3-33, and the individual and mean data are given in Appendix A (Tables 
A63-A67). There were no alterations in mean lactic acid or mean total VFA concentrations 
with time or drug concentration.
3.6.3 Acid pH
A plot of penicillin G concentrations (mean±SEM) remaining following in vitro incubation 
for 1 h at pH 1.9 versus initial penicillin G concentrations is shown in Figure 3-34, and the 
individual and mean data are given in Appendix A (Table A68). There was a large amount of 
penicillin G destroyed by incubation at acid pH; on average there was only 15.3% of drug 
remaining. There may be some variation in the percentage of drug activity destroyed at 
different initial concentrations; 9, 12, 16 and 24% of drug remained (mean) at 1, 2,5 and 10 
|ig/ml respectively. However, this may be associated with the assay technique.
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Figure 3-32. Concentrations (mean±SEM) of penicillin G in caecal liquor 
following incubation in vitro for 3 and 24 h
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3.6.4 B inding to hay
A plot of penicillin G concentrations remaining following in vitro incubation with chopped 
hay at pH 1.9 and pH 7.0 is shown in Figure 3-35. There was only 1 replicate of this study 
performed. There was a range of concentrations remaining following incubation at pH 1.9, 
namely 1.05 1.06, 1.43 and 0.89 pg/ml of the initial 10, 25, 50 and 100 pg/ml. There was a 
wide range of concentrations remaining following incubation at pH 7.0, namely 0.21, 0.25, 
7.65 and 9.84 fig/ml of the initial 10, 25, 50 and 100 pg/ml. However, it is interesting that 
only 10.49, 10.57, 14.34 and 8.85% or an average of 11.06% remained at pH 1.9, and 2.1, 
1, 15.3 and 9.84% or an average of 7.1 % remained at pH 7.0.
3.7 D iscussion
Durr (1976) calculated the elimination half-life of penicillin G to be 53.3±4.5 min (mean 
±SEM) following intravenous administration of penicillin G at dose rates of 21 and 36.3 
mg/kg bwt. Whereas, Knight (1975) noted that the elimination half-life of potassium 
penicillin G was 47 min following intravenous administration at dose rates of 12.5, 18 or 
37.6 mg/kg bwt. In the present study, the elimination half-life (harmonic mean) of penicillin 
G was 38.95, 27.25 and 31.52 min in horses, ponies and donkeys, respectively. However, 
the elimination half-life of penicillin G following intravenous administration to ponies II, 12, 
III and 112 was 69.60, 38.82, 36.78 and 62.70 min respectively. The long elimination half- 
life calculated for ponies II and 112 may reflect perivenous administration but it was not 
much longer than the elimination half-life calculated following intravenous administration of 
penicillin G to horses by Durr (1976). Although the elimination half-life of penicillin G 
reported in the present study following intravenous administration to horses, ponies and 
donkeys was shorter than the values reported by other authors, it may not affect the regime 
required to maintain adequate therapeutic plasma concentrations of penicillin G.
Knight (1975) stated that a plasma or serum concentration of drug 2-4 times the MIC was 
required to ensure the bactericidal activity of a penicillin. The MIC of susceptible equine 
Gram positive and Gram negative aerobic bacteria is <1 p.g/ml penicillin G (Adamson et al.y 
1985). Similarly, Knight (1975) stated that most bacteria susceptible to penicillin G had an 
MIC of 0.05-1 jig/ml and that these included 6 haemolytic streptococci, non-B-lactamase 
producing staphylococci and C. tetani. Other organisms, such as Rhodococcus equi (MIC 
<4 pg/ml) (Prescott, 1991, Prescott and Nicholson, 1984) are less susceptible to penicillin 
G. If plasma concentrations are to be maintained above a minimum concentration, for 
susceptible bacteria, of 0.1 pg/ml (twice 0.05 pg/ml) then intravenous administration of 
penicillin G at a dose rate of 10 mg/kg bwt should be repeated every 4 h in horses, ponies 
and donkeys.
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Generally, the computation of optimum drug dose rates tries to maintain plasma or serum 
drug concentrations at several times above the MIC of an organism and ignores the post­
antibiotic effect (Prescott and Baggot, 1985). The so-called post-antibiotic effect is defined 
as the absence of bacterial growth for several hours after the removal of a drug which was 
present at or above the MIC. The penicillins act by binding covalently and irreversibly to the 
active site of the cross-linking enzyme in bacterial cell walls and therefore affect bacteria that 
are growing rapidly. However, the effect of the penicillins continues even when bacteria are 
no longer in the active growth phase since drug remains bound to the receptor sites (Tobin, 
1979). The post-antibiotic effect is more marked in vivo than in vitro (Prescott and Baggot, 
1985). If plasma concentrations are allowed to fall temporarily below the MIC (0.05 |ig/ml) 
then intravenous administration of penicillin G at a dose rate of 10 mg/kg bwt would need to 
be repeated less frequently than 6 times per day. Thus, intravenous administration of 
penicillin G every 6 or 8 h would probably be adequate. This is similar to the inter-dosing 
interval of 6 h suggested by Knight (1975), although the dose rates of 30-250 mg/kg bwt 
were much higher than the dose rate used in the present study. Following intravenous 
administration of penicillin G at a dose rate of 10 mg/kg bwt the CpO (mean±SEM) values 
were 62.90±8.87, 74.52±14.65 and 126.42±43.13 |ig/ml in horses, ponies and donkeys, 
respectively. The CpO following intravenous administration of penicillin G at a dose rate of 
30-250 mg/kg bwt would be veiy high. This may be of no additional benefit since there is an 
optimum concentration above which there is no increase in the rate of bacterial killing 
(Prescott and Baggot, 1985).
The amount of the total dose of penicillin G in caecal liquor following intravenous 
administration can be expressed as a percentage of the AUC0bs plasma taking into 
account the differences between the estimated volume of caecal contents (6.67 and 6.17 1 in 
ponies I and II, respectively) and the estimated plasma volume of 51 ml/kg bwt (Swenson, 
1977) which was equal to 11.88 and 11.02 1, in ponies I and II, respectively. Penicillin G 
(1.95%) was detected in the caecal liquor of 1 animal only following intravenous 
administration. This suggests that penicillin G was excreted in the bile into the intestinal 
tract, although entry into the intestinal lumen by other routes is not ruled out. In the other 
ponies it is possible that penicillin G was present within the intestinal lumen following 
intravenous administration and was destroyed prior to the analysis of samples. Other authors 
have shown that penicillin G is inactivated rapidly in the gastrointestinal tract (Prins, 1987) 
and by Blactamase producing organisms (De Louvois and Hurley, 1977). Beta-lactamase 
production has been described for a number of different organisms, including coliforms and 
Bacteroides spp. which were present in high numbers in the caecal liquor of ponies in the 
present study (De Louvois and Hurley, 1977).
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Penicillin G was absorbed rapidly (maximum plasma concentrations at 0.5 h after 
administration) following oral administration to ponies. This is similar to the results of the 
study by Schwark et al. (1983) who reported maximum plasma concentrations at 0.5-1 h 
after oral administration of penicillin V. The bioavailability of penicillin G following oral 
administration to ponies was low (0.12-0.34%). This was probably due to destruction of the 
drug by gastric acid since only 15% of penicillin G remained following in vitro incubation at 
pH 1.9 for 1 h. In addition, penicillin G appears to be bound to hay. Watson (1986) 
reviewed the influence of food on the absorption of antimicrobial agents and noted that, in 
man, the systemic availability of both penicillin G and penicillin V were reduced by the 
presence of food in the intestine. In the present study, drug administration took place prior to 
the ponies receiving their morning hay. Schwark et al. (1983) withheld food from horses for 
8 h prior to drug administration. The results may have been different if food had been 
withheld prior to drug administration, however it is unlikely that this would be practical in a 
clinical situation.
Some penicillin G was absorbed from the gastrointestinal tract following oral administration 
but the maximum plasma concentrations were low; 0.19, 0.09, 0.14 and 0.16 |!g/ml in 
ponies II, 12, III and 112, respectively. Although these plasma concentrations would be 
sufficient to treat infections caused by susceptible bacteria, the short MRT (32.31, 45.00, 
33.33 and 38.18 min in ponies II, 12, III and 112, respectively) would require very frequent 
repetition of drug administration, at a dose rate of 10 mg/kg bwt, to maintain adequate 
therapeutic concentrations in plasma. Schwark et al. (1983) and Ducharme et al. (1983) 
administered a much higher dose rate of penicillin V, than the dose rate of penicillin G used 
in the present study, to obtain plasma concentrations that would be useful clinically. 
However, Baggot et al. (1990) reported that not only was there poor systemic availability of 
penicillin G and penicillin V, following oral administration at a dose rate of 90 mg/kg bwt to 
horses, but also that the animals developed clinical signs culminating in the development of 
profuse watery diarrhoea at 8 h after drug administration. Thus, an increase in the dose rate 
may not only fail to produce adequate plasma concentrations for therapy, but also increase 
the likelihood of the development of antimicrobial-associated diarrhoea.
There were high concentrations of penicillin G measured in caecal liquor following oral 
administration. This was surprising since 85% of penicillin G appeared to be destroyed at a 
pH similar to that found in the stomach of the equine (pH 1.63-1.97) (Sangiah et al., 1989). 
However, other authors have reported that gastric pH is much higher than this when digesta 
are present (Bogan et al., 1984). In the present study it was shown that penicillin G was 
destroyed or inactivated by caecal liquor in vitro. In vivo, this appeared to occur following 
oral administration of drug to one animal only. However, alterations in the number of viable
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bacteria isolated from caecal liquor and in the concentrations of SCFAs were similar in both 
ponies on both occasions.
The time to maximum caecal liquor concentrations of penicillin G varied quite markedly 
between animals. The peak concentration occurred at 1.5 and 1 h in ponies 11 and 12, and at 
6 h after oral administration to ponies III and 112. This suggests that gastric and small 
intestinal transit times may differ markedly in individual animals. There was a wide variation 
(24.15-746.24 |ig.h/ml) in the amount of penicillin (AUC) in the caecal liquor and in the 
length of time that penicillin remained (MRT) in the caecum (2.46-6.69 h) following oral 
administration. Although, the MRT was similar between occasions in the two ponies despite 
the differences in AUC.
The coliform counts recorded in the present study fall into both the range of 103-l()4/g 
faeces described by Smith (1965) and around 106/g faeces described by White and Prior 
(1982) but were much lower than the control values used by Garner et al. (1978). There 
were no consistent alterations in the number of coliforms isolated following intravenous 
administration of penicillin G to horses, ponies and donkeys or ponies with cannulated 
caecal fistulas. There were apparent increases in the mean number of coliforms isolated from 
pony and donkey faeces following intravenous administration of penicillin G. In addition, 
high caecal liquor coliform counts of up to 109/ml were recorded for up to 168 h after oral 
administration of penicillin G to ponies with cannulated caecal fistulas. In previous studies, 
Andersson et al. (1971) recorded an increase in the number of coliforms isolated from faeces 
1-2 days after intravenous administration of oxytetracycline at a very high dose rate to 
horses, and White and Prior (1982) recorded viable coliform counts of around 109/g faeces 
following repeated oral administration of high doses of oxytetracycline. In addition, 
Andersson et al. (1971) and White and Prior (1982) found significant alterations in the 
number of faecal streptococci isolated following oxytetracycline administration. There were 
no marked alterations in the number of viable streptococci isolated following the intravenous 
administration of penicillin G, but there were increases in the number of viable streptococci 
isolated following oral administration of penicillin G, in the present study. There were 
increases in the number of Clostridium spp. isolated following intravenous administration of 
penicillin G to donkeys and following oral administration of penicillin G to ponies. It is 
interesting that there were increases in the number of bacteria that are susceptible to penicillin 
G in vitro, such as streptococci and Clostridium spp..
Andersson et al. (1971) reported an increase in faecal pH from 6.1-6.5 to 6.9-8.1 following 
intravenous administration of a massive dose of oxytetracycline to horses. The control caecal 
pH range noted by Gamer et al. (1978) was around 7.2. In the present study there was a
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modest increase in caecal liquor pH following oral administration of penicillin G with a 
maximum pH of 8.3, 7.6, 7.5 and 7.3 in ponies II, 12, III and 112 respectively.
There were alterations in SCFA concentrations following both intravenous and oral 
administration of penicillin G. There were increases in lactic acid concentrations following 
both intravenous and oral administration of penicillin G, although these changes appeared 
mainly in the caecal liquor and not in the faecal samples, suggesting that the excess lactic 
acid was absorbed across the gastrointestinal mucosa. The increase in lactic acid 
concentrations could be explained by the increase in the number of lactic acid producing 
bacteria, such as streptococci and Clostridium spp.. The increased lactic acid concentrations 
occurred at variable times after intravenous or oral administration of penicillin G, although 
they occurred after the peak drug concentrations. It is interesting that the highest 
concentration of lactic acid was measured following intravenous administration of penicillin 
G to pony 12. This was the only animal in which penicillin G was measured in caecal liquor 
following intravenous administration. There was only one pony in which lactic acid 
concentrations were higher than the normal range of 0.0-24.4 mmol/1 following oral 
administration of penicillin G, and there was a slight increase in the lactic acid concentration 
in the faeces of this pony.
There were no consistent alterations in VFA concentrations or proportions following 
intravenous administration of penicillin G. However, in pony 12, the only pony in which 
penicillin G was measured in the caecal liquor following intravenous administration, 
propionic concentrations increased, butyric acid concentrations decreased, the proportions of 
acetic and propionic acids increased and the proportion of butyric acid decreased. There was 
a reduction in the concentrations of propionic and butyric acids, and a reduction in the 
proportion of butyric acid in caecal liquor, following oral administration of penicillin G. In 
addition, there was a reduction in the proportions of propionic plus butyric acids, which 
reflected a relative increase in the amount of acetic acid and a relative reduction in propionic 
and butyric acid concentrations. Prins (1987) noted that although penicillin G was 
inactivated rapidly by rumen contents, administration of the drug still produced a substantial 
reduction in the cellulolytic activity of rumen fluid. Interestingly, the high pH and low 
propionic and butyric acid concentrations occurred at similar times (between 6 and 24 h after 
drug administration). Although, there was a reduction in the total VFA concentrations in 
only two ponies, the alterations in the proportions of VFA concentrations may represent a 
reduction in production of VFA and hence explain the apparent increase in pH.
Alterations in propionic and butyric acid concentrations are associated with the 
administration of the so-called growth promoting antimicrobial agents. Generally, there is a 
shift in fermentation towards propionic acid production with reductions in methanogenesis
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and acetic and butyric acid concentrations. However, a reduction in propionic acid 
concentrations has been reported following administration of chloral hydrate to ruminants 
(Amgarten et al., 1981). The reduction in propionic acid and increase in lactic acid 
concentrations were attributed to inhibition of the reductive pathway from lactate to 
propionate. Propionic acid is produced, along with acetate and succinate, by Bacteroides 
spp. and Selenomonas spp. (Miller and Wolin, 1979). Butyric acid is formed by a variety of 
different bacteria in the gastrointestinal tract, including C. butyricum, Eubacterium spp., 
Butyrivibrio spp., Fusobacterium spp. and Bacteroides spp. (Miller and Wolin, 1979). It 
may be that the increase in the number of coliforms, streptococci and Clostridium spp. 
resulted in a relative reduction in the numbers of propionic and butyric acid producing 
bacteria.
An increase in intestinal lactic acid concentrations may be important in the development of 
systemic lactic acidosis and its clinical sequelae. It has been shown that butyric acid is an 
important respiratory fuel in colonocytes (Roediger, 1982) and a reduction in colonic butyric 
acid concentrations has been associated with adenomatous polyps and colonic cancer in man 
(Clausen et al., 1991). A prolonged reduction in butyric acid concentrations may result in a 
reduction in the energy supply to intestinal cells and the development of large intestinal 
disease. In addition, a prolonged elevation of intestinal pH removes the antibacterial effect of 
acetic and formic acids (pH 6.8 or less) and may promote bacterial overgrowth (Fleming and 
Arce, 1986).
There was an increase in the plasma urea concentrations following oral administration of 
penicillin G to pony I in the present study. In addition, there was an increase in the plasma 
bilirubin concentration at 24 h following oral administration of penicillin G to pony III. 
These alterations in clinical chemistry were noted by Andersson et al. (1971) following 
intravenous administration of a massive dose of oxytetracycline, although none of the other 
changes noted previously were seen in the present study. Moreover, there were no clinical 
signs associated with the onset of antimicrobial-associated diarrhoea and no alterations in 
either faecal dry matter content or consistency were observed.
The intravenous administration of penicillin G at a dose rate of 10 mg/kg bwt repeated every 
6-8 h would be suitable to treat infections due to susceptible bacteria. There is a low risk of 
developing antimicrobial-associated alterations in gastrointestinal microbial metabolism 
following a single intravenous administration of penicillin G at a dose rate of 10 mg/kg bwt. 
Oral administration of penicillin G at a dose rate of 10 mg/kg bwt would be unsuitable for 
systemic antimicrobial therapy of susceptible infections in the equine due to low systemic 
availability and to the alterations in gastrointestinal microbial metabolism caused by 
unabsorbed active drug remaining in the gastrointestinal lumen.
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4 Studies with ampicillin
4.1 Introduction
A number of penicillins, including ampicillin and amoxicillin, have an extended spectrum of 
activity, in that they retain the typical activity of penicillin G against Gram positive bacteria 
and, in addition, are active against some Gram negative bacteria not affected by penicillin G, 
but they are not active against 6-lactamase producing bacteria (Brander, 1977, Brumbaugh, 
1987).
Ampicillin has been used in the treatment of many conditions in the equine, including 
enteritis, metritis, pneumonia and septicaemia (Arbeiter et al., 1976, By water, 1982a, 
Huber, 1982a, Keefe et al., 1980, Van Miert, 1988). However, there is wide variation in the 
dose rates (2-20 mg/kg bwt) recommended for parenteral administration of ampicillin to 
Equidae (Bywater, 1982a, Brown et al., 1982, Huber, 1982a, Knight, 1975, Prescott and 
Baggot, 1988a, Van Miert, 1988). Different preparations of ampicillin may have different 
pharmacokinetics and, at equimolar dose rates, ampicillin sodium reaches higher 
concentrations in blood than ampicillin trihydrate and is therefore more likely to produce 
better clinical results (Tobin, 1979). A number of studies have examined the plasma 
disposition of ampicillin sodium in horses using a variety of different dose rates (Durr, 
1976, Keefe et al., 1980, Bowman et al., 1986).
Although there have been studies of the disposition of ampicillin following oral 
administration in other species (Dorrestein et al., 1987, Jusko, 1975, Thompson and Black, 
1978, Ziv et al., 1977), there is little information on the oral administration of ampicillin in 
the equine. However, Brown etal. (1984b) have reported serum concentrations of ampicillin 
in foals following a single oral dose of ampicillin trihydrate.
There have been a number of different studies of the plasma disposition and 
pharmacokinetics of amoxicillin following intravenous and oral administration. Baggot et al. 
(1988) studied the disposition of amoxicillin following intravenous administration at a dose 
rate of 20 mg/kg bwt to foals and reported that the disposition of the drug (the apparent 
volume of distribution and the CL5, and consequently the elimination half-life) were typical 
of a penicillin. This suggested that renal function (based upon the CLb) was adequate in 
neonatal foals. In man, amoxicillin is absorbed more rapidly and completely from the 
gastrointestinal tract than ampicillin, and therefore it is more useful clinically (Zarowny et 
al., 1974). In calves, amoxicillin is absorbed poorly following oral administration, but 
attains high concentrations in the gastrointestinal tract and would be suitable for treating 
gastrointestinal infections with susceptible pathogens (Palmer et al., 1977). However, oral
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administration of amoxicillin to calves would be unlikely to produce effective serum 
concentrations against the majority of Gram negative calf pathogens (Ziv and Horsey, 
1979). Love et al. (1981) reported serum concentrations of amoxicillin following oral 
administration, at a dose rate of 13-30 mg/kg bwt, to Thoroughbred foals. Peak plasma 
concentrations, of around 10 |ig/ml, were attained within 30-60 min of administration. 
Although the drug was absorbed adequately (mean systemic availability circa 40%) there 
was wide individual variation in the systemic availability (Baggot et al., 1988). Wilson etal. 
(1988) compared the pharmacokinetics and estimated bioavailability of amoxicillin in mares 
following intravenous and intramuscular administration (at a dose rate of 10 mg/kg bwt) and 
oral administration (at a dose rate of 20 mg/kg bwt). Mean peak plasma concentrations of 
around 3 |ig/ml were attained at 1.5 h after oral administration, however the systemic 
bioavailability was poor (circa 10%). Similarly, oral administration of amoxicillin, at a dose 
rate of 10 mg/kg bwt, was compared with oral administration of pivampicillin (the pivaloyl- 
oxymethyl ester of ampicillin), at a dose rate of 19.9 mg/kg bwt (equivalent to 15 mg/kg bwt 
ampicillin), to adult horses (Ensink et al., 1992). Pivampicillin, which is hydrolyzed to 
ampicillin as it is absorbed from the gastrointestinal tract, had a higher bioavailability than 
amoxicillin (30% and 5%, respectively) in adult horses (Ensink et al., 1992). Thus, the 
bioavailability of amoxicillin was low in adult horses and higher in foals.
Generally, the systemic availability of penicillins administered orally is low in the adult horse 
(Ensink et al., 1992, Wilson et al., 1988) and the risk of disrupting the commensal 
gastrointestinal microflora is high. That is, assuming that the antimicrobial agent is not 
destroyed within the gastrointestinal lumen, either by gastric acid or by bacterial metabolism, 
e. g. B-lactamase production. The extended spectrum penicillins, such as ampicillin, are acid 
stable and should pass unharmed through the acidic environment of the stomach. In 
addition, Palmer et al. (1977) showed that oral administration of amoxicillin to calves 
resulted in high drug concentrations throughout the gastrointestinal tract for around 8 h after 
administration. The advent of inactive prodrugs, such as pivampicillin, which, in theory, are 
activated following absorption from the gastrointestinal tract, may provide a suitable means 
of administration of extended spectrum penicillins in the equine.
Ampicillin has not been examined thoroughly with respect to its plasma disposition and 
pharmacokinetic behaviour in ponies and donkeys. The present study examined the plasma 
disposition of ampicillin sodium in horses, ponies and donkeys after intravenous 
administration at a dose rate of 10 mg/kg bwt. Alterations in the intestinal flora were studied 
by bacteriological examination of serial faecal samples and large intestinal fermentation was 
studied using faecal SCFA concentrations. The faecal dry matter content and the faecal 
consistency were used as indicators of the presence or absence of diarrhoea. Similar studies 
were carried out in ponies with cannulated caecal fistulas following single intravenous and
139
oral administrations of ampicillin sodium at a dose rate of 10 mg/kg bwt. In addition, drug, 
bacteriological and SCFA analyses were carried out in caecal liquor, and plasma 
biochemistry and haematology were monitored.
4.2 Materials and Methods
4.2.1 Intravenous administration of ampicillin to horses, ponies and 
donkeys
Four Thoroughbred geldings and one mare (No. 1-4 and 6), six ponies (No. 7-9 and 11-13) 
and three donkeys (No. 15-17) were used as outlined in the general Materials and Methods. 
Ampicillin sodium was administered by intravenous bolus injection at a dose rate of 10 
mg/kg bwt. Plasma samples were taken prior to intravenous administration of ampicillin and 
at 0.25, 0.5 0.75, 1, 1.5, 2, 4, 8, 12 and 24 h, with additional samples at 0.033, 0.083 and 
6 h in some animals. Faecal samples were taken at 0, 24, and 48 h for drug analysis, 
bacteriological examination, SCFA analysis and measurement of faecal dry matter content 
from horses 3, 4 and 6, ponies 7-9 and donkeys 15-17.
4.2.2 Intravenous administration of ampicillin to ponies with cannulated 
caecal fistulas
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 2 occasions (1 and 2). Ampicillin sodium was 
administered by intravenous bolus injection at a dose rate of 10 mg/kg bwt. Plasma samples 
for drug analysis and caecal liquor samples for drug analysis, measurement of pH and 
SCFA analysis were taken at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6 , 8, 12 and 24 h with an 
additional caecal liquor sample at 48 h. Bacteriological examination of caecal liquor was 
carried out at 0, 24 and 48 h. Faecal samples were taken for drug analysis, SCFA analysis 
and measurement of dry matter content at 0, 24 and 48 h. Plasma biochemistry and 
haematological examinations were carried out at 0, 24 and 48 h.
4.2.3 Oral administration of ampicillin to ponies with cannulated caecal 
fistulas
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 2 occasions (1 and 2) at least 6 weeks after 
intravenous administration of ampicillin sodium. Ampicillin sodium was administered via 
nasogastric tube at a dose rate of 10 mg/kg bwt. Plasma samples, for drug analysis, and 
caecal liquor samples, for drug analysis, pH measurement and SCFA analysis, were taken at 
0, 0.25, 0.75, 1, 1.5, 2, 4, 6, 8, 12 and 24 h with further caecal liquor samples taken at 28, 
32, 48, 52, 56, 72,96 and 168 h. Bacteriological examinations of caecal liquor were carried
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out at 0, 24, 48, 72, 96 and 168 h. Faecal samples were taken for measurement of drug 
concentrations, SCFA concentrations and dry matter content at 0, 24, 48, 72, 96 and 168 h. 
No plasma biochemistry or haematology samples were taken.
4.2.4 In vitro studies with ampicillin
A range of concentrations of ampicillin were incubated for 3 and 24 h in caecal liquor at 
body temperature in an anaerobic environment, as outlined in the general Materials and 
Methods, and drug and SCFA concentrations were measured following incubation. A range 
of concentrations of ampicillin were incubated at pFl 1.9 for 1 h at room temperature, as 
outlined in the general Materials and Methods. A range of concentrations of ampicillin were 
incubated in the presence of chopped hay at body temperature for 3 h at pH 1.9 and pH 7.0 
as outlined in the general Materials and Methods.
4.3 Results of intravenous administration of ampicillin to horses, ponies and 
donkeys
4.3.1 Plasma disposition and pharmacokinetics
A semilogarithmic plot of plasma concentrations (mean±SEM) following intravenous 
administration of ampicillin to horses, ponies and donkeys is shown in Figure 4-1. Plasma 
concentrations from individual animals are given in Appendix B (Tables B1-B3). In all 3 
groups, the initial plasma concentrations were similar, however the decline phase of the 
plasma concentration versus time plot was less steep in horses than it was in ponies and 
donkeys, which may reflect differences in the elimination of ampicillin. Ampicillin was 
detected in plasma (>0.02 |ig/ml) for up to 8 h in horses and donkeys, and 6 h in ponies.
The pharmacokinetic parameters calculated from the bi-exponential equations used to 
describe the plasma concentration versus time data are given in Table 4-1, and the individual 
data is given in Appendix B (Tables B4-B6). The harmonic mean of the elimination and 
distribution half-lives calculated for horses, ponies and donkeys were similar and quite 
short. The AUCs in horses and ponies were similar and were larger than the AUC in 
donkeys. There was a statistically significant difference between the AUC in horses and 
donkeys (p = 0.04). The Vc and Vd were similar in horses and donkeys but were smaller in 
ponies. This may reflect differences in the extracellular fluid volume or body water 
compartment. However, it is only a mathematical measure of the how the drug distributes 
within the body and does not represent actual body compartments. The CL5 was similar in 
magnitude in horses and ponies and was smaller than in donkeys. There was a statistically 
significant difference between the CLb in horses and donkeys (p = 0.04).
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Figure 4-1. Plasma concentrations (mean±SEM) of ampicillin following 
intravenous administration to horses, ponies and donkeys
Parameter Horses (n=5) Ponies (n=6) Donkeys (n=3)
tl/2 B2 (min)* 14.79 6.62 5.86
tl/2 B1 (min)* 60.88 52.34 42.80
CpO (pg/ml) 47.57±8.30 78.35111.40 55.00114.81
Vc (ml/kg) 246.19±53.43 152.78130.97 224.74180.34
AUCobs (ji-g.h/ml) 46.70±3.79 46.1718.07 25.4813.46
AUMCobs (Hg h2/ml) 84.72±33.10 55.86124.05 21.8613.46
AUC (ng.h/ml) 44.17±2.65 40.3817.31 24.7013.06
AUMC (ng.h2/ml) 73.73±25.86 51.01118.65 22.0013.71
MRT (min) 100.07±31.57 63.38113.29 52.0117.74
Vdarea(nil/kg) 430.05±96.23 386.16193.22 499.201172.79
VdSs (ml/kg) 345.31±85.99 260.44136.74 422.491174.80
CLb (ml/h.kg) 229.67113.64 257.68135.14 418.80156.43
kel(/h) 1.1210.22 1.9710.32 2.1510.44
k21 (/h) 1.8210.79 2.3610.71 3.2310.69
k l2 (/h) 0.5610.19 2.7011.52 2.6910.80
Table 4-1. Disposition kinetics of ampicillin in plasma following intravenous administration
to horses, ponies and donkeys
Key: data as mean±SEM; * harmonic mean
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4.3.2 Faecal concentrations
There was no ampicillin detected in faeces following intravenous administration to horses, 
ponies and donkeys.
4.3.3 Bacteriological examinations
Counts of viable bacteria (mean±SEM) in faeces following intravenous administration of 
ampicillin are shown in Figures 4-2, 4-3 and 4-4 and the individual data is given in 
Appendix B (Tables B7-B9).
Salmonella spp. and C. difficile were selected for but not isolated.
In the horses, the mean number of coliforms isolated was high (lO^/g) at 48 h after drug 
administration (Figure 4-2). However, there were no coliforms isolated from horse 3 at 0 
and 48 h, no marked alterations in the number of coliforms isolated from horse 4, and a high 
number of coliforms (10^ /g )  isolated from horse 6 at 48 h after drug administration. The 
mean number of streptococci isolated from horses was high (lOfyg) at 48 h after drug 
administration. There was an increase in the number of streptococci isolated at 48 h (lOfyg) 
after drug administration to horse 6. There were no marked alterations in the number of 
lactobacilli, Bacteroides spp ., or Clostridium spp. isolated from horses following 
intravenous administration of ampicillin. However, the number of Bacteroides spp. isolated 
from horses was low (lO^-lOfyg) on all occasions, except from horse 4 (lO^/g) prior to 
drug administration.
There was a slight increase (to lO^/g) in the mean number of coliforms isolated from ponies 
at 24 and 48 h after drug administration (Figure 4-3). There was an increase (to lOfyg) in the 
number of coliforms isolated from pony 8 at 24 h, and from pony 7 at 24 and 48 h after drug 
administration. There was a slight increase (to 107/g) in the mean number of streptococci 
isolated from ponies at 24 and 48 h after drug administration. There was an increase in the 
number of streptococci isolated from pony 7 at 24 h (10^/g) and from pony 8 at 48 h 
(lOfyg). There were no marked alterations in the number of lactobacilli, Clostridium spp. or 
Bacteroides spp. isolated following drug administration. Although, there were low numbers 
of Bacteroides spp. (<l()9/g) isolated at all times, except at 24 h from pony 7 and 48 h from 
pony 8. There were moderately high numbers of Clostridium spp. isolated from pony 7 
(lOfyg) at 24 h and from pony 9 (lOfyg) at 48 h.
There was a slight increase (to lO^/g) in the mean number of coliforms isolated from 
donkeys at 48 h after drug administration (Figure 4-4). This was due to an increase in the 
number of coliforms isolated from donkey 16 at 48 h (lO^/g). The mean number of
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Figure 4-2. Counts of viable bacteria (mean±SEM) in faeces following 
intravenous administration of ampicillin to horses
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Figure 4-3. Counts of viable bacteria (mean±SEM) in faeces following
intravenous administration of ampicillin to ponies
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Figure 4-4. Counts of viable bacteria (mean±SEM) in faeces following 
intravenous administration of ampicillin to donkeys
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streptococci isolated was high (lO^-lO^/g) throughout the study. There were high numbers 
(lO^-lO^/g) of streptococci isolated from donkey 15 at 0,24 and 48 h, from donkeys 16 and 
17 prior to drug administration, and from donkey 16 at 48 h. There was a slight increase (to 
10^/g) in the mean number of lactobacilli isolated at 48 h after drug administration to 
donkeys. There were high numbers (lO^-lO^/g) of lactobacilli isolated from donkeys 15 and 
17 at 48 h after drug administration. There were no marked alterations in the number of 
Bacteroides spp. or Clostridium spp. isolated following intravenous administration of 
ampicillin to donkeys. However, the number of Bacteroides spp. isolated was low 
throughout the study (lO^-lO^/g), except from donkeys 16 and 17 (lO^/g) at 48 h.
4.3.4 Faecal SCFA concentrations
Faecal lactic acid and total VFA concentrations (mean ±SEM) following intravenous 
administration of ampicillin to horses, ponies and donkeys are shown in Figures 4-5 and 4- 
6 , and the individual and mean data are given in Appendix B (Tables B10-B19). The SCFA 
concentrations in faeces of horses, ponies and donkeys were very variable. Lactic acid 
concentrations in faeces remained within the normal range of 0.0-24.4 mmol/1 (Figure 4-5).
There were marked variations in faecal total and individual VFA concentrations in horses, 
ponies and donkeys following intravenous administration of ampicillin (Appendix B, Tables 
B10-B18). In horses, mean total VFA concentrations were below the normal range of 24.4-
109.2 mmol/1 at 0, 24 and 48 h after intravenous administration of ampicillin. In ponies, 
mean total VFA concentrations were within the normal range prior to drug administration, 
and lower than normal at 24 and 48 h after intravenous administration of ampicillin. In 
donkeys, the mean total VFA concentrations were within the normal range at 0, 24 and 48 h. 
The variations in total and individual VFA concentrations were considered not to be 
associated with intravenous administration of ampicillin.
4.3.5 Faecal dry matter content and consistency
A plot of faecal dry matter content (mean±SEM) versus time following intravenous 
administration of ampicillin to horses, ponies and donkeys is shown in Figure 4-7, and the 
individual data is given in Appendix B (Tables B20-B22). The mean faecal dry matter 
content was reduced slightly (circa 17%) in horses at 24 h after ampicillin administration. 
Faecal dry matter content was low (<17%) at 24 h in horses 4 and 6, and at 48 h in horse 6. 
There were no marked alterations in the mean faecal dry matter content following 
intravenous administration of ampicillin to ponies and donkeys. The faecal dry matter 
content was low {circa 13%) in donkey 17 prior to drug administration. No alterations in 
faecal consistency were observed following intravenous administration of ampicillin to
146
701 
^  60 i  
|  501
co
«u
C<ytjao
U
4 0-
30-
2 0 -
10 { 
o O
0 24
Time (h)
Horses Ponies
48
Donkeys
Figure 4-5. Lactic acid concentrations (mean±SEM) in faeces following 
intravenous administration of ampicillin to horses, ponies and donkeys
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Figure 4-6. Total VFA concentrations (mean±SEM) in faeces following
intravenous administration of ampicillin to horses, ponies and donkeys
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Figure 4-7. Faecal dry matter content (mean±SEM) following intravenous 
administration of ampicillin to horses, ponies and donkeys
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horses, ponies and donkeys. Although, faecal consistency was soft prior to drug 
administration to donkey 17.
4.4 R esults of in travenous adm in istration  of am picillin  to ponies with 
cannulated caecal fistulas
4.4.1 Plasma disposition and pharm acokinetics
The plasma concentrations of ampicillin following intravenous administration to ponies I and 
II on occasions 1 and 2 are given in Appendix B (Table B23).
A bi-exponential equation best described the data from ponies II and 112. The plasma 
concentration versus time data from pony 12 and II1 could not be described using a bi­
exponential equation since it was distributed very rapidly and the disposition curve was 
described by a one-compartment model (elimination phase only). The pharmacokinetic 
parameters calculated from the plasma concentration versus time data of each animal on each 
occasion are given in Table 4-2.
4.4.2 Caecal liquor and faecal concentrations
The caecal liquor concentrations of ampicillin following intravenous administration to ponies 
I and II on occasions 1 and 2 are given in Appendix B (Table B24). No ampicillin was 
detected in caecal liquor from ponies III or 112 following intravenous administration. The 
caecal liquor concentrations of ampicillin versus time from pony I are shown in Figure 4-8. 
Maximum caecal liquor concentrations were 2.26 and 1.13 |Ag/ml at 1.5 and 0.25 h on 
occasions 1 and 2, respectively. The caecal AUC was expressed as a percentage of the 
intravenous AUC, taking into account the estimated volume of caecal contents of 6.67 1 in 
pony II and the estimated plasma volume of 51 ml/kg bwt (Swenson, 1977) or 11.88 1, and 
was 3.66% in pony II and 3.18% in pony 12.
Drug disposition within the caecum was described using AUC and AUMC for observed 
values and the ratio of these (MRT). The pharmacokinetic variables that were calculated are 
given in Table 4-3.
There was no ampicillin detected in faecal samples following intravenous administration to 
ponies.
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Parameter Il§ 12* n i* II2§
tl/2 B2 (min) 3.42 - - 40.74
tl/2 B1 (min) 70.62 87.78 101.82 144.30
CpO (|ig/ml) 118.36 20.57 21.31 17.70
Vc (ml/kg) 84.50 486.17 469.28 565.01
AUCobs (ltg.h/ml) 54.77 45.61 53.01 52.24
AUMCobs (fig.h2/ml) 73.21 90.90 119.89 171.63
AUC (Hg.h/ml) 48.21 43.43 52.18 50.55
AUMC (jj.g.h2/ml) 69.30 91.70 127.79 164.77
MRT (min) 80.20 119.58 135.70 197.12
Vdarea (ml/kg) 352.30 486.17 469.28 686.70
Vdss (ml/kg) 298.18 486.17 469.28 644.95
CLb (ml/h.kg) 207.43 230.26 191.63 197.84
kel (Ai) 2.46 0.47 0.41 0.35
k21 (Ai) 2.91 - - 0.84
k l2 (Ai) 7.74 - - 0.12
Table 4-2. Disposition kinetics of ampicillin in plasma following intravenous administration 
to ponies
Key: * calculated from a mono-exponential equation;§ calculated from a bi-exponential 
equation
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Figure 4-8. Caecal liquor concentrations o f ampicillin following intravenous 
administration to ponies II and 12
Parameter 11 12
AUCobs (M-g.h/ml) 
AUMCobs (|ig.h2/ml) 
MRT (h)
3.57
6.36
1.78
2.58
8.60
3.34
Table 4-3. Disposition kinetics o f ampicillin in caecal liquor following intravenous 
administration to pony I
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4.4.3. Bacteriological exam inations
Counts of viable bacteria in caecal liquor following intravenous administration of ampicillin 
are shown in Figures 4-9 to 4-13, and the individual data is given in Appendix B (Table 
B25).
Salmonella spp. and C. difficile were selected for but not isolated.
There were no marked alterations in the number of coliforms (Figure 4-9), lactobacilli 
(Figure 4-11), Bacteroides spp. (Figure 4-12) or Clostridium spp. (Figure 4-13) isolated 
from ponies following intravenous administration of ampicillin. There was an increase in the 
number of streptococci (up to lOfyml) isolated from pony II at 24 h, and from pony III at 
48 h after intravenous administration of ampicillin (Figure 4-10). Otherwise there were no 
marked alterations in the number of streptococci isolated. The number of Bacteroides spp. 
isolated was low (10^-10^/ml) at 48 h in pony II, at 24 and 48 h in pony 12, and at 24 h in 
ponies II1 and 112. Clostridium clostridiiforme was isolated and identified using the API 
system.
4.4.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
Caecal liquor pH values following intravenous administration of ampicillin are shown in 
Figure 4-14, and the individual data is given in Appendix B (Table B26). The caecal liquor 
pH was slightly high (7.3-7.5) at 0.25, 0.75, 1, 1.5, 2, 4 and 6 h after drug administration 
to pony II. In pony 12, caecal liquor pH was high (7.3-7.8) at 0.25, 0.5, 0.75, 1, 1.5, 2 
and 8 h after drug administration. In pony III, caecal liquor pH was low (6.6-6.7) at 0,0.25 
and 12 h after drug administration and slightly high (7.3-7.5) at 2 and 48 h after drug 
administration. In pony 112, caecal liquor pH was lower than normal (6.4-6.7) at 0, 0.25, 
0.5,0.75, 1, 1.5, 2, 4, 6, 24 and 48 h following intravenous administration of ampicillin.
Lactic acid concentrations in caecal liquor following intravenous administration of ampicillin 
to ponies are shown in Figure 4-15, and the individual data is given in Appendix B (Tables 
B27a-B30a). In pony II, lactic acid concentrations were increased to 10.1-43.6 mmol/1 at 4, 
6 , 8, 12 and 24 h after drug administration and outside the normal range of 0.0-24.4 mmol/1 
at 6 , 8 , and 12 h after drug administration. In pony 12, lactic acid concentrations were 
increased to 9.5-44.4 mmol/1 at 8, 12 and 24 h after drug administration and were outside 
the normal range at 24 h after drug administration. In ponies III and 112, caecal lactic acid 
concentrations were within the normal range at all times sampled.
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Figure 4-9. Counts of viable coliforms in caecal liquor following intravenous administration 
of ampicillin to ponies
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Figure 4-10. Counts of viable streptococci in caecal liquor following
intravenous administration of ampicillin to ponies
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Figure 4-11. Counts of viable lactobacilli in caecal liquor following 
intravenous administration of ampicillin to ponies
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Figure 4-12. Counts of viable Bacteroides spp. in caecal liquor following intravenous
administration of ampicillin to ponies
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Figure 4-13. Counts of viable Clostridium spp. in caecal liquor following intravenous 
administration of ampicillin to ponies
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Figure 4-14. Caecal liquor pH following intravenous administration of
ampicillin to ponies
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Figure 4-15. Lactic acid concentrations in caecal liquor following 
intravenous administration of ampicillin to ponies
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Figure 4-16. Total VFA concentrations in caecal liquor following
intravenous administration of ampicillin to ponies
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Caecal liquor total VFA concentrations are shown in Figure 4-16, and the total VFA and 
individual acid concentrations are given in Appendix B (Tables B27a-B30a). There were 
fluctuations in the total and individual VFA concentrations around the normal range. In pony 
II, the caecal liquor total VFA concentration of 12.5 mmol/1 was lower than the normal 
range of 24.4-109.2 mmol/1 at 24 h after intravenous administration of ampicillin. In 
addition, acetic (8.4-11.0 mmol/1) and butyric (0.0 mmol/1) acid concentrations were lower 
than the normal ranges of 12.6-64.5 and 4.8-67.3 mmol/1 at 6, 8 and 24 h, and 0.25 and 24 
h, respectively. In ponies 12, III and 112, total VFA and individual VFA concentrations were 
all within or around the normal ranges following intravenous administration of ampicillin.
The proportions of acetic, propionic and butyric acids in pony II, as a percentage of total 
VFA concentrations, are given in Appendix B (Table B27b). The percentage of acetic acid 
was increased to 80.6%, and was above the normal range of 27.9-67.0%, at 0.25 h after 
drug administration. There was an increase in the percentage of propionic acid to 56.9%, 
above the normal range of 4.9-38.5%, at 8 h after drug administration. There was no butyric 
acid detected at 0.25 and 24 h after drug administration. There was a reduction in the 
percentage of propionic plus butyric acid to 19.4% (normal 27.1-72.1%) at 0.25 h and an 
increase to 73.6-77.7% at 6 and 8 h after drug administration. The ratios of acetic, propionic 
and butyric acid concentrations in ponies 12, III and 112 are given in Appendix B (Table 
B28b, B29b, B30b) and were all within or around the normal ranges.
Lactic acid concentrations in faeces were within the normal range of 0.0-24.4 mmol/1 at all 
sample times in all ponies, and the individual data is given in Appendix B (Tables B31- 
B34). Total VFA concentrations in faeces are shown in Figure 4-17, and the individual data 
is given in Appendix B (Tables B31-B34). The total VFA concentrations in faeces were 
lower than normal range of 24.4-109.2 mmol/1 prior to drug administration in pony II, at 48 
h in pony 12, and throughout the study in pony 112. In pony III, total VFA concentrations 
were within the normal range throughout the study. There were considerable fluctuations in 
individual VFA concentrations but none of these were attributed to the intravenous 
administration of ampicillin.
4.4.5 Faecal dry matter content and consistency
The faecal dry matter content following intravenous administration of ampicillin to ponies is 
shown in Figure 4-18, and the individual data is given in Appendix B (Table B35). There 
were no marked alterations in the faecal dry matter content following drug administration. 
The faecal diy matter content was high {circa 33%) at 0 and 24 h in pony 12. No changes in 
faecal consistency were observed.
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Figure 4-17. Total VFA concentrations in faeces following intravenous 
administration of ampicillin to ponies
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Figure 4-18. Faecal dry matter content following intravenous administration
of ampicillin to ponies
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4.4.6 Plasma biochemistry and haematological examinations
The plasma biochemistry results are given in Appendix B (Tables B36 and B37) and the 
results of the haematological examinations are given in Appendix B (Tables B38 and B39). 
There were no alterations in plasma biochemistry or in haematology that were considered to 
be associated with the intravenous administration of ampicillin.
4.5 Results of oral administration of ampicillin to ponies with cannulated 
caecal fistulas
4.5.1 Plasma disposition and pharmacokinetics
The plasma concentrations of ampicillin following oral administration to ponies are shown in 
Figure 4-19, and the individual data is given in Appendix B (Table B40). Maximum plasma 
concentrations of 2.30, 1.16, 1.96 and 0.74 pg/ml were measured at 0.5 h in ponies II and 
12, 0.75 h in pony III, and 0.5 h in pony 112, respectively.
The pharmacokinetic parameters calculated following oral administration of ampicillin to 
ponies are given in Table 4-4. A lag time of 8.82 min was required to describe the plasma 
concentration versus time data following oral administration of ampicillin to pony III. The 
MAT was calculated as the difference between the mean MRT, following intravenous 
administration to each animal and the MRT following oral administration on each occasion. 
The systemic availability of ampicillin was calculated from the observed AUCoral and the 
mean observed AUQntra venous was low (1-6%) following oral administration.
4.5.2 Caecal liquor and faecal concentrations
The caecal liquor concentrations following oral administration of ampicillin to ponies are 
shown in Figure 4-20, and the individual data is given in Appendix B (Table B41). 
Maximum caecal liquor concentrations of 101.31, 144.53, 47.40 and 3.63 |i.g/ml were 
measured at 2 h in ponies II and 12, and 6 h in ponies III and 112, respectively. The caecal 
concentrations were much higher than the plasma concentrations of ampicillin following oral 
administration.
The disposition of ampicillin in the caecal liquor was described using observed AUC and 
AUMC to calculate MRT (Table 4-5). The AUC, AUMC and MRT were much larger than 
those calculated for ampicillin in plasma following oral administration. There was a marked 
difference in MRT between the 2 animals, a fact that was also reflected in the difference in 
the time to maximum caecal liquor concentrations.
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Figure 4-19. Plasma concentrations following oral administration of 
ampicillin to ponies
Parameter 11 12 III 112
tl/2 B2 (min) 10.44 10.50 12.54 8.76
tl/2 B1 (min) 26.40 39.78 20.16 23.52
Cmax (M-g/ml) 2.30 1.16 1.96 0.74
tmax (min) 30 30 45 30
AUCobs (Hg.h/ml) 2.78 1.69 1.97 0.63
AUMCobs (Ugh2/ml) 2.59 1.94 2.22 0.50
AUC (jig.h/ml) 2.68 1.69 1.97 0.73
AUMC (|Xg.h2/ml) 2.38 2.04 1.55 0.57
MRT (min) 55.90 68.88 67.61 47.62
MAT (min) -43.99 -31.01 -98.80 -118.79
F (%) 5.54 3.37 3.74 1.20
Table 4-4. Disposition kinetics of ampicillin in plasma following oral administration to 
ponies
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Figure 4-20. Caecal concentrations following oral administration of 
ampicillin to ponies
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Parameter 11 12 III 112
AUCobs (M-g.h/ml) 
AUMCobs (M-g.h /^ml) 
MRT (h)
450.82
1767.05
3.92
188.18
372.60
1.98
273.81
1848.00
6.75
8.37
52.44
6.27
Table 4-5. Disposition kinetics of ampicillin in caecal liquor following oral administration to 
ponies
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No ampicillin was detected in faecal samples following oral administration to ponies I and II 
on occasions 1 and 2.
4.5.3 Bacteriological examinations
Salmonella spp. and C. difficile were selected for but not isolated.
Counts of viable bacteria in caecal liquor following oral administration of ampicillin are 
shown in Figures 4-21 to 4-25, and the individual data is given in Appendix B (Table B42).
There was an increase (to 108-1011/ml) in the number of viable coliforms isolated following 
oral administration of ampicillin to ponies (Figure 4-21). However, in pony II, the initial 
number of coliforms isolated was high (10^/m l) and it remained so until 72 h after drug 
administration. In pony 12, there was a slight increase in the number of coliforms isolated at 
24 and 96 h after drug administration (10^-10^/ml). In ponies III and 112, the number of 
coliforms isolated was increased to 10^-l() ll/m l at 24 and 48 h following oral 
administration of ampicillin.
There was an increase (to 108-1010/ml) in the number of viable streptococci isolated 
following oral administration of ampicillin to ponies (Figure 4-22). However, in pony II 
there were high numbers of streptococci (1()8-1010/ml) isolated initially and up until 96 h 
after drug administration. In pony 12, there was a slight increase (up to 10^/ml) in the 
numbers of streptococci isolated at 24 and 48 h after drug administration. In pony III, there 
were high numbers (up to lO^O/ml) of streptococci isolated at 48 and 72 h after oral 
administration of ampicillin. In pony 112, there was an increase (to 10^-10^/ml) in the 
number of streptococci isolated at 48 and 72 h after drug administration, and a low number 
(l()3/ml) of streptococci isolated at 168 h.
There was an apparent increase in the number of viable lactobacilli isolated from caecal 
liquor following oral administration of ampicillin to ponies (Figure 4-23). There were high 
numbers of lactobacilli (lO^-lO* 1/ml) isolated from pony II at 0, 24 and 48 h, from pony 12 
at 24 h, and from ponies III and 112 at 0 and 48 h. Lactobacillus acidophilus was isolated 
and identified using the API system.
There were no marked alterations in the number of viable Bacteroides spp. isolated 
following oral administration of ampicillin to ponies (Figure 4-24). However, there were 
low numbers of Bacteroides spp. (lO^-lO^/ml) isolated from pony II at 72 and 168 h, from 
pony 12 throughout the study, from pony III at 0, 72 and 168 h, and from pony 112 at 0 and 
24 h. Bacteroides spp. identified using the API system were B. capillosus, B. diastonis^B. 
oralis, B. ovatus and B. thetaiotaomicron.
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Figure 4-21. Counts of viable coliforms in caecal liquor following oral 
administration of ampicillin to ponies
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Figure 4-22. Counts of viable streptococci in caecal liquor following oral
administration of ampicillin to ponies
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Figure 4-23. Counts of viable lactobacilli in caecal liquor following oral 
administration of ampicillin to ponies
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Figure 4-24. Counts of viable Bacteroides spp. in caecal liquor following oral
administration of ampicillin to ponies
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Figure 4-25. Counts of viable Clostridium spp. in caecal liquor following oral 
administration of ampicillin to ponies
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There was an apparent increase in the number of Clostridium spp. isolated from caecal liquor 
following oral administration of ampicillin (Figure 4-25). There was an increase in the 
number of Clostridium spp. isolated from pony II at 24 and 48 h (10^-10^/ml), and from 
pony 12 at 24 h (lO^/ml). The increase in the number of Clostridium spp. isolated from 
ponies III and 112 was less marked. There was an increase in the numbers of Clostridium 
spp. isolated from pony III at 48 and 96 h (lOfyml) and from pony 112 at 72 h (lOfyml). The 
Clostridium spp. identified using the API system were C. butyricum and C. ramosum.
In addition, Peptococcus spp. was isolated and identified using the API system.
4.5.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
The caecal liquor pH measurements are shown in Figure 4-26, and the individual data is 
given in Appendix B (Table B43). There were increases and decreases in caecal liquor pH 
measured following oral administration of ampicillin to ponies. In pony II, the caecal liquor 
pH was increased (up to a maximum of 7.5) at 6, 8, and 12 h and decreased (down to a 
minimum of 6.4) at 1.5, 24, 72 and 168 h after drug administration. In pony 12, the caecal 
liquor pH was increased (up to a maximum of 8.1) at 4, 6 , 8, 24, 96 and 168 h and 
decreased (down to a minimum of 5.7) at 0, 12, 28, 32 and 72 h after drug administration. 
There was an increase in the caecal liquor pH in pony HI at 72 h (7.3) and a decrease at 168 
h (6.7) after drug administration. There was an increase in the caecal liquor pH (up to a 
maximum of 7.5) at 6, 24, 32, 96 and 168 h and a decrease (down to a minimum of 6.6) at 
0, 0.25, 0.5, 0.75, 1 and 12 h after drug administration to pony 112.
Caecal liquor SCFA concentrations are shown in Figures 4-27 and 4-28, and the individual 
data is given in Appendix B (Tables B44a-B47a).
Caecal liquor lactic acid concentrations increased following oral administration of ampicillin 
to ponies (Figure 4-27). In pony II, lactic acid concentrations were increased to 9.8-42.7 
mmol/1 at 4, 6, 8, 12, 24, 28 and 32 h, and were above the normal range of 0.0-24.4 mmol/1 
at 8, 12, 24, 28 and 32 h after drug administration. Caecal liquor lactic acid concentrations 
were elevated to 6.5-51.6 mmol/1 in pony 12 at 4, 8, 12, 32 and 48 h and were outside the 
normal range at 6 and 8 h after drug administration. In pony III, caecal liquor lactic acid 
concentrations were increased to 5.7-39.6 mmol/1 at 8, 12, 24, 28 and 32 h and were outside 
the normal range at 24, 28 and 32 h after drug administration. Similarly, in pony 112 lactic 
acid concentrations in caecal liquor were elevated to 6.3-40.5 mmol/1 at 8, 12, 24, 28, 32 
and 48 h, and outside the normal range at 12 and 24 h after drug administration.
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Figure 4-26. Caecal liquor pH following oral administration of ampicillin to 
ponies
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Figure 4-27. Lactic acid concentrations in caecal liquor following oral
administration of ampicillin to ponies
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Figure 4-28. Total VFA concentrations in caecal liquor following oral 
administration of ampicillin to ponies
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There were no marked alterations in total VFA concentrations in caecal liquor following oral 
administration of ampicillin (Figure 4-28). In pony II, the total VFA concentration of 118.8 
mmol/1 at 12 h after drug administration was above the normal range of 24.4-109.2 mmol/1. 
There were variations in the individual acid concentrations that were outside the normal 
ranges. There was a reduction, compared with the normal range of 12.6-64.5 mmol/1, in the 
acetic acid concentrations to 4.4-10.6 mmol/1 at 6, 12 and 24 h in pony II and at 8 and 12 h 
in pony 12. In pony II, there was an increase in the concentrations of propionic acid to 41.5- 
99.9 mmol/1 at 8, 12 and 72 h, compared with the normal range of 4.7-24.5 mmol/1. There 
were reductions in the concentrations of propionic acid to 0.0-3.8 mmol/1, compared with 
the normal range, at 24 h in pony II, at 12 and 24 h in pony 12, at 6, 8, 12, 24, 28 and 32 h 
in pony III, and at 8, 12, 24, 28 and 32 h in pony 112. The butyric acid concentrations of 
1.2-2.7 mmol/1 were lower than the normal range of 4.8-67.3 mmol/1 at 8 h in pony 12 and 
at 48 h in pony III.
The proportions of acetic, propionic and butyric acids, as a percentage of the total VFA 
concentrations, are given in Appendix B (Tables B44b, B45b, B46b and B47b). In pony II, 
the acetic acid concentration ratio of 3.7-20.2%, at 4, 6 , 12 and 24 h, was lower than the 
normal range of 27.9-67.0%. The ratio of propionic acid was increased to 41.2-84.1% at 6, 
8 and 12 h in pony II and at 8 h in pony 12, compared with the normal range of 4.9-38.5%. 
The proportions of propionic acid were reduced to 0.0-3.8% at 24 h in pony 11,12 and 24 h 
in pony 12, 8, 12, 24 and 28 h in pony III and at 12, 24 and 28 h in pony 112, compared 
with the normal range of 4.9-38.5%. In pony II, the ratio of butyric acid was increased to 
79.8% at 24 h, compared with the normal range of 8.7-66.7%, whereas in ponies 12 and HI 
the ratio of butyric acid was reduced to 4.6-6.9% at 8 and 48 h, respectively. In pony II, the 
alterations in acetic, propionic and butyric acid resulted in an increase in the ratio of 
propionic plus butyric acids to 76.9-93.9% (normal 27.1-72.1%) at 4, 6, 12, 24, and 48 h 
after drug administration.
Faecal SCFA concentrations are shown in Figures 4-29 and 4-30, and the individual data is 
given in Appendix B (Tables B48-B51). Faecal lactic acid concentrations were elevated to 
35.6-64.2 mmol/kg at 24 and 48 h in pony II, at 24, 48, 72 and 96 h in pony III, and at 24, 
48 and 96 h in pony 112 (Figure 4-29). The lactic acid concentrations were outside the 
normal range of 0.0-24.4 mmol/1 at 24 h in pony II, and at 24 and 48 h in ponies III and 
112. There were considerable variations in individual VFA concentrations however none of 
these were related to the oral administration of penicillin G. The faecal total VFA 
concentrations were higher than normal at 168 h in pony II, prior to drug administration to 
pony 12, and at 24 and 72 h in pony 112 (Figure 4-30). Faecal total VFA concentrations were 
lower than normal at 72 h in pony 12 and at 0 h in pony III.
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Figure 4-29 Lactic acid concentrations in faeces following oral 
administration of ampicillin to ponies
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Figure 4-30. Total VFA concentrations in faeces following oral administration of ampicillin
to ponies
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4.5.5 Faecal dry matter content and consistency
The faecal dry matter content following oral administration of ampicillin is shown in Figure 
4-31, and the individual data is given in Appendix B (Table B52). There were no marked 
alterations in faecal dry matter content. Although, the faecal dry matter content was slightly 
low (<17%) at 48 h in pony III. No alterations in faecal consistency were observed.
4.6 Results of in vitro studies with ampicillin
4.6.1 Caecal liquor concentrations
A plot of caecal liquor concentrations (meaniSEM) following incubation in vitro is shown 
in Figure 4-32, and the individual and mean data are given in Appendix B (Tables B53a and 
b). After 3 h incubation there was an average of 16% of ampicillin remaining at the initial 
concentration of 0.25 |ig/ml and 95% of ampicillin remaining in the 1,5, 10, 20,40 and 80 
|ig/ml samples. The largest reductions in concentration (zone diameter) were seen at either 
end of the concentration range due to limitations of the assay technique (zone diameter, limit 
of detection). Following 24 h incubation, there was an average of 36.4 % (excluding 0.25 
and 1 pg/ml samples) of the drug activity remaining. There were no inhibition zones for the 
0.25 Jig/ml or 1 |ig/ml sample following 24 h incubation.
4.6.2 SCFA concentrations
Lactic acid and total VFA concentrations (mean±SEM) following in vitro incubation of 
ampicillin in caecal liquor are shown in Figure 4-33, and the individual data is given in 
Appendix B (Tables B54-B58). There were no alterations in mean lactic acid or mean total 
VFA concentrations with time or drug concentration.
4.6.3 Acid pH
Ampicillin concentrations (mean±SEM) remaining following in vitro incubation at pH 1.9 
for 1 h are shown in Figure 4-34, and the individual data is given in Appendix B (Table 
B59). There was little or no ampicillin destroyed by incubation at acid pH and on average 
there was 98.8% of the drug activity remaining.
4.6.4 Binding to hay
A plot of ampicillin concentrations (mean±SEM) remaining following in vitro incubation for 
1 h with chopped hay versus initial concentrations is shown in Figure 4-35, and the results 
of the individual incubation experiments are given in Appendix B (Tables B60a and b). At 
pH 1.9, 64.6, 101.48, 116.62 and 106.62% remained, whereas at pH 7.0, an average of
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Figure 4-31. Faecal dry matter content following oral administration of 
ampicillin to ponies
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incubation in vitro with ampicillin for 3 and 24 h
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24.2, 36.0, 44.26 and 58.7% remained of the initial concentrations of 10, 25, 50 and 100 
(Xg/ml. The extremely high percentages recorded at pH 1.9 were probably due to the pH of 
the solution effecting the rate of diffusion of the drug in the agar during the assay. However, 
it is interesting that 97.3% was free at pH 1.9, whilst only 40.8% of drug was measured at 
pH 7.0.
4.7 Discussion
The elimination half-life of ampicillin in horses, ponies and donkeys was similar to the 
elimination half-life in pigs (Galtier and Charpenteau, 1979) and calves (Black, 1976, Long 
et al.> 1983, Ziv and Horsey, 1979). The elimination half-life of ampicillin in horses and 
ponies was longer than in donkeys in the present study, but there were no statistically 
significant differences between the three groups. Baggot and Prescott (1987) stated that the 
elimination half-lives of the penicillins are short (0.5-1 h) and this was confirmed by the 
results of the present study (43-61 min). However, Durr (1976) calculated an elimination 
half-life of ampicillin sodium of 93 min in the horse. In the present study, Bacillus subtilis 
was used as the test organism with a limit of detection of 0.02 |ig/ml, whereas Durr (1976) 
used Sarcina lutea and achieved a limit of detection of 0.05 pg/ml and administered 
ampicillin at a higher dose rate (40 mg/kg bwt). The slightly lower limit of detection in the 
present study should have lengthened rather than shortened the apparent elimination half-life. 
However, it may merely mean that small zones of inhibition were better defined in the 
present study. The range of the elimination half-lives reported in the present study was wide 
(34.08-148.74 min, 33.48-122.28 min and 30.06-66.12 min in horses, ponies and 
donkeys, respectively). The differences in elimination half-life may represent normal 
individual variations. Hence the importance of including large numbers of animals in studies 
of drug disposition and pharmacokinetics. The elimination half-life of ampicillin in the 
present study was similar to that reported by Durr (1976) for penicillin G (53 min).
It is interesting that the mean AUC in horses was greater than in donkeys, and that there was 
a statistically significant difference (p<0.05) between the median AUC of 42.56 and 25.81 
p.g.h/ml in horses and donkeys, respectively. Similarly, the mean CLb was slower in horses 
than in donkeys, and there was a statistically significant difference (p<0.05) between the 
median CLb of 234.90 and 387.50 ml/h.kg in horses and donkeys, respectively. A similar 
difference was demonstrated by Kinabo and Bogan (1989) following administration of the 
flukicidal drug triclabendazole to horses, ponies and donkeys. It may be that horses have a 
lower metabolic capacity for some drugs than donkeys, however, ampicillin is not thought to 
be extensively metabolized prior to excretion. The differences observed in the present study 
may reflect a different capacity for renal excretion. The renal excretion of the 8-lactam 
antimicrobial agents is governed partly by an active transport system, and this may be
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accelerated by increasing urinary pH. However, acidification and alkalisation of urine in the 
horse did not effect the pharmacokinetic variables calculated following intravenous 
administration of ampicillin sodium (Sarasola et al.> 1992). In addition, the effects of 
probenecid, a competitor of the active transport mechanism would be of use potentially in 
slowing the elimination of ampicillin from the body. In man, Arvidsson et al. (1981) 
showed that probenecid slowed the renal elimination of the cephalosporin, cefoxitin, after 
single and repeated doses. In the pig, Galtier and Alvinerie (1979) demonstrated that the 
systemic availability of ampicillin was enhanced following administration of probenecid due 
to a reduction in the plasma clearance of the former. In the horse, Juzwiak et al. (1989) 
reported a 50% reduction in the clearance of cephapirin (at a dose rate of 20 mg/kg bwt) in 
mares following concurrent administration of probenecid (at a dose rate of 50 mg/kg bwt) 
and Sarasola and McKellar (1992) reported a similar reduction in the CLb of ampicillin in 
horses, following intravenous administration at a dose rate of 10 mg/kg bwt, due to the 
concurrent administration of probenecid (at a dose rate of 75 mg/kg bwt).
The overall effectiveness of penicillin therapy is influenced by the height of peak serum 
concentrations and the time, which is not necessarily continuous, that the effective serum 
concentrations are maintained. The cumulative area under the plasma concentration versus 
time curve determines the amount of antibiotic reaching the site of infection (Baggot, 1982) 
and the height of the peak concentration in serum determines the rate of penetration and 
concentration attained at the site of infection (Bergan, 1978). Powers et al. (1984) stated that 
tissue or blood concentrations that are greater than or equal to the MIC should be maintained 
throughout the period of therapy especially with the so-called bacteriostatic antimicrobial 
agents. Although the maintenance of plasma concentrations greater than the MIC is important 
for the bacteriostatic antimicrobial agents, it is less important for the bactericidal 
antimicrobial agents where intermittent exposure may be equally effective since bactericidal 
antimicrobial agents are active mainly against multiplying bacteria (Knifton, 1982). The peak 
serum concentration of a given antimicrobial agent must exceed a certain minimum 
concentration, which is some multiple of the MIC of a pathogen, such as four to eight times 
the MIC (Koritz 1984, Sande and Mandell, 1985). Intermittent or pulse dosing is not any 
more or less effective than continuous infusion. In the present study, plasma concentrations 
of greater than eight times the MIC of sensitive equine bacteria were achieved.
The dosage regimen necessary to maintain therapeutic plasma concentrations is disputed. 
Prescott and Baggot (1988a) and Van Miert (1988) recommend that a dose rate of 10-20 
mg/kg bwt administered every 6-8 h was suitable. The dosage regimen suggested by 
By water (1982a) was 2-7 mg/kg bwt every 12-24 h. On the other hand, Huber (1982a) 
reported that currently the recommended dose rate for Equidae is 11-16 mg/kg bwt every 4-8 
hours. It is difficult to predict the dosage interval precisely since some studies have indicated
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hours. It is difficult to predict the dosage interval precisely since some studies have indicated 
that intermittent dosing with B-lactam antimicrobial agents may be more efficient (Tauber et 
al., 1984), whilst other studies have suggested that constant activity may be superior 
(Gerber et al., 1983), and the choice may remain essentially empirical (Weinstein, 1977). 
The MIC of ampicillin for Streptococcus equi was 0.025-0.05 (lg/ml (Keefe et al., 1980), 
whereas the MIC of Rhodococcus equi was 4 p.g/ml (Prescott and Nicholson, 1984). Zanon 
(1977) reported that the minimum antibiotic concentration of ampicillin was V8-V64 of the 
minimum bactericidal concentration. If a maintenance concentration of >0.1 |!g/ml (i. e. four 
times 0.025 |ig/ml) is desired then intravenous administration of ampicillin sodium, at a dose 
rate of 10 mg/kg bwt, would have to be repeated every 8 h (three times per day) in horses 
and every 6 h (four times per day) in ponies and donkeys. This is similar to the regimen 
recommended by Prescott and Baggot (1988a) and Van Miert (1988) of 10-20 mg/kg bwt 
every 6-8 h and would seem to be a sensible compromise, however less frequent dosing 
may be effective clinically.
In man, there is considerable variation (20-75%) in the systemic availability of ampicillin 
following oral administration (Jusko, 1975). Absorption of ampicillin was rapid following 
oral administration to ponies. However, the systemic availability of ampicillin was low 
(5.54, 3.37, 3.74 and 1.20% in ponies II, 12, III and 112 respectively). Brown et al. 
(1984b) did not calculate the systemic availability of ampicillin trihydrate following oral 
administration to foals. However, the mean peak serum concentrations (5 M-g/ml at 1 h) 
reported by Brown et al. (1984b) were higher than the peak plasma concentrations of 
ampicillin sodium reported in the present study (2.30, 1.16, 1.96 and 0.74 |ig/ml at 0.5, 
0.5, 0.75 and 0.5 h in ponies II, 12, III and 112, respectively). This may be due to the fact 
that Brown et al. (1984b) administered ampicillin trihydrate at the higher dose rate of 20 
mg/kg bwt. In the present study, the sodium salt of ampicillin was administered, whereas 
Brown et al. (1984b) administered the trihydrate salt. Different salts, and even different 
formulations, of a drug may have different systemic availabilities. However, it has been 
suggested that the sodium salt of ampicillin may be more effective clinically, compared with 
the trihydrate salt, through the production of higher concentrations in the body. It would be 
interesting to examine the effect of dose rate on the systemic availability of ampicillin 
sodium.
In man, amoxicillin is absorbed rapidly from the gastrointestinal tract following oral 
administration and has a systemic availability of 88.7% (70.9-105.5%) (Zarowny et al., 
1974). In the adult horse, the bioavailability of amoxicillin following oral administration was 
reported as 5.3% (Ensink et al., 1992) and 10.4% (Wilson et al., 1988). However, the 
systemic availability of amoxicillin (36.2±13.1% (mean±SD) at a dose rate of 20 mg/kg bwt 
and 42.7±15.0% at a dose rate of 30 mg/kg bwt) following oral administration to neonatal
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foals was higher than in the adult horse (Baggot et al., 1988). The peak concentrations of 
amoxicillin (2.03 Jig/ml at 1 h) following oral administration at a dose rate of 15 mg/kg bwt 
were similar (Ensink et al., 1992) to the peak plasma ampicillin concentrations described in 
the present study. In the present study, ampicillin was measured in plasma >0.1 pg/ml for 
1.5-2 h following oral administration, thus dosing would require to be repeated frequently to 
maintain therapeutic plasma concentrations.
Ampicillin was measured in the caecal liquor following intravenous and oral administration 
to ponies. In the present study, an estimated 3.66% and 3.18% of the administered 
ampicillin were measured in caecal liquor from 1 and 0.25 h after intravenous administration 
to pony I on occasions 1 and 2, respectively. Following intravenous administration of 
ampicillin to pigs, around 1% was eliminated in bile within 4 h (Galtier and Alvinerie, 
1979), and ampicillin was measured in caecal contents from 30 min onwards (Galtier and 
Charpenteau, 1979). In the present study, there was considerable variation in peak caecal 
liquor concentrations following oral administration (101.31, 144.53, 47.40 and 3.63 (Xg/ml 
in ponies II, 12, III and 112, respectively). In the calf, amoxicillin was measured in caecal 
contents from 0.5 h, after oral administration at a dose rate of 7 mg/kg bwt, at concentrations 
(mean±SEM) of up to 635.5±79.5 jig/g at 6 h (Palmer et al., 1977). The inter-animal 
variation in peak caecal liquor concentrations in the present study was possibly due to the 
difference between the two animals in the stomach to caecum transit time; the peak 
concentrations were reached at 2 h after drug administration to ponies II and 12, and at 6 h 
after drug administration to ponies III and 112. Moreover, the length of time that ampicillin 
remained in the caecum (MRT) was shorter in ponies II and 12 than in ponies III and 112 
(3.92, 1.98, 6.75 and 6.27 h, respectively). Although, there were differences in the peak 
caecal liquor concentrations, the AUC of ampicillin in the caecal liquor was of a similar 
magnitude (450.82, 188.18 and 273.81 pg.h/ml, respectively) in ponies II, 12 and III. 
However, in pony 112 the peak caecal liquor concentration was 3.63 p.g/ml only, and the 
AUC of ampicillin reaching the caecal liquor was 8.37 jig.h/ml. This may have been due to 
the destruction of ampicillin in the gastrointestinal lumen by, e. g. 6-lactamase enzymes, due 
to differences in the gastrointestinal microflora between animals and even between 
occasions.
There was no ampicillin detected in faecal samples following intravenous or oral 
administration. It seems unlikely that the high concentrations of ampicillin in caecal liquor 
were absorbed in the caecum or colon since ampicillin was detected in plasma for up to 4 h 
only, although plasma samples were taken for up to 48 h following oral administration. 
Incubation of ampicillin in vitro for 24 h resulted in destruction of around 70% of the initial 
concentrations of 0.25-80 pg/ml. There may have been destruction of ampicillin in the colon 
or in the faecal samples, e. g. by 6-lactamase enzymes, prior to analysis. However, faecal
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samples were stored at 4 "C, alongside caecal liquor samples, prior to analysis and high 
concentrations were present in caecal liquor following storage.
There was an apparent increase in the number of viable coliforms, streptococci, lactobacilli 
and Clostridium spp. isolated from caecal liquor following oral administration of ampicillin. 
The alterations in the number of coliforms, streptococci, lactobacilli and Clostridium spp. 
reported in the present study were not dissimilar to those recorded by Andersson et al. 
(1971) and White and Prior (1982) following intravenous and oral administration, 
respectively, of oxytetracycline. There were no marked alterations in the caecal liquor pH 
following intravenous administration of ampicillin. However, there were both increases and 
decreases in caecal liquor pH following oral administration of ampicillin. This result is not 
surprising since there were alterations in the SCFA concentrations. The most marked 
alterations in the SCFA concentrations were in the caecal liquor lactic acid concentrations. 
There were increases in the caecal liquor lactic acid concentrations in one pony on both 
occasions following intravenous administration of ampicillin, but these were much more 
pronounced and occurred in both ponies following oral administration. In addition, faecal 
lactic acid concentrations were elevated in three animals following oral drug administration. 
Thus, it appears that high caecal liquor lactic acid concentrations are reflected by elevated 
faecal lactic acid concentrations and suggests that lactic acid, at least at high concentrations, 
was not absorbed in the large intestine. The increase in the lactic acid concentrations could be 
explained by the increase in the number of lactic acid producing bacteria such as 
streptococci, lactobacilli and Clostridium spp. isolated. The peak in lactic acid concentrations 
may have been due to an increase in the production of D- or L-lactic acid. The increased 
lactic acid concentrations in the present study occurred at variable times following 
intravenous and oral administration of ampicillin although they always occurred following 
the peak drug concentration. Interestingly, there was an increase in the caecal liquor lactic 
acid concentrations in the only pony in which drug concentrations were measured in caecal 
liquor following intravenous administration of ampicillin.
There were changes in the concentrations of individual VFAs following both intravenous 
and oral administration of ampicillin. There were alterations in the VFA concentrations in 
pony I following intravenous administration of ampicillin.There were no alterations in the 
caecal liquor VFA concentrations where no ampicillin was detected in the caecal liquor. 
Following oral administration of ampicillin, the most obvious trend was a reduction in the 
propionic acid concentrations in caecal liquor. In addition, there were both increases in the 
acetic acid concentrations, increases in the concentrations and proportions of propionic acid, 
and an apparent reduction in the concentrations and proportions of butyric acid following 
oral administration of ampicillin. It is interesting to note that the peak lactic acid 
concentrations almost always coincided with the lowest propionic acid concentrations in
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caecal liquor. Moreover, the alterations in the propionic acid concentrations in caecal liquor 
were similar in both ponies on both occasions despite the differences in peak caecal liquor 
concentration. In addition, the reduction in the caecal liquor propionic acid concentrations 
was shorter in ponies II and 12 (up to 12 h) than in ponies III and 112 (up to 32 h). 
Although, it would have been useful to have sampled between 12 and 24 h after drug 
administration in pony II in particular. The peak caecal liquor concentrations were higher in 
ponies II and 12, but the MRT was longer in ponies III and 112. This suggests that the 
alterations in propionic acid concentrations may be related to the length of time that the drug 
was present in the caecum and not to peak concentrations. Thus, it may be that ampicillin can 
alter bacterial metabolism in the caecum even if it is destroyed rapidly. A shift in 
fermentation away from acetate, butyrate and methane production towards propionate 
production is the basis of the use of antimicrobial agents for growth promotion in ruminants 
and is associated with defaunation (Demeyer and Van Nevel, 1987, Prins, 1987). A 
prolonged reduction in propionic acid concentrations in caecal liquor may represent a 
reduction in VFA production and may result in a reduction in glucose available to the animal 
since propionate via succinate is the main source of glucose in the animal.
It is interesting to note that a high percentage {circa 59%) of ampicillin was bound to hay 
following in vitro incubation at pH 7.0. This would mean that only 40% would be available 
for absorption in the small intestine. However, at acid pH, similar to that seen in the 
stomach, essentially no drug was bound to hay {circa 3%). Ziv et al. (1977) noted that 
fasting of calves improved the systemic availability of ampicillin by 2.67 times. In the adult 
horse, pivampicillin had a bioavailability of 30.9% in starved horses and 35.9% in fed 
horses (Ensink et al., 1992). The withholding of food prior to drug administration may 
improve absorption. However, this would be difficult to maintain for prolonged periods in a 
clinical situation. Moreover, unless there was a substantial improvement in the systemic 
availability by withholding food prior to oral administration of ampicillin sodium in the 
equine, the risk of inducing antimicrobial-associated diarrhoea would be high due to the high 
concentrations of ampicillin reaching the large intestine.
Intravenous administration of ampicillin sodium at a dose rate of 10 mg/kg bwt every 6-8 h 
would provide and maintain suitable plasma concentrations for the treatment of infections 
caused by susceptible bacteria in horses, ponies and donkeys. Oral administration at a dose 
rate of 10 mg/kg bwt would be impractical for the treatment of systemic bacterial infections 
in the equine. An increase in the oral dose rate of ampicillin would probably produce higher 
plasma concentrations. However, it is contraindicated because it would result in very high 
intestinal drug concentrations and may result in the development of enterocolitis.
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5 Studies with amikacin
5.1 Introduction
The aminoglycoside antimicrobial agents are large polar organic bases with a low lipid 
solubility, poor membrane penetration and increased activity at alkaline pH. The 
aminoglycosides are absorbed poorly from the gastrointestinal tract but retain their activity 
within it (English and Roberts, 1979). They are bactericidal antimicrobial agents which act 
on ribosomal protein synthesis. Aminoglycosides containing 2-deoxystreptamine 
(kanamycin, gentamicin, tobramycin, netilmicin and amikacin) are valuable for the treatment 
of infections caused by Gram negative bacteria (Price and Siskin, 1984). Resistance to these 
agents is due to a plasmid-mediated modification of the antimicrobial agent by a bacterial 
enzyme and, less commonly, to a defect in the transfer of the antimicrobial agent to the 
intracellular ribosomal target site in susceptible bacteria (Price and Siskin, 1984). However, 
the use of the aminoglycosides is limited by their low therapeutic index (Prescott and 
Baggot, 1985). The adverse side effects that occur following administration include 
ototoxicity and nephrotoxicity.
A variety of aminoglycosides, including streptomycin, neomycin, kanamycin, gentamicin 
and amikacin, are used in veterinary practice. In the equine, a wide range of dose rates have 
been suggested for their administration. Baggot et al. (1981) suggested that intravenous or 
intramuscular administration of streptomycin at a dose rate of 10 mg/kg bwt every 12 h 
would be suitable. In their review Roberts and English (1979) suggested that intravenous or 
oral administration of neomycin at a dose rate of 20-50 mg/kg bwt every 6-8 h was a suitable 
dosage regime. However, Baggot et al. (1981) and Baggot et al. (1985) noted that 
intravenous or intramuscular administration of neomycin at a dose rate of 10 mg/kg bwt 
every 12 h would provide therapeutic plasma concentrations and avoid the development of 
signs of toxicity. Boyd and Allen (1988) reported the use of neomycin at a dose rate of 3 
mg/kg bwt as an intrauterine infusion. Knight (1975) recommended the administration of 
kanamycin at a dose rate of 5 mg/kg bwt every 8 h, however Baggot et al. (1981) suggested 
that intravenous or intramuscular administration of kanamycin at a dose rate of 10 mg/kg bwt 
every 8 h would be appropriate, and Roberts and English (1979) recommended the dose 
rates of 11-15 mg/kg bwt every 8-12 h. Dose rates ranging from 2 to 18 mg/kg bwt every 6- 
12 h have been recommended for intravenous or intramuscular administration of gentamicin 
(Baggot et al., 1986, English and Roberts, 1979, Gilman et al., 1987, Haddad et al., 1985, 
Pedersoli etal., 1980, Riviere et al., 1983a, Smith et al., 1988).
Amikacin is produced by the chemical alteration of kanamycin A (Monteleone etal., 1983). 
Frequently, it has the advantage of being effective in the treatment of infections due to
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organisms resistant to other aminoglycosides (Cudd, 1985, Gingerich et al., 1983). 
Amikacin retains its antimicrobial activity in the the presence of around 90% of the different 
enzymes which destroy other aminoglycoside antimicrobial agents, and it has potent activity 
against Pseudomonas spp., E. coli, Proteus spp., Providencia spp., K lebsiella- 
Enterobacter-Serratia spp., Acinebacter spp., Citrobacter freundii, and non-B-lactamase and 
B-lactamase producing staphylococci (Caudle et al., 1983, Gingerich et al., 1983). In 
addition, resistance to amikacin is slow to develop (Price and Siskin, 1984) and it has been 
shown that resistance to gentamicin and tobramycin was reduced when amikacin was used 
as the aminoglycoside of choice (Gingerich et al., 1983). However, Price and Siskin (1984) 
reported that there were no alterations in resistance patterns due to amikacin usage. The 
amikacin preparation which is available at present, in veterinary medicine, was designed for 
use as an intrauterine infusion in mares. Brook (1982) suggested that an infusion of 2 g of 
amikacin dissolved in 250 ml of normal saline daily for 5 days was a suitable regime for 
treating susceptible bacterial infections of the genital tract in mares. In the equine, 
intravenous or intramuscular administration of amikacin at dose rates ranging from 4.4 to 
7.0 mg/kg bwt every 12 h have been recommended (Adland-Davenport et al., 1990, Brown 
et al., 1984c, Brown et al., 1986, Orsini et al., 1985).
Aminoglycosides are retained within the gastrointestinal lumen following oral 
administration. In man, this property has been utilized to suppress the gastrointestinal flora 
prior to colon surgery (Gorbach, 1983). Neomycin is used commonly, in combination with 
the macrolide erythromycin, to produce a concentration of 1-3 mg/ml of neomycin in the 
colonic contents, which is suitable to suppress the gastrointestinal flora (Gorbach, 1983). 
However, it has been shown that a number of rumen bacteria are not inhibited by the 
presence of kanamycin, neomycin and streptomycin (Prins, 1987). In fact, at concentrations 
of 5, 10 and 20 p.g/ml kanamycin, neomycin and streptomycin had no effect on cellulose 
breakdown in rumen fluid. However, ruminal function was depressed in sheep following 
oral administration of aminoglycoside antimicrobial agents at a dose rate of 0.5-1.0 g/day 
(Prins, 1987). In addition, amikacin is not absorbed beyond the endometrium following 
intrauterine administration to mares (Caudle et al., 1983).
The purpose of the present study was to determine the plasma disposition and 
pharmacokinetics of amikacin sulphate following intravenous administration at a dose rate of 
6 mg/kg bwt to horses, ponies and donkeys. Alterations in the intestinal flora were studied 
by bacteriological examination of serial faecal samples and large intestinal fermentation was 
studied using faecal SCFA concentrations. The faecal dry matter content and the appearance 
of faeces were used as indicators of the presence or absence of diarrhoea. Similar studies 
were carried out in ponies with cannulated caecal fistulas following a single intravenous or 
oral administration, via nasogastric tube, of amikacin sulphate at a dose rate of 6 mg/kg bwt.
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In addition, drug, bacteriological and SCFA analyses were carried out on caecal liquor, and 
plasma biochemistry and haematology were monitored.
5.2 Materials and Methods
5.2.1 Intravenous administration of amikacin to horses, ponies and donkeys
Three Thoroughbred geldings (No. 3-5), four ponies (No. 7-10) and three donkeys (No. 
14-16) were used as outlined in the general Materials and Methods. Amikacin sulphate was 
administered by intravenous bolus injection at a dose rate of 6 mg/kg bwt. Plasma samples 
were taken at 0, 0.033, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6 , 8, 12 and 24 h. Faecal 
samples were taken at 0, 24 and 48 h for drug analysis, bacteriological examination, SCFA 
analysis and measurement of faecal dry matter content.
5.2.2 Intravenous administration of amikacin to ponies with cannulated 
caecal fistulas.
Two pony mares with cannulated caecal fistulas (I and II), as outlined in the general 
Materials and Methods, were used on up to 2 occasions (1 and 2). Amikacin sulphate was 
administered by intravenous bolus injection at a dose rate of 6 mg/kg bwt. Plasma samples 
for drug analysis and caecal liquor samples for drug analysis, measurement of pH and 
SCFA analysis were taken at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6 , 8, 12 and 24 h, with 
additional plasma samples at 0.033 and 0.083 h and an additional caecal liquor sample at 48 
h. Bacteriological examination of caecal liquor was carried out at 0, 24 and 48 h. Faecal 
samples were taken at 0, 24 and 48 h for drug analysis, SCFA analysis and the measurement 
of dry matter content. Plasma biochemistry and haematological examinations were carried 
out at 0, 24 and 48 h on occasion 1 and 0, 24 and 120 h on occasion 2.
5.2.3 Oral administration of amikacin to ponies with cannulated caecal 
fistulas
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 2 occasions (1 and 2) at least 5 days after intravenous 
administration of amikacin sulphate. Amikacin sulphate was administered via nasogastric 
tube at a dose rate of 6 mg/kg bwt. Plasma samples for drug analysis and caecal liquor 
samples for drug analysis, pH measurement and SCFA analysis were taken at 0, 0.25, 0.5, 
0.75, 1, 1.5, 2, 4, 6 , 8, 12 and 24 h, with further plasma samples at 0.033 and 0.083 h, 
and caecal liquor samples taken at 28, 32, 48, 52, 56, 72, 96 and 168 h. Bacteriological 
examinations of caecal liquor were carried out at 0, 24, 48, 72, 96 and 168 h. Faecal 
samples were taken for the measurement of drug concentrations, SCFA concentrations and 
dry matter content at 0, 24, 48, 72, 96 and 168 h. Samples were taken for plasma
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biochemistry and for haematological examinations at 0, 24,48 and 168 h, with an additional 
haematology sample at 72 h.
In addition, amikacin sulphate was administered by nasogastric tube to pony 13 on one 
occasion. Plasma samples were taken at 0 to 24 h with no samples at 0.033 and 0.083 h. 
Faecal samples were taken at 0, 24, 48 and 72 h for drug analysis, bacteriological 
examination, SCFA analysis and the measurement of dry matter content.
5.2.4 In  vitro studies with amikacin
Amikacin sulphate was incubated with caecal liquor for 3 and 24 h and drug concentrations 
and SCFA concentrations were measured as described in the general Materials and Methods. 
In addition, amikacin concentrations were measured following incubation at pH 1.9 as 
outlined in the general Materials and Methods. Also, concentrations of amikacin were 
measured following incubation at pH 1.9 and 7.0 in the presence of chopped hay as outlined 
in the general Materials and Methods.
5.3 Results of intravenous adm inistration of amikacin to horses, ponies and 
donkeys
5.3.1 Plasma disposition and pharm acokinetics
A semilogarithmic plot of plasma concentrations (mean±SEM) following intravenous 
administration of amikacin to horses, ponies and donkeys is shown in Figure 5-1. The 
plasma concentration versus time data is given in Appendix C (Tables C1-C3). In all 3 
groups, the initial plasma concentration versus time plots were similar, however the decline 
phase of the plasma concentration versus time plot was similar in horses and donkeys and 
declined more steeply in ponies, suggesting that the elimination of amikacin was slower in 
horses and donkeys than in ponies. Amikacin was detected in plasma (>0.02 |ig/ml) for up 
to 12 h in horses and donkeys and 8 h in ponies (there was no 12 h sample in ponies).
The pharmacokinetic parameters calculated from the bi-exponential equations used to 
describe the plasma concentration versus time data are given in Table 5-1, and the individual 
data is given in Appendix C (Tables C4-C6). There were no statistically significant 
differences between the pharmacokinetic parameters of horses, ponies and donkeys 
calculated using a Kruskal Wallis test. The harmonic mean of the elimination half-life 
calculated for horses, ponies and donkeys was similar (1.6-3 h). The elimination half-life 
was longest in horses (2.84 h) and shortest in ponies (1.60 h). Similarly, the MRT was 
longest in horses, followed by donkeys and then ponies. The AUC and AUMC were lowest 
in ponies with the calculated AUC around 50% of the horse value and the AUMC around
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Figure 5-1 Plasma concentrations (mean±SEM) following intravenous 
administration of amikacin to horses, ponies and donkeys
Parameter Horses (n=3) Ponies (n=4) Donkeys (n=3)
tl/2 B2 (h)* 0.10 0.20 0.05
tl/2 B1 (h)* 2.84 1.60 1.93
CpO (p.g/ml) 64.92±18.37 64.77±2.82 87.97±11.45
Vc (ml/kg) 117.93±45.39 93.18±4.18 70.34±8.19
AUCobs (M-g-h/ml) 136.15±12.21 83.87±14.15 119.96±25.84
AUMCobs (|ig.h2/ml) 553.82±134.92 203.37±62.99 355.86±106.87
AUC (jig.h/ml) 134.69± 11.41 77.61±11.84 116.26±24.81
AUMC ftig.h2/ml) 639.83±191.93 173.84±55.49 340.87±103.70
MRT (h)* 4.01±0.86 2.28±0.29 2.82±0.35
Vdarea (ml/kg) 214.87±58.34 191.28+13.51 156.85±15.94
Vdss (ml/kg) 206.58±59.11 162.73±7.25 150.21±15.97
CLb (ml/h.kg) 45.19±3.76 82.37±11.27 57.98±15.05
kel (/h) 0.49±0.14 0.90±0.15 0.82±0.18
k21 (/h) 3.04±1.09 1.69±0.36 5.05±1.70
k l2 (/h) 3.50±2.40 1.22±0.26 6.39±2.79
Table 5-1. Disposition kinetics of amikacin in plasma following intravenous administration
to horses, ponies and donkeys
Key: data as mean±SEM; * harmonic mean
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33.3% of the horse value. In addition, the mean CLb and kei in horses were around twice 
and one-half of the CLb and k ^  calculated in ponies, respectively. The other calculated 
parameters were similar in each of the 3 groups. The distribution rate constants (k2 l and 
k i2) were similar in horses, ponies and donkeys, but the distribution rates were faster in 
horses and donkeys than in ponies.
The plasma disposition of amikacin was best described by a tri-exponential equation in horse 
3, pony 10, donkey 14 and donkey 15 where there were 7 ,4 , 6 and 6 points making up the 
elimination phase, respectively. The pharmacokinetic parameters calculated from the tri­
exponential equations used to describe the plasma concentration versus time data are given in 
Table 5-2. The movement of drug between the first and second compartments, (rate 
constants k21 and k i2 ) 2.99-17.57/h and 1.16-12.48/h, respectively, was faster than 
movement of drug between the first and third compartments, (rate constants k3 i and k i3) 
0.87-2.57/h and 0.22-3.44/h, respectively. In addition, k21 was generally faster than k i2, 
except in donkey 15 where k2 l and k j2 were similar, and k3 i was faster than k i3, except 
in horse 3 where they were similar.
5.3.2 Faecal concentrations
No amikacin was detected in faeces following intravenous administration to horses, ponies 
and donkeys.
5.3.3 Bacteriological examinations
Counts of viable bacteria (mean±SEM) in faeces following intravenous administration of 
amikacin are shown in Figures 5-2, 5-3 and 5-4, and the individual data is given in 
Appendix C (Tables C7-C9).
Salmonella spp. and C. difficile were selected for but not isolated.
There were no marked changes in the number of coliforms, streptococci, lactobacilli, 
Bacteroides spp. or Clostridium spp. isolated from horses following intravenous 
administration of amikacin (Figure 5-2). The mean number of streptococci was raised to 
10^-10^/g prior to and 48 h after drug administration. There were high numbers of 
streptococci isolated from horse 3 (108-10l0/g) throughout the study, and from horse 5 
(lOfyg) at 24 h after drug administration. There were low numbers of Bacteroides spp. (106- 
108/g) isolated from horse 3 at 48 h, from horse 4 throughout the study, and from horse 5 
prior to and at 48 h after drug administration.
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Parameter Horse 3 Pony 10 Donkey 14 Donkey 15
tl/2 B3 (h) 0.02 0.13 0.14 0.03
tl/2 B2 (h) 0.16 0.51 0.58 0.24
tl/2 B 1(h) 3.30 1.50 2.31 1.49
CpO (jig/ml) 103.67 68.34 74.13 81.78
Vc (ml/kg) 57.88 87.80 80.94 73.37
AUCobs (|ig.h/ml) 160.05 70.46 131.17 70.70
AUMCobs (|ig.h2/ml) 687.96 130.76 409.29 149.91
AUC (ng.h/ml) 155.62 64.85 126.24 68.10
AUMC (|ig.h2/ml) 716.96 107.78 388.64 139.91
MRT (h) 4.30 1.86 3.12 2.12
Vdarea (ml/kg) 185.28 200.50 158.61 189.32
VdSs (ml/kg) 177.64 153.77 146.32 181.03
CLb (ml/h.kg) 38.56 92.52 47.53 88.11
kei C/h) 0.67 1.05 0.59 1.20
k21 C/h) 17.57 3.54 2.99 10.24
k l2 (/h) 12.33 1.16 1.78 12.48
k31 C/h) 2.51 0.87 1.04 2.57
k l3 (/h) 3.44 0.37 0.22 0.64
Table 5-2. Disposition kinetics of amikacin in plasma following intravenous administration 
to horse 3, pony 10, donkey 14 and donkey 15
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Figure 5-2. Counts of viable bacteria (mean±SEM) in faeces following 
intravenous administration of amikacin to horses
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Figure 5-3. Counts of viable bacteria (mean±SEM) in faeces following
intravenous administration of amikacin to ponies
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There were no marked changes in the number of coliforms, streptococci, lactobacilli, 
Bacteroides spp. or Clostridium spp. isolated following intravenous administration of 
amikacin to ponies (Figure 5-3). The mean number of lactobacilli was high (lO^/g) prior to 
drug administration due to a high number of lactobacilli (10l0/g) isolated from pony 9. The 
mean number of Bacteroides spp. isolated was high at 48 h after drug administration. There 
were low numbers of Bacteroides spp. (105-108/g) isolated from all the ponies throughout 
the study, except from ponies 8 and 10 at 48 h when normal numbers (109-10l0/g) of 
Bacteroides spp. were isolated.
There were no marked changes in the numbers of coliforms, streptococci, lactobacilli, 
Bacteroides spp. or Clostridium spp. isolated from the 3 donkeys following the intravenous 
administration of amikacin (Figure 5-4). There were no streptococci isolated, on Slanetz and 
Bartley agar, from donkey 15 prior to the single intravenous administration of amikacin. The 
number of Bacteroides spp. isolated from donkeys faeces was low (105-l()7/g) on all 
occasions, except from donkey 15 (109/g) prior to drug administration. There were no 
Clostridium spp. isolated from donkeys 15 and 16. The number of Clostridium spp. isolated 
from donkey 14 prior to drug administration was quite high (107/g).
Bacteria isolated and identified using the API system were Actinomyces israelii, Bifidobacter 
adolescentis and Eubacterium limosum.
5.3.4 Faecal SCFA concentrations
Faecal lactic acid and total VFA concentrations (mean±SEM) following intravenous 
administration of amikacin to horses, ponies and donkeys are shown in Figures 5-5 and 5-6, 
and the data from individual animals is given in Appendix C (Tables C10-C20). The faecal 
SCFA concentrations were very variable following intravenous administration of amikacin to 
horses, ponies and donkeys. The faecal lactic acid concentrations were low following 
intravenous administration of amikacin to horses, ponies and donkeys, and were all within 
the normal range of 0.0-24.4 mmol/L In horses and donkeys, the mean total VFA 
concentrations were within the normal range of 24.4-109.2 mmol/1 at 0, 24 and 48 h, after 
intravenous administration of amikacin. In ponies, the mean total VFA concentrations of 0.0 
mmol/1 at 0, 24 and 48 h were lower than the normal range. There was considerable 
variation in total and individual VFA concentrations in individual animals however, these 
alterations were not considered to be associated with the intravenous administration of 
amikacin.
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Figure 5-4. Counts of viable bacteria (mean±SEM) in faeces following 
intravenous administration of amikacin to donkeys
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Figure 5-5. Lactic acid concentrations (mean±SEM) in faeces following
intravenous administration of amikacin to horses, ponies and donkeys
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Figure 5-6. Total VFA concentrations (mean±SEM) in faeces following 
intravenous administration of amikacin to horses, ponies and donkeys
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Figure 5-7. Faecal dry matter content (mean±SEM) following intravenous 
administration of amikacin to horses, ponies and donkeys
!
|
I
191
5.3.5 Faecal dry matter content and consistency
The faecal dry matter content (mean±SEM) following intravenous administration of amikacin 
to horses, ponies and donkeys is shown in Figure 5-7, and the data from individual animals 
is given in Appendix C (Tables C21-C23). There were no marked alterations in faecal dry 
matter content following intravenous administration of amikacin to horses, ponies and 
donkeys. The faecal dry matter content was slightly low (16.88%) in pony 7 prior to drug 
administration. There were no marked alterations of faecal consistency observed following 
intravenous administration of amikacin to horses, ponies and donkeys.
5.4 Results of intravenous administration of amikacin to ponies with 
cannulated caecal fistulas
5.4.1 Plasma disposition and pharmacokinetics
The plasma concentrations of amikacin following intravenous administration to ponies I and 
II on occasions 1 and 2 are given in Appendix C (Table C24).
A bi-exponential equation best described the data from ponies II, 12 and 112. The 
pharmacokinetic parameters calculated from the plasma concentration versus time data of 
each animal on each occasion are given in Table 5-3. In addition, the pharmacokinetic 
parameters calculated using the tri-exponential equation which best described the plasma 
concentration versus time data from pony III are given in Table 5-3.
5.4.2 Caecal liquor and faecal concentrations
There was no amikacin detected in caecal liquor or faecal samples from ponies following 
intravenous administration.
5.4.3 Bacteriological examinations
Counts of viable bacteria in caecal liquor following intravenous administration of amikacin 
are shown in Figures 5-8 to 5-12, and the individual data is given in Appendix C (Table 
C25).
Salmonella spp. and C. difficile were selected for but not isolated.
There were no marked alterations in the number of coliforms (Figure 5-8), streptococci 
(Figure 5-9), lactobacilli (Figure 5-10), Bacteroides spp. (Figure 5-11) or Clostridium spp. 
(Figure 5-12) isolated from caecal liquor following intravenous administration of amikacin. 
The number of streptococci isolated from ponies II and 112 ( lO ^ - l O ^ /m l) ,  prior to
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Parameter 11* 12* Ill* II1§ 112*
tl/2 B3 (h) - - - 0.03 -
tl/2 B2 (h) 0.28 0.14 0.04 0.65 0.28
tl/2 B1 (h) 2.22 2.55 1.85 1.89 2.69
CpO (jig/ml) 56.13 60.90 75.85 78.42 61.04
Vc (ml/kg) 106.89 98.52 79.11 76.51 98.30
AUCobs (M-g.h/ml) 110.86 139.60 107.53 107.58 126.52
AUMCobs (|ig.h2/ml) 324.69 559.32 283.74 283.75 444.13
AUC (p.g.h/ml) 106.72 137.47 102.99 102.79 123.83
AUMC (ng.h2/ml) 312.87 460.63 269.63 268.14 434.79
MRT(h) 2.93 4.01 2.64 2.64 3.51
Vdarea (ml/kg) 180.42 169.15 155.34 158.73 188.13
Vdss (ml/kg) 164.84 162.37 152.52 152.26 170.12
CLb (ml/h.kg) 56.23 45.99 58.26 58.67 48.45
kel(/h) 0.53 0.47 0.74 0.76 0.49
k21 (/h) 1.47 2.83 10.14 12.16 1.29
k l2 (/h) 0.80 1.84 9.41 10.87 0.94
k31 (/h) - - - 0.99 -
kl3 </h) - - - 0.10 -
Table 5-3. Disposition kinetics of amikacin in plasma following intravenous administration 
to ponies
Key: * calculated from a bi-exponential equation; § calculated from a tri-exponential equation
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Figure 5-8. Counts of viable coliforms in caecal liquor following 
intravenous administration of amikacin to ponies
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Figure 5-9. Counts of viable streptococci in caecal liquor following
intravenous administration of amikacin to ponies
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Figure 5-10 Counts of viable lactobacilli in caecal liquor following 
intravenous administration of amikacin to ponies
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Figure 5-11. Counts of viable Bacteroides spp. in caecal liquor following intravenous
administration of amikacin to ponies
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Figure 5-12. Counts of viable Clostridium spp. in caecal liquor following intravenous 
administration of amikacin to ponies
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intravenous administration of amikacin, was higher than expected (<10^/ml). The number of 
Bacteroides spp. isolated from ponies II and 12 was low (108/ml) at 48 h after and prior to 
drug administration, respectively. Bacteria identified using the API system were B. 
diastonis, Bacteroides spp. (B. ovatuslthetaiotaomicron) and C. butyricum.
5.4.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
Caecal liquor pH values following intravenous administration of amikacin are shown in 
Figure 5-13, and the individual data is given in Appendix C (Table C26). Caecal liquor pH 
was slightly low (6.6) prior to drug administration in ponies II and 12 and remained between 
pH 6.7 and 7.2 for the remainder of both studies.
Caecal liquor lactic acid concentrations following intravenous administration of amikacin to 
ponies are shown in Figure 5-14, and the individual data is given in Appendix C (Tables 
C27a-C30a). There were no marked fluctuations in lactic acid concentrations following 
intravenous administration of amikacin. Lactic acid concentrations increased to 5.7-8.9 
mmol/1 (normal range 0.0-24.4 mmol/1) at 4 and 6 h after drug administration to pony II.
Caecal liquor total VFA concentrations are shown in Figure 5-15, and the total VFA and 
individual acid concentrations are given in Appendix C (Tables C27a-C30a). There were 
alterations in VFA concentrations within the established normal ranges. However, there 
were very few VFA concentrations outside the normal ranges. In pony 12, the total VFA 
concentration of 131.3 mmol/1 at 12 h after drug administration was higher than the normal 
range of 24.4-109.2 mmol/1, due to a butyric acid concentration of 68.7 mmol/1, compared 
with the normal range of 4.8-67.3 mmol/1.
The proportions of acetic, propionic and butyric acids, as a percentage of the total VFA 
concentrations, are given in Appendix C (Tables C27b, C28b, C29b and C30b). The ratios 
of acetic, propionic and butyric acids fluctuated around the normal ranges.
Faecal SCFA concentrations in ponies following intravenous administration of amikacin are 
shown in Figures 5-16 and 5-17, and the individual data is given in Appendix C (Tables 
C31-C34). Lactic acid concentrations were within the normal range of 0.0-24.4 mmol/1 at all 
sample times in all ponies (Figure 5-16). The total VFA concentrations in faeces following 
intravenous administration of amikacin to ponies were very variable (Figure 5-17). There 
were variations in the total and individual VFA concentrations around the normal ranges. 
The total VFA concentration was lower than the normal range of 24.4 -109.2 mmol/1 at 24 h 
in pony II, at 0 and 48 h in pony 12, at 48 h in pony III, and at 48 h in pony 112. Prior to 
drug administration, the total VFA concentration of 182.3 mmol/kg was higher than normal
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Figure 5-13. Caecal liquor pH following intravenous administration of 
amikacin to ponies
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Figure 5-14. Lactic acid concentrations in caecal liquor following
intravenous administration of amikacin to ponies
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Figure 5-15. Total VFA concentrations in caecal liquor following intravenous administration 
of amikacin to ponies
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Figure 5-16. Lactic acid concentrations in faeces following intravenous
administration of amikacin to ponies
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Figure 5-17. Total VFA concentrations in faeces following intravenous 
administration of amikacin to ponies
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in pony III due to a very high butyric acid concentration of 179.3 mmol/kg, compared with 
the normal range of 4.8-67.3 mmol/1.
5.4.5 Faecal dry m atter content and consistency
The faecal dry matter content following intravenous administration of amikacin to ponies is 
shown in Figure 5-18, and the individual data is given in Appendix C (Table C35). There 
were no marked alterations in faecal dry matter content and no changes in faecal consistency 
were observed.
5.4.6 Plasma biochemistry and haematological exam inations
The plasma biochemistry results are given in Appendix C (Tables C36 and C37) and the 
results of the haematological examinations are given in Appendix C (Tables C38 and C39). 
There were no alterations in the plasma biochemistry or haematology values that were 
considered to be associated with the intravenous administration of amikacin to ponies.
5.5 Results of oral adm inistration of am ikacin to ponies with cannulated 
caecal fistulas
5.5.1 Plasma disposition and pharm acokinetics
The plasma concentrations of amikacin were below the limit of detection of the assay (<0.02 
pg/ml) following oral administration to ponies.
5.5.2 Caecal liquor and faecal concentrations
The caecal liquor concentrations following oral administration of amikacin to ponies are 
shown in Figure 5-19, and the individual data is given in Appendix C (Table C40). 
Maximum caecal liquor concentrations of 99.37, 83.68, 21.65 and 16.19 pg/ml were 
measured at 2, 1.5, 8 and 12 h in ponies II, 12, III and 112, respectively.
The disposition of amikacin in the caecal liquor was described using the observed AUC and 
AUMC to calculate the MRT (Table 5-4). There was a marked difference in the MRT 
between the 2 animals, a fact that was also reflected in the difference in the time to maximum 
caecal liquor concentrations.
Faecal concentrations following oral administration of amikacin to ponies are shown in 
Figure 5-20, and the individual data is given in Appendix C (Table C41).
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Figure 5-18. Faecal dry matter content following intravenous administration 
of amikacin to ponies
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Figure 5-19. Caecal liquor concentrations of amikacin following oral
administration to ponies
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Parameter 11 12 III 112
AUCobs (M-g.h/ml) 
AUMCobs (|ig.h2/ml) 
MRT (h)
335.94
1255.89
3.74
182.41
520.18
2.85
204.40
2268.44
11.10
215.07
2928.48
13.62
Table 5-4. Disposition kinetics of amikacin in caecal liquor following oral administration to 
ponies
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Figure 5-20. Faecal concentrations of amikacin following oral administration
to ponies
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5.5.3. Bacteriological examinations
Salmonella spp. and C. difficile were selected for but not isolated.
Counts of viable bacteria in caecal liquor following oral administration of amikacin are 
shown in Figures 5-21 to 5-26, and the individual data is given in Appendix C (Table C42).
There were no marked alterations in the number of coliforms isolated following oral 
administration of amikacin to ponies (Figure 5-21). There was an increase (lO^/ml) in the 
viable coliform counts at 96 h after drug administration to pony II. There were slight 
increases (up to lO^/ml) in the number of viable coliforms isolated from pony 12 at 72 and 
96 h after drug administration and from pony 112 at 72 h after drug administration.
There were slight increases (10^-10^/ml) in the number of viable caecal streptococci isolated 
from pony II at 48, 72 and 96 h, from pony 12 at 24 h and from pony III at 24 and 72 h 
following oral administration of amikacin (Figure 5-22).
There was a moderate increase in the number of viable lactobacilli isolated following oral 
administration of amikacin (Figure 5-23). These were increased slightly to lO ^-lO fym l at 24 
and 168 h in pony 12 and at 96 h in ponies III and 112.
There were no marked alterations in the number of viable Bacteroides spp. isolated from 
ponies following oral administration of amikacin (Figure 5-24). There were low numbers of 
Bacteroides spp. ( lO ^ -lO ^ /m l)  isolated from pony II at 168 h, and from pony 12 prior to 
and 48 h after drug administration.
There were no marked alterations in the number of Clostridium spp. isolated following oral 
administration of amikacin (Figure 5-25). There were relatively high numbers (10^-10^/ml) 
of Clostridium spp. isolated from ponies II and III prior to and from pony III at 48 h after 
drug administration. Clostridium butyricum was isolated and identified using the API 
system.
There was a marked increase in the number of viable faecal streptococci (up to 10^tyg) 
isolated from pony 13 at 24 and 48 h after drug administration (Figure 5-26; Appendix C, 
Table C42). The number of viable lactobacilli isolated from pony 13, at 24 and 48 h after 
drug administration, was high (10^-10^/g). There were no marked alterations in the number 
of Bacteroides spp. isolated from pony 13 following oral administration of amikacin, 
however low numbers (10^/g) were isolated prior to drug administration. There were high 
numbers of Clostridium spp. (lO^/g) isolated from pony 13 at 48 h after drug
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Figure 5-21. Counts of viable coliforms in caecal liquor following oral 
administration of amikacin to ponies
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Figure 5-22. Counts of viable streptococci in caecal liquor following oral
administration of amikacin to ponies
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Figure 5-23. Counts of viable lactobacilli in caecal liquor following oral 
administration of amikacin to ponies
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Figure 5-24. Counts of viable Bacteroides spp. in caecal liquor following oral
administration of amikacin to ponies
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Figure 5-25. Counts of viable Clostridium spp. in caecal liquor following oral administration 
of amikacin to ponies
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Figure 5-26. Counts of viable bacteria in faeces following oral
administration of amikacin to pony 13
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administration. Clostridium perfringens was isolated from pony 13 at 72 h after drug 
administration (10^/g), and identified using the API system.
5.5.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
The caecal liquor pH measurements are shown in Figure 5-27, and the individual data is 
given in Appendix C (Table C43). There appeared to be a reduction in the caecal liquor pH 
following oral administration of amikacin. Caecal liquor pH fell to lower than pH 6.6 at 6, 
8, 12, 28 and 32 h in pony II, at 2, 4, 6, 8, 12, 28, 32, 48, 52 and 56 h in pony 12, at 12, 
28 and 56 h in pony III, and at 2, 4 and 6 h in pony 112.
Caecal liquor SCFA concentrations are shown in Figures 5-28 and 5-29, and the individual 
data is given in Appendix C (Tables C44a-C47a).
Caecal liquor lactic acid concentrations increased following the oral administration of 
amikacin although the majority of concentrations lay within the normal range of 0.0-24.4 
mmol/1 (Figure 5-28). In pony II, lactic acid concentrations were elevated to 6.5-24.4 
mmol/1 at 2, 4, 6 , 8, 12, 28, 52 and 56 h, and at 4 h lactic acid concentrations were outside 
the normal range. In pony 12, lactic acid concentrations were elevated to 13.0-28.8 mmol/1 at 
4, 6, 8, 12, 24, 28 and 32 h, and were outside the normal range at 6, 8 and 12 h after drug 
administration. Lactic acid concentrations were increased to 14.4-20.3 mmol/1 at 12, 24 and 
28 h in pony III, and to 5.2-7.8 mmol/1 at 24, 28 and 56 h in pony 112.
Total VFA concentrations did not alter markedly following oral administration of amikacin 
(Figure 5-29). There were very few VFA concentrations outside the normal ranges. The 
butyric acid concentration fell to 3.7 mmol/1, compared with the normal range of 4.8-67.3 
mmol/1, at 6 and 12 h after drug administration to pony 12, and to 3.9 mmol/1 at 0.75 h after 
drug administration to pony 112.
The proportions of acetic, propionic and butyric acids, as a percentage of the total VFA 
concentrations are given in Appendix C (Table C44b, C45b, C46b, C47b). The ratios of 
acetic, propionic and butyric acids were all within or around the normal ranges.
SCFA concentrations in faeces are shown in Figures 5-30 and 5-31, and the individual data 
is given in Appendix C (Tables C48-C52). There were no marked alterations in the lactic 
acid concentrations in faeces following oral administration of amikacin (Figure 5-30). 
Although, in pony III the lactic acid concentration was increased to 15.4 mmol/kg at 24 h, 
compared with normal range of 0.0-24.4 mmol/1. There were no marked alterations in the 
total VFA concentrations in faeces (Figure 5-31). Total VFA concentrations in faeces were
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Figure 5-27. Caecal liquor pH following oral administration of amikacin to 
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Figure 5-28. Lactic acid concentrations in caecal liquor following oral
administration of amikacin to ponies
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Figure 5-29. Total VFA concentrations in caecal liquor following oral 
administration of amikacin to ponies
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Figure 5-30. Lactic acid concentrations in faeces following oral
administration of amikacin to ponies
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Figure 5-31. Total VFA concentrations in faeces following oral 
administration of amikacin to ponies
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lower than the normal range of 24.4-109.2 mmol/1 at 48 h in pony I I , at 48,72 and 168 h in 
pony 12, at 0, 48 and 72 h in pony III, at 24 h in pony 112 and throughout the study in pony 
13. In addition, the total VFA concentration was higher than normal at 24 h after drug 
administration to pony III. There were alterations in individual VFA concentrations, but 
there were no apparent trends in VFA concentrations that were associated with the oral 
administration of amikacin.
5.5.5 Faecal dry matter content and consistency
The faecal dry matter content following oral administration of amikacin is shown in Figure 
5-32, and the individual data is given in Appendix C (Table C53). There were no marked 
changes observed in either the faecal dry matter content or the faecal consistency following 
the oral administration of amikacin to ponies.
5.5.6 Plasma biochemistry and haematological examinations
The plasma biochemistry results are given in Appendix C (Tables C54-C57) and the results 
of the haematological examinations are given in Appendix C (Tables C58-C61). There were 
no alterations in plasma biochemistry or haematology that were associated with the oral 
administration of amikacin.
5.6 Results of in vitro studies with amikacin
5.6.1 Caecal liquor concentrations
Concentrations (mean±SEM) of amikacin in caecal liquor following incubation in vitro for 3 
and 24 h are shown in Figure 5-33, and the individual data is given in Appendix C (Tables 
C62a and b). After 3 h incubation, there was an average of 32% of amikacin remaining at the 
initial concentration of 0.25 |ig/ml, whilst the majority of the drug remained at 1, 5,10 and 
20 p.g/ml, and 55-75% of the drug remained at 40 and 80 |!g/ml. The largest reductions in 
concentration (zone diameter) were seen at either end of the concentration range due to 
limitations of the assay technique (zone diameter, limit of detection). There was an average 
of 90.8% of the drug activity remaining after 3 h incubation. Following 24 h incubation, the 
percentage reduction in concentration in all the samples was similar to that seen at 3 h, except 
there were no inhibition zones for the 0.25 fig/ml sample, and there was only 63% of the 1 
jig/ml sample remaining. There was an average of 85.0% (excluding the 0.25 p.g/ml sample) 
of the drug activity remaining following 24 h incubation.
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amikacin to ponies
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5.6.2 SCFA concentrations
Caecal lactic acid and total VFA concentrations (mean±SEM) following in vitro incubation 
are shown in Figure 5-34, and the individual data is given in Appendix C (Tables C63-C67). 
There were no alterations in mean lactic acid or mean total VFA concentrations with time or 
drug concentration.
5.6.3 Acid pH
Amikacin concentrations (mean±SEM) remaining following in vitro incubation at pH 1.9 are 
shown in Figure 5-35, and the individual data is given in Appendix C (Table C68). There 
was very little amikacin destroyed by incubation at pH 1.9; on average 85.6% of the drug 
remained after 1 h incubation. There may be some variation in percentage of drug destroyed 
with concentration; 87.0, 100.0, 84.6 and 70.9% of drug remained (mean) at 1, 2, 5 and 10 
pg/ml respectively.
5.6.4 Binding to hay
Amikacin concentrations remaining following in vitro incubation with chopped hay at pH 
1.9 and pH 7.0 for 3 h are shown in Figure 5-36. There was only 1 replicate of this study 
performed. There was a range of the initial 10, 25, 50 and 100 pg/ml amikacin remaining 
following incubation, namely 0.33, 1.35, 2.40, and 8.81 pg/ml at pH 1.9, and 0.23, 0.65, 
2.47 and 6.76 pg/ml at pH 7.0. However, it is interesting that only 3.3, 5.4, 4.8 and 8.8% 
remained at pH 1.9, and 2.3, 2.6, 5.0 and 6 .8% at pH 7.0, or an average of 5.6% and 
4.2%, respectively.
5.7. Discussion
In the present study, following intravenous administration of amikacin at a dose rate of 6 
mg/kg bwt to horses, ponies and donkeys, the elimination half-lives were 2.84, 1.60 and 
1.93 h (harmonic mean), respectively. In the present study, the elimination half-life of 
amikacin in horses was longer than in ponies and donkeys. Brown et al. (1984c) reported 
that the disposition of amikacin in plasma following intramuscular administration at a dose 
rate of 7 mg/kg bwt was best described by a bi-exponential equation with a mean elimination 
half-life of 2.3 h. Similarly, the mean elimination half-life of amikacin following 
intramuscular administration to foals was 3 h (Brown et al., 1986). Orsini et al. (1985) 
calculated elimination half-lives (harmonic mean) of 1.44, 1.57 and 1.14 h following 
intravenous administration of amikacin at dose rates of 4.4, 6.6 and 11 mg/kg bwt, 
respectively. In the present study the CL5 (mean±SEM) following intravenous 
administration to horses, ponies and donkeys was 45.19±3.76, 82.37±11.27 and
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Figure 5-34. SCFA concentrations (mean±SEM) in caecal liquor following 
incubation in vitro with amikacin for 3 and 24 h
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pH 1.9 and pH 7.0 for 3 h
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57.98±15.05 ml/h.kg, respectively, whereas in a previous study it was 76.6±11.3 ml/h.kg 
(mean±SD) following intravenous administration of amikacin to horses at a dose rate of 6.6 
mg/kg bwt (Orsini et al., 1985). Other pharmacokinetic parameters calculated in the present 
study were similar to those calculated in previous studies.
An optimum drug dose requires that the tissue concentrations of the drug equal or exceed the 
MIC of susceptible pathogens (Prescott and Baggot, 1985). Bacterial killing is directly 
proportional to the drug concentrations for the aminoglycosides (Prescott and Baggot, 
1985). Generally, the MIC of a susceptible Gram positive or Gram negative bacterium, 
including Pseudomonas aeruginosa, is <4 p.g/ml amikacin (Baggot and Prescott, 1987, 
Orsini et al.y 1985). Hirsch and Jang (1987) reported that 94% of coagulase-positive 
staphylococci isolated from the skeletal system of horses were susceptible in vitro to 4 |ig/ml 
amikacin and this increased to 100% at 8 (ig/ml. However, isolates of Streptococcus 
zooepidemicus from the lower respiratory tract of horses were more resistant (23% at 4 
|Xg/ml, 100% at 64 (ig/ml). In addition, 87% of isolates of Corynebacterium (Rhodococcus) 
equi were susceptible to 2 fig/ml amikacin, 98% at 4 |ig/ml, and 100% were susceptible to 
amikacin at a concentration of 8 pg/ml, in vitro. Although, clinical isolates of Bacteroides 
spp. and Klebsiella pneumoniae and Salmonella typhimurium were susceptible in vitro to <4 
|ig/ml amikacin, isolates of E. coli appeared to be more resistant (93% at 4 (ig/ml, 100% at 
>64 p.g/ml) in vitro (Hirsch and Jang, 1987). In the present study, the mean plasma 
concentrations of amikacin were greater than or equal to 4 }J.g/ml for 8 h in horses, and 6 h in 
ponies and donkeys following a single intravenous administration at a dose rate of 6 mg/kg 
bwt. Similarly, Orsini et al. (1985) reported that mean serum concentrations were maintained 
above 4 jLig/ml for 8 h, following intravenous administration of amikacin at dose rates of 6.6 
and 11.0 mg/kg bwt, and for around 5 h, following intravenous administration at a dose rate 
of 4.4 mg/kg bwt. This would suggest that intravenous administration of amikacin at a dose 
rate of 6 mg/kg bwt should be repeated every 8 h in horses and every 6 h in ponies and 
donkeys. This is similar to the recommendation of Van Dyk et al. (1982) who suggested that 
the intravenous administration of amikacin should be repeated every 6-8 h to maintain 
therapeutic plasma concentrations. However, Orsini et al. (1985) concluded that amikacin 
attained therapeutic concentrations in serum, peritoneal and synovial fluid and that 
intravenous administration at a dose rate of 4.4-6.6 mg/kg bwt every 12 h would provide 
suitable therapeutic plasma concentrations for treating susceptible infections, but for more 
serious, life-threatening infections, dosing three times daily was recommended.
It has been shown that at concentrations below the MIC, or the minimum bactericidal 
concentration, antimicrobial agents still show some inhibitory effects on the growth of 
bacteria, in vitro. The minimum bactericidal concentrations, for 10 clinical specimens of E.
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coli, were 4.0-40.0 |ig/ml amikacin and the minimum antibiotic concentration, based on 
two-fold broth dilutions and post-incubation counts of viable cfu, was V4 -V32 ° f  the 
minimum bactericidal concentrations for gentamicin and amikacin (Zanon, 1977). If the 
minimum antibiotic concentration has relevance in vivo then amikacin would need to be 
repeated less frequently, e. g. twice daily at a dose rate of 6 mg/kg bwt. This is of particular 
importance when an antimicrobial agent with a low therapeutic index is used.
There was no amikacin detected in caecal liquor or faeces following intravenous or oral 
administration. Snyder et al. (1986) measured peak concentrations of gentamicin in the 
tissue of the jejunum and large colon with peak concentrations of 2.26±1.35 |lg/ml at 0.33 h 
and 4.13±1.80 }ig/ml at 0.5 h, respectively, following intravenous administration of 
gentamicin. This is not surprising since the blood flow to the intestinal wall is quite high. 
However, the aminoglycosides are polar and have an apparent volume of distribution similar 
to the extracellular fluid volume of the animal. In the present study, the mean rate of 
distribution of amikacin to the hypothetical second compartment (k i2), representing well 
perfused tissues, was similar to the mean rate of elimination from this compartment (k2 l). 
Hence the predicted penetration of well-perfused tissues appeared to be poor. However, 
therapeutic concentrations of amikacin and gentamicin have been measured in peritoneal and 
synovial fluid (Bowman et al., 1986, Orsini et al., 1985), and amikacin has been used 
successfully to treat respiratory infections (Cudd, 1985). This suggests that the distribution 
of these polar antimicrobial agents is wider in vivo than it appears in pharmacokinetic 
models.
In the present study, it seems unlikely that amikacin was eliminated in bile to any great extent 
following intravenous administration, since the caecal liquor concentrations remained below 
the limit of detection of the assay (0.03 Jig/ml). Aminoglycosides are excreted unchanged by 
the kidney but Ziv et al. (1982) reported mean concentrations of 22.0, 12.5 and 8.2 jig/ml in 
bile at 4, 8 and 12 h after intravenous administration of gentamicin to calves. However, the 
concentration of free gentamicin in bile was <7% of the simultaneous urine concentrations 
and was <0.2% of the administered dose. The presence of biliary concentrations of an 
aminoglycoside may reflect the high concentrations present in the well-perfused hepatic 
tissue following intravenous administration. However, Ziv et al. (1982) reported that free 
concentrations of gentamicin in the liver were <1.2 |ig/ml at 4, 8 and 12 h after intravenous 
administration and that this represented <0.86% of the administered dose. The primary event 
in bile formation is the active secretion of bile salts, and this is accompanied by a passive 
flow of electrolytes and water. It seems more likely that gentamicin was present in bile 
through movement along with the aqueous phase of bile, since the concentrations discussed 
in this study were measured by bioassay, and represented free drug. The situation that
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occurs in the horse may be totally different since the horse has no gall bladder and the bile 
flow into the duodenum tends to be more or less continuous.
There were no marked changes in the number of viable bacteria isolated from caecal liquor or 
faeces following intravenous or oral administration of amikacin. There was a modest 
increase in the number of coliforms, streptococci and lactobacilli, and possibly Clostridium 
spp., isolated following oral administration of amikacin. The absence of marked alterations 
in the numbers of viable caecal luminal bacteria following oral administration should not 
have been particularly surprising since the aminoglycosides are of no value in an anaerobic 
environment (Brumbaugh, 1987). However, the aminoglycosides are used to sterilize the 
large intestine prior to surgery. In man, a one day dosage regime has been used to produce 
intra-operative suppression of the gastrointestinal flora and a lengthy 3 or 5 day pre- 
operative regime is considered to be unnecessary (Gorbach, 1983). However, in man the 
administration of antimicrobial agents prior to intestinal surgery is combined with 
administration of a low residue diet, magnesium sulphate and saline enemas. In addition, the 
estimated luminal concentrations of neomycin following oral administration were 1-3 mg/ml, 
whereas in the present study the peak caecal liquor concentrations of amikacin were 0 .1, 
0.08, 0.02 and 0.02 mg/ml in ponies II, 12, III and 112 following oral administration. Also, 
the neomycin oral bowel preparation regime utilizes concomitant administration of 
erythromycin to achieve the desired effects (Gorbach, 1983).
There was a reduction in caecal liquor pH following the oral administration of amikacin 
which may be explained by the increases in lactic acid concentrations. The number of viable 
lactic acid producing bacteria, such as streptococci, lactobacilli and Clostridium spp., 
increased slightly following oral administration. The peak lactic acid concentrations in the 
present study occurred at variable times following the oral administration of amikacin, 
although they always occurred following the peak drug concentrations. Similarly, the 
reduction in caecal liquor pH followed peak drug concentrations. However, the trough pH 
measurements did not occur at the same time as the peak lactic acid concentrations. It is 
interesting that there were practically no VFA concentrations outside the established normal 
ranges despite the large number of potentially susceptible Gram negative bacteria in the 
gastrointestinal lumen.
There were no marked alterations in plasma urea or creatinine concentrations in the present 
study. There have been reports of nephrotoxicity following the administration of gentamicin 
in the equine. Riviere et al. (1983b) reported clinical signs of nephrotoxicity (increased 
blood urea nitrogen and plasma creatinine concentrations) following the administration of 
gentamicin to foals and suggested that young horses may be more susceptible to gentamicin 
toxicity. Similarly, Riviere et al. (1982) recorded gentamicin nephrotoxicity at recommended
219
dose rates in three horses, although in one case it was reversed by drug withdrawal and 
volume diuresis. Sweeney et al. (1988) reported gentamicin induced acute renal failure 
following administration at a dose rate of 2.2 mg/kg every 6 h, and Hinchcliff et al. (1989) 
induced nephrotoxicosis in ponies by the administration of gentamicin at a dose rate of 20 
mg/kg bwt for up to 14 days. Following intravenous administration of amikacin to horses at 
a dose rate of 10 mg/lb (6.8 mg/kg) bwt daily for 15 days there was no clinical, laboratory 
or histopathological evidence of ototoxicity, nephrotoxicity or other adverse effects 
(Gingerich et al., 1983). Similarly, Adland-Davenport et al. (1990) noted no recognizable 
signs of amikacin-induced nephrotoxicosis following administration of amikacin to critically 
ill neonatal foals, and Cudd (1985) reported that intramuscular administration of amikacin at 
<11 mg/kg bwt every 8 h for up to 4 weeks did not result in the impairment of renal function 
in horses. The aminoglycosides bind to the brush border of the tubular epithelium in the 
kidney and translocate into the cytoplasm and lysosomes of cells resulting in lysosomal 
disruption and tubular necrosis (Davis, 1987). The nephrotoxic potential of the 
aminoglycosides appears to be dose-related (Brumbaugh, 1987, Davis, 1987) and in man, 
trough plasma concentrations of gentamicin of >2 jig/ml have been more closely associated 
with the development of nephrotoxicity than high peak concentrations (Brumbaugh, 1987). 
In view of this, it would be advisable to allow plasma concentrations to fall below 2 jig/ml in 
the inter-dosing interval. In addition, monitoring of plasma concentrations and indicators of 
renal function during therapy is useful when agents with a low therapeutic index, such as the 
aminoglycosides, are used for therapy (Brumbaugh, 1987).
The present study suggests that a suitable dosage regimen for the intravenous administration 
of amikacin sulphate to horses, ponies and donkeys, at a dose rate of 6 mg/kg bwt, would 
be every 12 h in horses, and every 8 h in ponies and donkeys. There appears to be no 
particular risk of development of enterocolitis following a single oral administration of 
amikacin sulphate, at a dose rate of 6 mg/kg bwt, to ponies. However, the luminal 
concentrations achieved in the present study may well be insufficient for suppression of the 
gastrointestinal flora. In addition, at a higher dose rate more extreme alterations in the 
number of viable bacteria, caecal liquor pH and lactic acid concentrations may result in the 
development of clinical changes associated with gastrointestinal acidosis.
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6 Studies with oxytetracycline
6.1 Introduction
In the horse, plasma and serum concentrations of oxytetracycline have been determined 
following intravenous administration at dose rates of 2.5-5.0 mg/kg bwt (Baggot, 1977b, 
Brown et al., 1981, Pilloud, 1973 and Teske et al., 1973). There is little information on the 
plasma concentrations of oxytetracycline following intravenous administration at 10 mg/kg 
bwt, the dose rate recommended frequently in other species (Bywater, 1982b, Prescott and 
Baggot, 1988b and Van Miert, 1988).
Prescott and Baggot (1988b) noted that many veterinarians have used the tetracyclines in 
horses without observing adverse effects. However, the tetracyclines have been reported to 
cause diarrhoea in the horse, both in clinical cases (Manahan, 1970, Baker and Leyland, 
1973, Mackellar et al., 1973) and in experimental animals (Andersson et al., 1971). It has 
been postulated that the intestinal flora of the horse is disturbed easily by the excretion of 
high concentrations of oxytetracycline in bile (Cook, 1973). Similarly, Swerczek (1979) 
reported that the use of antimicrobial agents, such as oxytetracycline, in healthy horses may 
alter the commensal gastrointestinal bacteria, and allow the overgrowth of bacterial 
pathogens such as C. perfringens. Therefore, it has been recommended that tetracycline 
therapy should be avoided in the equine due to the potential of inducing severe diarrhoea 
(Prescott and Baggot, 1988b).
The purpose of the present study was to determine the plasma concentrations of 
oxytetracycline hydrochloride in horses, ponies and donkeys after intravenous 
administration at the dose rate recommended for other species. Alterations in the intestinal 
flora were studied by bacteriological examination of serial faecal samples and large intestinal 
fermentation was studied by determining faecal SCFA concentrations. Faecal dry matter 
content and the gross appearance of faeces were used as indicators of the presence or 
absence of diarrhoea. Similar studies were carried out in ponies with cannulated caecal 
fistulas following a single intravenous or oral administration of oxytetracycline 
hydrochloride at a dose rate of 10 mg/kg bwt. In addition, drug, bacteriological and SCFA 
analyses were carried out on caecal liquor, and plasma biochemistry and haematology were 
monitored.
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6.2 Materials and Methods
6.2.1 Intravenous administration of oxytetracycline to horses, ponies and 
donkeys
Three Thoroughbred geldings (No. 1-3), four ponies (No. 7-10) and three donkeys (No. 
15-17) were used, as described in the general Materials and Methods. Oxytetracycline 
hydrochloride was administered by intravenous bolus injection at a dose rate of 10 mg/kg 
bwt. Plasma samples for drug analysis were taken at 0, 0.083, 0.25, 0.5 0.75, 1, 1.5, 2, 4, 
8, 12, 24, 28, 32, 36, 48, 52, 56, 72 and 96 h. Faecal samples were taken at 0, 24, 48, 72, 
96 and 168 h for drug analysis, bacteriological examination, SCFA analysis and 
measurement of faecal dry matter content. There were no faecal samples taken at 72 h after 
drug administration to ponies.
6.2.2 Intravenous administration of oxytetracycline to ponies with 
cannulated caecal fistulas
Three pony mares with cannulated caecal fistulas (No. I-III), as outlined in the general 
Materials and Methods, were used on up to 3 occasions (1-3). Oxytetracycline hydrochloride 
was administered by intravenous bolus injection at a dose rate of 10 mg/kg bwt. Plasma 
samples for drug analysis and caecal liquor samples for drug analysis and SCFA analysis 
were taken at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 24, 28, 32, 48, 52, 56, 72, 96 and 
168 h. In pony III1 samples were taken for up to 72 h, in pony III2 samples were taken at 
0.5, 1, 2, 4, 7, 24, 31, 48 and 72 h, and in pony III3 an additional sample was taken at 
0.083 h and sampling was stopped at 48 h. The pH of caecal liquor was measured in ponies 
I and II only. Bacteriological examinations of caecal liquor were carried out at 0, 24, 48, 72, 
96 and 168 h in ponies I and II, at 0, 24, 48 and 336 h in pony III1, and at 0, 24, 48, 72 
and 144 h in pony III2. Faecal samples were taken for drug analysis, SCFA analysis and 
measurement of dry matter content from ponies I and II at 0, 24, 48, 72, 96 and 168 h. 
Plasma biochemistry and haematological examinations were carried out at 0, 24, 48, 72,96 
and 168 h in ponies I and II, and at 0, 24, 48, 72 and 144 h in pony III1.
6.2.3 Oral administration of oxytetracycline to ponies with cannulated caecal 
fistulas
Two pony mares with cannulated caecal fistulas (No. I and II), as outlined in the general 
Materials and Methods, were used on 3 occasions (1-3) at least 10 months after intravenous 
administration of oxytetracycline hydrochloride. Oxytetracycline hydrochloride was 
administered via nasogastric tube at a dose rate of 10 mg/kg bwt. On occasions 1 and 2, 
plasma samples for drug analysis and caecal liquor samples for drug analysis, pH
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measurement and SCFA analysis were taken at 0, 0.25, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 24, 28, 
32, 48, 52, 56, 72, 96, 168 and 336 h. Bacteriological examinations of caecal liquor were 
carried out at 0, 24, 48, 72, 96, 168 and 336 h. Faecal samples were taken for the 
measurement of drug concentrations, SCFA concentrations and dry matter content at 0, 24, 
48, 72, 96, 168 and 336 h. Samples were taken for plasma biochemistry and for 
haematological examinations at 0, 24, 48, 168 and 336 h. On occasion 3, caecal liquor 
samples were taken at 0, 24, 48, 72, 96 and 168 h for a limited bacteriological examination 
(coliform and streptococcal counts and the isolation of Salmonella spp.) and measurement of 
pH and SCFA concentrations. Faecal samples were taken at 0, 24, 48,72, 96 and 168 h for 
isolation of Salmonella spp., SCFA analysis and the measurement of dry matter content. 
Samples were taken for plasma biochemistry and haematological examinations at 0, 24, 48 
and 168 h.
6.2.4 In vitro studies with oxytetracycline
Oxytetracycline hydrochloride was incubated with caecal liquor for 3 and 24 h, and drug 
concentrations and SCFA concentrations were measured, and bacteriological examinations 
were carried out, as outlined in the general Materials and Methods. In addition, 
oxytetracycline hydrochloride concentrations were measured following incubation at pH 1.9 
as outlined in the general Materials and Methods.
6.3 Results of intravenous administration of oxytetracycline to horses, 
ponies and donkeys
6.3.1 Plasma disposition and pharmacokinetics
A semilogarithmic plot of plasma concentrations (mean±SEM) of oxytetracycline, following 
intravenous administration to horses, ponies and donkeys, is shown in Figure 6-1. 
Individual plasma concentration versus time data is given in Appendix D (Tables D1-D3). In 
horses and ponies, the plasma concentration versus time plots were similar and 
oxytetracycline persisted at measurable concentrations (>0.08 |ig/ml) in plasma for 96 h in 
horses and 72 h in ponies. In donkeys, the slope of the terminal phase of the plasma 
concentration versus time plot was steeper than in horses and ponies and oxytetracycline 
could be detected in plasma for 48 h only.
The mean pharmacokinetic parameters calculated from the bi-exponential equations used to 
describe the plasma concentration versus time data are given in Table 6-1, and the data from 
individual animals is given in Appendix D (Tables D4-D6). The harmonic mean of the 
elimination half-lives calculated for horses and ponies was similar, whilst the value 
calculated for donkeys was circa 50% of this. The AUC and AUMC were around twice as
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Figure 6-1. Plasma concentrations (mean±SEM) of oxytetracycline following 
intravenous administration to horses, ponies and donkeys
Parameter Horses (n=3) Ponies (n=4) Donkeys (n=3)
tl/2 B2 (h)* 0.15 0.23 0.29
tl/2 B1 (h)* 11.69 11.77 5.40
CpO (pg/ml) 111.18±17.99 59.51±13.86 67.10±4.22
Vc (ml/kg) 94.34±13.67 204.50±56.41 150.20±9.30
AUCobs (M-g.h/ml) 217.17±7.56 156.23±29.70 97.32±4.29
AUMCobs (|ig.h2/ml) 3045.47±152.14 2399.18±608.06 631.53±183.17
AUC (jig.h/ml) 253.53±4.72 182.35±35.11 109.45±0.75
AUMC (jig.h2/ml) 3949.47±269.97 2898.98±699.09 780.41±228.67
MRT (h)* 14.05±0.78 15.10±1.36 6.67±2.23
Vdarea (ml/kg) 672.79±49.74 1048.23±218.47 776.52±193.43
Vdss (ml/kg) 615.97±47.36 956.26±202.98 649.27±185.17
CLb (ml/h.kg) 39.31±0.59 60.77±10.76 91.37±0.63
kel C/h) 0.44±0.08 0.32±0.03 0.59±0.08
k21 C/h) 0.60±0.02 0.54±0.02 0.61±0.04
ki2 C/h) 3.52±0.83 2.16±0.33 1.92±0.72
Table 6-1. Disposition kinetics of oxytetracycline in plasma following intravenous
administration to horses, ponies and donkeys
Key: data as mean±SEM; * harmonic mean
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high in horses and ponies compared with donkeys. There was a statistically significant 
difference in the variance of the AUC (p = 0.043) and the AUMC (p = 0.043), calculated 
using a Kruskal Wallis test. However, there were no statistically significant differences 
detected between the groups using a Mann Whitney U test. The CL5 was lowest in the 
horses, circa twice this in the ponies, and highest in donkeys (circa three times the horse 
value). There was a statistically significant difference (p = 0.043) in the CLb of horses, 
ponies and donkeys calculated using a Kruskal Wallis test, but there were no statistically 
significant differences detected using a Mann Whitney U test.
The plasma concentration versus time data from pony 10 and donkey 16 were best described 
using a tri-exponential equation, and the pharmacokinetic parameters calculated from these 
equations are given in Table 6-2.
6.3.2 Faecal concentrations
Oxytetracycline concentrations (mean±SEM) in faecal samples following intravenous 
administration to horses, ponies and donkeys are shown in Figure 6-2, and the data from 
individual animals is given in Appendix D (Tables D7-D9). Faecal drug concentrations were 
measured for up to 96 h in all 3 groups. Faecal oxytetracycline concentrations were higher 
than the simultaneous plasma concentrations in all the animals at all of the sampling times.
6.3.3 Bacteriological examinations of faeces
Counts of viable bacteria in faeces following intravenous administration of oxytetracycline 
are shown in Figures 6-3, 6-4 and 6-5, and the data from individual animals is given in 
Appendix D (Tables D10-D12).
Selective isolation of Salmonella spp. was not carried out. Clostridium difficile was looked 
for but not isolated.
In the horses, there were no marked changes in the number of coliforms or Bacteroides spp. 
isolated from faeces following intravenous administration of oxytetracycline (Figure 6-3). 
There were moderately high numbers of coliforms isolated from horse 3 (10^/g) at 72 h after 
drug administration. There was an increase in the mean number of streptococci (to 10^/g) 
isolated at 96 h after drug administration. There were high numbers of streptococci isolated 
from horse 3 at 48, 72, 96 and 168 h (10^-10^/g). The mean number of viable lactobacilli 
increased to 10^-10^ tyg at 48 and 96 h after drug administration. This was the result of an 
increase in the number of viable lactobacilli isolated from horse 1 (lO^-lO* tyg) at 48,96 and 
168 h and from horse 3 (1 0 ^ /g ) at 96 h after drug administration. The number of 
Bacteroides spp. isolated from horse faeces was low (lO^-lO^/g) throughout the study.
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Parameter Pony 10 Donkey 16
tl/2 B3 (h) 0.18 0.12
tl/2 B2(h) 1.29 1.64
tl/2 B 1(h) 12.18 14.66
CpO (|ig/ml) 60.7 71.09
Vc (ml/kg) 164.75 140.66
AUCobs (|ig.h/ml) 141.35 89.92
AUMCobs (|lg.h2/ml) 1633.55 997.87
AUC (|ig.h/ml) 137.71 89.75
AUMC (jig.h2/ml) 1795.11 1211.80
MRT(h) 11.56 11.10
Vdarea (ml/kg) 1275.87 2356.81
VdSs (ml/kg) 946.57 1504.40
CLb (ml/h.kg) 72.62 111.42
kel (/h) 0.44 0.75
k21 (/h) 1.65 1.36
k l2 (/h) 1.65 3.12
k3 i (/h) 0.17 0.10
kl3(/h) 0.62 0.83
Table 6-2. Disposition kinetics of oxytetracycline in plasma following intravenous
administration to pony 10 and donkey 16
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Figure 6-2. Faecal concentrations (mean±SEM) of oxytetracycline following 
intravenous administration to horses, ponies and donkeys
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Figure 6-3. Counts of viable bacteria (mean±SEM) in faeces following intravenous
administration of oxytetracycline to horses
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There was an increase in the mean number of viable Clostridium spp. (to lO^/g) isolated at 
96 h after drug administration due to an increase in the number of these organisms (to 10^- 
lOfyg) isolated from the faeces of horses 1 and 2.
There were no marked alterations in the mean number of bacteria isolated from the ponies at 
any of the sampling times, except for an increase in the mean number of viable streptococci 
(up to lO^/g) isolated at 24 h after drug administration (Figure 6-4). There were high 
numbers of streptococci (10^-10^/g) isolated from pony 8 at 24, 48, 72 and 168 h after 
oxytetracycline administration. The mean number of Bacteroides spp. isolated was low 
(<l()9/g) prior to and at 72 h after drug administration. In addition, there were moderately 
high numbers of Clostridium spp. (lOfyg) isolated at 24 and 48 h from pony 7, and at 48 
and 72 h from pony 9.
There was an increase in the mean number of coliforms (up to lOfyg) isolated from donkey 
faeces at 72 and 96 h after oxytetracycline administration (Figure 6-5). There was an 
increase in the number of coliforms isolated from donkey 17 (to lO^/g) at 72 h, and from 
donkey 16 (to lO^/g) at 96 h. There was an increase in the mean number of lactobacilli (up 
to lOfyg) isolated at 72 h after drug administration, which was primarily due to an increase 
in the number isolated from donkey 17 at this time. The number of Bacteroides spp. isolated 
from donkey faeces were low at all times, except at 96 h after drug administration. There 
were no alterations in the number of streptococci or Clostridium spp. isolated from donkey 
faeces following a single intravenous administration of oxytetracycline.
6.3.4 Faecal SCFA concentrations
Faecal lactic acid and total VFA concentrations (mean±SEM) following intravenous 
administration of oxytetracycline to horses, ponies and donkeys are shown in Figures 6-6 
and 6-7, and the mean data and data from individual animals are given in Appendix D 
(Tables D13-D23). Lactic acid concentrations (mean±SEM) were increased to 25.1±17.0 
mmol/kg at 48 h in horses, and to 6.4±3.3 mmol/kg at 48 and 72 h in ponies, although they 
were only outside the normal range of 0.0-24.4 mmol/1 in horses (Figure 6-6). The increase 
in the mean lactic acid concentration in horses was due to an increased lactic acid 
concentration in the faecal samples from horses 2 and 3 to 17.7 and 57.5 mmol/kg, 
respectively, although the 48 h sample from horse 3 was the only sample outside the normal 
range. In ponies, there was an increase in lactic acid concentrations at 48 h in pony 7 and at 
72 h in pony 8 to 14.3 and 36.5 mmol/kg, respectively, but only the sample from pony 8 
was outside the normal range. Lactic acid concentrations in donkey faecal samples were all 
within the normal range and showed no increases following intravenous administration of 
oxytetracycline.
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Figure 6-4. Counts of viable bacteria (mean±SEM) in faeces following 
intravenous administration of oxytetracycline to ponies
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Figure 6-5. Counts of viable bacteria (mean±SEM) in faeces following intravenous
administration of oxytetracycline to donkeys
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Figure 6-6 . Lactic acid concentrations (mean±SEM) in faeces following 
intravenous administration of oxytetracycline to horses, ponies and donkeys
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Figure 6-7. Total VFA concentrations (mean±SEM) in faeces following
intravenous administration of oxytetracycline to horses, ponies and donkeys.
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The total VFA concentrations (mean±SEM) in faeces from horses, ponies and donkeys 
following intravenous administration of oxytetracycline were very variable (Figure 6-7). In 
addition, there was considerable variation in individual VFA concentrations. In horses, total 
VFA concentrations were lower than the normal range of 24.4-109.2 mmol/1 at 24 and 72 h 
and higher than normal at 168 h after intravenous administration of oxytetracycline. In 
ponies, mean total VFA concentrations were higher than the normal range at 48 h and lower 
than normal at 168 h. In donkeys, the mean total VFA concentration was elevated above the 
normal range prior to and below normal at 48, 72, 96 and 168 h after intravenous 
administration of oxytetracycline. There were no trends in VFA concentrations in faeces that 
were associated with the intravenous administration of oxytetracycline.
6.3.5 Faecal dry m atter content and consistency
The faecal dry matter content (mean±SEM) following intravenous administration of 
oxytetracycline to horses, ponies and donkeys is shown in Figure 6-8. The mean values and 
data from individual animals are given in Appendix D (Tables D24-D26). The mean faecal 
dry matter content were reduced to <17% in horses at 96 h after oxytetracycline 
administration. There was a reduction in the faecal dry matter content at 24,48,72 and 96 h 
in horse 1 (14.40-16.50%), at 48 h in horse 2 (15.20%), and at 96 h in horse 3 (16.00%). 
In ponies, the mean faecal dry matter content was reduced to <17% at 48 h after drug 
administration. There was a reduction in the faecal dry matter content to 13.00-16.40% in 
pony 7 at 48,72 and 168 h. The faecal dry matter content was low (11.20-15.60%) in pony 
8 at 0, 24, 48 and 72 h after drug administration. The faecal dry matter content was low 
(12.50%) at 0 h in pony 10. The mean faecal dry matter content was reduced to 13.93- 
16.90% in donkeys at 24, 48, 72 and 96 h after intravenous administration of 
oxytetracycline. Faecal dry matter content was reduced at 48,72 and 96 h in donkeys 15 and 
16 (10.00-16.70%), and at 0, 24 and 48 h in donkey 17 (13.30-15.30%).
The faecal consistency was soft at 48, 72 and 96 h and as slightly soft at 24 h after drug 
administration to all 3 horses. The faecal consistency was soft in ponies 8 and 10 prior to 
drug administration. The faecal consistency was soft in donkey 17 prior to and at 24 h, in 
donkey 16 at 48 h, in all 3 donkeys at 72 h, and in donkey 16 at 96 h after drug 
administration. In addition, donkey 15 was noted to have passed a reduced volume of faeces 
at 48 h after drug administration.
6.3.6 Bromsulphalein clearance in horses and donkeys
A plot of the plasma bromsulphalein concentration versus time is shown in Figure 6-9. The 
elimination half-life of bromsulphalein was 2.5 min for each of the 3 horses (No. 1-3) and
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Figure 6-8. Faecal dry matter content (mean±SEM) following intravenous administration of 
oxytetracycline to horses, ponies and donkeys
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Figure 6-9. Plasma concentrations of bromsulphalein following intravenous
administration to horses and donkeys
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1.3, 3.3 and 1.8 min for the 3 donkeys (No. 15-17, respectively) indicating similar liver 
clearance of the compound.
6.4 Results of intravenous administration of oxytetracycline to ponies with 
cannulated caecal fistulas
6.4.1 Plasma disposition and pharmacokinetics
The plasma concentrations of oxytetracycline following intravenous administration to ponies 
I-III on occasions 1-3 are given in Appendix D (Table D27).
A bi-exponential equation best described the plasma concentration versus time data from 
ponies II, 12, III1 and III2. In addition, a tri-exponential equation was used to describe the 
data from ponies III, 112 and III3. The pharmacokinetic parameters calculated from the 
plasma concentration versus time data from each animal on each occasion are given in Tables 
6-3 and 6-4. The pharmacokinetic parameters that were calculated were similar to those 
obtained from ponies 7-10, except for pony III1 which had a very long elimination half-life.
6.4.2 Caecal liquor and faecal concentrations
The caecal liquor concentrations of oxytetracycline following intravenous administration to 
ponies I-III on occasions 1-3 are shown in Figures 6-10 and 6-11, and the individual data is 
given in Appendix D (Table D28). Oxytetracycline was measured in the caecal liquor for up 
to 72 h after a single intravenous administration. The maximum caecal liquor concentrations 
were 1.36, 1.37. 1.23, 1.52, 1.82 1.85 and 2.41 pg/ml in ponies, II, 12, III, 112, III1, III2 
and III3, respectively. The time taken for oxytetracycline to reach the caecum varied from 
animal to animal. A maximum concentration of oxytetracycline was measured at 4 h in 
ponies II, 12 and III3, at 28 h pony III, at 12 h in ponies 112 and III1, and at 7 h in pony 
III2 .
Drug disposition within the caecum was described using the AUC and the AUMC for 
observed values and the ratio of these (MRT). The pharmacokinetic variables that were 
calculated are given in Table 6-5.
Faecal concentrations of oxytetracycline following intravenous administration to ponies I and 
II are shown in Figure 6-12, and the individual data is given in Appendix D (Table D29). 
Oxytetracycline was measured in faecal samples for up to 72 h following a single 
intravenous administration.
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Parameter 11 12 III 112 III1 III2 m3
tl/2 B2 (h) 0.31 0.35 0.44 0.37 0.07 0.36 0.42
tl /2 B 1 (h) 10.48 12.08 12.07 11.53 17.48 10.96 9.45
CpO (|ig/ml) 42.17 51.33 27.22 33.04 101.02 70.63 52.60
Vc (ml/kg) 237.11 194.82 367.44 302.64 98.99 141.58 121.07
AUCobs (jig.h/ml) 106.14 200.57 82.23 142.96 210.15 231.32 154.18
AUMCobs (pg.h2/ml) 1299.18 3038.85 1106.14 2116.66 4695.10 2896.84 1347.25
AUC (|lg.h/ml) 113.26 189.76 88.65 157.70 196.20 228.05 157.41
AUMC (|ig.h2/ml) 1480.10 3295.31 1298.06 2416.64 4697.15 3149.77 1553.53
MRT (h) 12.24 15.15 13.45 14.81 22.34 12.52 8.74
Vdarea (ml/kg) 1334.89 833.99 1965.01 1054.94 1285.52 693.56 866.41
Vdss (ml/kg) 1153.80 754.90 1651.90 971.71 1220.18 605.66 626.98
CLb (ml/h.kg) 88.29 47.86 112.81 63.41 50.97 43.85 63.53
kel Uh) 0.37 0.25 0.31 0.21 0.52 0.31 0.53
k21 (/h) 0.40 0.46 0.29 0.54 0.72 0.40 0.23
k!2 (/h) 1.55 1.33 1.02 1.20 8.16 1.30 0.95
Table 6-3. Dispositiori kinetics of oxytetracycline in plasma following intravenous
administration to ponies II, 12, III, 112, III 1, III2 and III3
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Parameter III 112 ni3
tl/2 B3 (h) 0.19 0.21 0.27
tl/2 B2 (h) 1.81 1.79 0.56
tl /2 B 1 (h) 14.94 13.40 10.24
CpO (|ig/ml) 39.65 36.38 80.90
Vc (ml/kg) 252.22 274.90 123.61
AUCobs (Hg.h/ml) 83.78 143.38 154.49
AUMCobs (|ig.h2/ml) 1106.53 2116.77 1365.73
AUC (pg.h/ml) 83.07 143.84 151.69
AUMC (|ig.h2/ml) 1224.30 2255.25 1513.11
MRT (h) 13.21 14.76 8.84
Vdarea (ml/kg) 2595.14 1344.45 973.82
Vdss (ml/kg) 1774.18 1090.04 657.62
CLb (ml/h.kg) 120.38 69.52 65.93
kel(/h) 0.48 0.25 0.53
k21 </h) 1.22 1.53 2.20
k l2 (/h) 1.79 1.42 0.16
k31 (/h) 0.11 0.17 0.18
kl3(/h) 0.52 0.35 0.77
Table 6-4. Disposition kinetics of oxytetracycline in plasma following intravenous
administration to ponies III, 112 and III3
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Figure 6-10. Caecal liquor concentrations of oxytetracycline following 
intravenous administration to ponies I and II
OX)=L
C
eou
Co>uso
U
3
2
1
0
0 48 7224 96
m i
Time (h)
m 2 m3
Figure 6-11. Caecal liquor concentrations of oxytetracycline following
intravenous administration to pony ID
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Parameter 11 12 m H2 in i m 2 IH3
AUC obs (Hg.h/ml) 
AUM Cobs (Hg.h2/ml) 
MRT(h)
22.43
292.68
13.05
15.42
125.25
8.12
46.14
1579.20
34.23
20.28
352.80
17.40
40.65
909.40
22.37
69.71
2165.76
31.07
45.72
905.95
19.82
Table 6-5. Disposition kinetics of oxytetracycline in caecal liquor following intravenous 
administration to ponies
J 5JD
'Bi)n
c
u .
ca>oco
U
5
4
3
2
1
0
0 24 48 72 96
II
Time (h)
I 2 - - * - “ I I I -" * - -  112
Figure 6-12. Faecal concentrations of oxytetracycline following intravenous
administration to ponies
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6.4.3 Bacteriological exam inations
Counts of viable bacteria in caecal liquor following intravenous administration of 
oxytetracycline are shown in Figures 6-13 to 6-17, and the individual data is given in 
Appendix D (Table D30).
Salmonella spp. and C. difficile were selected for but not isolated.
There were no marked changes in the number of coliforms isolated from ponies I and II on 
occasions 1 and 2, although there was a slight increase (to 10^/ml) at 48 h in pony II 
(Figure 6-13). Pony III1 had a high coliform count of 10^-10^/ml at 24,48 and 336 h after 
drug administration, and in pony III2 the coliform counts were high (10^-10^/m l) at 0,48, 
72 and 144 h after drug administration.
The number of streptococci isolated from ponies II, 12 and 112 did not alter markedly 
following the intravenous administration of oxytetracycline (Figure 6-14). In pony III, there 
was an increase in the number of streptococci (10^/ml) isolated at 24 h after drug 
administration. The number of streptococci isolated from pony III was high (108- 1010/ml) 
prior to drug administration on occasions 1 and 2, at 24, 48 and 336 h after drug 
administration on occasion 1, and at 24, 72 and 144 h on occasion 2. Streptococcus 
intermedius was identified using the API system.
There were no marked alterations in the number of lactobacilli isolated from ponies I and II 
on occasions 1 and 2 (Figure 6-15). In pony III the number of lactobacilli isolated was 
increased to 10^-10^/ml at 24 and 48 h on occasion 1, and prior to and at 144 h after drug 
administration on occasion 2. Lactobacillus acidophilus was identified using the API system.
The number of Bacteroides spp. isolated prior to drug administration was low (<10^/ml) in 
ponies II, 112, III1 and III2 (Figure 6-16). There were low numbers (<10^/ml) of 
Bacteroides spp. isolated from pony II at 24, 48, 72 and 168 h, from pony 12 at 24, 48,72, 
96 and 168 h, from pony III at 24, 72 and 96 h, from pony 112 at 24, 48, 72 and 96 h, and 
from ponies III1 and III2 at 24 and 48 h after intravenous administration of oxytetracycline. 
Bacteroides spp. identified using the API system were B. oralis, B. ovatus, B . 
thetaiotaomicron and B. uniformis.
There were no marked alterations in the number of Clostridium spp. isolated from any of the 
ponies at any of the sampling times prior to or following the intravenous administration of 
oxytetracycline, although there were moderately high numbers (lOfyml) isolated from pony 
12 prior to drug administration (Figure 6-17). Clostridium spp. identified using the API
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Figure 6-13. Counts of viable coliforms in caecal liquor following intravenous 
administration of oxytetracycline to ponies
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Figure 6-14. Counts of viable streptococci in caecal liquor following intravenous 
administration of oxytetracycline to ponies
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Figure 6-15. Counts of viable lactobacilli in caecal liquor following intravenous 
administration of oxytetracycline to ponies
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Figure 6-16. Counts of viable Bacteroides spp. in caecal liquor following intravenous 
administration of oxytetracycline to ponies
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Figure 6-17. Counts of viable Clostridium spp. in caecal liquor following intravenous 
administration of oxytetracycline to ponies
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system were C. butyricum , C. perfringens (lO^/ml from pony 12 at 168 h after drug 
administration) and C. ramosum.
Other bacteria identified using the API system were Actinomyces israelii, Eubacterium 
lentum, Peptococcus asaccharolyticus and Veillonella parvula.
6.4.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
Caecal liquor pH values following intravenous administration of oxytetracycline are shown 
in Figure 6-18, and the individual data is given in Appendix D (Table D31). The caecal 
liquor pH was high (>7.2) prior to and at 2,4, 8, 12 and 52 h after drug administration and 
low (<6.8) at 168 h after drug administration to pony II. In pony 12, caecal liquor pH was 
high at 1.5 h and low at 8, 52, 72 and 96 h after drug administration. Caecal liquor pH was 
high in pony III at 0, 8, 12, 24, 72, 96 and 168 h and in pony 112 at 0.5, 0.75, 24, 72, 96 
and 168 h after intravenous administration of oxytetracycline.
Lactic acid concentrations in caecal liquor, following intravenous administration of 
oxytetracycline to ponies, are shown in Figure 6-19, and the individual data is given in 
Appendix D (Tables D32a-D38a). Lactic acid concentrations were increased to 5.4-20.3 
mmol/1 in pony II at 4, 8, 24, 28, 32, 36, 48, 52, 56 and 72 h, in pony 12 at 1, 1.5, 4, 8, 
12, 52 and 72 h, in pony III1 at 4, 8, 12, 24, 28, 32, 36, 52, 56 and 72 h in pony III1, and 
in pony III2 at 7, 31 and 72 h but all the concentrations lay within the normal range of 0.0-
24.4 mmol/1. There were no increases in caecal liquor lactic acid concentrations in pony 112. 
In pony III, caecal lactic acid concentrations were increased to 6.9-40.2 mmol/1 at 28, 32, 
36, 48, 52, 56 and 72 h after drug administration, and were higher than the established 
normal range at 48, 52, 56 and 72 h. In pony III3, caecal liquor lactic acid concentrations 
were elevated to 7.5-32.6 mmol/1 at 0.75, 1. 1.5, 4, 8, 12 and 36 h after drug 
administration, and were above the normal range at 4 and 8 h.
Total VFA concentrations in caecal liquor are shown in Figure 6-20, and the total VFA and 
individual acid concentrations are given in Appendix D (Tables D32a-D38a). Total and 
individual VFA concentrations fluctuated around the normal ranges. Total VFA 
concentrations in caecal liquor were increased to 137.7-143.3 mmol/1, compared with the 
normal range of 24.4-109.2 mmol/1, at 1.5 and 8 h in pony 12. There was a reduction in the 
total VFA concentrations to 18.3-19.4 mmol/1 at 1 and 72 h in pony III 1. There were some 
alterations in the individual VFA concentrations following intravenous administration of 
oxytetracycline. There was a reduction in acetic acid concentrations to 7.2-9.4 mmol/1, 
compared with the normal range of 12.6-64.5 mmol/1, at 0.75 h in pony 112 and at 8 h in
242
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Figure 6-18. Caecal pH following intravenous administration of 
oxytetracycline to ponies
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Figure 6-19. Lactic acid concentrations in caecal liquor following
intravenous administration of oxytetracycline to ponies
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Figure 6-20. Total VFA concentrations in caecal liquor following intravenous administration 
of oxytetracycline to ponies
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pony III1. There was a reduction in the propionic acid concentrations to 1.6-4.0 mmol/1, 
compared with the normal range of 4.7-24.5 mmol/1, at 0.75, 12, 24, 48, 52 and 56 h in 
pony II, at 8, 12, 28, 32 and 36 h in pony 12, at 0.75, 1 and 28 h in pony 112, and at 6, 24, 
48 and 72 h in pony III1. There was an increase in the butyric acid concentrations to 79.1-
121.4 mmol/1, compared with the normal range of 4.8-67.3 mmol/1, at 1.5 and 8 h in pony 
12. Butyric acid concentrations were reduced to 0.8-3.8 mmol/1 at 1, 8, 12, 24, 28, 52, 72 
and 144 h after drug administration to pony ni l ,  and at 8 h in pony m3.
The proportions of acetic, propionic and butyric acid concentrations, as a percentage of the 
total VFA concentrations, are given in Appendix D (Tables D32b-38b). The ratio of acetic 
acid was reduced to 10.0%, compared with the normal range of 27.9-67.0%, at 8 h in pony 
12. There was an increase in the percentage of acetic acid to 76.6-73.7% at 52 and 144 h in 
pony III1. The percentage of propionic acid fell to 1.8-3.5%, compared with the normal 
range of 4.9-38.5%, at 0.75, 12, and 48 h in pony II, at 8 h in pony 12. There was an 
increase in the percentage of propionic acid to 48.5-66.0% at 8, 12, 28 and 32 h in pony 
III1. The ratio of butyric acid was increased to 72.0-88.2%, compared with the normal 
range of 8.7-66.7%, at 12 h in pony II and at 8 h in pony 12. Whereas, the ratio of butyric 
acid fell to 4.1-6.9% at 1, 28, 52 and 144 h in pony III1. There was an increase in the ratio 
of propionic plus butyric acids to 78.3-90.0%, compared with the normal range of 27.1- 
72.1%, at 8 h in ponies 12 and III1.
Faecal SCFA concentrations in ponies following intravenous administration of 
oxytetracycline are shown in Figures 6-21 and 6-22, and the individual data is given in 
Appendix D (Tables D39-D42). There were no marked alterations in the lactic acid 
concentrations in faeces, except there was an increase to 25.7 mmol/kg at 48 h in pony III, 
and to 9.0 mmol/kg at 24 h in pony 112, compared with the normal range of 0.0-24.4 
mmol/1. There was considerable variation in the faecal VFA concentrations. The total VFA 
concentrations were lower than the normal range of 24.4-109.2 mmol/1 in pony II. In pony 
12, the total VFA concentration was higher than normal at 48, 72 and 96 h after drug 
administration. In pony III, there was an elevation of the total VFA concentration at 48 h 
and a reduction at 72 and 168 h. In pony 112, the total faecal VFA concentration was higher 
than normal at 0, 24, 48, 72 and 96 h after drug administration, due to a higher than normal 
(normal 4.8-67.3 mmol/1) butyric acid concentrations at these times. There were no trends in 
total and individual VFA concentrations that were associated with the intravenous 
administration of oxytetracycline.
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Figure 6-21. Lactic acid concentrations in faeces following intravenous 
administration of oxytetracycline to ponies
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Figure 6-22. Total VFA concentrations in faeces following intravenous
administration of oxytetracycline to ponies
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6.4.5 Faecal dry matter content and consistency
Faecal dry matter content following intravenous administration of oxytetracycline to ponies 
is shown in Figure 6-23, and the individual data is given in Appendix D (Table D43). There 
were few changes in faecal dry matter content. There were no changes observed in faecal 
consistency.
6.4.6 Plasma biochemistry and haematological examinations
The plasma biochemistry results are given in Appendix D (Tables D44-D48) and the results 
of the haematological examinations are given in Appendix D (Tables D49-D53). Values 
fluctuated around the normal ranges. There were no alterations in plasma biochemistry or 
haematology values that were associated with the intravenous administration of 
oxytetracycline.
6.5 Results of oral administration of oxytetracycline to ponies with 
cannulated caecal fistulas
Both ponies were depressed in appearance and reluctant to eat at 24, 48, 72 and 96 h after 
drug administration. This occurred each time the drug was administered, although it was 
most obvious on the first 2 occasions. In addition, the depression and anorexia were most 
marked in pony I.
6.5.1 Plasma disposition and pharmacokinetics
The plasma concentrations of oxytetracycline following the oral administration to ponies are 
shown in Figure 6-24, and the individual data is given in Appendix D (Table D54). The 
maximum plasma concentrations of 0.53, 0.84, 0.49 and 0.38 pg/ml were measured at 
0.75, 1.5, 0.75 and 0.5 h in ponies II, 12, III and III, respectively.
The pharmacokinetic parameters calculated following oral administration of oxytetracycline 
to ponies are given in Table 6-6. The MAT was calculated as the difference between the 
mean MRT following intravenous administration, and the MRT following oral 
administration for each animal on each occasion. The MAT was very long in all the animals. 
The bioavailability was calculated using the mean AUC following intravenous administration 
to each animal and was low.
6.5.2 Caecal liquor and faecal drug concentrations
The caecal liquor concentrations following oral administration of oxytetracycline to ponies 
are shown in Figure 6-25, and the individual data is given in Appendix D (Table D55). The
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Figure 6-23. Faecal dry matter content following intravenous administration 
of oxytetracycline to ponies
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Figure 6-24. Plasma concentrations of oxytetracycline following oral 
administration to ponies
Parameter 11 12 III 112
tl/2 B2 (h) 0.37 0.48 0.21 0.24
tl/2 B1 (h) 1.07 1.20 0.63 0.89
Cmax (Pg/ml) 0.53 0.84 0.49 0.38
tmax (min) 45 90 45 30
AUCobs (M-g.h/ml) 1.59 1.48 0.51 0.48
AUMCobs (|ig.h2/ml) 2.85 2.81 0.64 0.60
AUC (jig.h/ml) 1.44 1.44 0.51 0.48
AUMC (ng.h2/ml) 3.00 3.48 0.62 0.78
lag time (min) - - 9.24 6.00
MRT (h) 1.79 1.33 1.26 1.25
MAT (h) -11.91 -12.37 -12.87 -12.88
F (%) 1.04 0.97 0.45 0.43
Table 6-6. Disposition kinetics of oxytetracycline in plasma following oral administration to
ponies
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Figure 6-25. Caecal liquor concentrations of oxytetracycline following oral 
administration to poniest
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Parameter 11 12 III 112
AUCobs (M-g.h/ml) 
AUMCobs (Pg.h2/ml) 
MRT (h)
295.93
1546.10
5.22
262.67
1544.22
5.88
547.87
8704.68
15.89
391.72
7773.12
19.84
Table 6-7. Disposition kinetics of oxytetracycline in caecal liquor following oral 
administration to ponies
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maximum caecal liquor concentrations of 80.50, 61.74, 34.11 and 18.40 Jig/ml were 
measured at 1.5, 2, 8 and 12 h after drug administration to ponies II, 12, III and 112, 
respectively. The caecal liquor concentrations were much higher than the plasma 
concentrations of oxytetracycline following oral administration.
The disposition of oxytetracycline within the caecum was described using the observed AUC 
and AUMC to calculate the MRT (Table 6-7). The AUC, AUMC and MRT were much 
larger than those calculated for oxytetracycline in plasma following oral administration. 
There was a marked difference in MRT between the 2 animals, a fact that was also reflected 
in the difference in the time to maximum caecal liquor concentrations.
Faecal oxytetracycline concentrations following oral administration of oxytetracycline to 
ponies are shown in Figure 6-26, and the individual data is given in Appendix D (Table 
D56). Faecal drug concentrations were measured for up to 72 h in both animals on both 
occasions with the highest concentration in the 24 h samples.
6.5.3 Bacteriological examinations
Salmonella spp. were isolated and identified at 24 and 96 h after drug administration to pony 
12. The organisms produced an alkaline slope, hydrogen sulphide and gas when inoculated 
into TSI slopes. The organisms agglutinated 'O', 'H' and 'B' antisera. The organisms were 
identified as S. typhimurium phage type 204c by the Salmonella Reference Laboratory. The 
isolates were susceptible to furazolidone and resistant to ampicillin, chloramphenicol, 
neomycin, oxytetracycline, potentiated sulphonamide, streptomycin, and sulfafurazole.
Clostridium difficile was selected for but not isolated.
Counts of viable bacteria in caecal liquor following oral administration of oxytetracycline are 
shown in Figures 6-27 to 6-31, and the individual data is given in Appendix D (Table D57).
There was an increase in the viable coliform count to 10^-lO^Vml following oral 
administration of oxytetracycline to ponies (Figure 6-27). This was most marked (10^- 
10* tyml) at 24 h after drug administration to ponies II, 12,13, III and 112. In pony II the 
caecal liquor coliform count remained elevated (lO^/m l) at 48 h, fell at 72 h, and increased 
to 10^/ml at 96 h. In pony 12 the coliform count was elevated to lO^-lO^/ml at 168 and 336 
h after drug administration. The alterations in the number of viable coliforms isolated from 
pony 113 at 24 h after drug administration were very slight (up to lO^/ml).
There was an increase in the number of viable caecal streptococci (to 10^-10^ tyml) isolated 
from all the ponies and this was most marked at 24 h after drug administration to ponies II,
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Figure 6-26. Faecal concentrations of oxytetracycline following oral 
administration to ponies
E
ao
V
3
03
-------- -
24 48 72 96 120 144 168
Time (h)
— □—  12 — 13
n2 -■*  JJ3
Figure 6-27. Counts of viable coliforms in caecal liquor following oral
administration of oxytetracycline to ponies
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12 and III (Figure 6-28). The number of viable streptococci remained elevated (10^- 
10* 1/ml) in ponies II, 12 and III at 48 h after drug administration and at 72 h (lOfyml) in 
pony III. All the counts were similar to the initial counts of 10^-10^/ml at 96 h after drug 
administration.
The number of viable lactobacilli in caecal liquor was increased to lO^-lO^O/ml at 24,48 and 
72 h in pony II, at 48 h in pony 12, and at 24, 48 and 72 h in pony III, compared with the 
initial values (Figure 6-29). In pony 112 the number of lactobacilli isolated was high (10^- 
lO^/ml) prior to and at 48 h after drug administration. Lactobacillus acidophilus and L. 
minutus were isolated and identified using the API system.
There were no alterations in the number of viable Bacteroides spp. isolated from caecal 
liquor, except from pony 112 at 48 h after drug administration when there was a reduced 
count (lOfyml) (Figure 6-30). Bacteroides spp. {ovatus/thetaiotaomicronluniformis), B . 
asaccharolyticus, B. bivius, B. fragilislvulgatus, B. ovatus and B. thetaiotaomicron were 
isolated and identified using the API system.
There were no Clostridium spp. isolated from caecal liquor prior to drug administration to 
ponies II, 12 and III (Figure 6-31). The number of Clostridium spp. isolated from caecal 
liquor appeared to be quite high (10^-10^/ml) at 24 h in ponies II, 12 and III, and 48 and 72 
h in ponies II and III. The number of viable Clostridium spp. isolated from pony 112 
remained low throughout the study. Bacteria identified using the API system were 
Clostridium spp., C. clostridiiforme, C. butyricum and C. perfringens. The latter was 
identified at 24 h after drug administration to ponies II (lOfyml), 12 (lO^/ml), III (lOfyml) 
and 112 (10^/ml), and at 72 h after drug administration to pony III (10^/ml).
Other bacteria identified using the API system were Actinomyces israelii, Actinomyces 
naeslundii and Bifidobacter adolescentis.
6.5.4 Caecal pH and SCFA concentrations and faecal SCFA concentrations
The caecal liquor pH measurements are shown in Figure 6-32, and the individual data is 
given in Appendix D (Table D58). In pony II, caecal liquor pH was increased (>7.2) at 8, 
12 and 48 h and reduced (<6.8) at 32, 36, 52, 56 and 96 h after drug administration. In 
pony 12, caecal liquor pH was low (<6.8) at 56 h after drug administration. There were no 
alterations in caecal liquor pH in pony 13. There was a reduction (<6.8) in caecal liquor pH 
at 48, 52, 56, 72 and 96 h in pony III, at 56 and 96 h in pony 112, and on no occasions in 
pony 113.
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Figure 6-28. Counts of viable streptococci in caecal liquor following oral 
administration of oxytetracycline to ponies '
£
a
.223
10
10
10
10
10
10
10
10
10
10
10
0 24 48 72 96 120 144 168
Time (h)
1 2 - - * - -  II2
Figure 6-29. Counts of viable lactobacilli in caecal liquor following oral
administration of oxytetracycline to ponies
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Figure 6-30. Counts of viable Bacteroides spp. in caecal liquor following oral 
administration of oxytetracycline to ponies
£
a
3C9
>
0 24 48 72 96 120 144 168
Time (h)
— O— II — D -  1 2 m — 112
Figure 6-31. Counts of viable Clostridium spp. in caecal liquor following oral administration
of oxytetracycline to ponies
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Figure 6-32. Caecal liquor pH following oral administration 
oxytetracycline to ponies
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Caecal liquor SCFA concentrations are shown in Figures 6-33 and 6-34, and the individual 
data is given in Appendix D (Tables D59a-D64a).
Caecal lactic acid concentrations (Figure 6-33) were increased to 5.5-53.9 mmol/1 at 4, 6, 8, 
12, 24, 28, 32 and 56 h, and were above the normal range of 0.0-24.4 mmol/1 at 8, 12, 24 
and 32 h after drug administration to pony II. In pony 12, caecal lactic acid concentrations 
were elevated to 7.0-24.9 mmol/1 at 4, 6, 8, 12, 24, 48, 52, 56 and 72 h, and were above 
the normal range at 8 h after drug administration. Lactic acid concentrations were slightly 
increased to 5.4 mmol/1 at 168 h after drug administration to pony 13. In pony HI caecal 
lactic acid concentrations were elevated to 5.6-46.4 mmol/1 at 12, 24, 28, 32, 48, 52, 56,72 
and 96 h, and were above the normal range at 24 and 28 h after drug administration. 
Similarly, in pony 112 there was an increase in lactic acid concentrations to 7.0-32.0 mmol/1 
at 24, 28, 32, 48, 52, 56 and 72 h, and these were above the normal range at 56 h after drug 
administration. There were no marked increases in lactic acid concentrations in pony 113 
following oral administration of oxytetracycline.
The total VFA concentrations fluctuated around the normal range of 24.4-109.2 mmol/1 
(Figure 6-34). There was a high total VFA concentration of 120.7 mmol/1 prior to drug 
administration to pony 13. There were variations in the individual VFA concentrations that 
were outside the normal ranges following the oral administration of oxytetracycline. Acetic 
acid concentrations fell below the normal range of 12.6-64.5 mmol/1 to 5.3-10.8 mmol/1 at 
28 h in pony II, at 4, 6, 8 and 12 h in pony 12, and at 8 and 12 h in pony III. There was an 
increase in the propionic acid concentrations to 32.3-37.7 mmol/1 at 8 and 12 h in pony II, 
and at 168 h in pony 13. There was a reduction in propionic acid concentrations to 2.3-4.1 
mmol/1, compared with the normal range of 4.7-24.5 mmol/1, at 24 and 28 h in pony II, at 
24, 28, 32, 48, 52 h in pony 12, and at 28 and 32 h in pony 112. There was a reduction in 
the butyric acid concentrations to 3.4-4.5 mmol/1, compared with the normal range of 4.8- 
67.3 mmol/1, at 12 h in pony 12, and at 32 and 52 h in pony 112.
The proportions of acetic, propionic and butyric acids, expressed as a percentage of the total 
VFA concentrations, are given in Appendix D (Tables D59b-D64b). There were some 
variations in the ratios of acetic, propionic and butyric acids. There was a reduction in the 
percentage of acetic acid to 13.6-17.3%, compared with the normal range of 27.9-67.0%, at 
12 h in pony II, and at 4 and 8 h in pony 12. There was an increase in the percentage of 
propionic acid to 56.4-63.5%, compared with the normal range of 4.9-38.5%, at 12 h in 
pony II, and at 4, 6, 8 and 12 h in pony 12. There was an increase in the percentage of 
propionic plus butyric acids to 76.0-86.4%, compared with the normal range of 27.1- 
72.1%, at 48 h in pony II, at 4, 6, 8 and 12 h in pony 12, and at 72 h in pony 13.
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Figure 6-33. Lactic acid concentrations in caecal liquor following oral 
administration of oxytetracycline to ponies
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Figure 6-34. Total VFA concentrations in caecal liquor following oral
administration of oxytetracycline to ponies
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Faecal SCFA concentrations are shown in Figures 6-35 and 6-36, and the individual data is 
given in Appendix D (Tables D65-D70). There was an increase in lactic acid concentrations 
in faeces to 15.4-58.6 mmol/kg at 24 and 48 h in pony II, at 48 and 72 h in pony 12, and at 
24 h in pony 13, but only in pony 12 were the lactic acid concentrations outside the normal 
concentration range of 0.0-24.4 mmol/1 (Figure 6-35). There was an increase in lactic acid 
concentrations to 5.0-65.4 mmol/kg at 24, 48, 72 and 168 h in pony HI and at 24, 48, 72 
and 96 h in pony 112, with the 24,48 and 72 h concentrations on both occasions lying above 
the normal range. There were no marked alterations in lactic acid concentrations in pony 113. 
There were considerable variations in the total and individual VFA concentrations (Figure 6- 
36). In pony II, the faecal total VFA concentration was lower than the normal range of 24.4-
109.2 mmol/1 prior to and at 168 h after drug administration. In pony 12, the total VFA 
concentration was lower than normal prior to drug administration due to a low acetic acid 
concentration at this time. In ponies 13, III and 113, the faecal total VFA concentrations were 
all within the normal range. In pony III, the faecal total VFA concentrations were elevated 
above normal at 336 h. The VFA concentrations in faeces did not follow any particular 
trends following the oral administration of oxytetracycline to ponies.
6.5.5 Faecal dry matter content and consistency
The faecal dry matter content did not alter markedly following oral administration of 
oxytetracycline (Figure 6-37), and the individual data is given in Appendix D (Table D71). 
The faecal dry matter content was <17% prior to drug administration to pony 13 and at 24 h 
in pony III. Faecal consistency was soft at 1.5 and 8 h in pony II, and at 24, 48 and 72 h 
after drug administration to ponies II, 12, III and 112.
6.5.6 Plasma biochemistry and haematological examinations
The plasma biochemistry results are given in Appendix D (Tables D72-D77). There was an 
increase in plasma urea concentrations up to 4.9-7.5 mmol/1 following oral administration of 
oxytetracycline to pony II. This was above the normal range at 24 h in pony 12. Fluctuations 
in other variables were around the normal ranges. The results of the haematological 
examinations are given in Appendix D (Tables D78-D83) and the parameters were all around 
the normal ranges.
6.6 Results of in vitro studies with oxytetracycline
6.6.1 Caecal liquor concentrations
A plot of concentrations (mean±SEM) of oxytetracycline in caecal liquor following
incubation in vitro are shown in Figure 6-38, and the individual data is given in Appendix D
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Figure 6-35. Lactic acid concentrations in faeces following oral 
administration of oxytetracycline to ponies
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Figure 6-38. Concentrations (mean±SEM) of oxytetracycline in caecal liquor
following incubation in vitro for 3 and 24 h
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(Tables D84a and b). The limit of detection of the assays was poor; there were no inhibition 
zones at a concentration of 0.25 pg/ml. The largest reductions in concentration (zone 
diameter) were seen with the 1 pg/ml sample, probably due to limitations of the assay (zone 
diameter, limit of detection). In the other samples, following both 3 and 24 h incubation 
there was an average of circa 83 % of drug activity remaining.
6.6.2 Bacteriological examinations
The counts of viable bacteria (mean±SEM) in caecal liquor following in vitro incubation 
without or with oxytetracycline are shown in Figures 6-39 and 6-40, and the individual data 
is given in Appendix D (Table D85a and b). There were no alterations in the number of 
viable bacteria isolated following incubation of caecal liquor in the absence of 
oxytetracycline. There was an increase in the number of coliforms and Clostridium spp. 
isolated following 24 h incubation of caecal liquor with oxytetracycline at a concentration of 
80 fig/ml.
6.6.3 SCFA concentrations
Lactic acid and total VFA concentrations (mean±SEM) in caecal liquor following in vitro 
incubation are shown in Figure 6-41, and the individual data is given in Appendix D (Tables 
D86-D90). There were no alterations in the mean lactic acid or mean total VFA 
concentrations with time or drug concentration.
6.6.4 Acid pH
Oxytetracycline concentrations (mean±SEM) remaining following in vitro incubation at pH 
1.9 for 1 h are shown in Figure 6-42, and the individual data is given in Appendix D (Table 
D91). There were only very slight alterations in drug activity (mean concentration remaining 
circa 96 %) following incubation at pH 1.9.
6.7 Discussion
A variety of different dose rates have been used for oxytetracycline in the horse. Pilloud 
(1973) used a dose rate of 2.5 mg/kg bwt and, based on observed plasma concentrations and 
known MIC data, suggested that the dose rates recommended currently for horses by some 
authors and pharmaceutical companies, could well underestimate the amount of 
oxytetracycline necessary for successful treatment of some bacterial infections. Teske et al. 
(1973) and Baggot (1977b) administered oxytetracycline at a dose rate of 4.4 mg/kg bwt, 
and Brown et al. (1981) used a dose rate of 5 mg/kg bwt and were able to measure 
oxytetracycline for 48 h after drug administration using a microbiological assay. In a study
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Figure 6-39. Counts of viable bacteria (mean±SEM) in caecal liquor 
following incubation in vitro for 3 and 24 h
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Figure 6-40. Counts of viable bacteria (mean ±SEM) in caecal liquor
following incubation in vitro with 80 Jig/ml oxytetracycline for 3 and 24 h
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to evaluate the tissue concentrations of oxytetracycline Larson and Stowe (1981) collected 
blood samples over a period of 4 h after intravenous administration of oxytetracycline at a 
dose rate of 10 mg/kg bwt and recorded plasma concentrations similar to the ones measured 
in the present study. The very long period over which oxytetracycline could be detected in 
the present study may reflect a more sensitive assay and a more appropriate sampling 
regimen than those used previously.
The dosage regimen necessary to maintain therapeutic plasma levels has been disputed. 
Prescott and Baggot (1988b) recommend a loading dose of 5 mg/kg bwt followed at 12 h 
intervals by maintenance doses at a rate of 3 mg/kg bwt to maintain therapeutic plasma 
concentrations of 1-5 |!g/ml. The dosage regimen suggested by Van Miert (1988) utilizes the 
same interval between doses but suggested a higher dose rate of 5-10 mg/kg bwt. On the 
other hand, By water (1982b) suggested that serum concentrations of 0.5-1.0 |ig/ml are 
appropriate, and indicated that a single daily intramuscular dose at a dose rate of 5-11 mg/kg 
bwt would be required to achieve this in cattle, dogs and horses. In the present study, the 
mean plasma concentrations measured were >1 pg/ml for 36 h in horses and ponies, and 24 
h in donkeys, and were >0.5 pg/ml for 48 h in horses and ponies, and 24 h in donkeys. 
Thus, to maintain a therapeutic plasma concentration of 0.5-5.0 pg/ml the dosage interval of 
oxytetracycline hydrochloride, when administered intravenously at a dose rate of 10 mg/kg 
bwt, should be 48 h in horses and ponies, and 24 h in donkeys. This does not take into 
account the putative post-antibiotic effect.
It is interesting that the harmonic mean of elimination half-life was much higher in horses 
and ponies, than it was in donkeys. The variation in elimination half-life may be due to an 
inter-species variation in drug elimination of oxytetracycline since horses and ponies are E. 
caballus whilst donkeys are E. asinus. Kirkwood and Widdowson (1990) demonstrated that 
there was a linear relationship between the elimination half-life of oxytetracycline and the 
bodyweights of different species. The bodyweights of the animals used in the present study 
were applied to the equation described by Kirkwood and Widdowson (1990), however the 
estimates of elimination half-life were lower than calculated in the present study for horses 
and ponies (9.20-9.63 h and 7.37-8.78 h, respectively) and higher than calculated for 
donkeys (7.37-7.79 h). Thus, there appeared to be a greater difference in elimination half- 
life of oxytetracycline in horses, ponies and donkeys than could be explained merely by 
inter-species variation in bodyweight.
There were marked inter-species differences in other pharmacokinetic parameters. The mean 
AUC and AUMC were higher in horses than they were in donkeys. In addition, the mean 
CLb was much slower in horses than it was in donkeys. This did not seem to be due to a 
difference in clearance of drug by the liver since the elimination half-life of bromsulphalein
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was similar in horses and donkeys. A similar difference was demonstrated by Kinabo and 
Bogan (1989) following the oral administration of the flukicidal drug triciabendazole to 
horses, ponies and donkeys. A similar dosage regime of oxytetracycline could be used in 
horses and ponies, but donkeys, due to differences in pharmacokinetics, would require more 
frequent dosing to maintain therapeutic plasma concentrations of oxytetracycline.
The penetration of oxytetracycline into the large intestine following intravenous 
administration was estimated from the observed AUCs in caecal liquor and plasma, the 
estimated volume of caecal contents, and the estimated plasma volume (Swenson, 1977), 
and was expressed as a percentage. This was quite variable ranging from 4.32-31.43%, but 
was less than 17% in 6 of the 7 ponies. Thus it appears that up to 31.43% of oxytetracycline 
may be in the gastrointestinal lumen following intravenous administration. Although it is 
likely that a figure of between 4 and 17% of the total dose of oxytetracycline is eliminated 
into the gastrointestinal lumen following a single intravenous administration. It would be 
interesting to examine biliary excretion of oxytetracycline in the equine either by comparing 
gastrointestinal elimination with renal drug elimination or by using direct techniques, i. e. by 
measurement of biliary excretion rates.
The systemic availability of oxytetracycline following oral administration to ponies was very 
low. This was not due to the destruction of the drug either by acid pH or by the 
gastrointestinal contents. The poor systemic availability of oxytetracycline in ponies was 
quite surprising since in other species, such as the dog and cat, most tetracyclines are 
absorbed adequately from the gastrointestinal tract. Although, oxytetracycline was absorbed 
from the gastrointestinal tract following oral administration, and the plasma concentrations 
were in some cases sufficient to treat infections caused by susceptible bacteria, the fact that 
the MRT was short means that frequent dosing would be required to maintain adequate 
therapeutic concentrations in plasma.
The faecal samples from horses, ponies and donkeys, following intravenous administration 
of oxytetracycline, had similar concentrations of oxytetracycline which could be measured 
for 96 h in all three groups. This was an unexpected result since plasma concentrations of 
oxytetracycline were measurable for 96 h in horses, 72 h in ponies and 48 h in donkeys. 
Moreover, the faecal concentrations were greater than the simultaneous plasma 
concentrations in all the samples from the horses, ponies and donkeys. Similarly, there was 
a large amount of oxytetracycline measured in the caecal liquor (AUCobs 262.67-547.87 
p.g.h/ml) following intravenous administration to ponies with cannulated caecal fistulas. This 
was not especially surprising since biliary concentrations can average at least five to ten 
times higher than simultaneous plasma concentrations of oxytetracycline (Owen, 1975).
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In the present study, S. typhimurium phage type 204c was isolated from pony 12 on two 
separate occasions following oral administration of oxytetracycline. Owen et al. (1983) 
stated that the use of oxytetracycline prolonged the stress-activated excretion of Salmonella 
spp., and advised that oxytetracycline should not be administered to ponies after stress 
(transport), to ponies with diarrhoea, or to ponies which are known carriers of Salmonella 
spp. infection. However, the Salmonella spp. was isolated from only 1 animal in the present 
study, and the administration of oxytetracycline was repeated on a further occasion and 
failed to activate further excretion of the organism, despite meticulous attempts to isolate it. 
Other authors have reported a series of cases of S. typhimurium infection where the 
organism was excreted for less than 1 month and where there was no subsequent excretion 
of the organism for at least 1 year (Smith et al., 1980). In Equidae, Salmonella spp. 
infection is sporadic, and the clinical signs can range from asymptomatic infection, or fever, 
anorexia and depression, to severe acute diarrhoea or septicaemia (Smith, 1981). In the 
present case, there was anorexia and slight diarrhoea which may have been attributed to S. 
typhimurium infection but may have been due to drug administration since the clinical signs 
were seen in the absence of the isolation of Salmonella spp., too. Neither prolonged 
excretion of Salmonella spp. nor neutropaenia were recorded in the present study. Hird et al. 
(1984) and Hird etal. (1986) noted that there was a predisposition to salmonellosis in horses 
in which the treatment had involved a variety of factors, such as nasogastric intubation (3.9 
or 2.85 times greater risk) and oral antimicrobial therapy (1.28 times greater risk). In the 
present study, S. typhimurium was a hospital acquired infection. A number of equine cases 
had been admitted to the Glasgow University Veterinary School with Salmonella spp. 
infection of the same serotype and phage type identified here. As an adjunct to the present 
study, the selective isolation of Salmonella spp. was carried out from the terminal ileum, 
caecum and mesenteric lymph nodes of a series of 12 ponies, at slaughter, which were kept 
in the same area as the ponies I and II. However, no Salmonella spp. were isolated. 
Perhaps, the type of treatment involved in the present study predisposed the animals 
involved to the development of Salmonella spp. infection. Although, it is strange that the 
organism was isolated from one animal only and that there were no obvious clinical signs, 
apart from depression and anorexia, and that the organism was not excreted for a prolonged 
period.
A variety of different serotypes of Salmonella spp., including typhimurium, krefeld, saint- 
paul, typhisuis and dublin, have been isolated from animals (Ikeda et al., 1986) with group 
B predominating (Benson et al., 1985). A variety of different Salmonella spp. have been 
isolated from the equine gastrointestinal tract with the prevalence ranging from 0.36-27 % 
(Al-Mashat and Taylor, 1986, Gibbons, 1980, Morse et al., 1976). Over 40 different 
serotypes of Salmonella spp. have been isolated from Equidae and around 66.31% of these
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isolates were S. typhimurium whilst other serotypes, such as S. enteritidis, made up less 
than 10% of the isolates (Morse et al., 1976). Therefore, it is not surprising that S. 
typhimurium was the serotype isolated in the present study, particularly in view of the 
preceding antimicrobial therapy.
In one survey, greater than 60% of Salmonella spp. isolates were resistant to ampicillin, 
kanamycin, neomycin, streptomycin and the sulfonamides (Ikeda et al., 1986). However, 
resistance to chloramphenicol, gentamicin and the potentiated sulphonamides was infrequent 
except for serotypes krefeld and saint-paul. A second study reported that most Salmonella 
spp. isolated from large animals were resistant to ampicillin and tetracycline (Benson et al., 
1985). Thus, treatment of Salmonella spp. infection must follow careful antimicrobial 
susceptibility testing of isolates, although a knowledge of the common resistance patterns is 
useful. In the present study, S. typhimurium was resistant in vitro to all the standard 
antimicrobial agents tested against enteric pathogens, except furazolidone, and to 
erythromycin, benzylpenicillin, oxytetracycline and lincomycin (P. Sarasola, unpublished 
data). In addition, MIC data from the isolate of S. typhimurium in the present study reflected 
resistance in vitro to ampicillin (>128 p.g/ml), mezlocillin (>128 fig/ml), 
amoxycillin/clavulanic acid (32/16 M-g/ml), cephalothin (16 p.g/ml), cefoxitin (8 jig/ml), 
tetracycline (>16 pg/ml), carbenicillin (>128 fig/ml), ceftizoxime (<16 |ig/ml), and 
trimethoprim/sulphonamide (> 16/>304 |ig/ml) and susceptibility to amikacin (<1 jig/ml), 
ciprofloxacin (<0.06 (ig/ml), gentamicin (<0.5 pg/ml), and norfloxacin (<1 p.g/ml) (P. 
Sarasola, unpublished data). The resistance pattern of the isolate in the present study was 
similar to other S. typhimurium isolates of equine origin.
The coliform counts recorded in the present study fall into both the range of 103-104/g 
faeces described by Smith (1965), and 106/g faeces described by White and Prior (1982), 
but were much lower than the control values used by Garner et al. (1978). Andersson et al. 
(1971) recorded an increase in the number of coliforms isolated from faeces 1-2 days after 
intravenous administration of oxytetracycline to horses at a dose rate of 15-26 mg.kg bwt. 
White and Prior (1982) recorded viable coliform counts of around 109/g faeces following 
repeated oral administration of oxytetracycline at a dose rate of 40 mg/kg bwt. Similarly, in 
the present study there was an increase in the number of coliforms isolated from donkey 
faeces at 72 and 96 h after intravenous administration of oxytetracycline. There was an 
increase in caecal coliform counts up to 10^/ml at 24 h and for up to 168 h after oral 
administration of oxytetracycline to ponies with cannulated caecal fistulas. In addition, there 
was an increase in the number of coliforms isolated from caecal liquor following incubation 
in vitro in the presence of a high concentration of oxytetracycline.
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Andersson et al. (1971) and White and Prior (1982) found that there were significant 
alterations in the number of streptococci isolated from faeces following administration of 
oxytetracycline. There were no marked increases in the number of streptococci isolated 
following intravenous administration, but there were increases in the number of viable 
streptococci isolated following oral administration of oxytetracycline in the present study. 
However, these changes were not reflected in the in vitro study.
There was an apparent increase in the number of lactobacilli isolated following intravenous 
administration of oxytetracycline to horses, and following oral administration of 
oxytetracycline to ponies contrary to the findings of White and Prior (1982). There were no 
alterations in the number of lactobacilli isolated in the in vitro study.
White and Prior (1982) examined the faecal flora of horses after the oral administration of 
oxytetracycline, and compared this to the effect of the oral administration of a 
trimethoprim/sulphadiazine combination. They isolated C. perfringens on 4 out of 8 
occasions only, and described this as an alteration in the faecal flora since the isolations 
occurred after drug administration. Clostridium spp. were counted in the present study. 
There was an increase in number of Clostridium spp. isolated at 96 h after intravenous 
administration of oxytetracycline to horses, but C. perfringens was not identified. However, 
there was an increase in the number of Clostridium spp. isolated from caecal liquor for up to 
72 h after oral administration of oxytetracycline to ponies with cannulated caecal fistulas. 
Clostridium perfringens was identified at 24 h after drug administration to ponies with 
cannulated caecal fistulas. Clostridium spp. were not isolated on all occasions partly due to 
the limit of detection of the assay, a fact that was also noted in the study by White and Prior 
(1982). The Clostridium spp. identified in the present study (C. perfringens, C. 
clostridiiforme and C. butyricum) have been isolated from enteric lesions of horses (Al- 
Mashat and Taylor, 1986).
Andersson et al. (1971) reported an increase in the faecal pH from 6.1-6.5 to 6.9-8.1 
following intravenous administration of a massive dose of oxytetracycline to horses. The 
control caecal pH range noted by Garner et al. (1978) was around 7.2. In the present study 
there was a modest reduction in the caecal liquor pH following oral administration of 
oxytetracycline to ponies. This result may not be all that surprising since there were 
alterations in the SCFA concentrations in caecal liquor.
The marked alterations in SCFA concentrations were in lactic acid concentrations, and not in 
VFA concentrations, in which there were no obvious trends. There was an increase in the 
mean lactic acid concentration in faeces at 48 h in horses and 72 h in donkeys following 
intravenous administration of oxytetracycline. There were increases in both caecal and faecal
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lactic acid concentrations following both intravenous and oral administration of 
oxytetracycline to ponies with cannulated caecal fistulas. The increase in lactic acid 
concentrations could be explained by the increase in the number of lactic acid producing 
bacteria, such as streptococci, lactobacilli and Clostridium spp. that were isolated. Both D- 
and L-lactic acid are produced by gastrointestinal bacteria although only the latter is utilized 
in mammals. It would have been useful to separate D- and L-lactic acid. The increased lactic 
acid concentrations in the present study occurred at variable times following intravenous or 
oral administration of oxytetracycline, although they always occurred following the peak 
drug concentration. Systemic acidosis, important in a number of equine diseases, may be 
due to the absorption of lactic acid from the gastrointestinal tract or to a reduction in plasma 
bicarbonate ion concentrations due to the movement of these ions from the plasma into the 
gastrointestinal lumen to act as a buffer. Lactic acid that is not absorbed from the 
gastrointestinal lumen may play a role in the development of osmotic diarrhoea, either by an 
increase in the secretion or a reduction in the absorption of water and electrolytes.
Prescott and Baggot (1988b) reported that a mild pastiness of the faeces is often recorded 
after administration of oxytetracycline to horses. Cook (1973) postulated that the 
administration of the tetracyclines is associated with the development of diarrhoea in horses 
but there are often other factors, such as anaesthesia or surgery, involved. In the present 
study, there were slight alterations in the faecal dry matter content particularly following 
intravenous administration of oxytetracycline to horses, ponies and donkeys. Following oral 
administration of oxytetracycline, faecal consistency was softer than normal, however there 
were no marked alterations in the faecal dry matter content.
Andersson et al. (1971) described a clinical syndrome, with signs of diarrhoea, apathy and 
anorexia, which occurred 3-4 days after an intravenous administration of a massive dose of 
oxytetracycline to horses. Similar clinical signs were described by White and Prior (1982) 
following repeated oral administrations of a high dose (40 mg/kg bwt) of oxytetracycline, 
and in the present study, following oral administration of a single dose of oxytetracycline at 
a dose rate of 10 mg/kg bwt. It may be that repeated administrations or administration at a 
higher dose rate would precipitate the clinical syndrome described previously.
There was an increase in the plasma urea concentrations following oral administration of 
oxytetracycline to ponies in the present study. This alteration in clinical chemistry was noted 
by Andersson et al. (1971) although none of the other changes noted by these authors were 
observed in the present study.
In man, the tetracyclines have been recorded as inducing diarrhoea by altering the normal 
gastrointestinal microflora and allowing superinfections, such as Salmonella spp. infection, 
to take place (Finger and Wood, 1955, Weinstein et al., 1954). In the present study, there
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were alterations in the normal gastrointestinal microflora, particularly following oral 
administration of oxytetracycline. The presence of Salmonella spp. infection was identified 
in one animal. In addition, there were alterations in the concentrations of microbial 
fermentation products, particularly lactic acid concentrations, in the gastrointesdnal lumen.
A single intravenous administration of oxytetracycline hydrochloride at an appropriate dose 
rate, such as 10 mg/kg bwt, did not appear to pose a severe risk to gastrointestinal microbial 
function. A study of repeated administrations would provide further information on the 
potential and reported gastrointestinal side effects. However, oxytetracycline should be used 
with caution in the equine since there were increases in caecal liquor and faecal lactic acid 
concentrations following a single intravenous administration. In view of the clinical signs, 
low plasma concentrations, and the alterations in the commensal bacterial population in the 
gastrointestinal tract following a single oral administration of oxytetracycline hydrochloride, 
this route of administration should probably be avoided.
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7 General Discussion
The present study set out to evaluate the plasma disposition and pharmacokinetics of 
penicillin G, ampicillin, amikacin and oxytetracycline following intravenous administration 
to horses, ponies and donkeys. Penicillin G and ampicillin are eliminated primarily by the 
kidneys. In the present study, up to 1.95% of the penicillin G and up to 3.66% of the 
ampicillin appeared to be eliminated in the bile or passed into the lumen through the 
gastrointestinal mucosa from the systemic circulation. The aminoglycosides are eliminated 
by the kidneys and, in the present study, no amikacin was detected in the gastrointestinal 
contents following intravenous administration. In comparison, the tetracyclines are 
eliminated by the kidneys and in the bile, and in the present study there was a large amount 
of oxytetracycline (up to 16.95%) eliminated into the gastrointestinal tract following 
intravenous administration.
There may be inter-species differences in drug disposition and pharmacokinetics which 
affect the calculation of optimum dose rates and regimes. This may be due to differences in 
the total body water, extracellular fluid volume, fat content, or metabolism. The donkey 
(Equus asinus) is used widely throughout the world as a draught animal. It has been 
suggested that there are differences between the disposition and pharmacokinetics of drugs 
in the donkey and in the horse and pony {Equus caballus) which manifest as a lower AUC 
and a higher CLb (Kinabo and Bogan, 1989). This was corroborated in the present study 
where the CLb of ampicillin, and possibly oxytetracycline, was faster in donkeys than in 
horses and ponies. Differences in drug elimination may result in differences in the optimal 
dosage requirements. However, the implications of the results of the present study are 
limited by the small number of animals used. It would be interesting to compare the total 
body water, and the renal and hepatic clearance rates in horses and donkeys. Bromsulphalein 
clearance involves active uptake into hepatocytes, conjugation to glutathione and biliary 
excretion. In the present study, bromsulphalein was used as an indicator of hepatic clearance 
and the elimination half-life of bromsulphalein was within the range (2.0-3.7 min) quoted 
normally for the horse (Anon, 1986). This suggests that the biliary clearance rate was similar 
in horses and donkeys. It would have been useful to measure the urinary excretion of the 
antimicrobial agents since a large proportion of the antimicrobial agents studied were 
eliminated by the kidneys. In a recent study, the aminoglycoside gentamicin was used as an 
indicator of renal excretion in the horse since the aminoglycosides are eliminated exclusively 
by renal filtration (Clarke et al., 1992). However, in the present study the CLbs of the 
aminoglycoside amikacin were similar in horses and donkeys but approximately twice as fast 
in ponies.
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The differences in the pharmacokinetics of penicillin G, ampicillin, amikacin and 
oxytetracycline reflect differences in the physicochemical nature of the four antimicrobial 
agents. The penicillins are water soluble and polar and are eliminated rapidly by the kidneys, 
and have an apparent volume of distribution similar to the extracellular fluid volume of the 
animal (23% bwt). In the present study, penicillin G had a short elimination half-life in 
horses, ponies and donkeys (38.95, 27.25 and 31.52 min, respectively), a short distribution 
half-life (5.85, 2.52 and 4.28 min, respectively), a VdSs similar to the extracellular fluid 
volume of the animal (362.32, 314.05 and 204.53 ml/kg, respectively) and a high CLb 
(514.46, 505.36 and 462.86 ml/h.kg, respectively). Similarly, the semisynthetic penicillin, 
ampicillin had a relatively short elimination half-life in horses, ponies and donkeys (60.88, 
52.34 and 42.80 min, respectively), a short distribution half-life (14.79, 6.62 and 5.86 min, 
respectively), a VdSs similar to penicillin G (345.31, 260.44 and 422.49 ml/kg, 
respectively) and a high CLb (229.67, 257.68 and 418.80 ml/h.kg, respectively). The 
aminoglycosides are poorly lipid soluble and highly polar compounds and therefore 
distribute in a volume similar to the extracellular fluid volume although they have been 
shown to attain measurable concentrations in intracellular compartments (Bowman et al., 
1986, Orsini et al., 1985). Amikacin had a slightly longer elimination half-life than the 
penicillins in horses, ponies and donkeys (2.84, 1.60 and 1.93 h, respectively), a short 
distribution half-life (6, 12 and 3 min), a Vdss similar to but slightly smaller than the 
penicillins (206.58, 162.73 and 150.21 ml/kg, respectively) and a slower CLb (45.19,
82.37 and 57.98 ml/h.kg, respectively). Oxytetracycline distributes widely in the body and 
reaches high concentrations in bronchial fluid, synovial fluid, peritoneal fluid, lung and renal 
tissue (Brown etal., 1981, Larson and Stowe, 1981). In the present study, oxytetracycline 
had a long elimination half-life in horses, ponies and donkeys (11.69, 11.77 and 5.40 h, 
respectively), a reasonably short distribution half-life (9, 13.8 and 17.4 min, respectively), 
an apparent VdSs greater than the extracellular fluid volume of the animal (615.97, 956.26 
and 649.27 ml/kg, respectively) and a slower CLb than the penicillins (39.31, 60.77 and
91.37 ml/h.kg, respectively). The CLbs of amikacin and oxytetracycline were slower than 
for penicillin G and ampicillin. This may be due to differences in the elimination of the 
antimicrobial agents by the kidney or to differences in the distribution of the agents within 
the body. It is interesting that both amikacin and oxytetracycline, which have been shown to 
achieve therapeutic concentrations in body fluids such as peritoneal and synovial fluid, had 
slower CLbs than the penicillins. Amikacin is polar and has a low lipid solubility, whilst 
oxytetracycline is much more lipid soluble and hence has a larger VdSs reflecting apparently 
greater distribution within the body. The greater distribution of oxytetracycline or 
enterohepatic circulation, i. e. reabsorption of drug from the intestinal lumen following 
biliary elimination, may have resulted in the longer elimination half-life.
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In the present study, an evaluation of the systemic availability of penicillin G, ampicillin, 
amikacin and oxytetracycline was made, following administration by nasogastric tube to 
ponies, to assess their potential application in systemic antimicrobial therapy in the equine. 
Following oral administration, a drug must pass from the gastrointestinal lumen through the 
gastrointestinal wall and the liver prior to entering the systemic circulation. An agent may be 
absorbed poorly due to insufficient time for absorption, decomposition within the 
gastrointestinal tract, poor availability for absorption (e . g. bound to food), or biliary 
elimination. An agent may be eliminated by the liver prior to entering the systemic 
circulation, the so-called first pass effect. The absorption time may be insufficient for polar 
compounds, such as aminoglycosides which are essentially unabsorbed. In addition, only 
unionized agents are absorbed normally, and most drugs are ionized in the gastrointestinal 
tract. The penicillins are acidic and are more likely to be absorbed from an acidic 
environment such as the stomach or the upper small intestine. The aminoglycosides have a 
high molecular weight and are polar and poorly lipid soluble resulting in a very low rate of 
absorption. The tetracyclines are amphoteric but tend to be basic and are more likely to be 
absorbed at the higher pH that occurs in the distal small intestine. In the present study, 
penicillin G, ampicillin and oxytetracycline were absorbed rapidly and attained peak plasma 
concentrations at 0.5,0.5-0.75 and 0.5-1.5 h, respectively. The peak plasma concentrations 
may have been measured slightly later for oxytetracycline because it was absorbed at a 
different region of the small intestine. The systemic availability of these antimicrobial agents 
was poor (0.12-0.34, 1.20-5.54 and 0.43-1.04%, respectively). In the present study, the 
apparent half-life of the terminal phase (tl/2  B l) for penicillin G, ampicillin and 
oxytetracycline was shorter than the elimination half-life calculated following intravenous 
administration. The elimination half-life cannot be calculated directly from the terminal phase 
of the plasma concentration versus time data following oral drug administration because it is 
a composite of the absorption, distribution and elimination of a drug. In some instances, 
where the systemic availability is limited by the rate of absorption, the apparent half-life of 
the terminal phase is in fact the absorption half-life, the so-called flip-flop phenomenon. It is 
not particularly surprising that the systemic availability of penicillin G appeared to be lower 
than the systemic availability of ampicillin since penicillin G is hydrolyzed (around 85%) at 
acid pH. In man and young animals, it is recommended that milk and antacids are avoided 
during oral administration of the tetracyclines because the latter complex with polyvalent 
cations such as calcium and magnesium ions. The systemic availability of oxytetracycline 
was low following oral administration and this may have been due to binding of the drug to 
feed. Although, the calculated values in the present study may be erroneous due to 
differences between the preparations used for intravenous and oral administration in the 
present study. It would have been useful to have examined the binding of oxytetracycline to 
hay in vitro. In the present study, 92.9% of the penicillin G and 59.2% of the ampicillin
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were bound to hay following incubation in vitro at pH 7.0. Around 19.8, 5.0 and 17.0% of 
the activity of penicillin G, ampicillin and oxytetracycline, respectively, was lost following 
in vitro incubation in caecal liquor for 3 h. It appears that the low systemic availability of 
antimicrobial agents following oral administration to equines may be partly due to acid 
hydrolysis, binding to feedstuffs and destruction within the gastrointestinal lumen. It would 
be interesting to re-examine the systemic availability of these three antimicrobial agents 
following oral administration to animals that had feed withheld.
The interactions of antimicrobial agents with the gastrointestinal microflora, and the effects 
of the route of administration on the magnitude of the gastrointestinal side effects were 
evaluated in the present study. Much of the work relied on the use of two ponies with 
cannulated caecal fistulas. Intestinal cannulation/fistulation is a technique that has been used 
in many of the studies of digestion in animals. Consequently, a number of different 
techniques have been described (Alexander, 1970, Boyd, 1985, Lowe et al., 1970, Roberts 
and Hill, 1974, Simmons and Ford, 1988). It is arguable whether the gastrointestinal 
microclimate of a fistulated animal is normal. Some authors have reported alterations in 
digestion following caecal fistulation whilst others reported no differences in the rate of 
passage of digesta or digestibility of feed (Lowe et al., 1970, Pulse et al., 1973). Mackie 
and Wilkins (1988) commented that the total viable counts of bacteria were higher in fresh 
post mortem samples compared with samples taken from animals with caecal fistulas. In 
their study, a total of 2.59 x lO^/g were isolated from the caecal contents of horses and this 
was not dissimilar to the results of the present study (>10^ Bacteroides spp./ml). Moreover, 
there were higher numbers of viable bacteria {Bacteroides spp.) isolated on anaerobically 
incubated horse blood agar in the present study than Mackie and Wilkins (1988) isolated on 
anaerobe blood agar containing defibrinated horse blood (5.25 x lO^/g of contents). It 
appears that the gastrointestinal microenvironment of animals with caecal fistulas provides an 
adequate representation of the caecal environment in normal ponies.
Clostridium perfringens is implicated in the pathogenesis of so-called colitis 'X' in the 
equine (Swerczek, 1979), however problems were encountered in the isolation and 
identification of C. perfringens in the present study. The number of viable Clostridium spp., 
in equine caecal liquor and faeces following intravenous or oral administration of 
antimicrobial agents, were counted. The perfringens agar base utilized in the present study 
aids in identification of C. perfringens by colonial morphology because the colonies have a 
black pigmented centre. However, a number of different colonies of similar appearance were 
seen following incubation of diluted caecal liquor and faecal samples. This was not 
surprising since there are a huge number of different bacterial species in samples from the 
gastrointestinal tract. Bacteroides melaninogenicus produces a characteristic intracellular or 
cell-associated water soluble pigment when cultured on blood agar. In addition, a wide range
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of organisms have been reported to produce black pigment, due to hydrogen sulphide 
production, when cultured on cooked meat media containing ferrous sulphate in vitro. These 
include reference strains and laboratory isolates of Bacteroides spp., E. coli, Proteus 
mirabilis, S. typhimurium and C. perfringens (Duerden, 1975). In the present study, B. 
melaninogenicus was not identified using the API system but a number of black colonies 
from horse blood agar were identified as B. asaccharolyticus. Another difficulty was the fact 
that the limit of detection of the assay of 10^ cfu was similar to the number of viable 
Clostridium spp. isolated from the samples. The most commonly identified species of the 
genus Clostridium was C. butyricum. This organism produced colonies which spread on the 
agar and may have masked the presence of other Clostridium spp.. In addition, following 
identification of C. perfringens by colonial morphology and Gram stain reaction, it was 
subcultured onto horse blood agar where it produced characteristic a  and B haemolysis 
following anaerobic incubation. Further identification was by inoculation and incubation of 
an API anaerobe identification test strip. There were problems in identifying C. perfringens 
due to the reduction of sugars in the test tubes and, despite the addition of bromocresol 
purple to the tubes where reduction had taken place, it was difficult to differentiate between a 
positive and a negative reaction. The increase in the number of Clostridium spp. recorded 
(>105 cfu/ml'or /g) was similar to that reported in previous studies (White and Prior, 1982, 
Wierup and Di Pietro, 1981) and to the number of Clostridium spp. isolated following 
carbohydrate overload (Gamer et al., 1978). It is unlikely that a significant increase in the 
number of one species of clostridia were masked, and it may be that an increase in the total 
number of viable Clostridium spp. is as significant as an increase in the number of one 
species of this genus.
There were apparent alterations in the number of viable caecal bacteria isolated, particularly 
following oral administration of antimicrobial agents, in the present study. Oral 
administration of penicillin G resulted in an increase in the number of viable coliforms, 
streptococci and Clostridium spp. isolated, even although penicillin G is active against Gram 
positive and some Gram negative bacteria. Similarly, oral administration of ampicillin 
resulted in an increase in the number of viable coliforms and probable increases in the 
number of streptococci, lactobacilli and Clostridium spp. isolated despite the fact that 
ampicillin has less activity, compared with penicillin G, in vitro against streptococci and 
Clostridium spp. but has greater activity against enterococci. Moreover, there were slight 
increases in the number of streptococci and lactobacilli isolated following oral administration 
of amikacin, which is effective mainly against Gram negative bacteria and is of little or no 
value in an anaerobic environment. There were increases in the number of coliforms, 
streptococci, lactobacilli and Clostridium spp. isolated following the oral administration of 
oxytetracycline which has a broad spectrum of activity. Thus, despite the differences in the 
spectrum of activity of the four antimicrobial agents used in the present study, the alterations
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in the gastrointestinal microflora appeared to be qualitatively and quantitatively similar. The 
response was most marked following the oral administration of oxytetracycline, the 
antimicrobial agent with a spectrum of activity against a wide range of Gram positive and 
Gram negative bacteria, as well as other microorganisms such as rickettsia. Interestingly 
clinical signs of depression and anorexia were apparent following oral administration of 
oxytetracycline to ponies and not following oral administration of the other antimicrobial 
agents. It would be interesting to investigate the alterations in gastrointestinal microflora 
following repeated administration of each of the four antimicrobial agents examined in the 
present study. It would seem probable that the alterations in gastrointestinal would be much 
more marked following repeated oral administrations, particularly of oxytetracycline, and 
this may also be the case following repeated intravenous administrations.
In view of the similarities in the response of the bacterial microflora to the different 
antimicrobial agents, it seems unlikely that the alterations in the number of viable bacteria 
isolated in the present study were a representation of their in vitro susceptibilities. However, 
an examination of the in vitro susceptibility of different gastrointestinal microorganisms to 
these antimicrobial agents would be required to confirm this.
The number of viable caecal bacteria isolated was similar in different animals and on 
different occasions. This is quite surprising given the marked variations in the amount of 
drug measured in the caecal lumen. It is interesting that the peak caecal liquor concentrations 
of all four of the antimicrobial agents occurred at a similar time after drug administration, 
namely 1-2 h in pony I and 6-12 h in pony II. Moreover, despite the differences in the dose 
rates of the four antimicrobial agents, the MRT was similar between occasions and was
I.98-3.92 h in pony I and 6.20-6.75 h in pony II for the penicillins (penicillin G and 
ampicillin). However, the MRT of amikacin and oxytetracycline, 2.85-5.88 h in pony I and
II.10-19.84 h in pony II, appeared to be longer. This is probably because less amikacin and 
oxytetracycline were destroyed within the gastrointestinal lumen hence the amount of drug 
measured in the caecum (AUC) was greater. Although, the volume of caecal contents was 
estimated the caecal volume varies in relation to feeding and thus the caecal concentrations 
and hence the AUC would be affected markedly by alterations in the volume of caecal liquor. 
It would have been useful, given the intestinal transit times of the animals used in the present 
study, to have taken samples between 12 and 24 h after drug administration.
An increase in the circulating concentrations of endotoxin develops following the disruption 
of the intestinal mucosal barrier (King and Gerring, 1988, Moore and Morris, 1992). In the 
present study, the increase in the number of viable coliform bacteria isolated following oral 
administration of penicillin, ampicillin and oxytetracycline probably would have resulted in 
an increase in the caecal endotoxin concentrations. Although, all other Gram negative
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bacteria (like Bacteroides spp.) also produce endotoxin. One could speculate that given a 
sufficient increase in the number of viable Gram negative bacteria and hence endotoxin (from 
effete Gram negative bacteria) in the gastrointestinal lumen there would be an increase in 
peritoneal and consequently plasma endotoxin concentrations. Moore et al. (1979) reported 
an increase in the intra-caecal endotoxin concentrations in the equine following carbohydrate 
overload, but Gamer et al. (1978) suggested that there was a reduction in the number of 
viable enterobacteria due to a drastic reduction in the luminal pH following carbohydrate 
overload. However, in the ruminant an increase in the number of viable coliform bacteria has 
been recorded following carbohydrate overload (Allison et al., 1975). The number of viable 
enterobacteria isolated by Gamer et al. (1978) was high (lO^O/ml) prior to carbohydrate 
overload. Plasma endotoxin concentrations have been measured in horses with colic and in 
the caecal fluid of horses following carbohydrate overload (King and Gening, 1988, Moore 
et al.y 1979). It may be useful to measure plasma endotoxin concentrations following oral 
administration of an antimicrobial agent given the subsequent increase in the number of 
viable coliforms.
Enterotoxin is of major importance in the development of antimicrobial-associated colitis in 
man. The major causative organism is C. difficile, although other toxin producing bacteria, 
including staphylococci and E. coli, have been isolated from human cases of antimicrobial- 
associated colitis. Clostridium difficile was not isolated in the present study although it has 
been isolated previously from equines (Jones et al . y 1987, Jones et al.y 1988). This was 
probably because C. difficile was not present in the environment of the animals used in the 
present study. Selective isolation of C. difficile is sensitive and specific. In man, the 
diagnosis of C. difficile infection is based on the isolation of the organism or the 
demonstration of toxin production. It would have been useful to examine for toxin 
production in the present study. However, C. difficile has been isolated from an equine 
source by one group of researchers only, thus the likelihood of isolating C. difficile would 
seem to be low. However, in a hospital environment, where C. difficile has been isolated 
from other sources, toxin detection would be a useful adjunct to the diagnostic armament.
In the present study, serial samples for bacteriological culture were taken every 24 h. 
However, antimicrobial concentrations were measured in caecal liquor as early as 15 min 
after drug administration, and peak drug concentrations occurred between 1.5 and 8 h after 
drug administration. A more frequent sampling regime, particularly in the first 24 to 48 h 
following antimicrobial administration would provide additional information on the effects of 
antimicrobial administration on the gastrointestinal microflora. For example, there was an 
increase in the number of coliforms isolated following oral administration of the two 
different broad spectrum antimicrobial agents. It may be that this alteration was secondary to 
a reduction in the number of viable commensal bacteria. It would be interesting to see
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whether the increase in the number of viable bacteria isolated was related to drug 
concentrations and whether the increase, e . g. up to 10^-10^ 1 coliforms per ml, reported in 
the present study was a maximal effect. The 24 hourly sampling regime was probably more 
appropriate for the faecal samples, given the time taken to reach maximum concentrations of 
the antimicrobial agents at each site, in the present study. An examination of the number of 
viable faecal bacteria isolated following oral administration of antimicrobial agents to normal 
horses would be a means of confirming or refuting the results reported in the present study. 
In addition, it would be interesting to study counts of caecal and faecal viable bacteria in 
parallel. This would provide information on how closely the population of microflora in the 
caecum is reflected by the faecal microbial population. In the present study, different animals 
kept under similar management conditions had similar numbers of viable bacteria in caecal 
liquor and in faeces.
Salmonella typhimurium phage type 204c was isolated from one pony on two separate 
occasions following oral administration of oxytetracycline. A further oral administration of 
oxytetracycline and repeated sampling failed to re-isolate the organism. It is possible that this 
was due to immunity to re-infection either due to an immune response following previous 
exposure to the organism, hence the absence of overt clinical signs on this occasion, or to a 
rapid protective immune response on the occasion in the present study. A sample of serum 
from this animal following isolation and identification of Salmonella typhimurium phage 
type 204c agglutinated the organism, which did not exhibit autoagglutination (unpublished 
data).
Caecal liquor pH was measured as a means of monitoring the large intestinal hydrogen ion 
concentrations, and the production of SCFAs by the bacteria in the caecal lumen. There was 
considerable variation in the caecal pH measurements in the present study. Murray (1988a) 
suggested that in the equine large intestine the pH was maintained between 6.8 and 7.2, and 
Gamer et al. (1978) reported control pH values of 7.18±0.14 (mean±SEM) for caecal fluid. 
However, other studies have reported that the caecal luminal pH was lower than this (pH 
6.5-6.9) (Argenzio et al.t 1974, Mackie and Wilkins, 1988) and Goodson et al. (1988) 
reported a much wider range of caecal pH of 6.4-7.7 for ponies on a forage diet. This 
suggests that, in the present study, the majority of the pH measurements were within the 
normal range. There were some apparent reductions and increases in the caecal pH outside 
the wider pH ranges and these alterations in the hydrogen ion concentration may reflect 
alterations in SCFA production in the gastrointestinal lumen. Marked reductions in luminal 
pH have been associated with diets high in concentrates, and following carbohydrate 
overload in ruminants and in horses, but in general the reduction in the pH following 
carbohydrate overload was to a pH of less than 6 (Gamer et al., 1978, Moore et al.t 1979, 
Wemery and Wensvoort, 1992). A pH range of pH 6.4-7.7 reported in the present study
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represents a wide range of hydrogen ion concentrations of around 2 x 10"8 to 4 x 10"? M. A 
pH range of 4 to 6, associated with the development of clinical signs of acidosis, represents 
a hydrogen ion concentration of 1 x 10~6 to 1 x 10”^  M, and this is up to 10000 times 
greater than the majority of pH values reported in the present study. It appears that although 
there were wide variations in hydrogen ion concentrations a marked reduction in caecal 
liquor pH was prevented by either combining with bicarbonate ions or by exchange with 
sodium ions across the caecal mucosa. In view of the wide range of normal caecal luminal 
pH values, an alteration in luminal pH following a single intravenous or oral administration 
was not a particularly useful indicator of an alteration in SCFA concentrations. There may be 
more marked alterations in caecal pH following the administration of antimicrobial agents 
either on a single occasion at a higher dose rate or following repeated dosing, and the 
measurement of luminal pH has the advantage of being almost instantaneous.
In the present study, SCFA concentrations were measured as a means of monitoring 
bacterial fermentation in the large intestine. SCFA production can be measured using either 
an indirect or a direct approach. Indirect methods measure SCFA concentrations or estimate 
SCFA production from a known amount of substrate metabolized by a known weight of 
bacteria. Short-chain fatty acids are metabolized and absorbed therefore SCFA 
concentrations do not represent SCFA production. A direct approach measures SCFA 
production rates. The technique used in the present study is an indirect means of measuring 
VFA production, and it assumes that the capacity of VFA absorption can be exceeded, and 
that changes in VFA absorption and secretion are proportional to changes in VFA 
production. Other indirect approaches include the use of a suitable fermentation equation, or 
the dry weight of bacteria excreted in faeces per day, along with the amount of available 
substrate to calculate theoretical VFA production (Fleming and Arce, 1986, Miller and 
Wolin, 1979, Smith and Bryant, 1979). However, these methods assume that the only non- 
gaseous end-products of microbial fermentation are VFAs, and the dietary fibre fermented in 
the colon is lost as bacterial cells in the faeces, respectively, and this may result in inaccurate 
estimates. Also, bacterial excretion rates vary with diet, e. g. in man it represents an average 
of 13% of the dry weight of faeces. In ruminants, VFA production rates have been 
measured directly using complex radioisotope dilution techniques (Bruce et al., 1987). An 
alternative approach to assessing gastrointestinal fermentation would be to measure SCFA 
concentrations outside the gastrointestinal tract e. g. in plasma or breath. This would be 
particularly useful since these methods are much less invasive than caecal fistulation and 
would permit the use of normal animals in studies of gastrointestinal microbial fermentation. 
In fact this approach has been used in man where there is limited or no access to samples of 
large intestinal contents. The method of extraction of SCFA from caecal liquor was applied 
to trial plasma samples and was suitable for the extraction of SCFA from plasma 
(unpublished data). However, blood from the gastrointestinal tract passes through the liver
280
and the extensive metabolism of SCFAs in the liver may result in SCFA concentrations in 
circulating plasma being an unreliable estimate of large intestinal SCFA concentrations.
A novel analytical method was developed to measure NVFA and VFA concentrations 
simultaneously and this was used to measure SCFA concentrations in equine caecal liquor 
and faeces. The method used in the present study is simple and rapid in comparison with the 
other available techniques (Boley and Colwell, 1987, Canale et al., 1984, Guerrant et al.> 
1982, Holdeman et al.t 1977, Mahadevan and Stenroos, 1967). In addition, this method 
would be applicable to the rapid identification of bacteria in vitro (Tabaqchali, 1982) and 
measurement of SCFA concentrations in plasma (unpublished data). There are some 
problems associated with the extraction and chromatography of SCFA from biological 
matrices. The high recovery of the seven SCFA obtained here shows that a solid-phase 
system is a suitable technique to overcome these problems.
During development of the method described in the present study, different buffering 
systems (borate and carbonate) were investigated to try and optimize the recovery and 
selectivity. Attempts to concentrate the effluent from the Sep-pak cartridges, using different 
buffers and by varying the elution volume, were unsuccessful. The other buffering systems 
prolonged the solvent front and interfered with the resolution of the lactic acid peak. 
Extraction with phosphate buffer (0.05 M, pH 7.0) resulted in the best solvent front and 
maximised the extraction (volume). Unfortunately lactic and acetic acids were eluted in the 
first 0.5 ml along with some of the dirt contained in the samples. Various attempts were 
made to clean up the samples by introducing a wash step after loading a sample onto a solid- 
phase cartridge. Distilled water, buffer (Clark and Lubbs KC1/HC1), and buffer components 
(KC1, HC1) were tried but this step removed some of the acids (lactic and acetic) and 
reduced the recoveries of the remaining acids to around 30 %. Filtering, prior to solid-phase 
extraction, was investigated as a possible clean-up step but this markedly reduced the 
percentage recoveries. Optimum results were obtained using 3.5 ml of phosphate buffer 
(0.05 M, pH 7.0) to elute the SCFA from the solid-phase cartridge, followed by filtering the 
eluted samples through a 0.45 pm cellulose nitrate filter prior to injection into the 
chromatograph.
The method described in the present study was suitable for measuring seven SCFAs in 
equine caecal liquor but requires further modification to improve the extraction of SCFAs 
from faecal samples. There was considerable variation in the faecal SCFA concentrations. 
This appears have been due to inconsistent extraction of SCFAs from faecal samples 
although many samples had SCFA concentrations within the normal ranges established for 
caecal liquor. In addition, faecal lactic acid concentrations appeared to be related to the caecal 
lactic acid concentrations, and were all within or above the normal range established for
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caecal liquor. In man, gastrointestinal VFA concentrations are measured in faecal water or in 
water from enema samples (Clausen et al., 1991, Fleming et al.y 1989, Holtug and 
Mortensen, 1989, Weaver et al., 1988). Commonly, the SCFAs are extracted from faecal 
samples using methods such as steam distillation prior to analysis by GLC (Bruce et al., 
1987, Clausen et al., 1991). The technique used in the present study was not dissimilar to 
the one described by Merritt and Smith (1980). These authors passed faeces through wire 
mesh prior to centrifugation, and extracted the VFAs using metaphosphoric acid. It may be 
that breaking up the sample to reduce the particle size, e. g. by seiving, would result in 
better mixing of the sample with the buffer, and more consistent extraction of faecal SCFA. 
In addition, a period of mixing or homogenizing of the faecal samples with the buffer may 
improve the extraction of SCFA from faecal samples. It would be unlikely that lengthening 
the centrifugation time would improve the recoveries of SCFA from faecal samples.
It was possible to separate the seven SCFA using a standard reverse phase HPLC column 
although the separation of lactic and acetic acid peaks was poor. A number of solvents 
containing ion-pairing agents (e. g. decylamine, sodium lauryl sulphate) were used to try 
and improve the separation of lactic and acetic acids but this was unsuccessful. The ion- 
exchange column used in the present study produced adequate separation and delineation of 
the seven SCFA peaks. A variety of concentrations of acid were tried in the mobile phase in 
an attempt to optimize the peak height and shape of each acid and to minimize retention times 
although these alterations had to be within a reasonably small range in order not to damage 
the polymer packing material in the column.
There were no endogenous peaks recorded that interfered with the resolution of the seven 
SCFAs on the chromatogram, although there was an unidentified peak that chromatographed 
between isovaleric and valeric acids. A similar unidentified peak was reported by Guerrant et 
al. (1982). These researchers examined a large number of biological acids by HPLC but 
failed to identify this peak. The unidentified peak appeared in standard solutions despite the 
use of reagents of high purity. In addition, the peak was present in some, but not all, 
samples at widely varying peak heights. One suggestion was that the unidentified peak 
represented 2-methylbutyric acid (an isomer of 3-methylbutyric or isovaleric acid). Usually, 
the unidentified peak was small and did not interfere with the desired peaks so the analytical 
method was considered to be satisfactory. Separation of the compound using a preparative 
HPLC would permit identification using an HPLC with a mass spectrometer interface.
The recovery of the SCFAs was calculated using the external standard method. Using an 
internal standard was considered, however there was some difficulty in choosing a suitable 
compound. Ideally an internal standard should be similar in retention time to and be 
extracted in a similar manner to the required compounds but should not interfere with the
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desired compounds in any way. This was difficult because of the proximity of the peaks, the 
relatively long retention times and the possibility of further endogenous peaks in samples. It 
would have been necessary to choose something that was not naturally occurring 
(Czerkawski, 1986).
Generally, caecal lactic acid concentrations are low in animals fed a forage d ie t In the 
present study, the median (range) lactic acid concentration of 1.5 mmol/1 (0.0-24.4 mmol/1) 
was similar to the control concentrations reported by Moore et al. (1979). There were 
increases in both caecal liquor and faecal lactic acid concentrations following intravenous 
and oral administration of antimicrobial agents, although the alterations were most marked 
following oral administration of antimicrobial agents. The increase in lactic acid 
concentrations may have been due to an increase in production of lactic acid or to either a 
decrease in metabolism, e. g. to propionate, or a reduction in transport across the intestinal 
mucosa. If the increase in lactic acid concentration was due to an increase in production of 
lactic acid then a concomitant reduction in luminal pH would be expected if the intestinal 
buffering systems were overwhelmed. A reduction in transmucosal transport of lactic acid 
may be due to inhibition, since butyric acid is a competitive inhibitor of L-lactate uptake 
(Wolffram et al., 1988). Moreover, lactic acid concentrations may accumulate in the 
gastrointestinal lumen due to slower absorption of the NVFA compared to the VFA 
(Umesaki et al., 1979). An increase in lactic acid concentrations may result in an increase in 
the luminal bicarbonate ion concentrations and a reduction in the absorption of water, which 
in an extreme situation may lead to the development of diarrhoea. The lactic acid 
concentrations measured in the present study represented a racemic mixture of both D- and 
L-lactic acid, and the increase in lactic acid concentrations may have been due to to an 
increase in D-lactic acid which cannot be metabolized by the animal. Slyter and Rumsey 
(1991) showed that there were peaks in both D- and L-lactic acid concentrations following 
carbohydrate overload. It would therefore have been useful to separate D- and L-lactic acid. 
Racemic mixtures can be separated into their enantiomers using a chiral HPLC column, and 
this type of separation was attempted unsuccessfully (unpublished data). The short 
wavelength (210 nm) meant that samples had to be very clean and problems arose with the 
selection of a solvent that would provide a sufficiently quiet baseline. The increase in 
gastrointestinal lactic acid concentrations may be related to the concentration of an 
antimicrobial agent in the gastrointestinal lumen, and to the subsequent effects on the 
proportions of the different commensal microflora. However, amikacin appeared to have 
only slight effects on the genera of organisms isolated in the present study, despite being 
present at high concentrations. An increase in lactic acid concentrations may not be related 
solely to antimicrobial activity in the gastrointestinal tract, and increased lactic acid 
concentrations have been recorded following carbohydrate overload. The elevated intestinal 
lactic acid concentrations observed in the present study following administration of
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antimicrobial agents were of a similar magnitude (circa 42.5 mmol/1) to those recorded by 
Moore et al. (1979) following carbohydrate overload in 2 horses. Lactic acidosis is of 
clinical importance in the horse and the lactic acid formed by the gastrointestinal microflora 
is a major source of plasma lactate concentrations (Coffman, 1975a, b). Peak caecal liquor 
lactic acid concentrations of 7.9-38.7 at 4-12 h, 39.6-51.6 mmol/1 at 8-32 h, 7.8-26.4 
mmol/1 at 4-24 h, and 24.9-50.6 mmol/1 at 8-56 h following oral administration of penicillin 
G, ampicillin, amikacin and oxytetracycline, respectively, were higher, in general, than the 
peak concentrations of 1.7-10.1 mmol/1 at 0.75-12 h, 2.1-5.1 mmol/1 at 8-24 h, 3.3-8.9 
mmol/1 at 4-12 h and 4.5-16.4 mmol/1 at 8-72 h following intravenous administration. 
Interestingly, the highest caecal liquor lactic acid concentrations occurred following oral 
administration of the broad spectrum antimicrobial agents, ampicillin and oxytetracycline. 
There was wide variation in the time at which peak lactic acid concentrations occurred 
despite the similarities in drug disposition in the caecum in each animal on different 
occasions. It appears that there is a greater risk of developing antimicrobial-associated 
gastrointestinal disturbances following the administration of broad spectrum antimicrobial 
agents.
It would have been useful to have measured plasma lactate concentrations in the present 
study to demonstrate whether the increased intestinal lactate concentrations were reflected in 
the plasma since lactic acid concentrations in plasma are a good prognostic indicator in 
horses with acidosis (Gossett et al., 1987). The gastrointestinal tract is by no means the only 
source of lactic acid in the body. A number of tissues and cell types, including skeletal 
muscle, red blood cells and hepatocytes, produce lactic acid under a variety of different 
conditions, including exercise. Moreover, Wolter etal. (1983) reported that intra-caecal L- 
lactate administration caused a high liberation of histamine in the pony caecum but that blood 
lactate and histamine concentrations were not altered. Thus, the increase in gastrointestinal 
lactic acid concentrations may only have local effects although this may be of importance in 
the development of disorders of the gastrointestinal tract, such as colitis. In addition, 
systemic acidosis may result due to the movement of large quantities of the bicarbonate ion 
into the gastrointestinal lumen to buffer high concentrations of acid produced there.
In general the total SCFA concentrations in the literature are equivalent to the total VFA 
concentrations discussed in the present study. The baseline studies demonstrated that there 
are a wide range of SCFA concentrations in the equine caecum. Rechkemmer et al. (1988) 
reported that in most mammals the SCFA concentrations in the hindgut are around 100 
mmol/1 despite inter-species differences in production. The ratio (% of total VFA 
concentration) of acetate, propionate and butyrate was similar in the bovine rumen and in 
human faeces (65, 20, and 15% and 47.8, 10.8 and 5.3%, respectively) (Miller and Wolin, 
1979, Wolin, 1981). In the equine, mean caecal VFA concentrations of 50-60 mmol/1 have
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been recorded and these were increased up to 80-100 mmol/1 following feeding (Argenzio et 
al.y 1974, Argenzio and Stevens, 1975). The ratio of acetic, propionic and butyric acids as a 
percentage of the total VFA concentration was approximately 70%, 22% and 6% (Argenzio 
et al.y 1974). In ponies, Hintz etal. (1971) reported that the ratio of acetic, propionic and 
butyric acids was 73,17 and 8% on a hay diet and 59, 25 and 11% on a diet of 1 part hay 5 
parts grain. A similar median (range) total VFA concentration of 65.0 mmol/1 (24.4-109.2 
mmol/1) and a median ratio (range) of 53.1% (27.9-67.0%) acetic acid, 18.7% (4.9-38.5%) 
propionic acid and 21.3% (8.7-66.7%) butyric acid was measured in the present study. 
There was a tendency to a higher ratio of butyric acid in the present study.
There were considerable variations in the concentrations of individual VFAs, particularly 
acetic, propionic and butyric acids, following administration of antimicrobial agents in the 
present study. These alterations were particularly marked following the oral administration 
of the antimicrobial agents, and there appeared to be different alterations in VFA 
concentrations with different antimicrobial agents. Oral administration of penicillin G 
produced a reduction in the concentrations of butyric and propionic acids and a reduction in 
the proportion of butyric acid, as a percentage of the total VFA concentrations; ampicillin 
produced an apparent reduction in the concentration of propionic acid and in the proportion 
of butyric acid; and amikacin and oxytetracycline, produced little or no alterations in total or 
individual VFA concentrations or proportions. Interestingly, the two penicillins affected 
individual VFA concentrations although there were no marked alterations in the total VFA 
concentrations, whereas amikacin, the antimicrobial agent which produced only slight 
alterations in numbers of viable bacteria had no marked effects on VFA concentrations or 
ratios. Oxytetracycline appeared to have the most marked effects on the number of viable 
bacteria isolated but had little or no effect on VFA concentrations. The antimicrobial agents 
that affect cell wall synthesis and result in lysis of bacterial cells produced apparent 
alterations in VFA concentrations whilst the antimicrobial agents which inhibit bacterial 
protein synthesis, either irreversibly or reversibly, did not affect individual VFA 
concentrations. Interestingly, the positive metabolic effect of the so-called growth promoting 
antimicrobial agents, such as the ionophores, is a shift in bacterial fermentation away from 
acetic and butyric acid and methane production to production of propionic acid. Thus, a 
relative or actual reduction in the amount of propionic acid may be detrimental to the energy 
metabolism of the animal.
The alterations in numbers of viable bacteria and lactic acid concentrations are not dissimilar 
to the alterations in the gastrointestinal tract described following carbohydrate overload in the 
horse (Gamer et al.y 1978, Moore et al.y 1979). Following carbohydrate overload, there is a 
predominance of lactic acid producing bacteria, an increase in the lactic acid concentrations 
with a concomitant reduction in the luminal pH. Lactic acid producing bacteria including
285
streptococci, lactobacilli and Clostridium spp. all increased, particularly following oral 
administration of the antimicrobial agents, in the present study. In addition, increases in the 
number of coliforms, lactobacilli, and Clostridium spp% isolated have been recorded 
following carbohydrate overload (Allison et al., 1975, Gamer et al., 1978). Slyter and 
Rumsey (1991) demonstrated that faecal coliform bacteria from horses produced D-lactic 
acid. However, in cattle there were peaks in both D- and L-lactic acid following 
carbohydrate overload with the former peak mimicking the peak number of lactobacilli and 
the latter corresponding to an increase in the number of coliforms. In the present study the 
reduction in caecal liquor pH was not marked but there were substantial increases in lactic 
acid concentrations. The changes in the gastrointestinal lumen that follow feeding have been 
described as a subclinical carbohydrate overload (Clarke et al., 1990b). It is also possible 
that the alterations in caecal liquor were in fact alterations that occurred within the small 
intestine and were carried into the caecum. This suggests that alterations reported in the 
present study may be either a non-specific response of the caecal luminal microflora to an 
alteration in their environment or a specific response to an increase in the amount of 
carbohydrate entering the caecum from the ileum, due to carbohydrate-sparing in the upper 
gastrointestinal tract. Also, it is relevant that the organisms isolated in the present study 
represent only part of the gastrointestinal microflora which includes many other species of 
bacteria as well as protozoa.
In the present study, there were no marked alterations in SCFA concentrations following 
incubation of caecal liquor in the presence of antimicrobial agents in vitro. However, there 
has been extensive work on bacterial fermentation in the rumen and the effects of growth 
promoting antimicrobial agents, such as the ionophores, in vitro which produced similar 
results to studies in vivo (Chalupa et al., 1980, Chirase et al., 1988, Demeyer and Van 
Nevel, 1987). The difference in results was probably due to the simplicity of the incubation 
technique used in the present study; more complex continuous culture techniques were used 
in previous studies. A method for studying the large intestinal microflora of the horse using 
continuous culture is available (Davies, 1979) and it would be interesting to repeat the 
studies using continuous culture.
There are only a limited number of antimicrobial agents available for oral administration in 
the equine. It appears, from the limited in vitro studies described in the present study, that 
feeding may markedly affect the amount of drug available for absorption from the 
gastrointestinal tract. Many of the agents retained their activity in caecal liquor, where they 
appeared to be unabsorbed, as demonstrated by the absence of plasma concentrations, but 
were able to affect the commensal microflora. It has been suggested that food should be 
withheld for a minimum of 2 h prior to and following oral administration of antimicrobial 
agents (Watson, 1986). In fact, in many of the published equine pharmacokinetic studies,
2 8 6
food was withheld for varying amounts of time prior to drug administration. In the present 
study, oral administration of antimicrobial agents was carried out prior to feeding, although 
food was not withheld deliberately. In addition, some authors have demonstrated that 
withholding food has little effect on the AUCpiasma following oral administration of some 
antimicrobial agents (Ensink et al., 1992). The apparently enhanced absorption of 
antimicrobial agents in the foal may be due to differences in diet. In the adult horse, it 
appears that, due to the binding of antimicrobial agents to hay in vitro, withholding of food 
prior to antimicrobial administration may be beneficial. In addition, there has been some 
interest in agents which increase the amount of drug in the body (AUC) either by increasing 
drug absorption from the gastrointestinal tract, by slowing transit time or by reducing drug 
elimination, by administration of probenecid, a competitive inhibitor of penicillin excretion 
(Sarasola et al., 1992).
Although a large part of the present study was carried out in two animals with cannulated 
caecal fistulas, it provides a useful indication of what may happen in the caecum following 
I intravenous or oral administration of an antimicrobial agent. It is interesting to note that the
| alterations in the caecal microflora appeared to be repeatable in these animals. Further studies
I utilizing a larger group of animals would be appropriate to confirm the results of the present
study. It may be possible, and more relevant, to repeat the studies in normal animals, using
|
! slightly different techniques to monitor alterations in large intestinal microbial function.
i
I
i
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C onclusions
A suitable therapeutic regime for penicillin G sodium in horses, ponies and donkeys, based 
on elimination half-lives and typical bacterial susceptibilities, would be intravenous 
administration at a dose rate of 10 mg/kg bwt every 4 h. Therapeutic plasma concentrations 
of ampicillin would be maintained by intravenous administration at a dose rate of 10 mg/kg 
bwt every 6-8 h to horses, ponies and donkeys. Intravenous administration of amikacin at a 
dose rate of 6 mg/kg bwt every 8 h to horses and 6 h to ponies and donkeys would be 
suitable for the treatment of susceptible bacterial infections. The long elimination half-life of 
oxytetracycline means that intravenous administration at a dose rate of 10 mg/kg bwt 
administered at 48 h in horses and ponies and at 24 h intervals in donkeys would maintain 
therapeutic concentrations of the drug in plasma. Oral administration of penicillin G, 
ampicillin, amikacin and oxytetracycline would be unsuitable for systemic antimicrobial 
therapy in the pony because of their poor systemic availability. A single administration of an 
antimicrobial agent is a useful means of studying its effects on the gastrointestinal microbial 
function. There were no clinical side effects following oral administration of penicillin G, 
ampicillin and amikacin but the ponies exhibited depression and anorexia following oral 
administration of oxytetracycline. There were alterations in gastrointestinal microflora 
following antimicrobial administration and these were particularly marked following oral 
administration and were probably related to the luminal concentrations of the antimicrobial 
agents. Although there were similarities between the response of the gastrointestinal 
microflora to different antimicrobial agents, there were quantitative differences which may 
relate to the mode of action of the antimicrobial agents studied. There were alterations in 
number of viable bacteria in caecal liquor following administration of penicillin G, 
ampicillin, amikacin and oxytetracycline. In particular there were increases in the number of 
coliforms, streptococci, lactobacilli and Clostridium spp. isolated with no apparent 
alterations in the number of Bacteroides spp. isolated. Luminal pH was not a particularly 
useful index for alterations in SCFA concentrations following a single intravenous or oral 
administration of the antimicrobial agents studied. There were alterations in SCFA 
concentrations following antimicrobial administration, particularly increases in lactic acid 
concentrations, although there were decreases in the concentrations of propionic and butyric 
acids following administration of the penicillins. In general, the response of the 
gastrointestinal tract to antimicrobial administration was similar to that described following 
carbohydrate overload. Accordingly, antimicrobial agents should be administered with care 
in the equine in particular agents which are eliminated to any extent into the gastrointestinal 
tract. The disruption in microbial metabolism (VFAs) appeared to be greater following 
administration of the so-called bactericidal antimicrobial agents, and the broad spectrum 
antimicrobial agents produced greater alterations in lactic acid concentrations than the narrow
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spectrum agents. The development of antimicrobial-associated colitis appears to be unrelated 
to the survival of non-susceptible bacteria, but may be related to the colonization of the 
gastrointestinal tract by non-susceptible pathogenic bacteria such as Salmonella spp. This 
would suggest that, as in man, a wide range of antimicrobial agents could result in the 
development of enterocolitis in the equine, particularly where a pathogenic bacterium is 
present in the environment.
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Appendix A - Penicillin G
Time (h) Horse 3 Horse 4 Horse 5 mean±SEM
0 0.00 0.00 0.00 0.0010.00
0.033 61.25 63.24 35.26 53.25±9.01
0.083 43.86 NS 30.09 36.9816.88
0.1 NS 44.20 NS 44.20
0.25 NS 25.71 11.11 18.4117.30
0.33 22.52 NS NS 22.52
0.5 16.35 18.61 6.38 13.7813.76
0.75 10.97 6.95 3.93 7.2812.04
1 7.51 4.69 2.57 4.9211.43
1.5 4.31 2.02 1.45 2.5910.87
2 2.26 1.42 0.68 1.4510.46
4 0.60 0.07 0.13 0.2710.17
6 0.16 0.00 0.03 0.0610.05
8 0.00 0.00 0.01 0.0010.00
12 0.00 0.00 0.00 0.0010.00
24 0.00 0.00 0.00 0.0010.00
Table A l. Plasma concentrations (|ig/ml) of penicillin G following intravenous 
administration to horses
Table A2.
administration to ponies
Time (h) Pony 7 Pony 8 Pony 10 meaniSEM
0 0.00 0.00 0.00 0.0010.00
0.033 74.10 57.98 30.37 54.15112.77
0.083 49.46 44.88 19.54 37.9619.30
0.25 23.90 21.91 14.71 20.1712.79
0.5 9.35 12.61 11.11 11.0210.94
0.75 5.09 10.93 7.19 7.7411.71
1 3.15 5.69 5.30 4.7110.79
1.5 1.24 3.25 3.15 2.5510.65
2 0.00 1.46 1.72 1.0610.54
4 0.00 0.22 0.25 0.1610.08
6 0.00 0.00 0.02 0.0110.01
8 0.00 0.00 0.00 0.0010.00
12 0.00 0.00 0.00 0.0010.00
48 0.00 0.00 0.00 0.0010.00
(jig/ml) of penici lin G following intravenous
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Time (h) Donkey 14 Donkey 15 Donkey 16 mean±SEM
0 0.00 0.00 0.00 0.00±0.00
0.033 NS 64.29 73.45 68.87±4.58
0.083 NS 48.14 58.35 53.25±5.10
0.117 40.93 NS NS 40.93
0.25 12.02 19.65 27.10 19.59±4.35
0.5 8.20 10.84 11.94 10.33±1.11
0.75 4.84 3.72 6.82 5.13±0.91
1 3.84 2.01 3.86 3.24±0.61
1.5 1.90 0.94 2.08 1.64±0.35
2 1.02 0.47 0.82 0.77±0.16
4 0.21 0.03 0.13 0.12±0.05
6 0.02 0.00 0.00 0.01±0.01
8 0.00 0.00 0.00 0.00±0.00
12 0.00 0.00 0.00 0.00±0.00
48 0.00 0.00 0.00 0.00±0.00
Table A3. Plasma concentrations (|ig/ml) of penicillin G following intravenous 
administration to donkeys
Parameter Horse 3 Horse 4 Horse 3
tl/2 B2 (min) 8.40 4.62 5.64
tl/2 B1 (min) 51.00 27.06 48.90
CpO (|ig/ml) 64.53 77.37 46.79
Vc (ml/kg) 154.96 129.24 213.74
AUCobs (p.g.h/ml) 30.36 25.45 13.29
AUMCobs (p.g.h2/ml) 24.41 12.93 7.86
AUC (jig.h/ml) 30.85 23.88 12.49
AUMC 0xg.h2/ml) 28.06 12.61 8.91
MRT (min) 48.24 30.48 35.49
Vdarea (ml/kg) 397.77 272.72 941.26
Vdss (ml/kg) 294.84 221.15 570.98
CLb (ml/h.kg) 324.17 418.72 800.49
kel (/h) 2.09 3.24 3.75
k21 (/h) 1.92 4.27 1.67
kl2(/h) 1.74 3.04 2.79
Table A4. Disposition kinetics of penicillin G following intravenous administration to horses
Parameter Pony 7 Pony 8 Pony 10
tl/2 B2 (min) 3.06 5.10 1.50
tl/2 B1 (min) 18.18 35.46 37.20
CpO (pg/ml) 101.30 71.41 50.85
Vc (ml/kg) 98.72 140.04 196.65
AUCobs (pg.h/ml) 20.52 24.94 18.12
AUMCobs (pg.h2/ml) 6.09 15.27 14.65
AUC (|ig.h/ml) 19.60 23.76 17.09
AUMC (fig.h2/ml) 6.76 15.72 14.25
MRT (min) 17.81 36.74 48.51
Vdarea (ml/kg) 222.83 359.12 523.31
Vdss (ml/kg) 175.78 278.43 487.93
CLb (ml/h.kg) 510.12 420.88 585.07
kel (/h) 5.17 3.01 2.98
k21 (/h) 6.04 3.18 10.32
kl2(/h) 4.71 3.15 15.29
Table A5. Disposition kinetics of penicillin G following intravenous administration to ponies
329
Parameter Donkey 14 Donkey 15 Donkey 17
tl/2 B2 (min) 2.64 5.70 6.78
tl/2 B1 (min) 39.96 25.02 33.12
CpO (|ig/ml) 212.51 78.61 88.15
Vc (ml/kg) 47.06 127.22 113.45
AUCobs Qig.h/ml) 27.21 18.81 24.96
AUMCobs (|ig.h2/ml) 11.89 6.52 10.96
AUC Olg.h/ml) 22.97 18.46 24.31
AUMC (Hg.h2/ml) 10.69 7.17 11.84
MRT (min) 26.22 20.80 26.35
Vdarea (ml/kg) 418.59 325.68 327.48
Vdss (ml/kg) 202.78 210.37 200.44
CLb (ml/h.kg) 435.45 541.72 411.41
kel (/h) 9.25 4.26 3.63
k21 (/h) 1.79 2.86 2.12
kl2(/h) 5.93 1.87 1.62
Table A6. Disposition kinetics of penicillin G following intravenous administration to 
donkeys
Time (h) Horse 3 Horse 4 Horse 5 mean±SEM
coliform s
0
24
48
1.00E+06 
1.00E+05 
2.00E+07
3.00E+04
4.00E+04
1.00E+05
1.00E+03
3.00E+04
1.00E+05
3.44E+05±3.28E+05 
5.67E+04±2.19E+04 
6.73E+06±6.63E+06
streptococci
0
24
48
1.00E+10
1.00E+07
1.00E+10
3.00E+07
1.00E+07
5.00E+06
1.00E+09
7.00E+05
3.00E+07
3.68E+09±3.17E+09 
6.90E+06±3.10E+06 
3.35E+09±3.33E+09
lacto bacilli
0
24
48
1.00E+05 
1.00E+08 
1.00E+05
3.00E+09
1.00E+06
1.00E+04
2.00E+05
1.00E+07
3.00E+05
1.00E+09±1.00E+09 
3.70E+07±3.16E+07 
1.37E+05±8.57E+04
Bacteroides spp.
0
24
48
1.00E+08
1.00E+09
1.00E+10
1.20E+10
1.00E+06
1.10E+06
7.00E+06
1.00E+05
1.20E+07
4.04E+09±3.98E+09
3.34E+08±3.33E+O8
3.34E+09±3.33E+09
Clostridium spp.
0
24
48
1.00E+04
2.10E+04
-
1.00E+04
1.00E+04
1.55E+04±4.49E+03
Table A7. Counts of viable bacteria per g faeces following intravenous administration of 
penicillin G to horses
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Time (h) Pony 7 Pony 8 Pony 10 mean±SEM
coliforms
0 4.00E+04 5.00E+04 2.00E+05 9.67E+04±5.17E+04
24 1.30E+07 1.00E+10 2.00E+10 1.00E+10±5.77E+09
48 1.00E+07 3.00E+10 2.00E+10 1.67E+10±8.82E+09
streptococci
0 1.00E+04 3.00E+04 1.00E+06 3.47E+05±3.27E+05
24 1.00E+05 6.00E+04 1.00E+06 3.87E+05+3.07E+05
48 3.00E+04 5.00E+05 2.00E+07 6.84E+06±6.5 8E+06
lacto bacilli
0 1.00E+05 1.00E+05 5.00E+05 2.33E+05±1.33E+05
24 2.00E+04 4.00E+04 1.00E+06 3.53E+05±3.23E+05
48 3.00E+07 1.00E+05 1.00E+04 1.00E+07±9.98E+06
Bacteroides spp.
0 9.50E+06 3.10E+06 8.00E+05 4.47E+06±2.60E+06
24 1.00E+06 1.10E+08 1.20E+10 4.04E+09±3.98E-f09
48 1.00E+06 1.00E+07 2.20E+08 7.70E+07±7.15E+07
Clostridium spp.
0 - - 1.00E+06 1.00E+06
24 - 2.00E+04 2.00E+04 2.00E+04±0.00E+00
48 1.00E+03 2.00E+05 3.00E+05 1.67E+05±8.79E+04
penicillin G to ponies
Time (h) Donkey 14 Donkey 15 Donkey 16 mean±SEM
coliforms
0
24
48
2.00E+04 
1.00E+06 
1.00E+08
1.00E+06
5.00E+05
2.90E+05
1.00E+04
1.00E+05
1.00E+05
3.43E+05±3.28E+05
5.33E+05±2.60E+05
3.35E+07±3.33E+07
streptococci
0
24
48
2.00E+03
9.00E+05
9.00E+05
2.00E+05
3.00E+04
1.00E+04
3.00E+03
2.30E+04
1.00E+05
6.83E+04±6.58E+04 
3.18E+05±2.91E+05 
3.37E+05±2.83E+05
lacto jacilli
0
24
48
4.00E+05
3.00E+04
1.00E+06
5.00E+04
6.00E+04
1.00E+05
2.00E+04
2.00E+04
4.00E+05
1.57E+05± 1.22E+05 
3.67E+04±1.20E+04 
5.00E+05±2.65E+05
Bacteroides spp.
0
24
48
3.00E+05
3.00E+06
1.50E+08
1.60E+05
2.70E+06
1.20E+07
3.20E+07
9.00E+05
1.00E+08
1,08E+07± 1.06E+07 
2.20E+06±6.56E+05 
8.73E+07±4.03E+07
Clostridium spp.
0
24
48 1.20E+08
2.00E+04
1.00E+06 1.00E+05
2.00E+04
4.04E+07±3.98E+07
Table A9. Counts of viable bacteria per g faeces following intravenous administration of
penicillin G to donkeys
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Time (h) L A P IB B IV V Total
0 3.0 0.0 0.0 0.0 68.2 0.0 0.0 68.2
24 0.0 2.2 0.0 0.0 40.1 0.0 0.0 42.3
48 0.0 0.0 0.0 0.0 43.4 0.0 0.0 43.4
Table A 10. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to horse 3
Time (h) L A P IB B IV V Total
0 1.9 1.7 12.3 0.0 50.2 0.0 0.0 64.2
24 0.0 0.0 2.4 0.0 0.0 0.0 0.0 2.4
48 0.0 0.0 2.7 0.0 0.0 0.0 0.0 2.7
of penicillin G to horse 4
Time (h) L A P IB B IV V Total
0 0.0 0.0 9.9 0.0 59.4 0.0 0.0 69.3
24 0.0 1.4 4.0 0.0 48.1 0.0 0.0 53.5
48 2.4 2.9 6.5 0.0 55.0 0.0 0.0 64.4
Table A 12. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to horse 5
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.5 0.0 1.9 0.0 13.0 0.0 0.0 14.9
48 0.0 0.0 0.0 0.0 11.8 0.0 0.0 11.8
of penicillin G to pony 7
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 31.8 0.0 0.0 31.8
24 0.0 0.0 0.0 0.0 17.0 0.0 0.0 17.0
48 0.0 0.0 6.9 0.0 45.7 0.0 0.0 52.6
Table A 14. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to pony 8
Time (h) L A P IB B IV V Total
0 4.5 3.5 14.7 0.0 90.0 0.0 0.0 108.2
24 2.9 3.5 4.9 0.0 55.6 0.0 0.0 64.0
48 3.7 11.2 8.4 0.0 0.0 0.0 0.0 19.6
Table A 15. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to pony 10
Time (h) L A P IB B IV V Total
0 3.7 6.3 17.1 0.0 0.0 0.0 0.0 23.4
24 2.5 5.2 9.9 0.0 0.0 0.0 0.0 15.1
48 3.1 56.6 14.0 0.0 46.4 0.0 0.0 117.0
Table A 16. SCFA concentrations (mmol/kg) in faeces following intravenous administration
of penicillin G to donkey 14
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Time (h) L A P IB B IV V Total
0 2.5 1.9 8.2 0.0 41.2 0.0 0.0 51.3
24 6.2 6.5 9.4 0.0 33.7 0.0 0.0 49.6
48 2.4 2.5 5.9 0.0 42.5 0.0 0.0 50.9
Table A 17. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to donkey 15
Time (h) L A P IB B IV V Total
0 1.8 5.2 9.5 0.0 56.1 0.0 0.0 70.8
24 1.4 4.5 19.7 0.0 88.0 0.0 0.0 112.2
48 2.8 8.0 7.7 0.0 43.0 0.0 0.0 58.7
Table A 18. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to donkey 16
Horses Ponies Donkeys
Time (h) L Total L Total L Total
0 1.610.9 67.211.5 1.511.5 46.7132.1 2.710.6 48.5113.8
24 0.010.0 32.7115.5 1.110.9 32.0116.0 3.411.5 59.0128.4
48 0.810.8 36.8118.1 1.211.2 28.0112.5 2.810.2 75.5120.9
Table A 19. SCFA concentrations (mmol/kg) (meaniSEM) in faeces following intravenous 
administration of penicillin G to horses, ponies and donkeys
Time (h) Horse 3 Horse 4 Horse 5 meaniSEM
0 21.04 21.59 19.98 20.8710.47
24 20.97 15.44 18.70 18.3711.60
48 22.34 21.97 20.01 21.4410.72
G to horses
Time (h) Pony 7 Pony 8 Pony 10 meaniSEM
0 18.83 17.77 21.19 19.2611.01
24 17.20 17.80 23.13 19.3811.88
48 15.86 14.98 19.92 16.9211.52
Table A21. Faecal dry matter content (%) following intravenous administration of penicillin 
G to ponies
Time (h) Donkey 14 Donkey 15 Donkey 16 meaniSEM
0 17.04 20.03 20.02 19.0311.00
24 24.67 30.46 23.71 26.2812.11
48 23.61 34.58 23.26 27.1513.72
Table A22. Faecal dry matter content (%) following intravenous administration of penicillin
G to donkeys
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Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.033 18.66 56.66 53.82 23.36
0.083 12.95 24.31 38.71 16.45
0.25 11.91 16.39 21.98 10.99
0.5 9.77 9.71 11.97 10.21
0.75 9.18 7.23 7.43 8.27
1 8.37 6.23 4.26 6.60
1.5 7.56 3.43 2.06 4.01
2 6.35 2.20 1.19 3.06
4 1.71 0.24 0.14 0.66
6 0.41 0.03 0.02 0.24
8 0.12 0.00 0.00 0.07
12 0.00 0.00 0.00 0.00
Table A23. Plasma concentrations (}ig/ml) of penicillin G following intravenous 
administration to ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.00 0.00 0.00 0.00
0.5 0.00 0.60 0.00 0.00
0.75 0.00 0.51 0.00 0.00
1 0.00 0.43 0.00 0.00
1.5 0.00 0.27 0.00 0.00
2 0.00 0.16 0.00 0.00
4 0.00 0.00 0.00 0.00
Table A24. Caecal liquor concentrations (jig/ml) of penicillin G fol 
administration to ponies
owing intravenous
Time (h) | 11 12 III 112
coliform s
0
24
48
7.00E+05
5.10E+05
1.00E+04
1.00E+08
3.00E+05
1.00E+04
2.00E+04
4.00E+05
2.00E+05
1.00E+05
1.00E+03
1.00E+04
streptococci
0 4.00E+05 1.00E+07 1.00E+05 1.00E+05
24 3.00E+07 4.00E+06 1.00E+08 1.00E+07
48 1.00E+06 3.00E+05 5.00E+04 2.00E+06
lactobacil l
0 1.00E+03 1.20E+06 1.00E+04 4.10E+05
24 1.00E+07 1.00E+06 1.00E+07 3.00E+06
48 1.00E+05 1.00E+05 3.00E+04 1.00E+07
Bacteroides spp.
0 1.10E+11 1.80E+11 2.10E+08 3.90E+11
24 3.10E+10 2.00E+10 4.10E+10 2.10E+10
48 7.00E+08 1.40E+09 1.30E+11 1.10E+11
Clostridium spp.
0 4.00E+06 1.00E+06 - 4.00E+04
24 3.00E+04 4.00E+06 1.00E+05 1.00E+03
48 1.00E+05 1.00E+05 - 1.10E+05
Table A25. Counts of viable bacteria per m caecal liquor following intravenous
administration of penicillin G to ponies
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Time (h) 11 12 III 112
0 7.2 7.1 7.2 6.7
0.25 7.4 7.0 7.1 6.7
0.5 7.2 6.9 7.2 6.8
0.75 7.2 6.7 7.2 6.7
1 7.1 6.7 7.1 6.8
1.5 7.0 6.9 7.2 6.8
2 7.1 7.2 7.2 6.7
4 6.8 6.7 7.1 6.7
6 7.0 7.0 7.0 7.0
8 6.9 6.7 7.0 6.7
12 6.9 6.8 6.9 6.8
24 6.8 6.9 6.8 6.9
48 7.0 6.9 6.8 7.0
Table A26. Caecal liquor pH following intravenous administration of penicillin G to ponies
Time (h) L A P IB B IV V Total
0 2.1 11.4 3.0 0.3 9.5 0.8 0.0 25.0
0.25 4.6 16.8 4.5 0.6 10.1 0.6 0.0 32.6
0.5 10.0 15.1 5.1 0.0 7.6 0.5 0.0 28.3
0.75 10.1 20.7 4.6 0.0 11.2 0.7 0.0 37.2
1 7.1 19.5 4.4 0.0 8.3 0.5 0.0 32.7
1.5 1.3 24.2 6.0 0.0 14.4 0.0 0.0 44.6
2 1.5 18.5 5.4 0.0 16.5 0.0 0.0 40.4
4 4.2 25.7 8.3 0.0 29.5 0.0 0.0 63.5
6 3.3 25.7 9.3 0.0 39.0 0.0 0.0 74.0
8 2.2 17.4 7.7 0.0 15.8 0.0 0.0 40.9
12 1.1 34.8 13.0 0.0 26.9 0.0 0.0 74.7
24 2.1 33.4 10.8 0.0 23.9 0.0 0.0 68.1
48 0.0 31.7 9.5 0.0 18.8 0.0 0.0 60.0
administration of penicillin G to pony II
in caeca liquor following intravenous
Time (h) A P B P+B
0 45.6 12.0 38.0 50.0
0.25 51.5 13.8 31.0 44.8
0.5 53.4 18.0 26.9 44.9
0.75 55.6 12.4 30.1 42.5
1 59.6 13.5 25.4 38.8
1.5 54.3 13.5 32.3 45.7
2 45.8 13.4 40.8 54.2
4 40.5 13.1 46.5 59.5
6 34.7 12.6 52.7 65.3
8 42.5 18.8 38.6 57.5
12 46.6 17.4 36.0 53.4
24 49.0 15.9 35.1 51.0
48 52.8 15.8 31.3 47.2
Table A27b. VFA concentrations (%) in caecal liquor following intravenous administration
of penicillin G to pony II
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Time (h) L A P IB B IV V Total
0 0.7 23.6 7.4 0.0 8.3 7.5 0.0 46.8
0.25 4.0 18.0 6.0 0.0 4.2 0.0 0.0 28.2
0.5 6.2 20.1 6.6 0.0 2.9 0.0 0.0 29.6
0.75 1.6 23.9 7.8 0.0 5.4 0.0 0.0 37.1
1 1.9 24.5 8.0 0.0 6.5 0.0 0.0 39.0
1.5 16.2 16.3 14.1 0.0 3.0 0.0 0.0 33.4
2 17.1 17.1 15.4 0.0 1.8 0.0 0.0 34.3
4 47.4 15.7 21.7 0.0 0.0 0.0 0.0 37.4
6 47.0 17.8 27.4 0.0 13.1 0.0 0.0 58.3
8 59.5 25.2 33.1 0.0 10.0 0.0 0.0 68.3
12 13.8 41.2 16.6 0.0 16.7 0.0 0.0 74.5
24 0.0 24.8 10.2 0.0 11.0 0.0 0.0 46.0
48 11.7 20.2 5.9 0.0 1.1 0.0 0.0 27.2
administration of penicillin G to pony 12
in caeca liquor following intravenous
Time (h) A P B P+B
0 50.4 15.8 17.7 33.5
0.25 63.8 21.3 14.9 36.2
0.5 67.9 22.3 9.8 32.1
0.75 64.4 21.0 14.6 35.6
1 62.8 20.5 16.7 37.2
1.5 48.8 42.2 9.0 51.2
2 49.9 44.9 5.2 50.1
4 42.0 58.0 0.0 58.0
6 30.5 47.0 22.5 69.5
8 36.9 48.5 14.6 63.1
12 55.3 22.3 22.4 44.7
24 53.9 22.2 23.9 46.1
48 74.3 21.7 4.0 25.7
Table A28b. VFA concentrations (%) in caecal liquor following intravenous administration 
of penicillin G to pony 12
Time (h) L A P IB B IV V Total
0 0.0 45.0 15.7 0.7 17.9 0.0 0.0 79.3
0.25 1.8 43.0 12.5 0.5 12.2 2.1 0.0 70.3
0.5 0.0 31.2 9.6 0.6 6.1 2.3 0.0 49.8
0.75 0.0 20.7 6.8 0.0 4.7 2.2 0.0 34.4
1 0.0 19.7 6.5 1.3 4.0 1.4 0.0 32.9
1.5 0.0 25.6 8.5 0.7 9.1 1.8 0.0 45.7
2 1.3 25.5 7.7 0.0 5.5 1.8 0.0 40.5
4 0.0 30.2 8.7 0.6 12.1 2.4 0.0 54.0
6 0.0 33.6 10.8 0.0 14.6 1.4 0.0 60.4
8 0.0 36.2 12.0 0.0 12.4 2.1 0.0 62.7
12 5.0 37.5 15.2 0.0 17.6 1.6 0.0 71.9
24 0.0 46.4 17.8 0.0 24.0 2.0 0.0 90.2
48 1.6 27.2 8.1 0.2 18.4 1.6 0.0 55.5
administration of penicillin G to pony III
in caeca liquor following intravenous
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Time (h) A P B P+B
0 56.7 19.8 22.6 42.4
0.25 61.2 17.8 17.4 35.1
0.5 62.7 19.3 12.2 31.5
0.75 60.2 19.8 13.7 33.4
1 59.9 19.8 12.2 31.9
1.5 56.0 18.6 19.9 38.5
2 63.0 19.0 13.6 32.6
4 55.9 16.1 22.4 38.5
6 55.6 17.9 24.2 42.1
8 57.7 19.1 19.8 38.9
12 52.2 21.1 24.5 45.6
24 51.4 19.7 26.6 46.3
48 49.0 14.6 33.2 47.7
Table A29b. VFA concentrations (%) in caecal liquor following intravenous administration 
of penicillin G to pony III
Time (h) L A P IB B IV V Total
0 0.0 40.5 11.7 1.3 7.8 0.0 0.0 61.3
0.25 0.0 32.6 13.0 0.0 7.2 0.0 0.0 52.8
0.5 0.0 34.5 13.8 0.0 7.2 1.9 0.0 57.4
0.75 0.0 31.5 10.8 0.0 6.9 0.0 0.0 49.2
1 0.0 34.5 10.0 0.0 10.5 0.0 0.0 55.0
1.5 0.0 38.4 13.3 2.9 8.7 0.0 0.0 63.3
2 0.6 25.6 8.8 1.2 6.4 2.7 0.0 44.7
4 1.7 40.4 13.6 0.0 13.0 0.0 0.0 67.0
6 0.0 36.5 12.3 0.0 14.6 0.0 0.0 63.4
8 1.4 44.0 15.8 0.0 14.6 2.5 0.0 76.9
12 0.0 42.3 16.7 0.9 6.1 6.3 0.0 72.3
24 0.0 40.4 17.6 0.0 9.4 0.0 0.0 67.4
48 2.1 32.2 10.9 0.0 13.6 0.0 0.0 56.7
Table A30a. SCFA concentrations (mmol/1) in caecal liquor following intravenous 
administration of penicillin G to pony 112
Time (h) A P B P+B
0 66.1 19.1 12.7 31.8
0.25 61.7 24.6 13.6 38.3
0.5 60.1 24.0 12.5 36.6
0.75 64.0 22.0 14.0 36.0
1 62.7 18.2 19.1 37.3
1.5 60.7 21.0 13.7 34.8
2 57.3 19.7 14.3 34.0
4 60.3 20.3 19.4 39.7
6 57.6 19.4 23.0 42.4
8 57.2 20.5 19.0 39.5
12 58.5 23.1 8.4 31.5
24 59.9 26.1 13.9 40.1
48 56.8 19.2 24.0 43.2
Table A30b. VFA concentrations (%) in caecal liquor following intravenous administration
of penicillin G to pony 112
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Time (h) L A P IB B IV V Total
0 0.0 0.0 3.2 0.0 28.0 0.0 0.0 31.2
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 1.0 6.5 3.1 0.0 10.6
of penicillin G to pony II
Time (h) L A p IB B IV V Total
0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 5.4
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table A32. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to pony 12
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 15.7 0.0 0.0 15.7
24 0.0 1.6 0.0 0.0 0.0 0.0 0.0 1.6
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
of penicillin G to pony III
Time (h) L A p IB B IV V Total
0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 4.8
24 0.0 0.0 11.5 0.0 5.1 0.0 0.0 16.6
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table A34. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of penicillin G to pony 112
Time (h) 11 12 III 112
0 23.38 20.25 22.19 20.49
24 22.38 22.00 22.04 24.11
48 23.07 25.55 23.58 24.78
Table A35. Faecal dry matter content (%) following intravenous administration of penicillin 
G to ponies
II 12
Time (h) 0 24 48 0 24 48
urea (mmol/1) 5.1 4.9 4.8 4.3 2.9 4.0
sodium (mmol/1) 139 139 139 139 134 134
potassium (mmol/1) 2.7 3.6 2.5 2.9 4.0 3.7
chloride (mmol/1) 93 94 101 99 97 96
calcium (mmol/1) 3.00 2.91 3.21 3.01 3.22 3.05
magnesium (mmol/1) 0.83 0.64 0.74 0.71 0.68 0.82
phosphate (mmol/1) 0.80 0.80 0.74 1.01 0.73 0.88
creatinine (jimol/1) 128 107 120 126 111 134
bilirubin (fimol/1) 17 11 12 14 11 13
SAP (U/l) 488 451 473 441 360 419
AST (U/l) 285 264 279 289 264 304
GGT (U/l) 35 25 27 24 23 26
total protein (g/1) 75 70 79 78 72 80
albumin (g/1) 31 29 29 30 28 32
globulin (g/1) 44 41 46 48 46 48
Table A36. Plasma biochemistry following intravenous administration of penicillin G to
pony I
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III 112
Time (h) 6 24 48 0 24 48
urea (mmol/1) 3.5 3.4 4.9 2.9 1.9 2.6
sodium (mmol/1) 141 141 139 140 137 138
potassium (mmol/1) 2.8 3.4 3.0 3.0 4.1 2.4
chloride (mmol/1) 96 96 102 9$ 100 99
calcium (mmol/1) 2.87 2.79 3.27 3.00 3.17 3.37
magnesium (mmol/1) 0.86 0.64 0.95 0.70 0.66 0.86
phosphate (mmol/1) 0.86 1.00 0.83 i . io 1.16 1.19
creatinine (jimol/1) 108 98 121 94 96 104
bilirubin (|imol/l) 13 10 14 4 8 8
SAP (U/l) 501 441 506 420 359 383
AST (U/l) 318 288 328 342 325 334
GGT (U/l) 41 32 36 3l 32 33
total protein (g/1) 73 66 77 76 74 76
albumin (g/1) 35 32 35 32 34 34
globulin (g/1) 38 34 42 44 40 42
pony II
II 12
Time (h) 0 24 48 0 24 48
W CC(xl0y/l) 6.8 7.9 7.4 6.8 7.0 7.1
RCC (xl0l^/l) 6.83 6.02 5.86 6.15 5.87 6.34
Hb (g/dl) 11.9 10.2 10.2 10.6 10.4 10.4
Hct (1/1) 0.330 0.288 0.276 0.291 0.279 0.300
MCV (fl) 48 48 47 47 48 47
MCH (pg) 17.4 16.9 17.4 17.2 17.7 16.4
MCHC (g/dl) 36.0 35.4 36.9 36.4 37.2 34.6
PLTS (10^/1) 82 108 105 144 110 139
MPV (fl) 6.2 6.1 6.2 6.3 6.3 6.2
PCT (%) 0.050 0.065 0.065 0.090 14.2 0.086
PDW 17.7 16.3 16.1 14.2 44.9 14.5
Neu (%) 50.0 38.0 45.0 46.0 52.5 53.0
Lym (%) 48.5 56.0 51.0 49.0 1.0 41.6
Mon (%) 1.5 3.0 3.0 4.0 1.0 3.9
Eos (%) 0.0 2.5 0.5 1.0 0.0 1.5
Bas (%) 0.0 0.5 0.5 0.0 0.6 0.0
Table A38. Haematology parameters following intravenous administration of penicillin G to 
pony I
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III 112
Time (h) 0 24 48 0 24 48
WCC (x 10^/1) 7.8 8.0 8.5 6.5 6.9 7.1
RCC (xlOl^/l) 7.82 7.11 1A6 6.97 6.50 6.34
Hb (g/dl) 12.2 11.0 12.0 11.3 11.2 10.0
Hct (1/1) 0.348 0.312 0.324 0.297 0.279 0.273
MCV (fl) 45 44 43 43 43 43
MCH(pg) 15.6 15.4 16.0 16.2 17.2 15.7
MCHC (g/dl) 35.0 35.2 37.0 38.0 40.1 36.6
PLTS (109/1) 86 96 99 103 91 121
MPV (fl) 6.6 6.3 6.5 6.5 6.7 6.6
PCT (%) 0.056 0.060 0.064 0.066 0.060 0.079
PDW 15.1 17.4 13.8 13.8 17.9 15.1
Neu (%) 53.0 45.0 65.0 47.0 44.1 57.0
Lym (%) 47.0 52.0 31.0 49.9 51.5 39.0
Mon (%) 0.0 3.0 4.0 2.0 3.0 2.0
Eos (%) 0.0 0.0 0.0 1.1 1.0 2.0
Bas (%) 0.0 0.0 0.0 0.0 0.4 0.0
Table A39. Haematology parameters following intravenous administration of penicillin G to 
pony II
Time (h) 11 12 III 112
0
0.25
0.5
0.75
1
1.5
0.00
0.18
0.19
0.09
0.04
0.00
0.00
0.00
0.09
0.04
0.02
0.00
0.00
0.08
0.14
0.09
0.04
0.00
0.00
0.09
0.16
0.10
0.06
0.00
Table A40. Plasma concentrations (pg/ml) of penicillin G following oral administration to 
ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.00 0.00 0.00 0.00
0.5 39.66 0.00 0.00 0.00
0.75 139.53 60.38 0.00 0.00
1 150.45 89.65 0.00 0.90
1.5 157.12 89.28 0.00 0.88
2 146.11 89.73 0.00 1.18
4 96.06 1.96 98.65 2.17
6 42.49 1.96 118.98 4.96
8 35.58 1.39 89.16 0.92
12 0.00 1.65 0.00 0.61
24 0.00 0.00 0.00 0.00
Table A41. Caecal liquor concentrations (fig/ml) of penicillin G following oral 
administration to ponies
Table A42. Faeca
ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
24 0.00 0.65 0.00 0.00
48 0.00 0.00 0.00 0.00
concentrations (}ig/g) of penicillin G fo lowing oral administration to
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Time (h) 11 12 n i 112
coliform s
0 1.00E+07 1.00E+06 1.00E+06 2.00E+04
24 2.00E+09 1.00E+07 2.00E+09 1.00E+10
48 2.00E+08 2.00E+07 1.00E+10 3.00E+09
72 1.00E+10 1.00E+06 1.00E+10 5.20E+10
96 1.00E+06 1.00E+06 1.00E+06 1.00E+08
168 1.00E+06 1.00E+06 2.00E+04 1.00E+06
streptococci
0 2.00E+06 3.00E+05 3.00E+06 3.00E+05
24 1.00E+08 2.00E+08 5.00E+07 3.00E+06
48 1.00E+07 1.00E+06 3.00E+10 1.00E+07
72 1.00E+06 5.00E+04 5.00E+10 1.00E+06
96 1.00E+06 5.00E+04 5.00E+06 3.00E+04
168 3.00E+05 4.00E+05 3.00E+05 5.00E+04
lactobacil i
0 1.00E+06 3.00E+05 7.00E+05 2.00E+05
24 2.00E+08 2.00E+06 6.00E+07 1.00E+06
48 1.00E+07 2.10E+07 1.00E+09 3.00E+06
72 3.00E+05 - 1.00E+07 -
96 1.00E+06 2.10E+05 1.00E+05 1.00E+07
168 3.00E+05 1.00E+06 2.00E+05 2.00E+04
Bacteroides spp.
0 1.40E+09 1.20E+09 2.40E+11 2.10E+10
24 7.00E+10 1.90E+11 4.00E+10 1.60E+10
48 1.30E+10 - 2.00E+10 5.20E+09
72 1.20E+09 1.10E+08 1.70E+10 1.30E+10
96 6.10E+09 1.20E+10 2.10E+10 8.60E+09
168 1.20E+09 6.60E+08 2.10E+10 1.20E+11
Clostridium spp.
0 2.10E+05 1.00E+06 1.00E+05 5.00E+05
24 2.20E+08 9.00E+08 2.30E+06 1.00E+05
48 4.80E+07 6.10E+06 2.10E+08 2.00E+06
72 5.00E+05 1.00E+06 1.00E+08 5.30E+08
96 5.00E+04 1.20E+06 5.00E+04 2.00E+07
168 l.OOE+06 5.00E+05 5.00E+05 4.00E+04
Table A43. Counts of viable bacteria per ml caecal liquor following oral administration of
penicillin G to ponies
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Time (h) 11 12 III 112
0 7.1 7.1 7.0 7.1
0.25 7.1 7.2 7.1 6.9
0.5 7.1 7.1 7.0 7.0
0.75 7.0 7.3 7.1 6.9
1 6.9 7.3 7.2 7.0
1.5 7.1 7.3 7.0 7.1
2 7.3 7.2 7.1 7.0
4 7.7 7.5 7.3 7.2
6 8.3 7.6 7.5 7.3
8 7.9 7.2 7.1 7.2
12 7.4 7.0 6.9 7.1
24 7.5 7.2 7.1 7.0
28 7.0 7.0 7.2 7.1
32 7.0 7.0 7.1 7.0
48 7.1 7.1 6.9 6.8
72 7.1 7.3 6.9 7.2
96 6.8 7.0 6.9 6.9
168 7.1 6.9 7.1 7.0
Table A44. Caecal liquor pH following oral administration of penicillin G to ponies
Time (h) L A P IB B IV V Total
0 0.0 19.6 6.6 0.0 4.3 0.0 0.0 30.5
0.25 0.0 19.8 6.5 0.0 4.1 0.0 0.0 30.4
0.5 0.0 20.2 9.0 0.0 6.7 1.4 1.6 38.9
0.75 0.0 24.9 8.7 0.0 10.0 0.0 0.0 43.6
1 0.0 24.7 7.7 0.0 10.2 0.0 0.0 42.6
1.5 0.0 24.9 5.0 0.0 21.6 0.0 0.0 51.5
2 0.0 17.6 7.0 0.0 23.8 0.0 0.0 48.4
4 18.7 14.5 36.4 0.0 14.1 0.0 0.0 65.0
6 22.3 10.9 56.6 0.0 0.0 0.0 0.0 67.5
8 38.7 6.7 46.6 0.0 0.0 0.0 0.0 53.3
12 13.1 8.7 14.7 0.0 0.0 0.0 0.0 23.4
24 2.7 10.2 2.8 0.0 4.5 0.0 0.0 17.5
28 10.1 24.4 4.4 0.0 9.5 0.0 0.0 38.3
32 10.6 28.0 6.9 0.0 6.1 1.6 0.0 42.6
48 0.0 21.7 7.1 0.0 9.4 1.6 0.0 39.8
72 0.0 27.5 8.5 0.0 6.9 2.1 0.0 45.0
96 1.0 30.8 10.2 0.0 5.0 0.0 0.0 46.0
168 0.0 26.1 7.2 1.1 3.8 1.6 0.0 39.8
penicillin G to pony II
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 64.3 21.6 14.1 35.7
0.25 65.1 21.4 13.5 34.9
0.5 51.9 23.1 17.2 40.4
0.75 57.1 20.0 22.9 42.9
1 58.0 18.1 23.9 42.0
1.5 48.3 9.7 41.9 51.7
2 36.4 14.5 49.2 63.6
4 22.3 56.0 21.7 77.7
6 16.1 83.9 0.0 83.9
8 12.6 87.4 0.0 87.4
12 37.2 62.8 0.0 62.8
24 58.3 16.0 25.7 41.7
28 63.7 11.5 24.8 36.3
32 65.7 16.2 14.3 30.5
48 54.5 17.8 23.6 41.5
72 61.1 18.9 15.3 34.2
96 67.0 22.2 10.9 33.0
168 65.6 18.1 9.5 27.6
Table A45b. VFA concentrations (%) in caecal liquor following oral administration of 
penicillin G to pony II
Time (h) L A P IB B IV V Total
0 0.0 26.1 7.2 1.1 3.8 1.6 0.0 39.8
0.25 0.0 16.3 3.7 0.0 6.2 0.0 0.0 26.2
0.5 0.0 15.3 3.6 0.0 4.8 0.7 0.0 24.4
0.75 0.0 12.5 3.1 0.0 6.9 0.0 0.0 22.5
1 0.0 17.1 3.6 0.0 7.5 1.4 0.0 29.6
1.5 0.0 15.1 3.2 0.0 11.3 0.0 0.0 29.6
2 0.0 12.5 3.3 0.0 11.6 0.0 0.0 27.4
4 10.1 6.2 44.4 0.0 13.4 0.0 0.0 64.0
6 0.0 4.3 55.0 0.0 0.0 3.0 0.0 62.3
8 9.4 4.3 60.7 0.0 0.0 0.0 0.0 65.0
12 8.9 12.2 0.0 0.0 3.5 1.9 0.0 17.6
24 5.1 25.1 4.5 0.0 11.1 0.0 0.0 40.7
28 3.1 12.9 1.8 0.0 2.5 0.0 0.0 17.2
32 0.0 25.2 7.1 0.0 7.3 0.0 0.0 39.6
48 0.0 24.5 6.8 0.0 9.5 0.0 1.7 42.5
72 2.8 12.6 4.1 0.0 2.0 1.2 0.0 19.9
96 1.9 24.3 8.9 0.0 12.6 0.0 0.0 45.8
168 1.5 37.5 13.1 0.5 9.3 1.9 0.0 62.3
penicillin G to pony 12
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 65.6 18.1 9.5 27.6
0.25 62.2 14.1 23.7 37.8
0.5 62.7 14.8 19.7 34.4
0.75 55.6 13.8 30.7 44.4
1 57.8 12.2 25.3 37.5
1.5 51.0 10.8 38.2 49.0
2 45.6 12.0 42.3 54.4
4 9.7 69.4 20.9 90.3
6 6.9 88.3 0.0 88.3
8 6.6 93.4 0.0 93.4
12 69.3 0.0 19.9 19.9
24 61.7 11.1 27.3 38.3
28 75.0 10.5 14.5 25.0
32 63.6 17.9 18.4 36.4
48 57.6 16.0 22.4 38.4
72 63.3 20.6 10.1 30.7
96 53.1 19.4 27.5 46.9
168 60.2 21.0 14.9 36.0
Table A46b. VFA concentrations (%) in caecal liquor following oral administration of 
penicillin G to pony 12
Time (h) L A P IB B IV V Total
0 0.0 35.5 10.2 0.0 7.4 2.2 0.0 55.3
0.25 0.0 29.9 9.4 0.0 5.8 2.4 0.0 47.5
0.5 0.0 30.2 8.5 0.0 6.8 2.6 0.0 48.1
0.75 0.0 26.6 7.6 1.0 7.4 0.0 0.0 42.6
1 0.0 29.0 10.2 1.5 8.4 2.1 0.0 51.2
1.5 0.0 25.9 8.6 0.0 5.7 1.7 0.0 41.9
2 0.0 28.9 10.1 1.1 7.7 2.2 0.0 50.0
4 0.0 24.6 4.6 0.6 7.8 0.0 0.0 37.6
6 0.0 26.6 6.6 0.7 7.5 0.0 0.0 41.4
8 2.4 24.8 4.9 0.7 1.8 1.6 1.1 34.9
12 11.7 23.3 8.5 0.8 0.0 0.0 0.0 32.6
24 9.7 31.2 0.0 0.0 4.8 0.0 0.0 36.0
28 6.2 31.5 4.3 0.0 4.4 3.0 2.2 45.4
32 3.5 23.7 5.9 1.9 3.0 1.2 9.4 45.1
48 8.1 46.2 10.5 0.0 15.9 0.0 0.0 72.6
72 0.0 41.7 12.0 0.0 8.1 2.1 0.0 63.9
96 0.0 43.0 8.8 0.0 9.2 0.0 0.0 61.0
168 0.0 40.7 13.3 0.0 7.3 0.0 0.0 61.3
penicillin G to pony III
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 64.2 18.4 13.4 31.8
0.25 62.9 19.8 12.2 32.0
0.5 62.8 17.7 14.1 31.8
0.75 62.4 17.8 17.4 35.2
1 56.6 19.9 16.4 36.3
1.5 61.8 20.5 13.6 34.1
2 57.8 20.2 15.4 35.6
4 65.4 12.2 20.7 33.0
6 64.3 15.9 18.1 34.1
8 71.1 14.0 5.2 19.2
12 71.5 26.1 0.0 26.1
24 86.7 0.0 13.3 13.3
28 69.4 9.5 9.7 19.2
32 52.5 13.1 6.7 19.7
48 63.6 14.5 21.9 36.4
72 65.3 18.8 12.7 31.5
96 70.5 14.4 15.1 29.5
168 66.4 21.7 11.9 33.6
Table A47b. VFA concentrations (%) in caecal liquor following oral administration of 
penicillin G to pony III
Time (h) L A P IB B IV V Total
0 0.0 40.7 13.3 0.0 7.3 0.0 0.0 61.5
0.25 0.0 26.9 9.7 0.0 5.2 0.0 0.0 41.8
0.5 0.0 37.5 12.3 0.0 7.7 0.0 0.0 57.5
0.75 0.0 38.2 11.8 0.0 7.4 0.0 0.0 57.4
1 0.0 39.7 12.9 0.0 7.8 0.0 0.0 60.4
1.5 0.0 41.1 12.0 0.0 4.8 1.4 0.0 59.3
2 0.0 43.9 14.8 0.0 7.4 0.0 0.0 66.1
4 0.0 19.4 6.2 0.0 4.0 0.0 0.0 29.6
6 0.0 26.6 7.6 0.9 6.9 0.0 3.8 45.8
8 0.0 32.0 6.3 0.0 4.1 0.0 0.0 42.4
12 7.9 30.9 0.0 0.0 5.7 0.0 0.0 36.6
24 7.9 27.3 7.3 0.0 5.3 1.8 0.0 41.7
28 6.2 26.7 10.0 0.0 0.0 0.0 0.0 36.7
32 6.3 29.0 13.2 0.0 7.8 3.0 0.0 53.0
48 0.0 44.9 13.6 0.0 10.4 0.0 0.0 68.9
72 3.4 35.3 15.1 0.0 4.0 2.0 0.0 56.4
96 1.7 41.2 15.7 0.5 7.2 2.5 0.0 67.1
168 0.0 48.1 14.2 2.0 8.2 0.0 0.0 72.5
penicillin G to pony 112
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 66.4 21.7 11.9 33.6
0.25 64.4 23.2 12.4 35.6
0.5 65.2 21.4 13.4 34.8
0.75 66.6 20.6 12.9 33.4
1 65.7 21.4 12.9 34.3
1.5 69.3 20.2 8.1 28.3
2 66.4 22.4 11.2 33.6
4 65.5 20.9 13.5 34.5
6 58.1 16.6 15.1 31.7
8 75.5 14.9 9.7 24.5
12 84.4 0.0 15.6 15.6
24 65.5 17.5 12.7 30.2
28 72.8 27.2 0.0 27.2
32 54.7 24.9 14.7 39.6
48 65.2 19.7 15.1 34.8
72 62.6 26.8 7.1 33.9
96 61.4 23.4 10.7 34.1
168 66.3 19.6 11.3 30.9
Table A48b. VFA concentrations (%) in caecal liquor following oral administration of 
penicillin G to pony H2
Time (h) L A P IB B IV V Total
0 6.2 7.9 3.0 0.0 0.0 0.0 0.0 10.9
24 0.0 0.0 12.4 0.0 12.0 0.0 0.0 12.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 6.5 5.0 0.0 0.0 0.0 0.0 0.0 5.0
96 0.0 0.0 0.0 0.0 18.5 0.0 0.0 18.5
168 0.0 0.0 0.0 0.0 18.5 0.0 0.0 18.5
penicillin G to pony II
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 18.5 0.0 0.0 18.5
24 0.0 13.5 3.7 0.0 3.2 0.0 0.0 20.4
48 0.0 14.9 5.8 0.0 6.4 0.0 0.0 27.1
72 0.0 0.0 15.4 0.0 0.0 0.0 0.0 15.4
96 0.0 0.0 2.8 0.0 0.0 0.0 0.0 2.8
168 0.0 0.0 2.8 0.0 2.5 0.0 0.0 5.3
penicillin G to pony 12
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 5.3
24 0.0 0.0 0.0 0.0 6.5 0.0 0.0 6.5
48 0.0 29.3 12.2 0.0 12.4 0.0 0.0 53.9
72 0.0 6.7 16.0 0.0 43.2 0.0 0.0 65.9
96 0.0 0.0 7.7 0.0 23.3 0.0 0.0 31.0
168 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
penicillin G to pony III
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Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 9.3 0.0 0.0 9.3
48 6.0 9.0 9.5 0.0 0.0 0.0 0.0 18.5
72 0.0 0.0 0.0 0.0 2.5 0.0 0.0 2.5
96 0.0 0.0 13.2 0.0 3.3 0.0 0.0 15.5
168 0.0 0.0 3.3 0.0 21.7 0.0 0.0 25.0
penicillin G to pony 112
Time (h) 11 12 III 112
0 23.55 19.29 24.89 22.14
24 24.32' 25.28 25.82 17.43
48 23.01 22.32 29.24 18.21
72 22.84 23.80 23.09 22.85
96 21.95 27.62 23.88 24.18
168 19.29 24.78 22.14 22.68
Table A53. Faecal dry matter content (%) following oral administration of penicillin G to 
ponies
Time (h) 0 24 48 168
urea (mmol/1) 4.5 7.1 5.3 4.1
sodium (mmol/1) 140 137 139 138
potassium (mmol/1) 2.8 2.4 2.8 3.3
chloride (mmol/1) 98 100 98 100
calcium (mmol/1) 3.01 3.09 2.84 2.84
magnesium (mmol/1) 0.58 0.61 0.53 0.56
phosphate (mmol/1) 0.64 0.53 0.56 1.09
creatinine (pmol/1) 137 137 126 98
bilirubin (p.mol/1) 13 26 18 13
SAP (U/l) 427 450 421 358
AST (U/l) 277 270 254 273
GGT (U/l) 24 27 26 27
total protein (g/1) 75 76 72 71
albumin (g/1) 30 29 28 31
globulin (g/1) 45 47 44 40
Table A54. Plasma biochemistry following oral administration of penicillin G to pony II
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Time (h) 0 24 48
urea (mmol/1) 4.1 7.3 6.5
sodium (mmol/1) 138 135 138
potassium (mmol/1) 3.3 3.4 2.9
chloride (mmol/1) 100 102 99
calcium (mmol/1) 2.84 2.95 2.90
magnesium (mmol/1) 0.56 0.55 0.68
phosphate (mmol/1) 1.09 0.85 0.88
creatinine (pmol/1) 98 124 117
bilirubin (fimol/1) 13 17 13
SAP (U/l) 358 428 354
AST (U/l) 273 252 226
GGT (U/l) 27 14 19
total protein (g/1) 71 78 71
albumin (g/1) 31 31 29
globulin (g/1) 40 47 42
Table A55. Plasma biochemistry following oral administration of penicillin G to pony 12
Time (h) 0 24 48 168
urea (mmol/1) 3.2 4.3 3.5 6.5
sodium (mmol/1) 141 138 139 136
potassium (mmol/1) 2.9 2.5 2.0 3.4
chloride (mmol/1) 100 101 99 98
calcium (mmol/1) 2.90 3.10 2.81 2.91
magnesium (mmol/1) 0.60 0.73 0.59 0.53
phosphate (mmol/1) 0.70 0.71 0.61 1.11
creatinine (|imol/l) 117 125 109 127
bilirubin (jimol/1) 17 30 25 14
SAP (U/l) 424 502 429 365
AST (U/l) 331 330 299 249
GGT (U/l) 34 37 29 26
total protein (g/1) 78 79 73 71
albumin (g/1) 34 34 32 29
globulin (g/1) 44 45 41 42
Table A56. Plasma biochemistry following oral administration of penicillin G to pony III
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Time (h) 0 24 48
urea (mmol/1) 6.5 5.3 3.9
sodium (mmol/1) 136 137 139
potassium (mmol/1) 3.4 2.5 2.9
chloride (mmol/1) 98 101 99
calcium (mmol/1) 2.91 2.85 3.26
magnesium (mmol/1) 0.53 0.53 0.67
phosphate (mmol/1) 1.11 1.02 1.06
creatinine (pmol/l) 127 96 97
bilirubin (p.mol/1) 14 16 10
SAP (U/l) 365 380 372
AST (U/l) 249 271 251
GGT (U/l) 26 23 36
total protein (g/1) 71 76 73
albumin (g/1) 29 32 31
globulin (g/1) 42 44 42
Table A57. Plasma biochemistry following oral administration of penicillin G to pony 112
Time (h) 0 24 48 168
WCC (x 109/1) 7.2 5.5 6.8 7.0
RCC (x 1012/1) 5.81 5.03 5.81 6.15
Hb (g/dl) 10.3 8.8 10.4 9.5
Hct (1/1) 0.276 0.243 0.276 0.264
MCV (fl) 48 48 48 43
MCH(pg) 17.7 17.4 17.9 15.4
MCHC (g/dl) 37.3 36.2 37.6 35.9
PLTS (109/1) 90 126 114 125
MPV (fl) 6.6 5.7 6.1 6.5
PCT (%) 0.059 0.071 0.069 0.081
PDW 15.1 15.7 16.3 16.9
Neu (%) 49.0 66.0 42.1 48.0
Lym (%) 45.0 32.0 53.5 47.0
Mon (%) 1.0 1.4 0.4 3.0
Eos (%) 4.0 0.6 2.5 2.0
Bas (%) 1.0 0.0 1.5 0.0
Table A58. Haematology parameters following oral administration of penicillin G to pony II
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Time (h) 0 24 48
WCC (xlOtyl) 7.0 6.8 6.1
RCC (xlOl^/1) 6.15 5.71 5.12
Hb (g/dl) 9.5 10.2 8.7
Hct (1/1) 0.264 0.273 0.246
MCV (fl) 43 48 48
MCH (pg) 15.4 17.8 16.9
MCHC (g/dl) 35.9 37.3 35.3
PLTS (109/1) 125 130 124
MPV (fl) 6.5 6.2 6.2
PCT (%) 0.081 0.080 0.076
PDW 16.9 14.5 16.1
Neu (%) 48.0 54.0 50.0
Lym (%) 47.0 42.0 50.0
Mon (%) 3.0 3.0 0.0
Eos (%) 2.0 0.0 0.0
Bas (%) 0.0 1.0 0.0
Table A59. Haematology parameters following oral administration of penicillin G to pony 12
Time (h) 0 24 48 168
WCC (x 10^/1) 7.6 6 .8 6.4 6.4
RCC (x l0 ^ /l) 6.69 6.91 7.07 5.68
Hb (g/dl) 11.8 11.0 11.8 10.1
Hct (1/1) 0.285 0.294 0.30() 0.267
MCV (fl) 43 43 42 47
MCH (pg) 16.7 15.9 15.8 17.7
MCHC (g/dl) 39.2 37.4 37.3 37.8
PLTS (109/1) 93 107 114 119
MPV (fl) 6.6 6.0 6.4 6.0
PCT (%) 0.061 0.064 0.072 0.071
PDW 15.1 16.6 17.1 16.6
Neu (%) 53.0 62.6 46.6 40.9
Lym (%) 39.0 35.0 50.9 57.0
Mon (%) 6.0 1.9 2.0 2.0
Eos (%) 2.0 0.0 0.5 0.0
Bas (%) 0.0 0.5 0.0 0.0
Table A60. Haematology parameters following oral administration of penicilin G to pony HI
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Time (h) 0 24 48
WCC (xlOtyl) 6.4 5.8 6.4
RCC (xlOlZ/1) 5.68 6.34 6.50
Hb (g/dl) 10.1 10.0 10.0
Hct (1/1) 0.267 0.270 0.279
MCV (fl) 47 43 43
MCH (pg) 17.7 15.7 15.3
MCHC (g/dl) 37.8 37.0 35.8
PLTS (10^/1) 119 127 129
MPV (fl) 6.0 6.6 6.3
PCT (%) 0.071 0.083 0.081
PDW 16.6 15.1 14.2
Neu (%) 40.9 56.0 49.1
Lym (%) 57.0 37.9 47.0
Mon (%) 2.0 5.0 0.9
Eos (%) 0.0 0.0 2.0
Bas (%) 0.0 1.0 0.9
Table A61. Haematology parameters following oral administration of penicillin G to pony
Cone. (M-g/ml) 1 I  “ 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.01 0.02 0.02 0.0110.00
1 0.59 0.34 0.71 0.63 0.57±0.08
5 5.97 6.70 4.99 4.79 5.61±0.44
10 11.75 9.11 8.81 11.81 10.37±0.82
20 22.70 15.07 22.11 18.26 19.54±1.78
40 27.65 29.85 33.36 39.57 32.61±2.60
80 56.61 61.07 48.28 56.01 55.49±2.66
vitro for 3 h
Cone. (|Lig/ml) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.00 0.00 0.00 0.00±0.00
1 0.00 0.03 0.00 0.00 0.0110.01
5 2.52 2.76 0.00 0.00 1.3210.76
10 6.00 6.53 0.00 0.00 3.1311.81
20 19.46 17.69 0.00 1.73 9.7215.14
40 25.74 29.42 0.17 0.31 13.9117.93
80 37.90 75.17 0.00 0.00 28.27118.01
Table A62b. Concentrations (|ig/ml) of penicillin G in caecal liquor following incubation in 
vitro for 24 h
Cone (|ig/ml) L A P IB B IV V Total
0 0.0 42.5 11.0 0.0 5.9 1.6 0.0 61.0
0.25 0.3 43.6 14.3 0.3 7.0 0.0 0.0 65.2
1 0.0 38.7 14.3 0.0 6.8 0.0 0.0 59.8
5 0.0 38.1 11.9 0.0 5.9 0.0 0.0 55.9
10 0.0 41.2 13.7 0.0 6.5 0.9 0.2 62.5
20 0.0 45.2 14.9 0.0 8.6 0.7 0.0 69.3
40 0.0 38.5 12.5 0.0 7.0 0.8 0.0 58.8
80 1.5 49.2 14.2 0.0 8.3 0.0 0.0 71.7
Table A63a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with penicillin G for 3 h (replicate 1)
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Cone (|ig/ml) L A P IB B IV V Total
0 0.0 45.0 13.1 0.0 4.8 0.2 0.0 63.1
0.25 0.0 47.8 14.7 0.0 6.7 0.8 0.8 70.8
1 0.0 43.4 11.2 0.0 4.5 2.4 0.0 61.5
5 0.2 43.9 11.8 0.0 4.6 0.7 1.0 62.1
10 0.0 50.8 12.6 0.0 4.5 2.6 0.0 70.6
20 0.0 47.7 13.6 0.0 5.7 0.2 0.6 67.7
40 0.0 18.4 5.5 0.0 2.9 0.6 0.6 28.0
80 0.0 50.7 16.0 0.0 4.8 0.0 0.0 71.5
Table A63b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 24 h (replicate 1)
Cone (jig/ml) L A P IB B IV V Total
0 0.0 50.5 13.4 0.0 4.0 0.9 0.6 69.4
0.25 0.0 46.6 12.0 0.0 4.8 0.0 0.0 63.4
1 0.0 44.8 11.7 0.0 6.0 1.0 0.6 64.1
5 0.0 49.1 13.0 0.0 5.7 0.0 0.0 67.9
10 0.0 46.6 12.5 0.0 6.5 0.0 0.0 65.7
20 0.0 53.7 12.2 0.0 4.6 1.8 0.0 72.2
40 0.0 50.9 12.8 0.0 5.9 0.3 0.0 69.8
80 0.0 55.2 17.5 0.0 4.3 0.0 0.0 77.0
with penicillin G for 3 h (replicate 2)
Cone (tig/ml) L A P IB B IV V Total
0 0.0 38.7 11.7 0.0 12.4 0.0 0.0 61.8
0.25 0.0 36.5 11.5 0.0 8.4 1.2 1.8 59.5
1 0.0 41.2 12.1 0.0 7.2 0.0 0.0 60.5
5 0.0 36.8 13.3 0.0 9.4 1.7 0.0 61.3
10 0.0 41.7 10.5 0.0 15.1 0.0 0.0 67.3
20 0.0 34.3 9.0 0.0 8.3 0.0 0.0 51.7
40 0.0 44.6 15.3 0.0 8.8 0.9 1.3 70.8
80 0.3 38.5 12.7 0.7 9.2 1.7 4.3 67.0
Table A64b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 24 h (replicate 2)
Cone (tig/ml) L A P IB B IV V Total
0 0.6 37.0 16.9 0.0 11.1 0.0 0.0 65.0
0.25 1.2 29.8 14.4 0.0 13.0 0.0 0.0 57.3
1 0.4 30.3 19.4 0.0 19.0 0.0 0.0 68.6
5 2.1 34.1 17.4 1.7 8.4 1.6 0.0 63.3
10 1.5 31.4 13.1 0.6 4.1 0.0 0.0 49.2
20 0.7 30.0 12.9 0.0 2.9 0.0 0.0 45.8
40 1.1 28.9 12.0 0.5 2.9 0.9 0.0 45.1
80 0.3 27.8 12.3 0.3 6.0 0.0 0.0 46.5
Table A65a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 3 h (replicate 3)
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Cone (|ig/ml) L A P IB B IV V Total
0 0.7 29.8 11.5 1.0 5.3 0.8 0.0 48.4
0.25 1.1 14.9 6.4 1.2 4.0 1.2 1.1 28.8
1 0.1 18.5 6.5 0.2 4.6 0.0 0.0 29.8
5 1.2 35.1 13.4 1.2 10.2 0.8 0.0 60.7
10 0.0 35.1 14.9 0.0 12.8 0.0 0.0 62.8
20 1.4 36.6 16.2 1.2 16.3 2.1 0.0 72.4
40 0.0 31.6 10.8 0.5 15.3 0.0 0.0 58.1
80 2.5 31.3 15.7 2.2 19.5 3.5 0.0 72.2
Table A65b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 24 h (replicate 3)
Cone (|ig/ml) L A P IB B IV V Total
0 0.3 34.2 13.2 0.7 7.3 1.3 1.1 57.8
0.25 2.0 33.6 13.6 1.7 8.6 2.2 2.9 62.7
1 0.3 35.0 12.9 0.0 7.1 2.0 0.0 57.0
5 2.2 32.7 12.2 1.3 9.7 2.3 2.5 60.7
10 0.9 40.4 14.9 0.3 11.2 1.8 1.5 70.1
20 2.6 34.7 14.0 1.7 14.2 1.1 0.0 65.7
40 1.9 35.3 15.0 1.1 13.6 1.5 2.5 69.0
80 0.3 34.3 15.2 0.0 15.5 0.0 0.0 65.0
Table A66a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 3 h (replicate 4)
Cone. (|ig/ml) L A P IB B IV V Total
0 1.4 34.3 14.9 1.5 10.3 2.1 0.0 63.1
0.25 0.2 35.9 13.9 0.0 6.0 0.7 0.0 56.6
1 2.0 32.2 13.2 1.3 7.0 1.5 0.0 55.2
5 2.4 34.4 13.2 1.5 12.2 1.3 1.2 63.9
10 0.7 35.8 12.8 0.3 14.0 0.0 0.0 62.9
20 2.4 36.0 14.4 1.7 18.0 1.9 2.1 74.1
40 0.3 36.3 14.3 0.0 17.8 0.0 0.0 68.3
80 2.2 31.7 13.7 1.8 15.5 2.3 2.3 67.3
Table A66b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with penicillin G for 24 h (replicate 4)
3 h 24 h
Cone (M-g/ml) L Total L Total
0 0.4±0.2 63.312.5 0.510.3 59.413.7
0.25 0.9±0.5 62.211.7 0.310.3 53.918.9
1 0.210.1 62.912.4 0.510.5 51.817.5
5 1.110.6 62.012.5 1.010.6 62.010.7
10 0.610.4 61.914.5 0.210.2 65.911.9
20 0.810.6 64.816.6 1.010.6 67.015.2
40 0.810.5 60.715.8 0.110.1 56.319.8
80 0.510.3 65.116.7 1.310.6 69.511.4
Table A67. SCFA concentrations (mmol/1) (mean±SEM) in caecal liquor fol 
incubation with penicillin G
owing in vitro
Cone. (|ig/ml) 1 2 3 4 meaniSEM
0 0.00 0.00 0.00 0.00 0.0010.00
1 0.12 0.11 0.06 0.05 0.0910.02
2 0.33 0.29 0.17 0.16 0.2410.04
5 1.01 0.80 0.65 0.73 0.8010.08
10 2.34 2.26 2.85 2.25 2.4310.14
Table A68. Concentrations (|!g/ml) of penicillin G following incubation in vitro at pH 1.9
for 1 h
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Appendix B - Ampicillin
Time (h) Horse 1 Horse 2 Horse 3 Horse 4 Horse 6 meaniSEM
0 0.00 0.00 0.00 0.00 0.00 0.00±0.00
0.033 59.49 61.79 52.19 NS NS 57.8212.89
0.083 50.22 54.27 43.41 NS NS 49.3013.17
0.25 37.84 38.01 34.71 18.99 25.31 30.9713.78
0.5 29.58 25.94 27.18 14.90 18.81 23.2812.76
0.75 21.38 18.26 16.03 13.66 13.84 16.6311.45
1 14.39 14.11 7.01 11.51 12.17 11.8411.33
1.5 8.35 6.95 5.33 8.75 7.92 7.4610.61
2 4.16 3.39 3.21 8.06 6.02 4.9710.92
4 1.27 0.39 0.41 3.76 2.03 1.5710.63
6 NS NS NS 2.17 1.07 1.6210.55
8 0.13 0.03 0.03 1.55 0.61 0.4710.29
12 0.00 0.00 0.00 NS NS 0.0010.00
24 0.00 0.00 0.00 0.00 0.00 0.0010.00
Table Bl. Plasma concentrations (|ig/ml) of ampicillin following intravenous administration 
to horses
Time (h) Pony 7 Pony 8 Pony 9 Pony 10 Pony 11 Pony 12 meairfcSEM
0 0.00 0.00 0.00 0.00 0.00 0.00 o.ooto.oo
0.033 NS NS NS 50.76 41.93 NS 46.35±4.41
0.083 NS NS NS 31.76 40.07 53.48 41.77±6.33
0.25 54.02 44.99 37.57 25.35 35.19 29.17 37.7214.29
0.5 29.76 30.69 21.25 13.76 21.30 23.98 23.4612.56
0.75 18.16 29.12 12.50 10.06 14.93 14.70 16.5812.74
1 13.03 19.16 6.97 7.04 14.44 8.22 11.4812.01
1.5 7.44 15.17 3.41 3.88 7.39 4.60 4.2111.39
2 3.85 10.97 1.52 2.76 3.45 2.68 1.2010.49
4 0.32 3.52 1.36 0.85 0.62 0.53 0.5710.45
6 0.00 1.89 0.39 NS 0.00 NS 0.1510.15
8 0.00 0.90 0.00 0.00 0.00 0.00 0.0010.00
12 NS NS NS 0.00 0.00 0.00 0.0010.00
24 0.00 0.00 0.00 0.00 0.00 0.00 0.0010.00
Table B2. Plasma concentrations (jig/ml) of ampicillin following intravenous administration
to ponies
Time (h) Donkey 15 Donkey 16 Donkey 17 meaniSEM
0 0.00 0.00 0.00 6.0010.00
0.033 62.68 21.82 56.85 47.12112.76
0.083 49.24 17.42 50.56 39.07110.83
0.25 21.47 9.96 28.94 20.1215.52
0.5 14.32 7.88 14.87 12.3612.24
0.75 12.32 6.28 10.45 9.6811.79
1 6.43 6.27 7.53 6.7410.40
1.5 2.55 3.89 3.97 3.4710.46
2 1.32 3.03 2.93 2.4310.55
4 0.13 0.90 0.47 0.5010.22
6 NS 0.25 NS 0.25
8 0.00 0.09 0.00 0.0310.03
12 0.00 0.00 0.00 0.0010.00
24 0.00 0.00 0.00 0.0010.00
Table B3. Plasma concentrations ((ig/ml) of ampicillin following intravenous administration
to donkeys
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Parameter Horse 1 Horse 2 Horse 3 Horse 4 Horse 6
tl/2 B2 (min) 11.56 6.24 19.92 24.06 14.66
tl/2  B1 (min) 72.12 34.08 42.66 148.74 110.76
CpO (pg/ml) 59.70 67.92 53.16 23.01 34.07
Vc (ml/kg) 167.52 147.23 188.10 434.58 293.52
AUCobs (pg.h/ml) 48.63 42.73 36.33 59.34 46.49
AUMCobs (|ig.h2/ml) 51.71 32.72 28.28 205.08 105.80
AUC (|ig.h/ml) 47.89 41.27 36.97 52.14 42.56
AUMC (pg.h2/ml) 52.87 31.67 29.51 169.01 85.59
MRT (min) 63.80 45.94 46.71 207.36 136.55
Vdarea (ml/kg) 362.19 198.66 277.61 685.97 625.82
Vdss (ml/kg) 230.51 185.96 215.90 621.70 472.47
CLb (ml/h.kg) 208.80 242.31 270.47 191.80 234.95
kel(/h) 1.25 1.65 1.44 0.44 0.80
k21 (/h) 0.85 4.94 1.41 1.09 0.81
kl2(/h) 0.32 1.30 0.21 0.47 0.50
Table B4. Disposition kinetics of ampicillin following intravenous administration to horses
Parameter Pony 7 Pony $ Pony 9 Pony 11 Pony 12 Pony 13
tl/2 B2 (min) 7.38 16.62 15.48 2.40 i5 .20 5.28
tl/2 B1 (min) 33.48 96.72 122.28 48.78 48.42 39.84
CpO (pg/ml) 128.74 68.64 72.21 75.63 43.55 81.31
Vc (ml/kg) 77.67 145.69 138.49 132.23 299.63 122.98
AUCobs (|ig.h/ml) 55.64 82.18 36.57 28.63 37.86 36.14
AUMCobs (p.g.h2/ml) 37.17 175.88 34.14 27.98 32.28 27.71
AUC (pg.Vml) 32.79 76.10 36.19 26.33 37.14 33.75
AUMC (|lg.h2/ml) 32.57 143.64 40.86 27.24 35.02 26.71
MRT (min) 40.08 128.41 56.01 58.64 51.16 46.00
Vdarea (ml/kg) 155.28 305.76 812.49 445.56 313.78 284.11
Vdss (ml/kg) 121.15 248.06 311.99 392.97 253.94 234.54
CLb (ml/h.kg) 192.86 131.42 276.31 379.86 269.29 296.31
kel (/h) 2.48 0.90 2.00 2.87 1.17 2.41
k21 (/h) 2.82 1.19 0.46 5.08 1.21 3.39
k l2  (/h) 1.58 0.84 0.57 10.02 0.13 3.08
Table B5. Disposition kinetics of ampicillin following intravenous administration to ponies
Parameter Donkey 15 Donkey 16 Donkey 17
tl/2 B2 (min) 5.40 4.62 9.06
tl/2 B1 (min) 30.06 66.12 46.08
CpO (pg/ml) 74.60 25.98 64.43
Vc (ml/kg) 134.06 384.95 155.20
AUCobs (pg.h/ml) 26.05 19.23 31.16
AUMCobs (|ig.h2/ml) 14.98 25.93 24.67
AUC (jig.h/ml) 25.81 18.93 29.36
AUMC (|ig.h2/ml) 14.99 27.62 23.40
MRT (min) 34.50 80.90 47.50
Vdarea (ml/kg) 280.17 840.20 377.23
Vdss (ml/kg) 225.08 771.08 271.32
CLb (ml/h.kg) 387.49 528.37 340.55
kel (/h) 2.89 1.37 2.19
k21 (/h) 3.67 4.14 1.89
kl2(/h) 2.49 4.16 1.42
Table B6. Disposition kinetics of ampicillin following intravenous administration to donkeys
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Table B7. 
ampicillin to horses
Time (h) Horse 3 | Horse 4 Horse 6 mean±SEM
coliform s
0
24
48
3.00E+04
1.00E+03
1.00E+05
1.00E+04
1.00E+05
4.00E+06
1.00E+10
5.05E+O4±4.O4E+O4
1.38E+06±1.31E+06
5.00E+09±4.08E+09
strep tococci
0
24
48
1.00E+07
1.00E+06
2.00E+06
5.00E+06
1.00E+07
3.00E+06
4.00E+06
1.00E+07
9.00E+08
6.33E+06±1.86E-k)6
7.00E+06±3.00E+06
3.02E+08±2.99E+08
lacto bacilli
0
24
48
1.00E+06
6.00E+04
1.00E+06
1.00E+05
1.00E+07
1.00E+08
1.00E+06
3.00E+07
1.00E+08
7.00E+05±3.00E+05 
1.34E+07±8.80E+06 
6.70E+07±3.30E+07
Bacteroi des spp.
0
24
48
1.70E+07
5.00E+06
2.30E+08
1.00E+09
1.30E+07
1.10E+08
1.00E+06
5.30E+07
3.10E+08
3.39E+08±3.30E*f08
2.37E+07±1.48E+07
2.17E+08±5.81E-K)7
Clostridium spp.
0
24
48 1.00E+03
3.00E+03
2.00E+03
2.00E+04
1.00E+05
1.00E+05
2.00E+04 
5.15E+04±3.96E+04 
3.43E+04±3.28E+04
viable bacteria per g faeces following intravenous administration of
Time (h) Pony 7 Pony 8 Pony 9 mean±SEM
coliform s
0
24
48
1.00E+04
3.00E+07
1.90E+07
1.00E+05
1.00E+08
1.00E+07
1.00E+04
1.00E+08
2.00E+08
4.00E+04±3.00E+04
7.67E+07±2.33E+07
7.63E+07±6.19E+07
strep tococci
0 1.00E+05 1.00E+05 4.00E+05 2.00E+05± 1.00E+05
24 2.00E+08 1.00E-f05 1.00E+06 6.70E+07±6.65E+07
48 2.00E+07 1.00E+08 5.00E+06 4.17E+07±2.95E+07
lacto bacilli
0 3.00E+06 2.00E+04 1.00E+06 1.34E+06±8.77E+05
24 1.40E+07 1.00E+06 7.00E+05 5.23E+07±4.38E+07
48 2.00E+07 3.00E+05 2.00E+06 7.43E+06±6.30E+06
Bacteroides spp.
0 2.00E+07 8.00E+06 1.00E+06 9.67E+06±5.55E+06
24 1.10E+09 1.40E+07 3.20E+07 3.82E+08±3.59E+08
48 1.20E+08 1.40E+10 3.10E+08 4.8 lE+09±4.60E+09
Clostridium spp.
0 3.00E+03 2.00E+03 - 2.50E+03±4.08E+02
24 1.00E+06 6.00E+03 - 5.03E+05±4.06E+05
48 2.00E+05 3.00E+04 2.10E+06 7.77E+05±6.63E+05
Table B8. Counts of viable bacteria per g faeces following intravenous administration of 
ampicillin to ponies
/
356
Time (h) Donkey 15 Donkey 16 Donkey 17 | mean±SEM
coliform s
0
24
48
1.00E+05
1.00E+06
2.00E+05
1.00E+03
1.00E+05
1.00E+08
1.00E+04
2.00E+04
1.00E+06
3.7 0E+04±3.16E+04 
3.73E+05±3.14E+05 
3.37E+07±3.31E+07
streptococci
0 1.00E+08 1.00E+09 1.00E+08 4.00E+08±3.00E+08
24 1.00E+08 2.00E+06 3.00E+06 3.50E+07±3.25E+07
48 1.00E+08 1.00E+08 5.00E+06 6.83E+07±3.17E+07
lactobacilli
0 2.00E+07 1.00E+07 5.00E+06 1.17E+07±4.41E+06
24 1.00E+06 2.00E+05 2.00E+04 4.07E+05±3.01E+05
48 2.00E+08 1.00E+06 2.00E+09 7.34E+08+6.36E+08
Bacteroides spp.
0 1.00E+08 3.00E+06 4.00E+06 3.57 E+07 ±3.22E+07
24 9.00E+06 1.00E+07 1.10E+06 6.70E+06±2.81E+06
48 1.20E+07 2.10E+09 1.30E+09 1.14E+09±6.08E+08
Clostridium spp.
0 2.00E+05 - 1.00E+03 1.01 E+05±8.12E+04
24 1.00E+04 - - 1.00E+04
48 - 2.10E+04 1.00E+04 1.55E+04±4.49E+03
Table B9. Counts of viable bacteria per g faeces following intravenous administration of 
ampicillin to donkeys
Time (h) L A P IB B IV V Total
0 0.0 3.9 0.0 0.0 0.0 0.0 0.0 3.9
24 0.0 1.4 2.0 0.0 1.6 0.0 0.0 5.0
48 4.6 0.0 2.6 0.0 4.3 0.0 0.0 6.9
Table BIO. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to horse 3
Time (h) L A p IB B IV V Total
0 0.0 0.0 0.0 0.0 9.7 0.0 0.0 9.7
24 0.0 0.0 4.7 0.0 0.0 0.0 0.0 4.7
48 0.0 0.0 0.0 0.0 3.2 0.0 0.0 3.2
Table B ll. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to horse 4
Time (h) L A P IB B IV V Total
0 0.0 1.7 0.0 2.3 4.0 0.0 0.0 8.0
24 0.0 0.0 3.6 0.0 0.0 0.0 0.0 3.6
48 0.0 13.9 7.4 0.0 16.1 3.2 0.0 40.6
of ampicillin to horse 6
Time (h) L A P IB B IV V Total
0 0.0 11.3 5.0 0.0 15.5 0.0 0.0 31.8
24 0.0 10.4 4.9 0.0 6.6 2.4 2.8 27.1
48 0.0 5.6 8.0 0.0 0.0 0.0 0.0 13.6
Table B13. SCFA concentrations (mmol/kg) in faeces following intravenous administration
of ampicillin to pony 7
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Time (h) L A P IB B IV V Total
0 0.0 7.9 4.7 0.0 18.0 0.0 0.0 30.6
24 0.0 3.0 0.0 0.0 0.0 0.0 0.0 3.0
48 0.0 7.8 0.0 0.0 12.5 0.0 0.0 20.3
Table B14. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to pony 8
Time (h) L A P IB B IV V Total
0 3.1 11.6 7.7 0.0 19.4 0.0 0.0 38.7
24 0.0 0.0 0.0 0.0 3.4 0.0 0.0 3.4
48 0.0 6.2 4.4 0.0 20.9 0.0 0.0 31.5
of ampicillin to pony 9
Time (h) L A P IB B IV V Total
0 8.3 27.8 12.8 0.0 23.7 0.0 0.0 64.3
24 6.3 24.1 4.1 0.0 18.9 3.4 0.0 50.5
48 8.4 3.1 10.0 0.0 98.7 0.0 0.0 111.8
of ampicillin to donkey 15
Time (h) L A P IB B IV V Total
0 7.5 24.6 8.8 0.0 35.0 2.0 0.0 70.4
24 0.0 3.0 0.0 0.0 19.6 0.0 0.0 22.6
48 0.0 19.6 5.5 0.0 22.0 0.0 0.0 47.1
Table B17. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to donkey 16
Time (h) L A P IB B IV V Total
0 7.7 25.0 7.7 0.0 42.9 0.0 0.0 75.6
24 0.0 6.6 0.0 0.0 8.8 1.5 0.0 16.9
48 0.0 13.5 5.5 0.0 17.9 0.0 0.0 36.9
Table B18. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to donkey 17
Horses Ponies Donkeys
Time (h) L Total L Total L Total
0 0.010.0 7.2±1.7 0.0±0.0 33.7±2.5 7.8±0.2 70.113.3
24 0.0±0.0 4.4±0.4 0.0±0.0 11.2±8.0 2.1±2.1 30.0110.4
48 1.5±1.5 16.9±11.9 1.0±1.0 21.8±5.2 2.8±2.8 65.3123.5
administration of ampicillin to horses, ponies and donkeys
Time (h) Horse 3 Horse 4 Horse 6 meaniSEM
0 17.22 17.79 23.41 19.4711.98
24 18.02 16.85 15.94 16.9410.60
48 19.57 18.32 16.62 18.1710.85
Table B20. Faecal dry matter content (%) following intravenous administration of ampicillin 
to horses
Time (h) Pony 7 Pony 8 Pony 9 meaniSEM
0 17.09 17.48 17.16 17.2410.12
24 20.59 19.23 20.22 20.0110.41
48 19.74 17.19 19.09 18.6710.77
Table B21. Faecal dry matter content (%) following intravenous administration of ampicillin
to ponies
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Time (h) Donkey 15 Donkey 16 Donkey 17 mean±SEM
0
24
48
19.15
21.26
21.93
28.09
26.56
18.19
l l &
17.97
21.06
19.96±4.48
21.93±2.50
20.39±1.13
to donkeys
Table B23. Plasma 
administration to ponies
Time (h) 11 12 111 112
0 0.00 0.00 0.00 0.00
0.25 25.08 16.42 19.47 15.74
0.5 17.95 14.69 17.25 13.59
0.75 15.43 14.19 15.17 13.25
1 13.09 13.98 14.65 11.91
1.5 9.51 10.91 11.43 9.48
2 7.01 9.40 9.13 8.05
4 2.37 2.60 4.25 3.44
6 0.81 1.39 1.97 2.75
8 0.19 0.43 0.77 1.59
12 0.00 0.00 0.00 0.37
24 0.00 0.00 0.00 0.00
concentrations (4g/ml) of ampicillin “ollowing intravenous
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.00 1.13 0.00 0.00
0.5 0.00 0.78 0.00 0.00
0.75 0.00 0.75 0.00 0.00
1 0.58 0.46 0.00 0.00
1.5 2.26 0.00 0.00 0.00
2 1.78 0.00 0.00 0.00
4 0.00 0.58 0.00 0.00
6 0.00 0.29 0.00 0.00
8 0.00 0.00 0.00 0.00
Table B24. Caecal liquor concentrations (pg/ml) of ampicillin following intravenous
administration to ponies
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Time (h) ...............11 12 HI H 112
coliform s
0 6.00E+05 3.00E+05 1.10E+05 7.00E+03
24 3.20E+06 3.00E+06 2.00E+06 2.00E+05
48 3.00E+05 3.00E+05 2.00E+06 3.00E+03
streptococci
0 1.40E+06 4.00E+05 1.00E+05 8.00E+05
24 1.00E+08 9.00E+05 3.00E+05 3.00E+06
48 2.00E+06 1.00E+05 2.00E+08 1.00E+05
lactobacil i
0 1.00E+07 1.00E+06 1.00E+07 1.00E+07
24 1.00E+07 6.00E+06 6.00E+05 5.00E+05
48 3.00E+06 1.00E+05 1.00E+07 5.00E+05
Bacteroides spp.
0 6.00E+09 2.00E+09 5.00E+1C) 2.00E+10
24 1.00E+10 2.00E+08 1.50E+07 4.30E+07
48 1.10E+08 5.00E+07 5.30E+9 3.20E+10
Clostridium spp.
0 - 3.00E+04 -
24 2.00E+04 1.90E+06 - 1.00E+04
48 1.20E+05 1.00E+05 5.00E+04 1.20E+05
[>unts of viable bacteria per m caecal lie uor followTable B25. 
administration of ampicillin to ponies
Time (h) 11 12 III 112
0 6.8 7.2 6.6 6.7
0.25 7.5 7.8 6.7 6.4
0.5 7.2 7.5 6.8 6.5
0.75 7.5 7.8 7.1 6.4
1 7.4 7.6 6.8 6.4
1.5 7.5 7.7 6.8 6.5
2 7.5 7.7 7.3 6.4
4 7.5 7.2 6.9 6.6
6 7.3 7.1 7.2 6.7
8 7.0 7.3 7.1 6.9
12 6.8 7.0 6.7 6.8
24 7.1 6.9 7.1 6.7
48 7.2 7.0 7.5 6.4
Table B26. Caecal liquor pH following intravenous administration of ampicillin to ponies
Time (h) L A P IB B IV V Total
0 0.0 40.2 13.7 0.0 12.9 0.0 0.0 66.8
0.25 0.0 24.5 5.9 0.0 0.0 0.0 0.0 30.4
0.5 0.0 22.6 7.3 0.0 6.4 0.0 0.0 36.3
0.75 0.0 22.7 6.2 0.0 7.0 0.0 0.0 35.9
1 0.0 23.5 6.1 0.0 5.9 0.0 0.0 35.5
1.5 0.0 26.5 6.8 0.0 7.5 1.0 1.0 42.8
2 1.2 23.8 7.2 0.0 8.4 0.0 0.0 39.4
4 19.5 16.3 6.6 0.0 28.0 0.0 0.0 50.9
6 24.7 11.0 17.1 0.0 13.5 0.0 0.0 41.6
8 43.6 8.8 22.4 0.0 8.2 0.0 0.0 39.4
12 33.4 13.6 9.8 0.0 11.9 0.0 0.0 35.3
24 10.1 8.4 4.1 0.0 0.0 0.0 0.0 12.5
48 2.2 33.2 14.7 0.0 24.8 0.0 0.0 72.7
Table B27a. SCFA concentrations (mmol/1) in caecal liquor following intravenous
administration of ampicillin to pony II
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Time (h) A P B P+B
0 60.2 20.5 19.3 39.8
0.25 80.6 19.4 0.0 19.4
0.5 62.3 20.1 17.6 37.7
0.75 63.2 17.3 19.5 36.8
1 66.2 17.2 16.6 33.8
1.5 61.9 15.9 17.5 33.4
2 60.4 18.3 21.3 39.6
4 32.0 13.0 55.0 68.0
6 26.4 41.1 32.5 73.6
8 22.3 56.9 20.8 77.7
12 38.5 27.8 33.7 61.5
24 67.2 32.8 0.0 32.8
48 45.7 20.2 34.1 54.3
Table B27b. VFA concentrations (%) m caecal liquor following intravenous administration 
of ampicillin to pony II
Time (h) L A P IB B IV V Total
0 0.0 20.9 4.8 1.3 9.8 1.2 0.0 38.0
0.25 0.0 18.1 3.7 0.0 7.5 0.0 0.0 29.3
0.5 0.0 17.4 2.8 0.0 8.9 0.0 0.0 29.1
0.75 0.0 20.0 4.7 0.0 9.2 1.1 0.0 35.0
1 0.0 19.4 4.1 0.6 7.0 1.8 0.0 32.9
1.5 0.0 17.9 3.4 0.0 8.3 2.6 0.0 32.2
2 0.0 17.9 3.4 0.0 8.3 2.6 0.0 32.2
4 1.9 23.2 7.9 0.0 27.1 1.2 0.0 59.4
6 4.8 20.8 5.2 0.0 19.4 0.0 0.0 45.4
8 9.5 19.7 6.1 0.0 28.5 0.0 0.0 54.3
12 19.9 20.0 6.3 0.0 20.2 0.0 0.0 46.5
24 44.4 16.5 9.1 0.0 20.8 0.0 5.7 52.1
48 0.0 54.5 24.6 0.0 15.1 0.0 0.0 94.2
Table B28a. SCFA concentrations (mmol/1) in caeca 
administration of ampicillin to pony 12
liquor following intravenous
Time (h) A P B P+B
0 55.0 12.6 25.8 38.4
0.25 61.8 12.6 25.6 38.2
0.5 59.8 9.6 30.6 40.2
0.75 57.1 13.4 26.3 39.7
1 59.0 12.5 21.3 33.7
1.5 55.6 10.6 25.8 36.3
2 55.6 10.6 25.8 36.3
4 39.1 13.3 45.6 58.9
6 45.8 11.5 42.7 54.2
8 36.3 11.2 52.5 63.7
12 43.0 13.5 43.4 37.0
24 31.7 17.5 39.9 57.4
48 57.9 26.1 16.0 42.1
Table B28b. VFA concentrations (%) in caecal liquor following intravenous administration
of ampicillin to pony 12
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Time (h) L A P IB B IV V Total
0 0.0 27.9 7.0 0.0 6.9 0.0 0.0 41.8
0.25 0.0 35.9 9.9 0.0 10.0 0.0 0.0 55.8
0.5 0.0 27.1 6.1 0.0 6.5 0.0 0.0 39.7
0.75 0.0 30.4 9.2 0.0 8.9 0.0 0.0 48.5
1 0.0 27.7 7.3 0.0 6.7 0.0 0.0 41.7
1.5 0.0 25.1 6.7 0.7 5.0 0.0 0.0 37.5
2 0.0 14.0 4.1 0.0 4.4 0.0 0.0 22.5
4 0.0 28.1 7.0 0.0 7.5 0.7 0.0 43.3
6 0.0 28.8 8.2 0.0 8.5 0.0 0.0 45.5
8 5.1 37.7 13.5 0.0 22.0 0.0 0.0 73.2
12 3.8 25.7 16.6 0.0 7.0 0.0 0.0 49.3
24 5.1 18.3 10.7 0.0 4.0 0.0 0.0 33.0
48 0.0 15.9 6.9 0.0 3.7 3.4 0.0 29.9
Table B29a. SCFA concentrations (mmol/1) in caeca 
administration of ampicillin to pony III
liquor following intravenous
Time (h) A P B P+B
0 66.7 16.7 16.5 33.3
0.25 64.3 17.7 17.9 35.7
0.5 68.3 15.4 16.4 31.7
0.75 62.7 19.0 18.4 37.3
1 66.4 17.5 16.1 33.6
1.5 66.9 17.9 13.3 31.2
2 62.2 18.2 19.6 37.8
4 64.9 16.2 17.3 33.5
6 63.3 18.0 18.7 36.7
8 51.5 18.4 30.1 48.5
12 52.1 33.7 14.2 47.9
24 55.5 32.4 12.1 44.5
48 53.2 23.1 12.4 35.5
Table B29b. VFA concentrations (%) in caecal liquor following intravenous administration 
of ampicillin to pony III
Time (h) L A P IB B IV V Total
0 0.0 37.9 12.6 1.1 9.3 3.4 0.0 64.3
0.25 0.0 33.8 9.4 1.1 6.8 0.0 0.0 51.1
0.5 0.0 36.0 9.0 0.0 6.6 0.0 0.0 51.6
0.75 0.0 39.9 11.0 1.3 7.9 0.0 3.1 63.2
1 0.0 34.8 8.0 1.6 7.7 0.0 0.0 52.1
1.5 0.0 32.8 9.1 0.0 5.5 0.0 2.0 49.4
2 0.0 42.9 11.5 1.3 9.0 0.0 1.7 66.4
4 0.0 45.0 11.5 0.8 8.0 0.0 0.0 65.3
6 0.0 33.1 7.9 0.0 6.0 0.0 0.0 47.0
8 0.0 37.2 10.2 0.0 7.4 0.0 0.0 54.8
12 0.0 36.7 9.0 0.7 7.7 0.0 0.0 54.1
24 2.1 40.9 17.8 0.0 7.5 0.0 0.0 66.2
48 0.6 31.9 10.1 0.7 6.0 0.0 0.0 48.7
Table B30a. SCFA concentrations (mmol/1) in caecal liquor following intravenous
administration of ampicillin to pony 112
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Time (h) A P B P+B
0 58.9 19.6 14.5 34.1
0.25 66.1 18.4 13.3 31.7
0.5 69.8 17.4 12.8 30.2
0.75 63.1 17.4 12.5 29.9
1 66.8 15.4 14.8 30.1
1.5 66.4 18.4 11.1 29.6
2 64.6 17.3 13.6 30.9
4 68.9 17.6 12.3 29.9
6 70.4 16.8 12.8 29.6
8 67.9 18.6 13.5 32.1
12 67.8 16.6 14.2 30.9
24 61.8 26.9 11.3 38.2
48 65.5 20.7 12.3 33.1
of ampicillin to pony 112
(%) in caecal liquor following intravenous administration
Time (h) L A P IB B IV V Total
0 0.0 7.5 0.0 0.0 15.8 0.0 0.0 2J.3
24 0.0 15.4 7.6 0.0 35.2 0.0 5.4 63.6
48 0.0 6.1 5.3 0.0 13.2 0.0 0.0 24.6
of ampicillin to pony II
Time (h) L A P IB B IV V Total
0 0.0 0.0 7.5 0.0 19.6 0.0 0.0 27.1
24 0.0 4.5 0.0 0.0 47.0 6.1 0.0 57.6
48 0.0 0.0 0.0 0.0 21.9 0.0 0.0 21.9
of ampicillin to pony 12
Time (h) L A P IB B IV V Total
0 0.0 6.5 4.6 0.0 21.4 0.0 0.0 32.5
24 0.0 30.3 7.5 0.0 57.5 0.0 0.0 95.3
48 0.0 10.8 4.9 0.0 23.2 0.0 2.9 41.8
Table B33. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to pony III
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 8.3 0.0 0.0 8.3
24 0.0 0.0 0.0 5.8 0.0 0.0 0.0 5.8
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table B34. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of ampicillin to pony 112
Time (h) 11 12 III 112
0 19.33 33.16 20.84 18.46
24 22.70 33.83 22.17 17.73
48 20.94 18.19 22.12 18.85
Table B35. Faecal dry matter content (%) following intravenous administration of ampicillin
to ponies
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II 12
Time (h) 0 24 48 0 24 48
urea (mmol/1) 1.4 3.3 2.7 4.3 5.7 2.4
sodium (mmol/1) 143 138 141 135 135 135
potassium (mmol/1) 4.3 3.9 3.6 1 9 3.8 4.2
chloride (mmol/1) 101 99 101 95 94 100
calcium (mmol/1) 2.66 2.99 3.05 to v© oo 2.92 3.05
magnesium (mmol/1) 0.62 0.60 0.62 0.56 0.60 0.70
phosphate (mmol/1) 0.95 0.61 0.88 0.44 0.45 1.32
creatinine (|imol/l) 142 157 159 142 148 154
bilirubin (p.mol/1) 6 11 8 21 20 7
SAP (U/l) 381 380 366 500 466 465
AST (U/l) 269 276 264 291 289 278
GGT (U/l) 13 8 14 21 23 17
total protein (g/1) 65 69 67 68 68 69
albumin (g/1) 27 28 28 27 27 29
globulin (g/1) 38 41 39 41 41 40
Table B36. Plasma biochemistry following intravenous administration of ampicillin to pony 
I
III 112
Time (h) 0 24 48 0 24 48
urea (mmol/1) 0.4 0.9 0.9 3.1 2.8 1.8
sodium (mmol/1) 141 140 141 138 137 137
potassium (mmol/1) 4.1 3.7 3.3 3.2 3.6 3.$
chloride (mmol/1) 104 105 103 97 95 101
calcium (mmol/1) 3.16 3.18 2.98 2.85 2.84 2.98
magnesium (mmol/1) 0.62 0.71 0.68 0.59 0.60 0.71
phosphate (mmol/1) 1.04 0.60 0.92 0.54 0.41 0.61
creatinine (fimol/1) 117 133 134 108 113 105
bilirubin (p.mol/1) 6 12 11 16 19 13
SAP (U/l) 450 461 459 631 585 526
AST (U/l) 348 363 375 414 414 498
GGT (U/l) 42 44 45 55 53 58
total protein (g/1) 72 73 72 69 66 71
albumin (g/1) 32 32 32 29 30 32
globulin (g/1) 40 41 40 31 36 39
Table B37. Plasma biochemistry following intravenous administration of ampicillin to pony
n
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II 12
Time (h) 0 24 48 0 24 48
WCC (x 109/1) 8.3 6.7 7.5 6.0 5.5 8.6
RCC (x 1012/1) 6.56 5.77 5.98 5.83 5.86 6.13
Hb (g/dl) 11.4 9.9 10.4 10.4 10.2 11.0
Hct (1/1) 0.333 0.291 0.303 0.294 0.297 0.306
MCV (fl) 51.0 50.0 51.0 50.0 51.0 50.0
MCH (pg) 17.3 17.1 17.3 17.6 17.4 17.9
MCHC (g/dl) 34.2 34.0 34.3 35.3 34.3 35.9
PLTS (109/1) - 107 106 97 115 122
MPV (fl) - 6.4 6.1 6.0 6.0 6.2
PCT (%) - 0.068 0.064 0.058 0.069 0.075
PDW - 17.1 16.3 18.3 16.6 17.7
Neu (%) 44.8 45.0 41.0 65.0 50.4 35.0
Lym (%) 54.4 52.9 55.4 31.0 46.5 58.9
Mon (%) 0.5 0.0 1.5 4.0 2.0 3.0
Eos (%) 0.4 1.0 1.1 0.0 0.5 2.6
Bas (%) 0.0 1.0 1.1 0.0 0.5 0.5
pony I
III 112
Time (h) 0 24 48 0 24 oo
WCC (x 109/1) 7.5 6.9 6 A 5.0 5.0 4.6
RCC (x 1012/1) 7.46 7.06 6.72 6.56 6.84 7.66
Hb (g/dl) 11.7 11.2 10.4 10.4 10.3 11.2
Hct (1/1) 0.342 0.318 0.303 0.288 0.303 0.312
MCV (fl) 46.0 45.0 45.0 44.0 44.0 44.0
MCH (pg) 15.6 15.8 15.4 15.6 15.0 15.8
MCHC (g/dl) 34.2 35.2 34.3 36.1 33.9 35.8
PLTS (109/1) 83 105 106 102 123 109
MPV (fl) 7.1 6.8 6.5 6.5 6.8 6.8
PCT (%) 0.058 0.071 0.068 0.066 0.083 0.074
PDW 18.3 16.1 16.9 16.9 16.1 16.1
Neu (%) 46.9 43.0 51.0 67.0 62.0 52.6
Lym (%) 50.9 51.9 47.0 31.0 33.0 42.0
Mon (%) 0.5 1.4 0.0 1.0 3.0 5.0
Eos (%) 1.1 3.0 1.5 0.0 1.0 0.0
Bas (%) 0.5 0.6 0.5 1.0 1.0 0.0
Table B39. Haematology parameters following intravenous administration of ampicillin to 
pony II
Time (h) 11 12 • III 112
0 0.00 0.00 0.00 0.00
0.25 1.67 0.38 0.00 0.24
0.5 2.30 1.16 0.67 0.74
0.75 2.05 1.10 1.96 0.59
1 1.55 1.02 1.81 0.42
1.5 0.64 0.47 0.69 0.16
2 0.30 0.33 0.23 0.00
4 0.00 0.00 0.00 0.00
ponies
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Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.00 0.00 0.00 0.00
0.5 0.00 0.00 0.00 0.00
0.75 0.76 0.00 0.00 0.00
1 45.24 0.00 0.00 0.00
1.5 100.67 15.03 0.00 0.00
2 101.31 144.53 0.00 0.00
4 65.07 0.00 19.11 0.00
6 27.95 0.00 47.40 3.63
8 23.55 0.00 46.93 0.37
12 0.00 0.00 0.00 0.00
uor concentrations (pg/ml) o f ampicil in follow
to ponies
Time (h) I 11 12 III 112
coliform s
0 1.60E+11 1.40E+05 4.00E+05 4.00E+05
24 1.10E+11 1.00E+08 4.40E+11 2.20E+10
48 1.20E+11 2.00E+06 6.10E+11 1.00E+09
72 2.00E+07 1.00E+06 3.00E+06 1.70E+06
96 2.00E+05 1.00E+07 2.00E+05 5.00E+04
168 1.40E+05 1.10E+06 2.00E+04 2.30E+04
streptococci
0 2.00E+10 1.00E+06 1.00E+07 1.00E+07
24 1.40E+10 1.00E+07 1.00E+10 2.00E+07
48 6.00E+10 1.00E+07 4.00E+10 1.00E+09
72 3.00E+08 5.00E+05 1.30E+O7 4.00E+08
96 3.00E+07 2.00E+05 1.00E+07 3.00E+05
168 1.00E+06 8.00E+04 2.00E+05 7.00E+03
lactobacil i
0 2.00E+10 1.00E+06 1.00E+09 1.00E+09
24 1.00E+10 1.00E+09 5.00E+07 1.00E+07
48 1.10E+11 1.00E+06 1.00E+09 1.00E+10
72 2.00E+06 3.00E+05 6.00E+07 6.00E+06
96 2.00E+07 1.00E+06 4.00E+06 8.00E+08
168 1.00E+06 5.00E+04 2.00E+05 1.00E+05
Bacteroides spp.
0 1.70E+11 1.30E+07 5.00E+08 5.00E+08
24 2.10E+11 4.00E+08 5.80E+11 1.10E+07
48 1.00E+12 1.60E+08 1.00E+12 2.00E+10
72 1.90E+08 1.10E+07 3.40E+08 2.00E+10
96 1.10E+10 5.90E+07 3.30E+10 2.00E+10
168 1.30E+07 3.50E+07 3.20E+07 3.00E+10
Clostridium spp.
0 6.00E+05 - - -
24 8.00E+07 1.20E+07 3.00E+05 3.00E+04
48 3.00E+10 1.00E+05 2.00E+06 3.00E+05
72 - 1.00E+04 - 1.30E+06
96 1.00E+06 1.00E+05 1.00E+06 1.00E+03
168 - 3.00E+04 1.00E+03 2.00E+03
Table B42. Counts of viable bacteria per ml caecal liquor fol owing oral administration of
ampicillin to ponies
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Time (h) 11 12 III 112
0 7.0 6.7 7.0 6.7
0.25 6.9 6.9 6.8 6.7
0.5 6.8 6.9 6.8 6.6
0.75 6.8 6.8 6.9 6.7
1 6.9 6.9 6.9 6.6
1.5 6.7 6.8 6.9 6.9
2 6.9 6.9 6.9 6.8
4 7.0 7.5 6.8 6.9
6 7.3 7.8 6.9 7.5
8 7.3 7.6 6.9 7.0
12 7.5 5.7 7.0 6.6
24 6.7 7.3 6.8 7.3
28 7.0 6.7 6.9 7.0
32 6.8 6.7 7.1 7.4
48 7.0 6.8 7.1 7.2
72 6.4 6.5 7.3 7.0
96 7.0 8.1 7.1 7.5
168 6.7 7.9 6.7 7.4
Table B43. Caecal liquor pH following oral administration of ampicillin to ponies
Time (h) L A P IB B IV V Total
0 13.6 31.1 28.3 0.0 19.9 0.0 0.0 79.3
0.25 6.5 18.8 16.7 0.0 5.8 0.0 0.0 41.3
0.5 6.2 37.8 30.0 0.0 21.2 0.0 0.0 89.0
0.75 4.3 28.7 21.2 0.0 20.1 0.0 0.0 70.0
1 2.4 24.0 12.3 0.0 17.8 0.0 0.0 54.1
1.5 2.7 32.6 16.5 0.0 18.5 0.0 0.0 67.6
2 4.0 27.9 14.1 0.0 29.4 0.0 0.0 71.4
4 9.8 12.3 10.8 0.0 43.2 0.0 0.0 66.3
6 23.5 6.9 24.6 0.0 28.2 0.0 0.0 59.7
8 35.4 34.7 53.1 0.0 13.6 0.0 0.0 101.4
12 40.3 4.4 99.9 0.0 11.6 2.9 0.0 118.8
24 42.7 7.1 0.0 0.0 28.1 0.0 0.0 35.2
28 41.8 12.2 7.5 0.0 24.5 0.0 0.0 44.2
32 26.6 17.1 22.6 0.0 28.2 1.4 0.0 69.3
48 0.0 21.6 25.8 0.0 46.1 0.0 0.0 93.5
72 3.3 22.7 41.5 0.0 33.1 2.5 1.9 101.7
96 0.0 12.3 17.3 0.0 13.6 0.0 0.0 43.2
168 0.7 19.3 10.1 0.0 7.7 0.0 0.0 37.1
ampicillin to pony II
in caecal liquor following oral administration of
367
Time (h) A P B P+B
0 39.2 35.7 25.1 60.8
0.25 45.5 40.4 14.0 54.5
0.5 42.5 33.7 23.8 57.5
0.75 41.0 30.3 28.7 59.0
1 44.4 22.7 32.9 55.6
1.5 48.2 24.4 27.4 51.8
2 39.1 19.7 41.2 60.9
4 18.6 16.3 65.2 81.4
6 11.6 41.2 47.2 88.4
8 34.2 52.4 13.4 65.8
12 3.7 84.1 9.8 93.9
24 20.2 0.0 79.8 79.8
28 27.6 17.0 55.4 72.4
32 24.3 32.6 40.7 73.3
48 23.1 27.6 49.3 76.9
72 22.3 40.8 32.5 73.4
96 28.5 40.0 31.5 71.5
168 52.0 27.2 20.8 48.0
Table B44b. VFA concentrations (%) in caecal liquor following oral administration of 
ampicillin to pony II
Time (h) L A P IB B IV V Total
0 0.7 19.3 10.1 0.0 7.7 0.0 0.£> 37.1
0.25 0.5 19.0 8.7 0.0 29.4 0.0 0.0 57.1
0.5 0.4 20.5 9.6 0.0 21.9 0.0 0.0 52.0
0.75 1.9 20.5 9.4 0.0 19.0 0.0 0.0 48.9
1 3.1 22.8 10.5 0.0 19.8 0.8 0.9 54.8
1.5 2.2 22.3 11.4 0.0 14.2 0.0 0.0 47.9
2 3.6 23.8 12.7 0.0 27.1 0.0 0.0 63.6
4 9.1 18.8 17.4 0.0 26.6 0.0 0.0 62.8
6 24.5 13.8 19.9 0.0 17.2 0.0 0.0 50.9
8 51.6 9.0 15.9 0.0 1.2 0.0 0.0 26.1
12 14.0 10.6 0.0 1.8 24.4 0.0 0.0 36.8
24 4.7 17.7 1.7 0.0 28.6 0.0 0.0 48.0
28 4.5 25.3 5.9 0.0 20.1 0.4 0.0 51.7
32 6.5 26.2 8.2 0.0 23.2 0.0 0.0 57.6
48 7.3 30.2 16.7 0.0 30.8 0.0 0.0 77.7
72 0.9 21.5 10.7 0.0 9.4 0.0 1.9 43.5
96 0.4 23.3 12.5 0.0 31.2 0.0 0.0 67.0
168 0.2 18.0 7.4 0.0 16.3 0.0 0.0 41.7
ampicillin to pony 12
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 52.0 27.2 20.8 48.0
0.25 33.3 15.2 51.5 66.7
0.5 39.4 18.5 42.1 60.6
0.75 41.9 19.2 38.9 58.1
1 41.6 19.2 36.1 55.3
1.5 46.6 23.8 29.6 53.4
2 37.4 20.0 42.6 62.6
4 29.9 27.7 42.4 70.1
6 27.1 39.1 33.8 72.9
8 34.5 60.9 4.6 65.5
12 28.8 0.0 66.3 66.3
24 36.9 3.5 59.6 63.1
28 48.9 11.4 38.9 50.3
32 45.5 14.2 40.3 54.5
48 38.9 21.5 39.6 61.1
72 49.4 24.6 21.6 46.2
96 34.8 18.7 46.6 65.2
168 43.2 17.7 39.1 56.8
Table B45b. VFA concentrations (%) in caecal liquor following oral administration of 
ampicillin to pony 12
Time (h) L A P IB B IV V Total
0 0.5 33.7 7.3 0.0 12.5 1.4 0.0 54.9
0.25 0.6 30.1 6.3 0.5 8.9 0.9 0.0 46.7
0.5 0.0 27.1 5.8 0.6 5.5 1.1 0.0 40.1
0.75 0.3 30.2 5.6 0.0 6.0 0.0 0.0 41.8
1 0.5 29.3 6.4 0.2 6.2 1.7 0.0 43.8
1.5 0.0 34.9 7.2 0.0 7.7 0.6 0.0 50.4
2 0.0 45.2 10.2 0.3 11.7 0.0 0.0 67.4
4 0.9 35.9 6.4 0.6 11.7 0.0 0.0 54.6
6 3.1 32.0 3.5 0.0 18.0 0.0 0.4 53.9
8 5.7 28.8 1.9 0.0 25.5 0.0 0.0 56.2
12 14.8 17.5 0.0 0.0 20.1 0.0 0.0 37.6
24 36.4 25.3 0.0 0.0 37.0 0.0 0.0 62.3
28 34.3 14.5 1.0 0.0 20.7 0.0 0.0 36.2
32 39.6 14.0 2.9 0.0 18.4 0.0 0.0 35.3
48 0.7 22.9 10.0 0.3 2.7 3.0 0.0 38.9
72 0.7 39.1 11.3 0.2 22.3 1.4 0.0 74.3
96 0.9 42.3 14.0 0.5 18.3 0.6 0.0 75.7
168 0.7 28.1 9.4 0.3 13.4 0.3 0.0 51.2
Table B46a. SCFA concentrations (mmol/1) in caecal liquor following oral administration of
ampicillin to pony III
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Time (h) A P B P+B
0 61.4 13.3 22.8 36.1
0.25 64.5 13.5 19.1 32.5
0.5 67.6 14.5 13.7 28.2
0.75 72.2 13.4 14.4 27.8
1 66.9 14.6 14.2 28.8
1.5 69.2 14.3 15.3 29.6
2 67.1 15.1 17.4 32.5
4 65.8 11.7 21.4 33.2
6 59.4 6.5 33.4 39.9
8 51.2 3.4 45.4 48.8
12 46.5 0.0 53.5 53.5
24 40.6 0.0 59.4 59.4
28 40.1 2.8 57.2 59.9
32 39.7 8.2 52.1 60.3
48 58.9 25.7 6.9 32.6
72 52.6 15.2 30.0 45.2
96 55.9 18.5 24.2 42.7
168 54.9 18.3 25.5 43.7
Table B46b. VFA concentrations (%) in caecal liquor following oral administration of 
ampicillin to pony III
Time (h) L A P IB B IV V Total
0 0.7 28.1 9.4 0.3 13.4 0.0 0.0 51.2
0.25 0.2 29.8 10.9 0.3 15.2 2.1 1.4 59.7
0.5 0.2 27.9 10.6 0.1 9.9 0.0 3.1 51.6
0.75 0.4 36.2 12.4 0.0 11.7 0.9 0.0 61.2
1 0.4 27.8 9.9 0.0 6.6 1.5 0.0 45.8
1.5 0.9 32.3 11.8 0.0 10.9 1.2 0.0 56.2
2 0.5 37.1 12.7 0.0 11.2 1.3 0.0 62.3
4 0.4 38.4 14.0 0.0 15.4 1.5 0.0 69.3
6 1.0 26.7 7.2 0.0 18.5 1.2 0.0 53.6
8 6.3 29.9 3.8 0.0 24.2 1.3 0.0 59.2
12 40.5 27.9 0.3 0.0 21.9 0.0 0.0 50.1
24 35.3 20.4 0.7 0.0 22.5 0.0 0.0 43.6
28 15.3 22.0 1.9 0.0 24.9 1.2 0.0 50.0
32 13.6 24.3 2.6 0.0 16.2 1.7 0.0 44.8
48 10.2 24.0 9.0 0.0 18.4 2.8 0.0 54.2
72 1.1 36.3 13.3 0.0 57.7 0.0 0.0 107.3
96 0.2 32.8 12.0 0.7 24.9 1.6 0.0 72.0
168 0.5 29.0 9.7 0.4 13.3 0.0 0.0 52.4
Table B47a. SCFA concentrations (mmolA) in caecal liquor following oral administration of
ampicillin to pony 112
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Time (h) A P B P+B
0 54.9 18.3 25.5 43.7
0.25 54.1 20.5 19.2 39.7
0.5 54.1 20.5 19.2 39.7
0.75 59.2 20.3 19.1 39.4
1 60.7 21.6 14.4 36.0
1.5 57.5 21.0 19.4 40.4
2 59.6 20.4 18.0 38.4
4 55.4 20.2 22.2 42.4
6 49.8 13.4 34.5 47.9
8 50.5 6.4 40.9 47.3
12 55.7 0.6 43.7 44.3
24 46.8 1.6 51.6 53.2
28 44.0 3.8 49.8 53.6
32 54.2 5.8 36.2 42.0
48 44.3 16.6 33.9 50.6
72 33.8 12.4 53.8 66.2
96 45.6 16.7 34.6 51.3
168 55.3 18.5 25.4 43.9
ampicillin to pony 112
caecal liquor following oral administration of
Time (h) L A P IB B IV V Total
0 1.9 14.8 5.1 0.0 12.5 0.0 0.6 32.4
24 50.2 36.2 0.0 0.0 15.7 0.0 0.0 51.9
48 16.4 17.9 0.0 0.0 27.6 0.0 0.0 45.5
72 1.9 0.0 0.0 0.0 57.4 0.0 0.0 57.4
96 1.6 2.9 4.7 0.0 11.6 2.5 0.0 21.7
168 0.0 33.4 12.2 0.0 65.7 0.0 0.0 111.3
ampicillin to pony II
Time (h) L A P IB B IV V Total
0 0.0 33.4 12.2 0.0 65.7 0.0 0.0 111.3
24 4.5 31.1 5.9 0.0 34.9 2.5 0.0 74.4
48 4.5 21.5 4.7 0.0 22.0 0.0 0.0 48.2
72 3.5 1.7 0.0 0.0 0.0 0.0 0.0 1.7
96 3.7 22.1 0.0 0.0 33.2 0.0 0.0 55.3
168 2.3 23.5 2.7 0.0 31.5 0.0 0.0 57.7
Table B49. SCFA concentrations (mmol/kg) in faeces following oral administration of 
ampicillin to pony 12
Time (h) L A P IB B IV V Total
0 0.0 7.9 0.0 0.0 8.2 0.0 0.0 16.1
24 64.2 24.2 0.0 0.0 31.2 0.0 0.0 55.4
48 37.4 18.1 0.0 0.0 27.7 0.0 0.0 45.8
72 8.0 0.0 0.0 0.0 25.5 0.0 0.0 25.5
96 5.9 0.0 0.0 0.0 40.5 2.8 0.0 43.3
168 3.7 8.1 0.0 0.0 31.5 0.0 0.0 39.6
Table B50. SCFA concentrations (mmol/kg) in faeces following oral administration of
ampicillin to pony III
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Time (h) L A P IB B IV V Total
0 3.7 8.1 0.0 0.0 31.5 0.0 0.0 39.6
24 35.6 10.7 0.0 0.0 106.9 0.0 0.0 117.6
48 43.6 12.4 0.0 0.0 23.8 0.0 0.0 36.2
72 4.5 3.2 0.0 0.0 187.2 0.0 0.0 190.4
96 5.2 15.4 5.2 0.0 79.6 0.0 0.0 100.2
168 3.9 29.1 0.0 0.0 66.5 0.0 0.0 95.6
ampicillin to pony 112
Time (h) 11 12 III 112
0 19.15 21.82 20.62 20.18
24 20.56 27.58 18.26 17.49
48 21.67 21.96 16.87 18.94
72 22.59 22.66 21.05 20.76
96 23.43 21.96 20.81 23.43
168 21.82 22.82 20.18 22.07
Table B52. Faecal dry matter content (%) following oral administration of ampicillin to 
ponies
Cone. (M-g/ml) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.00 0.00 0.16 0.04±0.04
1 0.43 0.49 0.28 1.24 0.61±0.21
5 5.68 5.32 4.36 6.32 5.42±0.41
10 11.50 9.65 9.25 11.98 10.60±0.67
20 23.61 21.40 19.56 24.52 22.27±1.12
40 44.89 38.11 33.69 47.51 41.05±3.15
80 66.06 61.29 59.32 73.61 65.07±3.18
vitro for 3 h
Cone. (M-g/ml) 1 2 3 4 meandbSEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.00 0.00 0.00 0.00±0.00
1 0.00 0.00 0.00 0.00 0.00±0.00
5 0.58 4.93 0.65 0.00 1.54±1.14
10 3.93 0.00 2.93 0.00 1.72±1.01
20 11.62 0.00 8.45 3.24 5.83±2.60
40 17.73 38.29 16.73 12.38 21.28±5.79
80 41.92 74.18 35.29 13.09 41.12±12.63
vitro for 24 h
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Cone (}ig/ml) L A P IB B IV V Total
0 0.8 21.5 10.5 0.0 10.1 1.9 0.0 44.0
0.25 2.4 22.3 8.6 2.3 7.3 2.7 2.3 45.5
1 1.0 26.8 10.1 0.6 8.4 0.0 0.0 45.9
5 2.8 31.8 15.1 2.4 11.1 2.4 4.6 67.4
10 1.5 26.5 14.4 0.0 7.8 0.0 0.0 48.7
20 1.3 25.4 10.2 1.0 7.7 1.2 0.0 45.5
40 0.5 28.8 10.1 0.0 7.8 0.0 0.0 46.7
80 2.0 24.8 10.5 1.3 11.0 1.8 2.3 51.7
with ampicillin for 3 h (replicate 1)
in caecal liquor following in vitro incubation
Cone (jig/ml) L A P IB B IV V Total
0 0.8 23.4 9.1 0.7 5.3 0.0 0.(5 38.5
0.25 1.0 24.5 9.5 1.1 5.3 1.3 1.7 43.4
1 0.0 29.3 11.3 0.0 6.9 0.0 0.0 47.5
5 2.3 31.9 12.4 2.7 8.6 3.3 3.9 62.8
10 0.3 33.6 12.7 0.0 7.5 0.0 0.0 53.8
20 1.9 26.9 11.1 1.6 5.8 2.3 0.0 47.7
40 0.4 24.1 8.6 0.0 4.6 0.0 0.0 37.3
80 1.5 26.3 9.3 1.5 5.8 1.8 0.0 44.7
Table B54b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with ampicillin for 24 h (replicate 1)
Cone (|ig/ml) L A P IB B IV V Total
0 0.6 33.1 11.8 0.4 7.7 1.3 6.0 54.3
0.25 2.4 34.2 15.3 1.8 9.8 2.5 0.0 63.6
1 1.1 33.9 13.3 0.0 11.3 1.8 0.0 60.3
5 1.5 35.2 14.2 1.4 9.8 2.3 0.0 62.9
10 0.8 39.5 16.1 0.4 15.7 2.8 2.2 76.7
20 1.6 38.8 15.3 1.3 12.8 2.2 0.0 70.4
40 0.4 52.0 13.5 0.0 16.9 0.0 0.0 82.4
80 1.2 37.8 16.3 1.2 12.5 1.7 2.0 71.5
Table B55a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with ampicillin for 3 h (replicate 2)
Cone (|ig/ml) L A P IB B IV V Total
0 0.0 36.4 14.3 0.0 7.7 2.2 0.0 60.6
0.25 1.5 36.8 13.9 1.6 7.7 3.4 2.6 66.0
1 0.0 35.5 13.5 0.0 5.8 3.7 0.0 58.5
5 2.1 36.7 19.5 2.4 8.4 3.5 3.4 73.9
10 0.4 40.9 16.3 0.5 9.3 2.7 2.0 71.7
20 1.2 52.8 19.4 1.8 14.1 3.3 3.4 94.8
40 0.0 39.9 15.1 0.8 8.6 0.0 0.0 64.4
80 1.0 38.2 14.2 1.3 9.2 2.8 2.2 67.9
Table B55b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with ampicillin for 24 h (replicate 2)
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Cone (M-g/ml) L A P IB B IV V Total
0 0.5 25.5 10.7 0.0 4.6 0.0 0.0 40.8
0.25 1.3 27.8 11.1 0.8 8.1 0.8 0.0 48.6
1 1.5 27.3 11.9 1.5 8.8 2.1 0.0 51.6
5 0.0 28.2 10.8 0.0 7.4 1.5 0.0 47.9
10 2.4 28.5 11.9 2.1 8.7 2.9 4.0 58.1
20 0.6 28.8 9.9 0.0 9.3 0.0 0.0 48.0
40 2.5 31.6 13.6 2.8 10.5 1.9 3.4 63.8
80 0.5 33.2 14.5 0.0 13.2 0.0 0.0 60.9
Table B56a. SCFA concentrations (mmol/1) 
with ampicillin for 3 h (replicate 3)
in caecal liquor following in vitro incubation
Cone (|Hg/ml) L A P IB B IV V Total
0 2.3 33.4 13.7 2.0 0.7 2.9 2.9 55.6
0.25 0.1 29.0 10.5 0.0 4.3 2.5 0.0 46.3
1 1.3 26.9 10.8 1.5 6.4 2.3 3.6 51.5
5 0.3 30.8 10.5 0.4 3.7 0.0 0.0 45.4
10 2.2 36.6 12.4 2.2 7.9 4.2 4.0 67.3
20 0.6 31.7 12.0 1.2 5.6 2.3 0.0 52.8
40 2.4 34.4 14.3 2.6 8.9 3.9 0.0 64.1
80 0.0 28.7 10.5 0.7 4.8 1.2 0.0 45.9
with ampicillin for 24 h (replicate 3)
in caecal liquor following in vitro incubation
Cone (M-g/ml) L A P IB B IV V Total
0 0.0 37.2 11.6 0.0 6.7 0.0 o.b 56.5
0.25 0.0 34.4 11.5 0.0 9.3 0.0 0.0 55.2
1 0.0 38.7 13.7 0.0 11.4 1.4 0.0 65.2
5 0.0 27.9 9.8 0.0 9.7 0.3 0.0 47.7
10 0.9 29.8 9.6 0.3 10.5 0.0 0.0 50.2
20 0.0 30.9 8.9 0.0 11.6 0.2 0.0 51.6
40 0.4 36.1 10.9 1.3 10.8 0.5 0.0 59.6
80 0.0 27.8 8.8 0.0 7.0 0.5 0.0 44.1
Table B57a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with ampicillin for 3 h (replicate 4)
Cone, (jig/ml) L A P IB B IV V Total
0 0.0 30.9 9.2 0.7 4.1 0.0 0.0 44.9
0.25 0.2 35.7 11.8 0.0 10.7 0.3 0.0 58.5
1 0.0 32.8 12.5 0.0 10.6 0.3 0.0 56.2
5 0.0 34.1 13.4 0.0 10.3 0.7 0.0 58.5
10 0.0 31.7 12.5 0.5 10.0 0.7 0.0 55.4
20 0.1 38.2 12.3 0.0 10.6 2.2 0.0 63.3
40 0.5 36.6 13.0 0.0 11.4 0.0 0.0 61.0
80 0.5 40.7 17.5 0.0 12.8 0.3 0.0 71.3
Table B57b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with ampicillin for 24 h (replicate 4)
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3 h 24 h
Cone (M-g/ml)
0
0.25
1
5
10
20
40
80
0.5±0.2
1.5±0.6
0.9±0.3
1.1±0.7
1.4±0.4
0.9±0.4
1.0±0.5
0.910.4
Total
48.713.7
53.214.0
55.814.3
56.515.1
58.416.4
53.915.7
63.117.4 
57.115.9
0.810.5
0.710.3
0.310.3
1.210.6
0.710.5
1.010.4
0.810.5
0.810.3
Table B58. SCFA concentrations (mmol/1) (meaniSEM) m caeca 
incubation with ampicillin
Total
49.915.0
53.615.3 
53.412.5 
60.215.9
62.114.4 
64.7110.6 
56.7+6.5
57.517.1 
liquor following in vitro
Cone, (jig/ml) 1 2 3 4 meaniSEM
0 0.00 0.00 0.00 0.00 0.0010.00
1 1.05 0.99 0.92 0.85 0.9510.04
2 2.11 1.98 2.65 2.19 2.2310.15
5 5.56 4.87 4.60 4.77 4.9510.21
10 9.49 9.76 8.42 8.24 8.9810.38
1 h
Cone. (M-g/ml) 1 2 3 4 5 (T meaniSEM
0
10
25
50
100
0.00
6.88
30.77
62.96
127.98
0.00
8.13
24.38
52.74
105.68
0.00
8.48
22.98
62.26
86.96
0.00
8.04
26.14
46.83
89.87
0.00
6.92
23.19
44.47
87.82
0.00
0.30
24.73
80.62
141.39
0.0010.00
6.4611.26
25.3711.18
58.3115.44
106.6219.46
"able B60a. Concentrations (|ig/ml) 
pH 1.9 for 3 h
of ampicillin following incubation in vitro with hay i
Cone. (|ig/ml) 1 2 3 4 5 6 meaniSEM
0
10
25
50
100
0.00
0.21
7.55
10.98
51.67
0.00
3.85
5.99
15.53
32.69
0.00
1.57
8.23
15.78
43.68
0.00
I.73
II.17 
27.98 
59.56
0.00
2.41
10.28
29.94
89.94
0.00
4.72
10.78
32.57
74.92
0.0010.00
2.4210.67
9.0010.84
22.1313.71
58.7418.55
able B60b. Concentrations (|ig/ml) of ampicillin following incubation in vitro with hay at 
pH 7.0 for 3 h
Appendix C - Amikacin
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Time (h) Horse 3 Horse 4 Horse 5 mean±SEM
0 0.00 0.00 0.00 o.ooto.oo
0.033 67.79 30.20 78.48 58.82±14.64
0.083 49.64 21.23 60.16 43.68±11.63
0.25 36.88 17.90 55.80 36.86±10.94
0.5 27.53 17.22 41.58 28.78±7.06
0.75 27.33 15.70 33.16 25.40±5.13
1.0 26.60 14.28 29.56 23.48±4.68
1.5 21.46 12.97 26.10 20.18±3.84
2 19.60 12.83 16.38 16.27±1.96
4 13.49 11.33 8.56 11.13±1.43
6 8.71 12.16 3.46 8.11±2.53
8 6.66 7.70 1.76 5.37±1.83
12 2.39 2.92 0.47 1.93±0.74
24 0.00 0.00 0.00 0.00±0.00
Table C l. Plasma concentrations (jig/ml) of amikacin following intravenous administration 
to horses
Time (h) Pony 7 Pony 8 Pony 9 Pony 10 meaniSEM
0 0.00 0.00 0.00 0.00 O.OOiti.M
0.033 56.59 64.00 65.64 62.47 62.17±2.26
0.083 47.14 53.95 51.11 56.50 52.1712.79
0.25 38.95 41.25 38.54 40.51 39.81i0.68
0.5 27.13 39.44 22.23 28.96 29.4413.83
0.75 25.49 33.99 19.35 23.80 25.6613.15
1 23.15 28.33 14.33 17.86 20.9213.02
1.5 15.45 18.00 9.21 12.14 13.7011.70
2 12.70 14.90 7.14 9.83 11.1411.47
4 4.20 7.79 2.51 3.42 4.4811.35
6 2.01 4.73 0.99 1.11 2.2111.09
8 0.88 2.67 0.57 0.54 1.1610.66
24 0.00 0.00 0.00 0.00 0.0010.00
Table C2. Plasma concentrations (fig/ml) of amikacin following intravenous administration 
to ponies
Time (h) Donkey 14 Donkey 15 Donkey 16 meaniSEM
0 0.00 0.00 0.00 0.0010.00
0.033 71.83 54.79 85.07 70.5618.77
0.083 57.80 38.41 76.65 57.62111.04
0.25 45.90 29.72 45.01 40.2115.25
0.5 40.90 23.78 39.78 34.8215.53
0.75 28.06 21.38 32.05 27.1613.11
1 26.56 19.53 31.34 25.8113.43
1.5 23.66 14.56 27.89 22.0413.93
2 17.23 9.79 24.62 17.2114.28
4 10.32 5.75 11.49 9.1911.75
6 5.75 1.91 7.67 5.1111.70
8 3.95 0.82 4.24 3.0011.10
12 0.82 0.10 1.19 0.7110.32
24 0.00 0.00 0.00 0.0010.00
Table C3. Plasma concentrations (|ig/ml) of amikacin following intravenous administration
to donkeys
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Parameter Horse 3 Horse 4 Horse 5
tl/2 B2 (h) 0.05 0.21 0.22
tl/2 B1 (h) 3.24 5.01 1.82
CpO (jig/ml) 88.66 28.77 77.34
Vc (ml/kg) 67.67 208.53 77.58
AUCobs (|ig.h/ml) 159.80 129.59 119.07
AUMCobs (|ig.h2/ml) 687.96 689.51 283.99
AUC (p.g.h/ml) 155.65 132.03 116.38
AUMC (jig. h2/ml) 709.14 932.14 278.20
MRT(h) 4.31 5.32 2.39
Vdarea (ml/kg) 180.25 328.68 135.67
Vdss (ml/kg) 175.63 320.86 123.24
CLb (ml/h.kg) 38.55 45.45 51.56
kel(/h) 0.57 0.22 0.67
k21 (/h) 5.20 2.13 1.78
kl2(/h) 8.30 1.15 1.05
Table C4. Disposition kinetics of amikacin following intravenous administration to horses
Parameter Pony 7 Pony 8 Pony 9 Pony 10
tl/2  B2 (h) 0.17 0.42 0.16 0.19
tl/2  B1 (h) 1.48 2.59 1.44 1.34
CpO (jig/ml) 57.57 63.65 70.92 66.95
Vc (ml/kg) 104.23 94.27 84.60 89.62
AUCobs (|ig.h/ml) 82.31 123.84 58.90 70.44
AUMCobs (pg.h2/ml) 183.83 386.76 112.13 130.76
AUC (pg.h/ml) 77.51 110.50 55.58 66.83
AUMC (|i.g.h2/ml) 154.30 335.89 93.80 111.36
MRT(h) 2.23 3.12 1.90 1.86
Vdarea (ml/kg) 165.49 202.84 223.80 173.00
Vdss (ml/kg) 154.08 165.05 182.18 149.61
CLb (ml/h.kg) 77.41 54.30 108.00 89.78
kel (/h) 0.74 0.58 1.28 1.00
k21 (/h) 2.51 0.77 1.61 1.85
kl2(/h) 1.20 0.58 1.86 1.24
Table C5. Disposition kinetics of amikacin following intravenous administration to ponies
Parameter Donkey 14 Donkey 15 Donkey 16
tl/2 B2 (h) 0.14 0.03 0.07
tl/2 B1 (h) 2.23 1.48 2.34
CpO (|ig/ml) 74.18 79.03 110.69
Vc (ml/kg) 80.89 75.92 54.21
AUCobs (jxg.h/ml) 131.17 70.66 158.05
AUMCobs (pg.h2/ml) 409.29 149.91 508.38
AUC (jig.h/ml) 129.15 68.33 151.31
AUMC (|ig.h2/ml) 392.76 141.03 488.82
MRT(h) 3.12 2.12 3.22
Vdarea (ml/kg) 149.16 187.50 133.90
Vdss (ml/kg) 141.28 181.24 128.11
CLb (ml/h.kg) 46.46 87.81 39.66
kel (/h) 0.57 1.16 0.73
k21 (/h) 2.70 8.36 4.08
kl2(/h) 2.02 11.59 5.57
Table C6. Disposition kinetics of amikacin following intravenous administration to donkeys
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Time (h) Horse 3 Horse 4 Horse 5 mean±SEM
coliform s
0
24
48
2.00E+07
1.00E+04
1.00E+05
1.00E+05
4.00E+03
1.00E+05
1.00E+05 
1.00E+06 
1.00E+05
6.73E+06±6.63E+06 
3.38E+05±3.31E+05 
1.00E+05+0.00E+05
streptococci
0 1.00E+10 5.00E+06 3.00E+07 3.35E+09±3.33E+09
24 1.00E+08 3.00E+06 1.00E+08 6.77E+07±3.23E+07
48 2.00E+09 2.00E+06 4.00E+06 6.69E+08±6.66E+08
lacto bacilli
0 1.00E+05 1.00E+04 3.00E+05 1.37E+05±8.57E+04
24 5.00E+05 2.00E+05 1.00E+04 2.37E+05± 1.43E+05
48 4.00E+04 3.00E+04 5.00E+03 2.50E+04±1.04E+04
Bacteroides spp.
0 1.00E+10 1.10E+06 1.20E+07 3.34E+09±3.33E+09
24 2.00E+09 2.20E+07 1.00E+11 3.40E+10±3.30E+10
48 1.00E+06 3.60E+06 2.20E+08 7.49E+07±7.26E+07
Clostridium spp.
0 2.10E+04 - 1.00E+04 1.55E+04±4.49E+03
24 - 1.00E+05 - 1.00E+05
48 - - 1.00E+04 1.00E+04
Table C7. Counts of viable bacteria per g faeces following intravenous administration of 
amikacin to horses
Time (h) | Pony 7 | Pony 8 Pony 9 Pony 10 | mean±SEM
coliform s
0
24
48
1.00E+06
1.30E+04
1.00E+04
2.00E+05
1.00E+04
1.00E+06
2.00E+05 
1.00E+05 
2.00E+05
2.00E+05
1.00E+06
2.00E+04
4.00E+05±2.00E+05 
2.81 E+05±2.41E+05 
3.08E+05±2.35E+05
streptococci
0
24
48
1.00E+06
4.00E+04
1.00E+05
6.00E+04
4.00E+04
1.00E+05
5.00E+06
1.00E+04
1.00E+05
1.80E+05
2.00E+04
1.00E+05
1.56E+06±1.17E+06 
2.75E+04±7.50E+03 
1.00E+05±0.00E+00
lactobacil l
0
24
48
5.00E+04
1.00E+06
1.00E+07
2.00E+07
1.00E+05
3.00E+04
2.00E+10
8.00E+04
2.00E+06
3.00E+04
3.00E+03
1.00E+05
5.01 E+09±5.00E+09 
2.96E+05±2.36E+05 
3.03E+06±8.83E+06
Bacteroides spp.
0
24
48
1.00E+06
1.80E+05
7.00E+06
4.00E+07
1.00E+08
4.20E+09
1.10E+07
1.60E+06
2.10E+06
5.00E+06
3.00E+06
2.10E+10
1.43E+07±8.83E+06
2.62E+07±2.46E+07
6.30E+09±5.00E+09
Clostridium spp.
0
24
48
1.00E+04
1.00E+03
2.00E+04
2.00E+04
1.00E+04
1.00E+03
1.00E+04
3.00E+04
1.00E+03
1.53E+04±6.26E+03
1.00E+03
1.03E+04±3.88E+03
Table C8. Counts of viable bacteria per g faeces following intravenous administration of
amikacin to ponies
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Time (h) Donkey 14 Donkey 15 Donkey 16 meaniSEM
coliforms
0 1.90E+04 2.00E+03 2.00E+04 1.37E+0415.84E+03
24 1.00E+03 1.00E+04 5.00E+04 2.03E+0411.51E+04
48 2.00E+04 1.00E+06 1.00E+04 3.43E+0513.28E+05
streptococci
0 4.00E+04 - 4.00E+03 2.20E+0411.80E+04
24 1.00E+05 1.00E+03 7.00E+03 3.60E+0413.20E+04
48 2.00E+03 2.00E+05 3.00E+03 6.83E+0416.58E+04
lactobacilli
0 6.00E+05 7.00E+04 4.00E+07 1. 36E+07 ± 1.32E+07
24 7.00E+05 1.30E+05 1.00E+05 3.10E+0511.95E+05
48 4.00E+05 5.00E+04 2.00E+04 1.57E+0511.22E+05
Bacteroides spp.
0 9.50E+06 2.00E+09 1.00E+05 6.70E+0816.65E+08
24 1.00E+06 2.20E+06 3.00E+05 1. 17E+0615.55E+05
48 1.00E+06 1.60E+05 3.20E+07 1.11 E+0711.05E+07
Clostridium spp.
0 1.00E+07 - - 1.00E+07
24 3.00E+05 - - 3.00E+05
48 3.00E+05 - - 3.00E+05
Table C9. Counts of viable bacteria per g faeces following intravenous administration of 
amikacin to donkeys
Time (h) L A p IB B IV V Total
0 0.0 0.0 0.0 0.0 43.4 0.0 0.0 43.4
24 0.0 0.0 0.0 0.0 122.2 0.0 0.0 122.2
48 1.5 1.1 5.5 1.4 5.7 1.2 0.0 14.9
Table CIO. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to horse 3
Time (h) L A P IB B IV V Total
0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 2.7
24 1.2 1.8 0.0 0.7 31.5 1.2 0.0 35.2
48 0.0 0.0 0.0 0.0 33.0 0.0 0.0 33.0
Table C ll. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to horse 4
Time (h) L A P IB B IV V Total
0 2.4 2.9 6.5 0.0 55.0 0.0 0.0 64.4
24 0.0 0.0 0.0 0.0 109.8 0.0 0.0 109.8
48 0.0 0.0 0.0 0.0 72.9 0.0 0.0 72.9
Table C l2. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to horse 5
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table C l3. SCFA concentrations (mmol/kg) in faeces following intravenous administration
of amikacin to pony 7
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Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table C l4. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to pony 8
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table C l5. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to pony 9
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
of amikacin to pony 10
Time (h) L A P IB B IV V Total
0 0.0 2.1 2.5 0.0 0.0 0.0 0.0 4.6
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 3.7 6.3 17.1 0.0 0.0 0.0 0.0 23.4
Table C17. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to donkey 14
Time (h) L A P IB B IV V Total
0 1.9 4.9 1.9 0.0 71.6 0.0 0.0 78.4
24 5.6 9.0 6.7 0.0 81.6 0.0 0.0 97.3
48 2.5 1.9 8.2 0.0 41.2 0.0 0.0 51.3
Table C l8. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to donkey 15
Time (h) L A P IB B IV V Total
0 1.8 5.2 0.0 0.0 69.6 0.0 0.0 74.8
24 1.4 5.2 10.1 0.0 64.8 0.0 0.0 80.1
48 1.8 5.2 9.5 0.0 56.1 0.0 0.0 70.8
Table C19. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of amikacin to donkey 16
Horses Ponies Donkeys
Time (h) L Total L Total L Total
0 0.8±0.8 36.8±18.11 0.0±0.0 0.0±0.0 1.2±0.6 52.6±24.0
24 0.4±0.4 89.1±27.2 0.0±0.0 0.0±0.0 2.3±1.7 59.1±30.0
48 0.5±0.5 40.3±17.1 0.0±0.0 0.0±0.0 2.7±0.6 48.5±13.8
Table D20. SCFA concentrations (mmol/kg) (mean±SEM) in faeces following intravenous 
administration of amikacin to horses, ponies and donkeys
Time (h) Horse 3 Horse 4 Horse 5 mean±SEM
0 22.34 21.97 20.01 21.44±0.72
24 20.30 19.36 16.89 18.8511.02
48 19.82 18.81 20.98 19.8710.63
Table C21. Faecal dry matter content (%) following intravenous administration of amikacin
to horses
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Time (h) Pony 7 Pony 8 Pony 9 Pony 10 mean±SEM
0 16.88 21.54 19.51 24.46 20.60±1.60
24 17.35 20.55 21.64 20.13 19.92±0.91
48 19.41 20.20 18.62 23.71 20.49±1.12
to ponies
Time (h) Donkey 14 Donkey 15 Donkey 16 mean±SEM
0 22.01 20.23 22.84 21.69±0.77
24 23.02 18.00 19.76 20.26±1.47
48 17.04 20.03 20.02 19.03±1.00
Table C23. Faecal dry matter content (%) following intravenous administration of amikacin 
to donkeys
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.033 58.27 57.93 56.99 55.73
0.083 43.12 49.87 43.97 54.46
0.25 42.04 39.86 38.85 47.35
0.5 35.59 36.15 30.40 33.88
0.75 29.15 22.59 30.79 23.55
1 23.52 21.55 22.93 22.53
1.5 22.29 20.27 20.59 18.81
2 16.11 18.09 18.25 16.82
4 8.42 11.99 8.67 10.41
6 3.83 7.81 3.59 5.51
8 2.18 3.92 2.05 4.14
12 0.84 1.90 0.42 1.24
24 0.00 0.04 0.00 0.00
Table C24. Plasma concentrations (fig/ml) of amikacin following intravenous administration 
to ponies
Time (h) II
0
24
48
0
24
48
0
24
48
0
24
48
0
24
48
12
coliforms
III 112
1.00E+06
2.00E+04
1.00E+05
2.00E+04
2.00E+05
2.00E+05
1.00E+06
2.00E+04
1.00E+05
4.00E+09
1.00E+06
1.00E+05
streptococci
1.00E+05
2.00E+04
1.00E+05
1.00E+06
1.00E+05
1.00E+04
lactobacil
1.00E+06
1.50E+06
2.00E+05
1.00E+08
1.00E+06
6.00E+04
1.00E+07
2.00E+05
5.00E+04
2.00E+08
4.00E+05
1.00E+05
1.00E+05
1.00E+06
1.00E+06
Bacteroides spp.
2.00E+06
1.00E+07
2.00E+06
3.00E+10
3.10E+10
2.30E+08
1.00E+08
1.10E+11
1.70E+11
7.80E+10
2.20E+10
2.00E+09
Clostridium spp.
1.00E+11 
1.50E+11 
1.40E+11
1.10E+05
2.00E+04
1.00E+03
2.00E+03
1.00E+03
Table C25. Counts of viable bacteria
administration of amikacin to ponies
per m
1.00E+04
4.00E+03
1.00E+03
caecal liq
2.00E+04
uor following intravenous
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Time (h) 11 12 III 112
0 6.6 6.6 6.8 6.7
0.25 6.7 6.7 6.9 6.8
0.5 6.7 6.9 6.8 6.9
0.75 6.7 6.9 6.9 6.8
1 6.7 6.9 6.9 6.9
1.5 6.7 7.0 6.8 6.8
2 6.7 7.0 6.9 6.8
4 6.7 6.8 6.8 7.0
6 6.7 6.6 6.9 6.6
8 6.7 6.5 6.9 6.7
12 6.9 6.5 6.9 6.8
24 6.9 7.0 6.9 6.7
48 7.1 6.9 7.2 6.9
Table C26. Caecal liquor pH following intravenous administration of amikacin to ponies
Time (h) L A P IB B IV V Total
0 2.1 31.5 12.9 0.9 12.0 2.9 2.4 62.6
0.25 1.9 28.8 12.0 0.0 16.7 1.2 0.0 58.7
0.5 1.9 27.5 10.2 0.5 10.5 1.0 0.0 49.7
0.75 0.9 24.3 10.0 0.0 10.6 0.0 0.0 44.9
1 1.7 22.6 9.5 0.3 9.3 0.8 0.7 43.2
1.5 1.9 22.5 9.8 0.0 13.2 0.0 0.0 45.5
2 2.9 24.8 11.7 0.0 15.4 0.8 0.7 53.4
4 8.9 27.2 17.9 0.0 56.0 0.0 0.0 101.1
6 5.7 27.0 13.0 0.0 25.3 0.0 0.0 65.3
8 3.6 27.3 14.2 0.0 24.0 0.4 0.0 65.9
12 2.2 28.4 12.2 0.0 16.5 0.0 0.0 57.1
24 1.0 19.8 9.6 0.0 13.5 0.0 0.0 42.9
48 2.0 16.3 10.2 0.0 8.4 0.6 0.0 35.5
administration of amikacin to pony II
in caeca liquor following intravenous
Time (h) A P B P+B
0 50.3 20.6 19.2 39.8
0.25 49.1 20.4 28.4 48.9
0.5 55.3 20.5 21.1 41.6
0.75 54.1 22.3 23.6 45.9
1 52.3 22.0 21.5 43.5
1.5 49.5 21.5 29.0 50.5
2 46.4 21.9 28.8 50.7
4 26.9 17.7 55.4 73.1
6 41.3 19.9 38.7 58.7
8 41.4 21.5 36.4 58.0
12 49.7 21.4 28.9 50.3
24 46.2 22.4 31.5 53.8
48 45.9 28.7 23.7 52.4
Table C27b. VFA concentrations (%) in caecal liquor following intravenous administration
of amikacin to pony II
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Time (h) L A P IB B IV V Total
0 1.7 26.1 7.6 0.6 11.4 1.9 0.0 47.6
0.25 0.7 25.5 8.5 0.2 8.7 0.4 0.0 43.3
0.5 1.3 21.5 7.9 0.4 9.1 0.6 0.0 39.5
0.75 0.6 21.7 8.1 0.0 10.5 0.5 1.6 42.4
1 1.4 23.1 9.6 0.7 13.2 1.2 2.2 50.0
1.5 0.7 23.4 7.5 0.0 24.9 0.0 0.0 55.8
2 2.1 21.9 7.7 0.6 20.6 1.0 1.8 53.6
4 1.1 35.1 10.8 0.6 9.3 0.8 0.0 56.6
6 2.0 12.8 5.2 1.2 8.0 1.9 0.0 29.1
8 1.1 28.9 8.6 0.0 19.1 0.9 0.0 57.5
12 3.3 50.5 12.1 0.0 68.7 0.0 0.0 131.3
24 1.1 21.8 8.7 0.0 12.4 0.0 0.0 42.9
48 1.9 26.1 9.7 0.6 20.2 1.1 0.0 57.7
administration of amikacin to pony 12
in caeca liquor following intravenous
Time (h) A P B P+B
0 54.8 16.0 23.9 39.9
0.25 58.9 19.6 20.1 39.7
0.5 54.4 20.0 23.0 43.0
0.75 51.2 19.1 24.8 43.9
1 46.2 19.2 26.4 45.6
1.5 41.9 13.4 44.6 58.1
2 40.9 14.4 38.4 52.8
4 62.0 19.1 16.4 35.5
6 44.0 17.9 27.5 45.4
8 50.3 15.0 33.2 48.2
12 38.5 9.2 52.3 61.5
24 50.8 20.3 28.9 49.2
48 45.2 16.8 35.0 51.8
of amikacin to pony 12
Time (h) L A P IB B IV V Total
0 1.0 37.4 13.7 1.6 8.5 2.1 0.0 63.3
0.25 1.6 33.0 12.5 1.6 9.6 3.1 0.0 59.8
0.5 0.2 34.5 13.3 1.0 9.6 1.3 0.0 59.7
0.75 1.4 35.3 14.0 1.4 11.9 3.0 0.0 65.6
1 0.5 36.1 12.9 0.8 10.3 3.5 0.0 63.6
1.5 1.5 33.6 13.3 1.8 11.5 2.5 0.0 62.7
2 0.5 34.5 13.6 1.3 12.3 2.1 1.3 65.1
4 3.6 38.1 16.1 1.7 18.4 4.0 1.8 80.1
6 0.9 31.2 13.4 1.2 12.6 1.8 0.0 60.2
8 3.0 37.5 15.9 2.2 14.0 3.6 1.7 74.9
12 1.0 36.9 15.4 0.6 12.0 4.6 0.0 69.5
24 2.0 32.2 12.9 1.2 13.5 3.1 1.3 64.2
48 0.7 33.1 13.6 0.0 12.0 0.0 0.0 58.7
administration of amikacin to pony III
caeca liquor following intravenous
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Time (h) A P B P+B
0 59.1 21.6 13.4 35.1
0.25 55.2 20.9 16.1 37.0
0.5 57.8 22.3 16.1 38.4
0.75 53.8 21.3 18.1 39.5
1 56.8 20.3 16.2 36.5
1.5 53.6 21.2 18.3 39.6
2 53.0 20.9 18.9 39.8
4 47.6 20.1 23.0 43.1
6 51.8 22.3 20.9 43.2
8 50.1 21.2 18.7 39.9
12 53.1 22.2 17.3 39.4
24 50.2 20.1 21.0 41.1
48 56.4 23.2 20.4 43.6
Table C29b. VFA concentrations (%) in caecal liquor following intravenous administration 
of amikacin to pony III
Time (h) L A P IB B IV V Total
0 1.0 51.7 15.5 0.7 11.3 0.0 6.0 79.2
0.25 2.4 45.1 13.5 1.7 11.8 0.0 0.0 72.1
0.5 1.1 43.0 12.2 0.0 11.9 0.0 0.0 67.1
0.75 1.5 32.9 10.6 0.5 7.7 0.0 0.0 51.7
1 1.9 40.6 13.9 0.0 11.5 0.0 0.0 66.0
1.5 1.5 34.8 12.0 1.9 12.5 1.3 0.0 62.5
2 0.0 32.5 10.8 0.9 8.2 0.0 0.0 52.4
4 0.5 19.4 7.4 0.0 41.6 1.4 0.0 69.8
6 3.3 39.3 10.9 2.3 29.4 2.3 3.4 87.6
8 0.4 32.9 10.5 0.9 28.6 1.2 0.0 74.1
12 1.3 52.9 15.4 0.9 23.9 1.5 0.0 94.6
24 2.4 40.1 15.7 2.3 15.6 0.0 0.0 73.7
48 0.0 51.6 15.7 0.0 16.2 0.0 0.0 83.5
Table C30a. SCFA concentrations (mmol/1) in caeca 
administration of amikacin to pony 112
liquor following intravenous
Time (h) A P B P+B
0 65.3 19.6 14.3 33.8
0.25 62.6 18.7 16.4 35.1
0.5 64.1 18.2 17.7 35.9
0.75 63.6 20.5 14.9 35.4
1 61.5 21.1 17.4 38.5
1.5 55.7 19.2 20.0 39.2
2 62.0 20.6 15.6 36.3
4 27.8 10.6 59.6 70.2
6 44.9 12.4 33.6 46.0
8 44.4 14.2 38.6 52.8
12 55.9 16.3 25.3 41.5
24 54.4 21.3 21.2 42.5
48 61.8 18.8 19.4 38.2
of amikacin to pony 112
Time (h) L A P IB B IV V Total
0 2.9 15.3 8.4 0.4 16.4 1.5 0.0 42.0
24 4.5 2.6 5.4 2.4 8.3 0.0 0.0 18.7
48 1.1 10.1 10.2 0.0 31.0 0.0 0.0 51.3
of amikacin to pony II
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Time (h) L A P IB B IV V Total
0 0.0 1.5 1.0 0.0 10.9 0.0 0.0 13.4
24 0.0 2.2 0.0 0.0 40.5 0.0 0.0 42.7
48 0.0 1.0 0.0 0.0 9.1 1.4 0.0 11.5
of amikacin to pony 12
Time (h) L A P IB B IV V Total
0 5.6 3.0 0.0 0.0 179.3 0.0 0.0 182.3
24 1.0 0.0 6.5 0.0 95.6 0.0 0.0 102.1
48 2.2 10.5 10.0 0.0 23.4 1.9 0.0 45.8
of amikacin to pony HI
Time (h) L A P IB B IV V Total
0 1.7 2.2 3.4 1.6 17.3 1.3 0.0 25.S
24 0.0 2.2 0.0 0.0 29.4 0.0 0.0 31.6
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
of amikacin to pony 112
Time (h) 11 12 III 112
0 22.89 18.63 22.82 19.66
24 25.09 22.66 26.66 23.04
48 24.33 23.79 22.16 20.46
to ponies
II 12
Time (h) 0 24 48 0 24 120
urea (mmol/1) 3.2 4.2 4.0 2.4 3.2 2.4
sodium (mmol/1) 134 142 137 134 137 137
potassium (mmol/1) 4.2 1.3 2.8 3.9 3.2 4.2
chloride (mmol/1) 96 99 97 98 97 99
calcium (mmol/1) 2.92 2.80 2.98 3.35 2.84 3.05
magnesium (mmol/1) 0.58 0.52 0.69 0.80 0.60 0.59
phosphate (mmol/1) 0.75 1.12 0.93 1.05 1.32 1.07
creatinine (pmol/1) 117 117 128 123 128 121
bilirubin (jimol/1) 7 6 8 6 7 6
SAP (U/l) 270 276 290 273 270 264
AST (U/l) 266 290 317 311 322 293
GGT (U/l) 21 20 18 27 23 20
total protein (g/1) 69 75 77 77 76 69
albumin (g/1) 28 30 30 31 30 29
globulin (g/1) 41 45 47 46 46 40
Table C36. Plasma biochemistry following intravenous administration of amikacin to pony I
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III 112
Time (h) 0 24 48 0 24 126
urea (mmol/1) 3.3 3.1 3.5 1.6 1.0 1.0
sodium (mmol/1) 134 139 137 134 132 136
potassium (mmol/1) 4.0 2.3 2.6 3.5 4.0 3.3
chloride (mmol/1) 99 100 101 97 99 97
calcium (mmol/1) 2.77 2.89 2.95 2.95 3.29 3.04
magnesium (mmol/1) 0.66 0.64 0.69 0.65 0.73 0.70
phosphate (mmol/1) 0.96 1.05 1.31 1.30 0.78 1.11
creatinine (|imol/l) 105 110 119 112 112 109
bilirubin (p.mol/1) 8 9 10 11 11 9
SAP (U/l) 265 261 278 267 292 285
AST (U/l) 255 270 288 330 366 329
GGT (U/l) 25 20 22 28 28 29
total protein (g/1) 77 80 81 74 83 72
albumin (g/1) 28 29 31 28 32 29
globulin (g/1) 49 51 50 46 51 43
n
II 12
Time (h) 0 24 48 0 24 120
WCC (x 109/1) 7.0 8.1 6.1 7.6 7.0 6.8
RCC (x 1012/1) 6.16 6.28 5.92 £.04 7.05 6.10
Hb (g/dl) 10.8 11.5 10.8 13.4 12.0 10.9
Hct (1/1) 0.309 0.318 0.306 0.381 0.357 0.307
MCV (fl) 50 51 52 47 51 50
MCH (pg) 17.5 18.3 18.2 16.6 17.0 17.8
MCHC (g/dl) 34.9 36.1 35.2 35.1 33.6 35.5
PLTS (109/1) 100 114 108 104 122 102
MPV (fl) 6.4 6.3 6.3 6.2 6.0 6.2
PCT (%) 0.064 0.071 0.068 0.064 0.073 0.063
PDW 15.6 17.4 15.8 16.1 15.0 16.1
Neu (%) 46.9 42.0 32.5 32.5 35.0 36.0
Lym (%) 49.9 56.0 64.0 64.5 61.0 61.5
Mon (%) 2.6 1.0 1.5 2.0 2.0 1.5
Eos (%) 0.6 1.0 1.5 1.0 1.6 1.0
Bas (%) 0.0 0.0 0.5 0.0 0.4 0.0
Table C38. Haematology parameters following intravenous administration of amikacin to
pony I
Ill 112
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Table C39. K 
pony II
Time (h) 0 24 48 0 24 120
WCC (x 109/1) 5.8 6.4 6.3 7.1 6.6 6.8
RCC (x 1012/1) 6.90 6.55 6.83 8.71 6.46 7.03
Hb (g/dl) 10.6 10.9 11.2 13.5 10.2 11.3
Hct (1/1) 0.312 0.300 0.315 0.387 0.i97 6.323
MCV (fl) 45 46 46 44 46 46
MCH (pg) 15.3 16.6 16.3 15.4 15.7 16.0
MCHC (g/dl) 33.9 36.3 35.5 34.8 34.3 34.9
PLTS (109/1) 113 98 104 92 97 87
MPV (fl) 6.6 6.5 6.4 6.7 6.8 6.8
PCT (%) 0.074 0.063 0.066 0.061 0.065 0.656
PDW 15.1 16.9 17.1 16.4 16.1 17.6
Neu (%) 45.0 40.5 45.0 43.9 40.4 40.5
Lym (%) 51.5 54.6 48.5 49.9 59.6 53.0
Mon (%) 2.9 3.4 3.0 5.0 0.0 4.6
Eos (%) 0.5 0.9 3.0 0.6 0.0 0.4
Bas (%) 0.0 0.5 0.5 0.6 0.0 1.5
aematology parameters following intravenous of amikacin to
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.06
0.25 0.00 0.00 0.00 0.00
0.5 0.00 0.00 0.00 0.00
0.75 0.00 0.00 0.00 0.00
1 6.00 26.54 0.00 0.00
1.5 79.71 83.68 0.00 0.00
2 99.37 49.10 0.00 0.00
4 46.06 27.12 0.76 0.00
6 19.72 4.86 11.83 4.22
8 9.74 1.18 21.65 12.59
12 1.11 0.22 12.37 16.19
24 0.00 0.00 0.94 3.29
28 0.00 0.00 1.05 1.68
32 0.00 0.00 0.36 0.63
48 - 0.00 - 0.00
Table C40. Caecal liquor concentrations (jig/ml) of amikacin following oral administration to 
ponies
Time (h) 11 12 III 112 Pony 13
0 0.00 0.00 0.00 0.00 0.00
24 20.99 17.65 17.88 4.06 46.28
48 3.54 1.18 5.08 2.74 6.93
72 0.00 0.00 0.00 0.00 -
96 0.00 0.00 0.00 0.00 -
Table C41. Faecal concentrations (pg/g) of amikacin following oral administration to ponies
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Time (h) 11 12 m 112 *Pony 13
colif orm s
0 1.00E+05 2.00E+05 2.00E+04 1.80E+04 1.00E+06
24 - 6.00E+04 2.00E+03 1.00E+03 2.10E+05
48 2.00E+04 2.00E+03 1.00E+04 4.00E+03 2.00E+06
72 2.00E+05 1.00E+07 1.00E+04 1.00E+07 7.00E+04
96 1.00E+09 1.00E+07 1.00E+04 1.00E+04 NS
168 2.00E+05 2.00E+03 1.80E+04 3.00E+03 NS
strep tococci
0 1.00E+04 9.00E+06 6.00E+04 3.00E+05 5.00E+04
24 2.00E+05 1.00E+07 2.00E+08 1.00E+05 2.00E+10
48 2.00E+07 1.00E+05 5.00E+05 1.00E+05 4.00E+10
72 6.00E+08 1.10E+05 2.00E+07 1.00E+05 3.00E+06
96 2.00E+07 5.00E+05 1.00E+05 4.00E+05 NS
168 9.00E+06 4.00E+04 3.00E+05 3.00E+06 NS
lacto bacilli
0 2.00E+05 3.00E+06 2.00E+05 2.00E+06 1.00E+06
24 1.00E+06 5.00E+08 3.00E+06 1.00E+06 3.00E+08
48 1.00E+05 1.00E+06 2.00E+05 4.00E+04 1.00E+09
72 1.00E+06 2.00E+05 1.00E+05 7.00E+05 3.00E+05
96 2.00E+06 2.00E+05 1.00E+07 2.00E+07 NS
168 3.00E+06 5.00E+07 2.00E+06 1.00E+05 NS
Bacteroides spp.
0 1.30E+11 9.70E+07 3.80E+11 1.00E+10 1.30E+08
24 1.50E+11 1.60E+11 7.10E+10 4.10E+10 2.10E+10
48 1.30E+11 2.00E+08 2.20E+11 1.20E+10 1.40E+11
72 1.40E+11 1.50E+11 1.50E+11 1.90E+11 1.30E+11
96 2.60E+11 1.00E+10 1.40E+09 1.60E+11 NS
168 9.70E+07 8.10E+10 1.00E+10 2.60E+11 NS
Clostridium spp.
0 1.60E+06 - 6.00E+06 1.10E+04 -
24 - - 2.30E+05 3.00E+03 1.00E+03
48 1.00E+04 2.00E+04 1.00E+06 1.00E+05 1.00E+07
72 - 2.00E+03 1.00E+04 - 3.20E+05
96 1.00E+03 - 1.00E+04 1.00E+04 NS
168 - - 1.10E+04 - NS
Table C42. Counts of viable bacteria per ml caecal liquor or *per g faeces following oral
administration of amikacin to ponies
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Time (h) 11 12 III 112
0 6.9 6.8 6.9 6.9
0.25 6.8 6.9 6.8 6.8
0.5 6.9 6.8 6.8 6.8
0.75 6.9 6.8 6.8 6.7
1 6.8 6.7 6.8 6.8
1.5 6.9 6.8 6.8 6.7
2 6.9 6.4 6.9 6.3
4 6.7 6.4 6.8 6.4
6 6.5 5.8 6.7 6.3
8 6.5 6.3 6.7 6.7
12 6.4 6.4 6.5 6.7
24 7.0 6.8 6.7 7.0
28 6.5 6.4 6.6 6.8
32 6.6 6.5 7.4 6.8
48 6.9 6.6 6.8 6.8
52 6.7 6.6 6.7 6.7
56 6.6 6.6 6.6 6.7
72 6.9 7.2 6.8 7.2
96 6.7 6.8 6.7 6.8
168 6.8 7.0 6.9 6.9
Table C43. Caecal liquor pH- following oral administration of amikacin to ponies
Time (h) L A P IB B IV V Total
0 0.9 29.9 9.9 0.0 15.5 0.0 0.0 55.3
0.25 1.5 19.1 7.4 1.1 9.9 1.2 1.7 40.4
0.5 0.5 20.1 6.9 0.0 10.0 0.0 0.0 37.0
0.75 1.0 15.1 7.5 0.3 5.5 0.0 0.0 28.4
1 0.0 21.3 12.5 0.0 13.9 0.0 0.0 47.7
1.5 0.9 14.5 4.7 0.2 3.1 0.0 0.0 22.5
2 11.1 23.2 12.5 0.6 7.7 0.8 0.0 44.8
4 24.4 39.7 16.6 0.0 13.0 0.0 0.0 69.3
6 22.9 37.9 18.7 0.0 11.3 0.0 0.0 67.9
8 12.9 24.0 20.0 1.5 14.9 1.3 0.0 61.7
12 16.1 22.9 13.8 0.0 13.5 0.0 0.0 50.2
24 1.3 18.3 10.4 0.0 12.4 0.0 0.0 41.1
28 17.5 27.3 12.4 0.5 6.4 1.0 0.0 47.6
32 1.2 36.4 13.1 0.6 9.7 0.0 0.9 60.7
48 0.6 34.4 14.4 0.0 32.0 0.0 0.0 80.8
52 6.5 27.5 12.1 0.0 33.7 0.0 0.0 73.3
56 8.0 27.4 10.5 0.9 18.3 1.7 1.6 60.4
72 1.2 23.9 10.5 0.0 17.8 0.0 0.0 52.2
96 0.7 31.9 7.8 0.0 17.6 0.0 1.2 58.5
168 0.3 23.6 13.0 0.0 6.4 0.0 0.0 43.0
amikacin to pony II
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 54.1 17.9 28.0 45.9
0.25 47.3 18.3 24.5 42.8
0.5 54.3 18.6 27.0 45.7
0.75 53.2 26.4 19.4 45.8
1 44.7 26.2 29.1 55.3
1.5 64.4 20.9 13.8 34.7
2 51.8 27.9 17.2 45.1
4 57.3 24.0 18.8 42.7
6 55.8 27.5 16.6 44.2
8 38.9 32.4 24.1 56.6
12 45.6 27.5 26.9 54.4
24 44.5 25.3 30.2 55.5
28 57.4 26.1 13.4 39.5
32 60.0 21.6 16.0 37.6
48 42.6 17.8 39.6 57.4
52 37.5 16.5 46.0 62.5
56 45.4 17.4 30.3 47.7
72 45.8 20.1 34.1 54.2
96 54.5 13.3 30.1 43.4
168 54.9 30.2 14.9 45.1
Table C44b. VFA concentrations (%) in caecal liquor following oral administration of 
amikacin to pony II
Time (h) L A P IB B IV V Total
0 0.3 23.6 13.0 0.0 6.4 0.0 6.0 43.0
0.25 0.7 22.5 14.4 0.0 9.1 0.0 0.0 46.0
0.5 1.0 19.0 9.5 0.0 6.7 0.0 0.0 35.2
0.75 0.5 20.4 9.3 0.0 6.7 0.0 0.0 36.4
1 0.4 16.8 7.7 0.0 6.5 0.0 0.0 31.0
1.5 0.4 16.6 6.7 0.0 5.4 0.0 0.0 28.7
2 1.2 21.5 7.4 0.3 6.6 0.0 0.0 35.8
4 22.9 19.8 8.8 0.0 4.2 0.0 0.0 32.8
6 26.4 20.1 10.2 0.0 3.7 0.0 0.0 34.0
8 24.9 20.6 10.2 0.5 5.2 1.1 0.0 37.6
12 28.8 17.4 9.4 0.0 3.7 0.0 0.0 30.5
24 15.7 16.6 14.6 0.0 8.4 0.0 0.0 39.6
28 14.8 18.4 12.9 0.0 6.8 0.0 0.0 38.1
32 13.0 18.9 10.0 0.0 6.9 0.0 0.0 35.8
48 3.1 25.8 11.4 0.0 17.8 0.0 0.0 55.0
52 4.0 31.8 13.5 0.0 12.1 0.0 0.0 57.4
56 1.6 21.1 9.4 0.0 12.1 0.0 0.0 42.6
72 0.6 19.4 9.6 0.0 11.2 0.0 0.0 40.2
96 2.1 29.6 10.5 0.0 8.1 0.0 0.0 48.2
168 2.8 21.0 9.3 1.2 8.5 1.1 0.9 42.0
amikacin to pony 12
in caecal liquor following oral administration of
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Time (h) A P B P+B
0 54.9 30.2 14.9 45.1
0.25 48.9 31.3 19.8 51.1
0.5 54.0 27.0 19.0 46.0
0.75 56.0 25.5 18.4 44.0
1 54.2 24.8 21.0 45.8
1.5 57.8 23.3 18.8 42.2
2 60.1 20.7 18.4 39.1
4 60.4 26.8 12.8 39.6
6 59.1 30.0 10.9 40.9
8 54.8 27.1 13.8 41.0
12 57.0 30.8 12.1 43.0
24 41.9 36.9 21.2 58.1
28 48.3 33.9 17.8 51.7
32 52.8 27.9 19.3 47.2
48 46.9 20.7 32.4 53.1
52 55.4 23.5 21.1 44.6
56 49.5 22.1 28.4 50.5
72 48.3 23.9 27.9 51.7
96 61.4 21.8 16.8 38.6
168 50.0 22.1 20.2 42.4
Table C45b. VFA concentrations (%) in caecal liquor following oral administration of 
amikacin to pony 12
Time (h) L A P IB B IV V Total
0 0.0 27.4 9.3 0.0 9.6 0.0 0.0 46.3
0.25 0.5 30.2 12.0 0.3 9.4 1.2 0.0 53.1
0.5 0.8 31.2 11.2 1.1 9.6 1.0 0.6 54.7
0.75 0.0 35.2 12.1 0.5 10.1 0.7 0.0 58.6
1 0.0 31.7 9.6 0.0 7.0 0.0 0.8 49.1
1.5 0.9 34.3 11.2 0.0 9.2 1.8 0.0 56.5
2 0.4 48.7 16.5 0.8 14.0 0.9 0.0 80.9
4 0.0 60.3 19.7 0.0 15.6 0.0 0.0 95.6
6 0.4 56.5 16.9 0.5 9.6 0.0 0.0 83.5
8 1.1 40.8 17.0 1.1 14.6 1.1 1.9 76.5
12 20.4 34.1 10.5 0.0 8.9 0.0 0.0 53.5
24 20.3 27.4 13.0 0.0 12.4 0.0 0.0 52.8
28 14.4 31.2 14.8 1.5 10.5 1.5 1.2 60.7
32 3.2 32.0 16.7 0.7 9.8 0.0 0.0 59.2
48 0.6 37.3 12.5 0.0 16.0 1.1 0.0 66.9
52 1.3 49.8 16.4 2.2 25.9 1.1 2.0 97.4
56 0.0 35.9 12.5 0.0 10.5 0.0 0.0 58.9
72 0.4 40.3 11.6 0.0 15.9 0.0 0.0 67.8
96 1.8 36.3 10.7 1.9 11.8 2.0 3.2 65.9
168 1.4 62.3 16.9 1.8 14.7 1.3 0.0 97.0
Table C46a. SCFA concentrations (mmol/1) in caecal liquor following oral administration of
amikacin to pony III
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Time (h) A P B P+B
0 59.2 20.1 20.7 40.8
0.25 56.9 22.6 17.7 40.3
0.5 57.0 20.5 17.6 38.0
0.75 60.1 20.6 17.2 37.9
1 64.6 19.6 14.3 33.8
1.5 60.7 19.8 16.3 36.1
2 60.2 20.4 17.3 37.7
4 63.1 20.6 16.3 36.9
6 67.7 20.2 11.5 31.7
8 53.3 22.2 19.1 41.3
12 63.7 19.6 16.6 36.3
24 51.9 24.6 23.5 48.1
28 51.4 24.4 17.3 41.7
32 54.1 28.2 16.6 44.8
48 55.8 18.7 23.9 42.6
52 51.1 16.8 26.6 43.4
56 61.0 21.2 17.8 39.0
72 59.4 17.1 23.5 40.6
96 55.1 16.2 17.9 34.1
168 64.2 17.4 15.2 32.6
Table C46b. VFA concentrations (%) in caecal liquor following oral administration of 
amikacin to pony III
Time (h) L A P IB B IV V Total
0 1.4 62.3 16.9 1.8 14.7 1.3 0.0 £7.0
0.25 1.4 35.7 10.1 1.6 5.8 1.6 0.0 54.8
0.5 0.3 39.5 10.1 0.9 6.9 0.0 0.0 57.4
0.75 0.0 32.3 9.2 0.7 3.9 0.0 0.0 46.1
1 0.8 35.8 8.8 0.0 4.7 0.0 0.0 49.3
1.5 0.0 47.1 11.5 0.5 6.5 0.0 0.0 65.6
2 1.6 33.7 10.8 2.2 7.2 1.8 2.2 57.9
4 0.5 33.2 9.2 0.0 4.7 0.0 0.0 47.1
6 0.0 36.1 9.3 0.0 5.1 0.0 0.0 50.5
8 1.2 41.3 14.6 1.5 6.4 1.6 0.0 65.4
12 0.6 41.5 18.3 0.0 7.2 0.0 0.0 67.0
24 7.8 31.8 12.3 0.0 4.4 0.6 0.0 49.1
28 5.2 35.6 16.2 1.6 5.6 1.7 2.9 63.6
32 0.6 29.9 12.9 0.3 4.8 0.0 0.0 47.9
48 0.8 38.8 14.1 0.3 8.4 0.0 0.0 61.6
52 1.5 34.8 13.3 1.3 7.8 0.0 0.0 57.2
56 5.8 35.3 13.5 0.0 10.0 0.0 0.0 58.8
72 2.3 34.9 15.2 0.0 9.1 0.0 0.0 59.2
96 1.1 33.4 15.0 0.7 8.9 0.8 0.0 58.8
168 0.4 28.8 8.5 0.5 5.4 0.6 0.0 43.8
Table C47a. SCFA concentrations (mmol/1) in caecal liquor following oral administration of
amikacin to pony 112
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Time (h) A P B P+B
0 64.2 17.4 15.2 32.6
0.25 65.1 18.4 10.6 29.0
0.5 68.8 17.6 12.0 29.6
0.75 70.1 20.0 8.5 28.4
1 72.6 17.8 9.5 27.4
1.5 71.8 17.5 9.9 27.4
2 58.2 18.7 12.4 31.1
4 70.5 19.5 10.0 29.5
6 71.5 18.4 10.1 28.5
8 63.1 22.3 9.8 32.1
12 61.9 27.3 10.7 38.1
24 64.8 25.1 9.0 34.0
28 56.0 25.5 8.8 34.3
32 62.4 26.9 10.0 37.0
48 63.0 22.9 13.6 36.5
52 60.8 23.3 13.6 36.9
56 60.0 23.0 17.0 40.0
72 59.0 25.7 15.4 41.0
96 56.8 25.5 15.1 40.6
168 65.8 19.4 12.3 31.7
Table C47b. VFA concentrations (%) in caecal liquor following oral administration of 
amikacin to pony 112
Time (h) L A P IB B IV V Total
0 3.8 5.9 2.8 1.1 27.1 1.7 0.0 38.6
24 3.2 2.4 9.1 0.0 31.3 0.0 0.0 42.8
48 3.2 1.5 0.0 0.0 20.2 0.0 0.0 21.7
72 0.0 0.0 5.7 0.0 37.4 0.0 0.0 43.1
96 2.3 0.0 0.0 0.0 49.5 0.0 0.0 49.5
168 0.0 3.1 3.4 0.0 30.0 0.0 0.0 36.5
amikacin to pony II
Time (h) L A P IB B IV V Total
0 0.0 3.1 3.4 0.0 30.0 0.0 0.0 36.5
24 0.0 4.1 7.9 0.0 13.8 0.0 0.0 25.8
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 1.4 6.2 7.9 0.0 0.0 0.0 0.0 14.1
96 0.0 11.4 7.9 0.0 25.4 0.0 0.0 44.7
168 2.2 0.0 5.9 0.0 14.1 0.0 0.0 20.0
amikacin to pony 12
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 15.4 0.0 62.2 0.0 74.9 0.0 0.0 137.1
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
96 0.0 3.1 3.5 0.0 83.3 0.0 0.0 89.9
168 0.0 2.4 3.9 0.0 36.5 0.0 0.0 42.8
amikacin to pony III
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Time (h) L A P IB B IV V Total
0 0.0 2.4 3.9 0.0 36.5 0.0 0.0 42.8
24 0.0 4.0 0.0 0.0 13.0 0.0 0.0 17.0
48 0.0 0.0 4.1 0.0 89.9 0.0 0.0 94.0
72 3.8 15.2 7.2 0.0 20.5 0.0 0.0 42.9
96 2.1 33.0 14.4 0.0 55.2 0.0 0.0 102.6
168 2.5 5.3 8.1 0.0 40.6 0.0 0.0 54.0
amikacin to pony 112
Time (h) L A p IB B IV V Total
0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
amikacin to pony 13
Time (h) 11 12 III 112 Pony 13
0 22.02 23.44 21.48 22.94 17.75
24 22.32 18.88 18.79 19.75 19.39
48 22.05 19.13 17.39 19.95 23.76
72 19.43 21.64 19.47 20.82 19.07
96 19.55 20.42 18.99 22.23 NS
168 23.44 20.21 22.94 20.11 NS
ponies
Time (h) 0 24 48 168
urea (mmol/1) 2.4 2.6 1.8 2.1
sodium (mmol/1) 137 136 134 136
potassium (mmol/1) 4.2 3.4 4.1 3.5
chloride (mmol/1) 99 100 98 99
calcium (mmol/1) 3.05 3.06 2.98 3.03
magnesium (mmol/1) 0.59 0.74 0.64 0.66
phosphate (mmol/1) 1.07 0.99 1.17 1.07
creatinine (jimol/1) 121 142 134 135
bilirubin (|imol/l) 6 6 6 5
SAP (U/l) 264 287 278 270
AST (U/l) 293 325 292 288
GGT (U/l) 20 22 19 21
total protein (g/1) 69 76 68 66
albumin (g/1) 29 30 30 27
globulin (g/1) 40 46 38 39
Table C54. Plasma biochemistry following oral administration of amikacin to pony II
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Time (h) 0 24 48 168
urea (mmol/1) 2.1 2.5 1.8 2.4
sodium (mmol/1) 136 133 135 135
potassium (mmol/1) 3.5 3.9 4.2 4.0
chloride (mmol/1) 99 106 103 95
calcium (mmol/1) 3.03 3.08 3.22 2.89
magnesium (mmol/1) 0.66 0.69 0.71 0.63
phosphate (mmol/1) 1.07 1.41 1.18 1.11
creatinine (p.mol/1) 135 133 127 133
bilirubin (pmol/1) 5 6 6 6
SAP (U/l) 270 294 309 276
AST (U/l) 288 308 326 289
GGT (U/l) 21 26 25 20
total protein (g/1) 66 69 71 62
albumin (g/1) 27 29 29 25
globulin (g/1) 39 40 42 37
Table C55. Plasma biochemistry following oral administration of amikacin to pony 12
Time (h) 0 24 48 \6s
urea (mmol/1) 1.0 1.2 1.0 0.5
sodium (mmol/1) 136 138 135 136
potassium (mmol/1) 3.3 2.5 3.2 3.3
chloride (mmol/1) 97 108 103 102
calcium (mmol/1) 3.04 3.14 2.77 "3.06
magnesium (mmol/1) 0.70 0.80 0.67 0.71
phosphate (mmol/1) 1.11 1.84 1.88 0.98
creatinine (pmol/1) 109 123 118 124
bilirubin (pmol/1) 9 9 10 9
SAP (U/l) 285 317 307 296
AST (U/l) 329 356 343 345
GGT (U/l) 29 22 17 21
total protein (g/1) 72 79 73 72
albumin (g/1) 29 29 31 29
globulin (g/1) 43 50 42 43
Table C56. Plasma biochemistry following oral administration of amikacin to pony III
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Time (h) 0 24 48 168
urea (mmol/1) 0.5 0.7 0.4 0.6
sodium (mmol/1) 136 134 136 134
potassium (mmol/1) 3.3 3.6 3.9 3.2
chloride (mmol/1) 102 104 105 100
calcium (mmol/1) 3.06 3.04 2.98 2.99
magnesium (mmol/1) 0.71 0.71 0.73 0.65
phosphate (mmol/1) 0.98 1.01 1.21 0.97
creatinine (jimol/1) 124 124 122 116
bilirubin (fimol/1) 9 9 10 8
SAP (U/l) 296 302 316 321
AST (U/l) 345 350 383 353
GGT (U/l) 21 20 23 28
total protein (g/1) 72 73 70 68
albumin (g/1) 29 30 28 28
globulin (g/1) 43 43 42 40
Table C57. Plasma biochemistry following oral administration of amikacin to pony 112
Time (h) 0 24 48 72 168
WCC (x 109/1) 6.8 6.4 6.7 6.9 6.2
RCC (xl012/l) 6.10 6.97 6.07 6.22 5.57
Hb (g/dl) 10.9 12.2 10.9 10.9 9.3
Hct (1/1) 0.307 0.355 0.307 0.316 0.281
MCV (fl) 50 51 51 51 50
MCH (pg) 17.8 17.5 17.9 17.5 16.6
MCHC (g/dl) 35.5 34.3 35.5 34.4 33.0
PLTS (109/1) 102 121 103 115 102
MPV (fl) 6.2 5.4 5.9 5.7 6.1
PCT (%) 0.063 0.065 0.060 0.065 0.062
PDW 16.1 20.3 16.9 15.7 16.3
Neu (%) 36.0 40.0 39.5 38.0 42.6
Lym (%) 61.5 56.0 59.0 59.0 55.0
Mon (%) 1.5 3.4 0.5 1.0 0.5
Eos (%) 1.0 0.5 1.0 2.0 1.4
Bas (%) 0.0 0.0 0.0 0.0 0.5
Table C58. Haematology parameters following oral administration of amikacin to pony II
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Time (h) 0 24 48 72 168
WCC (x 109/1) 6.2 6.1 7.3 6.1 6.9
RCC (xl012/l) 5.57 5.83 6.64 6.04 5.74
Hb (g/dl) 9.3 10.3 11.7 10.5 9.8
Hct (1/1) 0.281 0.297 0.332
^
r
oCOo 0.291
MCV (fl) 50 51 50 50 51
MCH (pg) 16.6 17.6 17.6 17.3 17.0
MCHC (g/dl) 33.0 34.6 35.2 34.5 33.6
PLTS (109/1) 102 101 108 113 80
MPV (fl) 6.1 5.8 5.7 5.6 5.8
PCT (%) 0.062 0.058 0.061 0.063 0.046
PDW 16.3 15.5 15.7 16.0 18.9
Neu (%) 42.6 36.0 31.0 41.0 33.0
Lym (%) 55.0 61.0 62.0 54.6 63.0
Mon (%) 0.5 1.0 3.0 3.9 2.5
Eos (%) 1.4 2.0 4.0 0.5 1.0
Bas (%) 0.5 0.0 0.0 0.0 0.4
Table C59. Haematology parameters following oral administration of amikacin to pony 12
Time (h) 0 24 48 72 168
WCC (x 109/1) 6.8 6.6 6.4 6.8 6.4
RCC (xl012/l) 7.03 7.03 6.67 6.79 6.58
Hb (g/dl) 11.3 11.3 10.6 10.7 10.3
Hct (1/1) 0.323 0.320 0.304 0.310 0.304
MCV (fl) 46 46 46 46 46
MCH (pg) 16.0 16.0 15.8 15.7 15.6
MCHC (g/dl) 34.9 35.3 34.8 34.5 33.8
PLTS (109/1) 87 102 103 101 95
MPV (fl) 6.8 6.2 6.7 6.3 6.5
PCT (%) 0.059 0.063 0.069 0.063 0.061
PDW 17.6 17.7 17.9 17.4 16.9
Neu (%) 40.5 41.0 36.0 42.0 43.0
Lym (%) 53.0 52.9 60.6 54.0 54.0
Mon (%) 4.6 3.5 0.9 3.0 3.0
Eos (%) 0.4 2.6 2.5 1.0 0.0
Bas (%) 1.5 0.0 0.0 0.0 0.0
Table C60. Haematology parameters following oral administration of ami cacin to pony HI
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Time (h) 0 24 48 72 168
WCC (x 109/1) 6.4 6.3 6.0 6.1 6.2
RCC (x 1012/1) 6.58 6.76 6.67 6.67 6.37
Hb (g/dl) 10.3 10.6 10.5 10.4 10.0
Hct (1/1) 0.304 0.313 0.307 0.308 0.297
MCV (fl) 46 46 46 46 47
MCH (pg) 15.6 15.6 15.7 15.5 15.6
MCHC (g/dl) 33.8 33.8 34.2 33.7 33.6
PLTS (109/1) 95 101 97 94 90
MPV (fl) 6.5 6.3 6.4 6.3 6.2
PCT (%) 0.061 0.063 0.062 0.059 0.055
PDW 16.9 15.8 17.1 17.4 16.1
Neu (%) 43.0 43.0 45.0 41.0 32.6
Lym (%) 54.0 51.9 52.0 51.0 61.9
Mon (%) 3.0 2.0 2.0 5.0 5.0
Eos (%) 0.0 2.0 1.0 3.0 0.5
Bas (%) 0.0 1.0 0.0 0.0 0.0
Table C61. Haematology parameters following oral administration of ami cacin to pony 112
Cone. (|ig/ml) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0 .00± 0.00
0.25 0.12 0.18 0.00 0.00 0.08±0.05
1 1.10 1.62 0.86 0.38 0.99±0.26
5 6.51 8.78 4.34 4.98 6.15±0.99
10 13.35 12.50 6.02 8.55 10.11±1.72
20 16.63 25.83 10.79 19.94 18.30±3.14
40 30.18 50.45 10.30 28.35 29.82±8.21
80 49.10 62.96 19.66 46.33 44.51±9.05
Table C62a. Concentrations (pg/ml) of amikacin in caecal liquor following incubation in 
vitro for 3 h
Cone, (jig/ml) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.00 0.00 0.00 0.0010.00
1 0.52 0.93 0.56 0.50 0.6310.10
5 5.52 5.71 6.42 5.08 5.6810.28
10 11.65 9.46 12.92 9.49 10.8810.85
20 18.68 20.94 22.88 14.5 19.2511.80
40 24.41 31.29 41.45 21.28 29.6114.47
80 40.15 39.00 65.99 29.56 43.6817.81
vitro for 24 h
cacin in caecal liquor following incubation in
Cone (jig/ml) L A P IB B IV V Total
0 1.8 27.9 10.9 1.7 6.0 0.0 0.0 46.5
0.25 0.3 28.0 11.0 0.0 6.5 1.0 0.0 46.6
1 1.2 31.5 12.3 0.8 6.5 0.0 0.0 51.1
5 0.3 24.4 10.5 0.0 5.1 0.6 0.0 40.6
10 3.6 28.2 11.8 0.0 4.9 1.5 0.0 46.4
20 3.9 28.1 10.7 1.0 7.1 1.8 0.0 48.7
40 3.5 28.8 12.6 0.9 5.8 0.0 0.0 48.0
80 5.7 28.2 11.0 1.3 8.2 2.2 0.0 50.8
Table C63a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with amikacin for 3 h (replicate 1)
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Cone Oig/ml) L A P IB B IV V Total
0 2.5 29.8 10.8 0.4 4.4 1.2 0.0 46.6
0.25 3.3 30.1 12.6 1.2 5.2 1.5 2.6 53.3
1 2.6 31.9 12.6 0.3 4.8 0.5 0.0 50.1
5 0.9 27.2 10.3 0.9 4.7 1.6 0.0 44.7
10 0.0 34.6 12.0 0.0 6.3 0.0 0.0 52.9
20 0.6 34.6 13.4 1.0 6.4 2.1 0.0 57.6
40 0.0 26.8 10.8 0.6 4.1 0.0 0.0 42.3
80 1.2 24.3 10.5 2.0 5.0 1.5 0.0 43.3
Table C63b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 24 h (replicate 1)
Cone (fig/ml) L A P IB B IV V Total
0 0.0 29.5 8.0 0.0 1.9 0.0 0.0 39.4
0.25 0.0 31.9 8.9 0.0 1.7 0.0 0.0 42.6
1 0.0 31.1 14.8 0.3 1.5 0.0 0.0 47.6
5 0.0 34.8 9.9 0.0 2.3 0.0 0.0 47.0
10 0.0 33.4 9.6 0.0 8.0 0.6 0.0 51.6
20 0.0 39.1 12.2 0.0 6.9 0.0 0.0 58.2
40 0.1 40.6 12.8 0.0 8.0 0.0 0.0 61.4
80 0.0 37.8 10.5 0.0 8.3 0.0 0.0 56.7
Table C64a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 3 h (replicate 2)
Cone (M-g/ml) L A P IB B IV V Total
0 0.0 35.2 9.3 0.0 3.0 0.5 0.0 48.0
0.25 0.0 36.7 10.4 0.0 4.5 0.0 0.0 51.7
1 0.0 38.0 11.3 0.6 4.5 0.0 0.0 54.4
5 0.0 39.1 9.9 0.0 3.3 0.0 0.0 52.3
10 0.0 38.8 11.1 0.0 5.1 0.2 0.0 55.2
20 0.0 39.4 13.0 0.0 4.1 0.0 0.0 56.6
40 0.0 38.4 12.3 0.4 4.6 0.3 0.0 55.9
80 0.0 41.8 13.3 0.0 13.2 0.0 0.0 68.3
Table C64b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 24 h (replicate 2)
Cone (jig/ml) L A P IB B IV V Total
0 1.2 45.5 15.3 0.1 7.4 1.2 0.6 70.1
0.25 0.0 41.8 12.5 0.0 6.1 1.6 0.0 62.0
1 0.0 42.6 14.1 0.0 6.5 0.6 0.9 64.7
5 0.0 44.9 15.9 0.0 5.7 1.7 0.0 68.3
10 0.4 44.7 18.9 0.3 6.9 1.6 0.6 73.2
20 0.0 43.8 14.4 0.0 5.9 2.2 0.0 66.3
40 0.1 48.8 17.5 0.0 7.9 0.0 0.0 74.1
80 0.0 52.0 16.2 0.0 10.0 2.0 0.0 80.2
Table C65a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with amikacin for 3 h (replicate 3)
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Cone (|ig/ml) L A P IB B IV V Total
0 0.1 46.2 13.2 0.0 6.8 1.0 0.0 67.2
0.25 0.0 48.3 13.7 0.0 6.5 4.7 0.0 73.2
1 0.9 44.6 14.0 0.2 7.2 2.1 1.0 69.1
5 0.3 50.3 12.8 0.0 6.8 0.9 1.1 71.9
10 0.0 48.4 11.9 0.0 5.9 0.3 0.0 66.5
20 0.2 45.1 11.8 0.0 6.6 1.6 1.3 66.3
40 0.0 55.1 14.4 0.0 6.6 0.6 0.4 77.1
80 0.0 47.0 12.7 0.0 6.2 0.8 0.5 67.2
Table C65b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 24 h (replicate 3)
Cone (jig/ml) L A P IB B IV V Total
0 0.0 52.3 14.0 0.0 5.8 0.9 0.0 73.0
0.25 0.0 43.8 11.0 0.0 4.2 0.2 0.0 59.2
1 0.0 47.1 12.1 0.0 6.2 1.2 0.0 66.6
5 0.0 52.1 14.3 0.0 7.8 0.0 0.0 74.2
10 0.3 46.6 13.5 0.1 6.8 1.2 1.2 69.4
20 0.0 43.8 13.4 0.3 7.6 0.6 0.0 65.7
40 0.1 44.3 14.6 0.0 8.5 1.4 2.0 70.8
80 0.0 47.2 13.0 0.0 6.8 0.0 0.0 67.0
Table C66a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 3 h (replicate 4)
Cone. (|ig/ml) L A P IB B IV V Total
0 0.6 34.0 7.9 1.0 6.2 1.7 0.8 51.6
0.25 0.0 37.4 12.0 0.0 6.4 1.1 0.4 57.4
1 1.5 38.8 11.0 1.2 8.0 1.9 1.6 62.5
5 0.0 41.5 10.9 0.7 7.3 0.9 0.0 61.3
10 0.8 36.2 9.2 1.1 6.1 1.4 0.0 53.9
20 0.0 38.0 10.9 0.9 6.7 1.4 0.0 57.9
40 1.3 35.1 9.5 0.6 5.6 0.0 0.0 50.9
80 0.5 41.5 10.3 0.0 4.8 1.8 0.0 58.5
Table C66b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with amikacin for 24 h (replicate 4)
3 h 24 h
Cone (|ig/ml) L Total L Total
0 0.8±0.5 57.318.4 0.810.6 53.414.7
0.25 0.1 ±0.1 52.614.7 0.810.8 58.914.9
1 0.3±0.3 57.514.8 1.310.5 59.014.3
5 0.110.1 57.518.1 0.310.2 57.615.9
10 1.110.8 60.116.6 0.210.2 57.113.2
20 1.011.0 59.714.1 0.210.1 59.612.3
40 1.010.8 63.615.8 0.310.3 56.517.4
80 1.411.4 63.716.4 0.410.3 59.315.8
CFA concentrations (mmol/ ) (meanlSEM) in caecal liquor fol owing in vitro
Cone. (p.g/ml) 1 2 3 4 meanlSEM
0 0.00 0.00 0.00 0.00 0.0010.00
1 0.81 0.78 1.04 0.86 0.8710.06
2 2.49 2.08 1.65 1.76 2.0010.19
5 3.81 4.33 4.38 4.39 4.2310.14
10 6.99 7.23 7.20 6.92 7.0910.08
at pH 1.9 for 1 h
Appendix D - Oxytetracycline
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Table D l. 
administration to horses
Time (h) Horse 1 Horse 2 Horse 3 mean±SEM
0 0.00 0.00 0.00 0.00±0.00
0.083 69.99 84.73 91.61 82.11±6.38
0.25 40.46 45.18 40.16 41.93±1.63
0.5 24.62 30.64 23.75 26.34±2.17
0.75 22.3 22.92 22.43 22.55±0.19
1 19.13 21.07 16.43 18.88±1.35
1.5 15.46 17.06 14.59 15.70±0.72
2 13.49 14.22 11.33 13.01±0.87
4 8.11 9.88 8.10 8.70±0.59
8 7.26 7.43 5.86 6.85±0.50
12 4.84 4.97 4.63 4.81±0.10
24 2.11 2.67 2.24 2.34±0.17
36 1.15 1.15 1.03 1.11 ±0.04
48 0.55 0.52 0.48 0.52±0.02
72 0.25 0.19 0.16 0.20±0.03
96 0.16 0.00 0.10 0.09±0.05
3lasma concentrations (pg/ml) of oxytetracycline following intravenous
Time (h) Pony 7 Pony 8 Pony 9 Pony 10 meanlSEM
0 0.00 0.00 0.00 0.00 0.0010.00
0.083 50.37 74.99 24.71 48.72 49.70110.27
0.25 30.32 42.88 16.12 32.63 30.4915.51
0.5 18.88 25.72 12.35 24.51 20.3713.06
0.75 16.97 22.12 9.66 17.34 16.5212.57
1 15.52 19.21 7.69 15.15 14.3912.41
1.5 11.82 15.31 6.36 12.13 11.4111.86
2 10.19 12.8 5.47 10.19 9.6611.53
4 6.29 8.12 3.57 6.28 6.0710.94
8 3.46 5.87 2.73 4.30 4.0910.67
12 2.33 4.5 2.64 2.84 3.0810.49
24 1.54 2.99 1.13 1.37 1.7610.42
28 1.32 NS 0.85 NS 1.0910.24
32 0.95 NS 0.83 NS 0.8910.06
36 0.91 2.4 0.64 0.60 1.1410.43
48 0.42 0.99 0.33 0.33 0.5210.16
72 0.22 0.39 0.25 0.11 0.2410.06
96 0.00 0.00 0.00 0.00 0.0010.00
Table D2. Plasma concentrations (|ig/ml) of oxytetracycline following intravenous
administration to ponies
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Time (h) Donkey 15 Donkey 16 Donkey 17 mean±SEM
0 0.00 0.00 0.00 0 .00± 0.00
0.083 57.77 47.96 64.77 56.83±4.88
0.25 35.69 26.71 43.30 35.23+4.79
0.5 30.83 14.45 33.64 26.31±5.98
0.75 22.45 11.48 20.70 18.21±3.40
1 19.99 9.51 19.12 16.21±3.36
1.5 14.96 7.55 11.66 11.39±2.14
2 11.59 6.94 9.01 9.18±1.35
4 6.03 3.82 4.94 4.93±0.64
8 2.66 2.15 2.24 2.35±0.16
12 1.58 1.15 1.32 1.35±0.13
24 0.27 1.1 0.32 0.56±0.27
36 0.00 0.54 0.12 0.22±0.16
48 0.00 0.22 0.00 0.07±0.07
72 0.00 0.00 0.00 0.0010.00
administration to donkeys
oxytetracycline following intravenous
Parameter Horse 1 Horse 2 Horse 3
tl/2 B2 (h) 0.19 0.20 0.11
tl/2 B1 (h) 13.13 10.38 11.89
CpO (|ig/mJ) 87.25 99.89 146.41
Vc (ml/kg) 114.60 100.11 68.30
AUCobs (p.g.h/ml) 216.36 230.64 204.50
AUMCobs (p.g.h2/ml) 3344.43 2945.05 2846.92
AUC (jig.h/ml) 255.89 260.23 244.41
AUMC (fig.h2/ml) 4463.10 3548.48 3836.83
MRT (h) 15.46 12.77 13.92
Vdarea (ml/kg) 740.40 575.78 702.19
Vdss (ml/kg) 681.61 524.00 642.31
CLb (ml/h.kg) 39.08 38.43 40.42
kel (/h) 0.34 0.38 0.60
k21 (/h) 0.56 0.61 0.62
kl2(/h) 2.78 2.60 5.18
Table D4. Disposition kinetics of oxytetracycline following intravenous administration to 
horses
Parameter Pony 7 Pony 8 Pony 9 Pony 10
tl/2 B2 (h) 0.20 0.18 0.29 0.30
tl/2 B1 (h) 11.36 13.30 13.17 9.93
CpO Qig/ml) 61.86 94.63 27.30 54.24
Vc (ml/kg) 161.66 105.67 366.30 184.35
AUCobs (fig.h/ml) 141.49 240.77 101.56 141.08
AUMCobs (|ig.h2/ml) 2027.97 4205.87 1729.36 1633.53
AUC (|ig.h/ml) 166.92 280.33 113.29 168.86
AUMC (p.g.h2/ml) 2485.98 4972.68 1981.88 2155.39
MRT (h) 14.33 17.47 . 17.03 11.58
Vdarea (ml/kg) 982.05 684.45 1677.69 848.72
Vdss (ml/kg) 892.26 632.77 1544.09 755.93
CLb (ml/h.kg) 59.91 35.67 88.27 59.22
kel (/h) 0.37 0.34 0.24 0.32
k21 (/h) 0.56 0.58 0.52 0.50
kl2(/h) 2.52 2.91 1.66 1.55
ponies
of oxytetracycline following intravenous administration to
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Parameter Donkey 15 Donkey 16 Donkey 17
tl/2  B2 (h) 0.31 0.16 0.30
tl/2 B1 (h) 3.84 8.79 5.50
CpO (|ig/ml) 60.32 66.14 74.84
Vc (ml/kg) 165.78 151.19 133.63
AUCobs (pg.h/ml) 104.56 89.71 97.70
AUMCobs (jig.h^/ml) 445.34 997.86 451.39
AUC Oig.h/ml) 110.15 110.26 107.95
AUMC (|ig.h2/ml) 510.50 1235.10 595.62
MRT (h) 4.26 11.12 4.62
Vdarea (ml/kg) 503.75 1150.47 675.33
Vdss (ml/kg) 420.78 1015.92 511.11
CLb (ml/h.kg) 90.79 90.69 92.63
kel (/h) 0.55 0.60 0.69
k21 (/h) 0.73 0.58 0.45
kl2  (/h) 1.13 3.35 1.28
Table D6. Disposition kinetics of oxytetracycline following intravenous administration to 
donkeys
Time (h) Horse 1 Horse 2 Horse 3 mean±SEM
0 0.00 0.00 0.00 0.00±0.00
24 7.58 12.04 5.91 8.51±1.83
48 6.96 7.23 3.76 5.98+1.11
72 0.76 2.65 1.33 1.58±0.56
96 0.72 0.91 0.54 0.72±0.11
168 0.00 0.00 0.00 0.0010.00
Table D7. Faecal concentrations (M-g/g) of oxytetracycline following intravenous 
administration to horses
Time (h) Pony 7 Pony 8 Pony 9 Pony 10 meanlSEM
0 0.00 0.00 0.00 0.00 0.0010.00
24 3.37 9.54 9.39 4.16 7.43+2.03
48 3.10 5.17 4.07 3.65 4.1110.60
72 0.71 0.88 2.45 1.44 1.3510.55
168 0.00 0.00 0.00 0.00 0.0010.00
Table D8. Faecal concentrations (p.g/g) of oxytetracycline following intravenous 
administration to ponies
Time (h) Donkey 15 Donkey 16 Donkey 17 meanlSEM
0 0.00 0.00 0.00 0.0010.00
24 10.69 5.98 13.16 9.9412.11
48 5.00 4.24 1.83 3.6910.96
72 1.61 1.01 0.67 1.1010.27
96 0.96 0.80 0.58 0.7810.11
168 0.00 0.00 0.00 0.0010.00
Table D9. Faecal concentrations (p.g/g) of oxytetracycline following intravenous
administration to donkeys
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Time (h) Horse 1 Horse 2 Horse 3 mean±SEM
coliforms
0 1.30E+06 1.00E+06 2.00E+04 7.73E+05±3.86E+05
24 2.00E+07 1.10E+05 1.90E+04 6.71 E+06±6.65E+06
48 1.20E+06 2.50E+05 1.00E+06 8.17E+05±2.89E+05
72 1.00E+06 1.00E+05 1.00E+08 3.37E+07±3.32E+07
96 3.00E+05 4.00E+05 1.00E+05 2.67E+05±8.8 2E+04
168 1.50E+06 1.00E+05 2.00E+05 6.00E+05±4.51E+05
streptococci
0 1.00E+05 1.00E+04 7.00E+07 2.34E+07±2.33E+07
24 1.00E+06 2.00E+04 9.00E+05 6.40E+05±3.11E+05
48 3.00E+04 1.00E+03 1.00E+08 3.33E+07±3.33E+07
72 2.00E+05 1.00E+04 1.00E+08 3.34E+07±3.33E+07
96 6.00E+07 2.00E+05 2.00E+10 6.69E+09±6.66E+09
168 5.00E+07 1.00E+05 2.00E+08 8.34E+07±6.01E+07
lacto bacilli
0 2.00E+06 2.00E+04 2.00E+08 6.73E+07±6.63E+07
24 1.00E+06 2.00E+04 8.00E+04 3.67E+05±3.17E+05
48 4.30E+11 1.00E+07 1.00E+08 1.43E+11±1.43E+11
72 3.00E+05 1.00E+05 2.00E+08 6.68E+07±6.66E+07
96 1.00E+10 5.00E+05 2.00E+10 1.00E+10±5.77E+09
168 1.00E+09 2.00E+05 1.00E+08 3.67E+08±3.18E+08
Bacteroides spp.
0 4.00E+06 1.00E+06 1.90E+08 6.50E+07±6.25E+07
24 2.00E+05 1.00E+06 3.10E+07 1.07E+07± 1.01 E+07
48 2.40E+07 3.00E+08 3.00E+07 1.18E+08±9.10E+07
72 4.00E+05 2.00E+04 - 2.10E+05±1.55E+05
96 1.00E+07 6.00E+06 1.00E+09 3.39E+08±3.31E+08
168 1.00E+07 1.10E+06 6.00E+07 2.37E+07±1.83E+07
Clostridium spp.
0 2.00E+03 1.00E+03 1.00E+03 1.33E+03±3.33E+02
24 1.00E+03 2.00E+03 2.00E+03 1.67E+03±3.33E+02
48 - 4.00E+03 - 4.00E+03
72 1.00E+03 1.00E+03 8.00E+04 2.7 3E+04±2.63E+04
96 1.00E+06 1.00E+08 2.00E+04 3.37E+07±3.32E+07
168 2.00E+05 1.00E+03 2.00E+04 7.37E+04±6.34E+04
Table DIO. Counts of viable bacteria per g faeces following intravenous administration of
oxytetracycline to horses
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Time (h) Pony 7 Pony 8 Pony 9 Pony 10 meanlSEM
coliform s
0 3.00E+05 1.70E+05 4.00E+05 4.00E+04 2.28E+0517.82E+04
24 4.00E+04 9.00E+03 1.00E+06 1.00E+05 2.87E+0512.38E+05
48 2.00E+05 1.00E+05 1.00E+06 1.10E+04 3.28E+0512.27E+05
72 4.00E+05 2.00E+05 1.00E+05 4.00E+05 2.75E+0517.50E+04
168 1.00E+06 5.00E+06 3.00E+05 1.00E+07 4.08E+0612.23E+06
streptococci
0 6.00E+06 2.10E+07 2.00E+07 3.00E+07 1.93E+0714.96E+06
24 1.00E+07 1.00E+10 3.00E+06 9.00E+06 2.51 E+0912.50E+09
48 1.00E+07 3.00E+08 1.00E+07 4.00E+06 8.10E+0717.30E+07
72 2.00E+06 2.00E+08 5.00E+05 5.00E+06 5.19E+0714.94E+07
168 1.00E+07 4.00E+08 6.00E+06 4.00E+07 1.14E+0819.56E+07
lactobacil i
0 2.00E+05 1.00E+08 2.00E+05 2.00E+07 3.01 E+0712.38E+07
24 2.00E+07 2.00E+09 3.00E+07 2.00E+07 5.18E+0814.94E+08
48 - 1.70E+08 - - 1.70E+08
72 - 7.00E+05 - 4.00E+06 2.35E+0611.65E+06
168 2.00E+06 - 2.00E+06 - 2.00E+0610.00E+00
Bacteroides spp.
0 2.40E+07 1.00E+06 1.00E+07 1.00E+07 1.13E+0714.75E+06
24 5.00E+09 3.00E+06 6.00E+07 1.00E+06 1.27E+0911.24E+09
48 - 1.00E+10 - 1.00E+08 5.05E+0914.95E+09
72 3.10E+07 1.10E+08 1.00E+09 7.00E+07 3.03E+0812.33E+08
168 3.60E+07 - 1.00E+06 1.00E+10 3.35E+0913.33E+09
Clostridium spp.
0 2.00E+05 1.00E+04 6.00E+05 1.00E+04 2.05E+0511.39E+05
24 1.00E+06 3.00E+03 2.00E+04 3.00E+03 2.57E+0512.48E+05
48 1.00E+06 8.00E+03 1.00E+06 1.00E+03 5.02E+0512.87E+05
72 3.00E+05 1.00E+04 1.00E+06 2.00E+04 3.33E+0512.32E+05
168 - - - 1.00E+03 1.00E+03
Table D ll. Counts of viable bacteria per g faeces following intravenous administration of 
oxytetracycline to ponies
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Time (h) Donkey 15 Donkey 16 Donkey 17 mean±SEM
coliform s
0
24
48
72
96
168
4.00E+04
2.00E+06
2.00E+06
5.00E+07
4.00E+06
1.00E+07
1.00E+05
1.10E+06
1.00E+05
1.00E+06
1.00E+09
1.00E+06
1.00E+06
2.00E+07
2.00E+06
1.00E+09
3.00E+06
2.00E+06
3.80E+05±3.10E+05 
7.70E+06±6.16E+06 
1.37E+06±6.33E+05 
3.50E+08±3.25E+08 
3.36E+08±3.32E+08 
4.33E+06±2.85E+06
streptococci
0 1.00E+05 3.00E+06 2.00E+06 1.70E+06±8.50E+05
24 3.00E+04 2.00E+06 3.00E+05 7.77E+05±6.17E+05
48 6.00E+05 1.00E+05 1.00E+07 3.57E+06±3.22E+06
72 4.00E+05 1.30E+05 8.00E+05 4.43E+05±1.95E+05
96 5.00E+05 3.00E+06 2.00E+06 1.83E+06±7.26E+05
168 3.00E+05 1.00E+06 1.00E+07 3.77E+06±3.12E+06
lacto bacilli
0 1.00E+06 2.00E+07 3.00E+06 8.00E+06±6.03E+06
24 1.00E+06 1.00E+06 3.00E+05 7.67E+05±2.33E+05
48 6.00E+05 1.00E+05 1.00E+06 5.67E+05±2.60E+05
72 3.00E+06 3.00E+05 1.00E+09 3.34E+08±3.33E+08
96 1.00E+06 6.00E+06 5.00E+07 1.90E+07±1.56E+07
168 1.00E+07 1.00E+07 4.00E+04 6.68E+06±3.32E+06
Bacteroides spp.
0 8.00E+04 5.30E+07 1.10E+06 1.81E+07±1.75E+07
24 1.00E+06 1.30E+06 1.00E+07 4.10E+06±2.95E+06
48 1.00E+06 9.00E+04 4.00E+06 1.70E+06±1.18E+06
72 2.00E+07 1.00E+06 2.40E+08 8.70E+07±7.67E+07
96 3.00E+08 2.20E+10 8.00E+07 7.46E+09±7.27E-f09
168 2.00E+06 2.00E+06 3.00E+05 1.43E+06±5.67E+05
Clostridium spp.
0 1.00E+05 - - 1.00E+05
24 _ _ _
48 - 1.00E+04 - 1.00E+04
72 2.00E+05 2.00E+05 - 2.00E+05±0.00E+00
96 NS NS NS NS
168 NS NS NS NS
Table D12. Counts of viable bacteria per g faeces following intravenous administration of 
oxytetracycline to donkeys
Time (h) L A P IB B IV V Total
0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3
24 0.0 0.0 0.0 0.0 0.0 4.1 0.0 4.1
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
96 0.0 0.0 1.4 0.0 0.0 0.0 0.0 1.4
168 0.0 39.2 4.3 0.0 283.6 0.0 0.0 327.1
Table D13. SCFA concentrations (mmol/kg) in faeces following intravenous administration
of oxytetracycline to horse 1
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Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 1.3 0.0 0.0 0.0 0.0 0.0 1.3
48 17.7 3.2 13.1 0.0 0.0 2.5 0.0 36.5
72 2.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0
96 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
168 2.8 0.0 6.2 0.0 215.4 0.0 0.0 224.4
of oxytetracycline to horse 2
Time (h) L A P IB B IV V Total
0 4.7 0.0 6.5 0.0 187 0.0 0.0 19&.2
24 1.3 2.7 0.0 0.0 16.9 2.0 0.0 22.9
48 57.5 0.0 0.0 0.0 58.8 0.0 0.0 116.3
72 3.3 2.0 0.0 0.0 8.5 0.0 0.0 13.8
96 5.5 48.4 8.0 0.0 183.4 0.0 7.3 252.6
168 5.2 55.6 15.3 0.0 178.6 0.0 0.0 254.7
of oxytetracycline to horse 3
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 17.9 0.0 0.0 17.9
24 0.0 0.0 0.0 0.0 39.6 0.0 0.0 39.6
48 14.3 13.4 4.4 0.0 166.4 0.0 0.0 198.5
72 3.5 0.0 0.0 0.0 126.1 3.6 0.0 133.2
168 0.0 0.0 0.0 0.0 39.5 0.0 0.0 39.5
of oxytetracycline to pony 7
Time (h) L A P IB B IV V Total
0 7.1 16.3 0.0 0.0 192.8 0.0 0.0 216.2
24 1.6 0.0 0.0 0.0 227.1 0.0 0.0 228.7
48 9.2 3.0 0.0 0.0 22.5 0.0 0.0 34.7
72 36.5 0.0 0.0 0.0 42.7 0.0 0.0 79.2
168 1.3 0.0 0.0 0.0 20.9 0.0 0.0 22.2
of oxytetracycline to pony 8
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 1.9 21.1 0.0 0.0 49.8 0.0 0.0 72.8
72 0.0 0.0 4.3 0.0 9.0 3.6 0.0 16.9
168 2.9 0.0 0.0 0.0 0.0 1.3 3.5 7.7
Table D18. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of oxytetracycline to pony 9
Time (h) L A p IB B IV V Total
0 0.0 1.2 0.0 0.0 0.0 0.0 4.0 5.2
24 0.0 0.0 1.5 1.8 0.0 0.0 0.0 3.3
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 1.1 0.0 0.0 0.0 0.0 0.0 0.0 1.1
168 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
of oxytetracycline to pony 10
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Time (h) L A p IB B IV V Total
0 0.0 0.0 16.5 0.0 147.9 0.0 0.0 164.4
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 6.0 3.0 0.0 9.0
72 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
96 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
168 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Table D20. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of oxytetracycline to donkey 15
Time (h) L A P IB B IV V Total
0 7.6 68.2 7.2 0.0 164.3 0.0 0.0 247.3
24 4.1 16.1 0.0 0.0 85.6 0.0 0.0 105.8
48 1.4 1.7 0.0 0.0 0.0 0.0 0.0 3.1
72 0.0 0.0 0.0 0.0 0.0 2.0 0.0 2.0
96 0.0 0.0 2.9 0.0 0.0 0.0 0.0 2.9
168 0.0 0.0 1.4 0.0 0.0 0.0 0.0 1.4
of oxytetracycline to donkey 16
Time (h) L A P IB B IV V Total
0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 2.7
24 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
48 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
72 0.0 0.0 0.0 0.0 6.0 0.0 0.0 6.0
96 0.0 0.0 0.0 1.8 0.0 4.4 0.0 6.2
168 0.0 0.0 2.2 3.0 3.0 3.4 0.0 11.6
of oxytetracycline to donkey 17
Horses Ponies Donkeys
Time (h) L Total L Total L Total
0 2.3±1.4 66.8±65.7 1.8+1.8 59.8±52.3 2.5±2.5 138.1171.8
24 0.4±0.4 9.4±6.8 0.4+0.4 67.9±54.4 1.4±1.4 35.3135.3
48 25.1±17.0 50.9±34.3 6.4±3.3 154.6±76.1 0.5±0.5 4.012.6
72 1.8±1.0 5.3±4.3 10.3±8.8 57.6±30.3 0.010.0 2.711.8
96 1.8±1.8 84.7±84.0 NS NS 0.010.0 3.011.8
168 2.7±1.5 268.7±30.5 1.1+0.7 17.4±8.7 0.010.0 4.313.7
Table D23. SCFA concentrations (mmol/kg) (meanlSEM) in faeces following intravenous 
administration of oxytetracycline to horses, ponies and donkeys
Time (h) Horse 1 Horse 2 Horse 3 meanlSEM
0 20.80 20.20 20.00 20.3310.24
24 15.20 17.40 20.60 17.7311.57
48 15.80 15.20 20.00 17.0011.51
72 16.50 17.00 17.60 17.0310.32
96 14.40 18.90 16.00 16.4311.32
168 17.60 17.00 18.50 17.7010.44
Table D24. Faecal dry matter content (%) following intravenous administration of
oxytetracycline to horses
408
Time (h) Pony 7 Pony 8 Pony 9 Pony 10 mean±SEM
0 17.50 15.60 28.70 12.50 18.58±3.53
24 21.10 13.00 21.10 19.70 18.73±1.94
48 13.00 11.20 20.40 18.50 15.78±2.19
72 13.50 14.30 23.70 20.00 17.88±2.42
168 16.40 17.00 17.40 20.40 17.8010.89
oxytetracycline to ponies
Time (h) Donkey 15 Donkey 16 Donkey 17 meanlSEM
0 23.40 19.50 13.30 18.7312.94
24 19.00 18.00 13.70 16.9011.63
48 16.50 10.00 15.30 13.9312.00
72 13.30 16.50 18.90 16.2311.62
96 16.70 12.30 19.30 16.1012.04
168 20.40 18.30 17.00 18.5710.99
Table I  
oxytetracycline to donkeys
matter content (%) following intravenous administration of
Time (h) 11 12 III 112 III1 III2 III3
0 0.00 0.00 0.00 o.tio 0.00 0.00 0.00
0.083 NS NS NS NS NS NS 66.72
0.25 26.13 35.13 21.17 24.99 16.35 NS 66.34
0.5 20.08 26.07 13.93 16.50 8.11 34.11 40.19
0.75 11.09 19.08 10.28 14.69 8.42 NS 27.61
1 10.28 15.89 9.37 11.82 7.67 20.07 23.08
1.5 8.19 13.71 6.41 9.78 6.05 NS 13.71
2 7.21 10.42 5.83 10.72 5.90 13.97 10.79
4 4.46 7.40 3.57 6.65 5.74 9.70 6.81
6 NS NS NS NS 6.14 NS NS
7 NS NS NS NS NS 7.14 NS
8 2.37 6.58 2.14 3.56 5.45 NS 4.09
12 2.33 4.71 1.62 2.90 5.38 NS 2.75
24 1.31 2.50 0.71 1.86 3.00 2.22 0.89
28 1.09 1.87 0.66 1.45 2.66 NS NS
31 NS NS NS NS NS 1.66 NS
32 0.83 1.58 0.59 1.12 2.24 NS NS
36 0.63 1.46 0.45 1.01 1.58 NS 0.54
48 0.34 0.74 0.31 0.49 0.92 0.72 0.34
52 0.19 0.56 0.22 0.38 0.76 NS NS
56 0.14 0.52 0.18 0.34 0.73 NS NS
72 0.00 0.16 0.09 0.13 0.57 0.13 NS
96 0.00 0.00 0.00 0.00 NS NS NS
168 0.00 NS 0.00 NS NS NS NS
Table D27. Plasma concentrations (jig/ml) of oxytetracycline following intravenous
administration to ponies
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Time (h) 11 12 III 112 m i III2 III3
0 0.00 0.00 0.00 0.00 0.00 0.00 NS
0.25 0.00 0.00 0.00 0.00 0.00 NS NS
0.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.75 0.00 0.00 0.00 0.00 0.00 NS 0.23
1 0.00 0.00 0.00 0.00 0.36 NS 0.47
1.5 0.44 0.22 0.00 0.00 0.53 NS 0.44
2 0.46 0.45 0.00 0.00 0.73 NS 2.24
4 1.36 1.37 0.00 0.00 0.62 NS 2.41
6 NS NS NS NS 0.60 NS NS
7 NS NS NS NS NS 1.85 NS
8 1.36 1.26 0.17 0.00 0.64 NS 0.35
12 0.78 0.70 0.50 1.52 1.82 NS 0.51
24 0.40 0.00 1.19 0.64 1.02 0.98 2.03
28 0.38 0.00 1.23 0.75 0.44 NS NS
31 NS NS NS NS NS 1.12 NS
32 0.29 0.00 1.05 0.00 0.22 NS NS
36 0.00 0.00 1.23 0.00 0.55 NS 0.23
48 0.00 0.00 0.69 0.00 0.26 0.66 0.44
52 0.00 0.00 0.74 0.00 0.16 NS NS
56 0.00 0.00 0.45 0.00 0.25 NS NS
72 0.00 0.00 0.00 0.00 0.00 0.77 NS
96 0.00 0.00 0.00 0.00 NS NS NS
Table D28. Caecal liquor concentrations (|ig/ml) of oxytetracycline following intravenous 
administration to ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
24 1.64 3.86 3.01 3.06
48 3.07 1.79 4.89 1.26
72 0.00 0.00 1.48 0.00
96 0.00 0.00 0.00 0.00
168 0.00 0.00 0.00 0.00
Table D29. Faecal concentrations (pg/g) of oxytetracycline following intravenous
administration to ponies
410
Time (h) 11 12 111 112 m i [ III2
coliform s
0 2.00E+07 3.00E+04 2.00E+06 3.00E+04 1.00E+06 2.00E+09
24 1.00E+07 3.00E+06 1.00E+06 1.00E+06 7.00E+10 1.00E+06
48 1.10E+08 7.00E+05 1.00E+07 6.00E+03 6.00E+08 1.00E+08
72 1.00E+06 4.00E+05 1.10E+05 2.00E+04 NS 1.00E+10
96 9.00E+06 6.00E+05 2.00E+04 5.00E+05 NS NS
144 NS NS NS NS NS 4.00E+09
168 1.00E+06 1.00E+06 4.00E+05 2.10E+05 NS NS
336 NS NS NS NS 9.00E+09 NS
streptococci
0 1.00E+04 1.00E+05 1.00E+06 2.00E+06 4.00E+08 1.00E+10
24 1.00E+05 7.00E+05 2.00E+08 1.00E+05 8.00E+10 1.00E+08
48 2.00E+06 2.00E+06 2.00E+06 1.00E+06 9.00E+10 3.00E+07
72 1.00E+07 6.00E+05 1.00E+06 2.00E+04 NS 2.00E+08
96 1.00E+05 4.00E+05 3.00E+05 3.00E+05 NS NS
144 NS NS NS NS NS 2.00E+09
168 3.00E+05 1.00E+05 2.00E+05 4.00E+04 NS NS
336 NS NS NS NS 7.00E+10 NS
lactobacii i
0 1.00E+05 2.00E+06 3.00E+07 1.00E+05 3.00E+06 2.00E+10
24 4.00E+05 6.00E+06 1.00E+07 1.00E+04 5.00E+09 1.00E+06
48 9.00E+07 3.00E+05 4.00E+07 2.00E+05 2.00E+08 -
72 1.00E+07 3.00E+05 1.00E+05 2.00E+05 NS -
96 2.00E+06 1.00E+06 6.00E+05 1.00E+05 NS NS
144 NS NS NS NS NS 2.00E+09
168 1.00E+06 3.00E+05 1.00E+06 2.00E+04 NS NS
336 NS NS NS NS - NS
Bacteroides spp.
0 7.00E+07 1.00E+10 1.00E+09 1.30E+08 4.00E+05 1.00E+08
24 1.60E+08 1.40E+07 3.00E+08 3.00E+06 - -
48 3.00E+06 1.30E+07 1.00E+09 2.10E+06 2.00E+05 1.00E+08
72 1.00E+08 1.20E+07 1.00E+08 1.70E+07 NS 1.00E+09
96 2.00E+09 2.20E+07 3.00E+08 2.00E+08 NS NS
144 NS NS NS NS NS 2.00E+10
168 5.00E+07 2.20E+08 8.00E+10 4.00E+10 NS NS
336 NS NS NS NS - NS
Clostridium spp.
0 - 1.00E+06 - 2.00E+04 1.00E+05 1.00E+04
24 - - - 2.00E+03 9.00E+03 5.00E+04
48 - - - - 2.00E+04 3.00E+05
72 - - - - NS 9.00E+04
96 1.00E+04 - 2.00E+03 - NS NS
144 NS NS NS NS NS 2.00E+05
168 1.00E+04 4.00E+05 2.00E+03 2.00E+03 NS NS
336 NS NS NS NS 2.00E+05 NS
administration of oxytetracycline to ponies
caecal liquor following intravenous
411
Time (h) 11 12 111 112
0 7.6 7.0 7.5 7.3
0.25 7.0 7.1 7.1 7.4
0.5 7.1 6.9 7.1 7.6
0.75 7.0 7.3 6.9 7.5
1 7.0 6.7 7.1 7.4
1.5 7.4 7.6 7.0 7.3
2 7.6 7.1 7.2 7.2
4 7.6 6.8 7.1 7.3
8 7.0 6.5 8.3 6.9
12 8.0 7.2 8.1 6.9
24 7.0 6.9 7.6 7.6
28 6.8 6.9 7.1 6.8
32 6.8 6.8 7.0 7.2
36 7.0 6.8 6.8 7.1
48 7.1 6.9 7.4 7.4
52 7.6 6.7 7.2 7.2
56 7.1 7.0 7.2 7.0
72 6.8 6.6 7.6 7.4
96 7.0 6.4 7.5 7.6
168 6.6 6.9 7.7 7.7
D31. Caecal liquor pH following intravenous administration of oxytetracycline
Time (h) L A P IB B IV V Total
0 2.3 28.4 8.2 0.0 11.6 1.0 0.0 49.2
0.25 1.8 33.6 8.8 0.0 13.7 0.0 0.0 56.1
0.5 1.4 34.0 10.6 0.0 11.5 0.0 2.1 58.2
0.75 2.6 34.9 1.6 0.0 11.7 0.0 0.0 48.2
1 0.0 42.6 13.0 0.0 12.4 0.0 0.0 68.0
1.5 3.6 42.0 9.6 0.0 15.8 0.0 0.0 67.4
2 2.3 31.1 6.9 0.0 13.7 0.0 0.0 51.7
4 7.6 18.7 7.3 0.0 12.5 0.0 0.0 38.5
8 11.5 32.1 4.4 0.0 29.5 0.0 0.0 66.0
12 3.7 15.1 1.9 0.0 43.8 0.0 0.0 60.8
24 7.9 26.8 2.3 0.0 13.1 3.3 0.0 45.5
28 10.9 19.3 8.4 0.0 16.0 0.0 0.0 43.7
32 16.4 43.3 6.8 0.0 16.6 0.0 0.0 66.7
36 12.0 40.8 5.4 0.0 14.8 0.0 0.0 61.0
48 9.8 25.6 1.7 0.0 21.5 0.0 0.0 48.8
52 12.2 27.1 2.7 0.0 13.6 0.0 0.0 43.4
56 14.1 31.8 3.1 0.0 35.2 2.6 0.0 72.7
72 12.7 39.4 11.3 0.0 50.7 0.0 0.0 101.4
96 0.0 44.0 10.5 0.0 15.1 0.0 0.0 69.6
168 0.0 39.4 9.1 0.0 10.3 0.0 0.0 58.8
Table D32a. SCFA concentrations (mmol/1) in caeca
administration of oxytetracycline to pony II
liquor following intravenous
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Time (h) A P B P+B
0 57.7 16.7 23.6 40.2
0.25 59.9 15.7 24.4 40.1
0.5 58.4 18.2 19.8 38.0
0.75 72.4 3.3 24.3 27.6
1 62.6 19.1 18.2 37.4
1.5 62.3 14.2 23.4 37.7
2 60.2 13.3 26.5 39.8
4 48.6 19.0 32.5 51.4
8 48.6 6.7 44.7 51.4
12 24.8 3.1 72.0 75.2
24 58.9 5.1 28.8 33.8
28 44.2 19.2 36.6 55.8
32 64.9 10.2 24.9 35.1
36 66.9 8.9 24.3 33.1
48 52.5 3.5 44.1 47.5
52 62.4 6.2 31.3 37.6
56 43.7 4.3 48.4 52.7
72 38.9 11.1 50.0 61.1
96 63.2 15,1 21.7 36.8
168 67.0 15.5 17.5 33.0
Table D32b. VFA concentrations (%) in caecal liquor following intravenous administration 
of oxytetracycline to pony II
Time (h) L A P IB B IV V Total
0 1.6 31.7 7.6 0.0 36.0 0.0 0.0 75.3
0.25 1.3 30.4 4.9 0.0 17.9 0.0 0.0 53.2
0.5 2.1 31.3 6.7 0.0 26.8 0.0 2.5 67.3
0.75 4.0 24.5 4.1 0.0 51.2 0.0 0.0 79.8
1 5.4 29.4 5.9 0.0 54.4 0.0 0.0 89.7
1.5 5.4 55.7 8.5 0.0 79.1 0.0 0.0 143.3
2 4.2 32.2 4.5 0.0 48.1 0.0 0.0 84.8
4 5.0 22.0 5.7 0.0 43.3 0.0 0.0 71.0
8 11.8 13.8 2.5 0.0 121.4 0.0 0.0 137.7
12 9.4 19.2 3.6 0.0 38.2 0.0 0.0 61.0
24 4.4 20.2 5.6 0.0 21.6 0.0 3.3 50.7
28 1.2 18.4 4.0 0.0 18.8 1.9 2.6 45.7
32 3.4 22.9 3.8 0.0 33.5 0.0 0.0 60.2
36 4.0 21.6 3.8 0.0 41.4 0.0 0.0 66.8
48 2.2 23.9 4.3 0.0 23.2 0.0 0.0 51.4
52 3.7 20.5 5.7 0.0 25.2 0.0 0.0 51.4
56 5.4 22.4 5.1 0.0 48.1 0.0 0.0 75.6
72 9.5 24.2 9.4 0.0 11.8 0.0 0.0 45.4
96 0.0 22.0 7.0 0.0 14.0 0.0 2.5 45.5
168 0.0 21.7 8.1 0.0 10.9 0.0 0.0 40.7
Table D33a. SCFA concentrations (mmol/1) in caeca liquor following intravenous
administration of oxytetracycline to pony 12
413
Time (h) A P B P+B
0 42.1 10.1 47.8 57.9
0.25 57.1 9.2 33.6 42.9
0.5 46.5 10.0 39.8 49.8
0.75 30.7 5.1 64.2 69.3
1 32.8 6.6 60.6 67.2
1.5 38.9 5.9 55.2 61.1
2 38.0 5.3 56.7 62.0
4 31.0 8.0 61.0 69.0
8 10.0 1.8 88.2 90.0
12 31.5 5.9 62.6 68.5
24 39.8 11.0 42.6 53.6
28 40.3 8.8 41.1 49.9
32 38.0 6.3 55.6 62.0
36 32.3 5.7 62.0 67.7
48 46.5 8.4 45.1 53.5
52 39.9 11.1 49.0 60.1
56 29.6 6.7 63.6 70.4
72 53.3 20.7 26.0 46.7
96 48.4 15.4 30.8 46.2
168 53.3 19.9 26.8 46.7
Table D33b. VFA concentrations (%) in caecal liquor following intravenous administration 
of oxytetracycline to pony 12
Time (h) L A P IB B IV V Total
0 0.0 49.5 12.4 1.0 13.9 0.0 6.0 76.8
0.25 0.0 41.3 11.6 0.0 10.3 1.4 0.0 64.6
0.5 0.0 45.3 11.8 1.0 9.9 0.0 0.0 68.0
0.75 0.0 34.2 6.7 0.0 7.0 0.0 4.5 52.4
1 0.0 43.7 10.1 0.0 8.4 1.3 0.0 63.5
1.5 2.1 46.4 13.0 1.7 7.9 5.1 0.0 74.1
2 0.0 48.2 10.0 0.0 11.5 0.0 0.0 69.7
4 0.0 50.7 12.0 0.0 16.5 1.9 3.9 85.0
8 4.5 40.9 6.2 0.0 25.3 0.0 0.0 72.4
12 3.1 39.7 5.7 0.8 16.7 0.0 0.0 62.9
24 4.5 36.1 7.3 1.4 11.0 2.4 1.6 59.8
28 6.9 24.6 8.1 1.1 10.6 2.4 0.0 46.8
32 16.2 29.1 9.4 1.4 13.2 0.0 0.0 53.1
36 21.0 31.6 11.2 0.0 11.3 0.0 0.0 54.1
48 35.2 19.9 12.1 0.0 17.9 4.2 0.0 54.1
52 35.2 14.5 11.3 0.0 8.9 4.0 4.7 43.4
56 40.2 16.1 10.1 0.0 5.4 3.6 7.3 42.5
72 28.2 24.6 6.0 0.0 9.9 0.0 0.0 40.5
96 0.0 30.3 9.8 1.0 8.1 0.0 0.0 49.2
168 0.0 16.6 9.3 0.0 10.1 1.9 0.0 37.9
administration of oxytetracycline to pony III
caeca liquor following intravenous
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Time (h) A P B P+B
0 64.5 16.1 18.1 34.2
0.25 63.9 18.0 15.9 33.9
0.5 66.6 17.4 14.6 31.9
0.75 65.3 12.8 13.4 26.1
1 68.8 15.9 13.2 29.1
1.5 62.6 17.5 10.7 28.2
2 69.2 14.3 16.5 30.8
4 59.6 14.1 19.4 33.5
8 56.5 8.6 34.9 43.5
12 63.1 9.1 26.6 35.6
24 60.4 12.2 18.4 30.6
28 52.6 17.3 22.6 40.0
32 54.8 17.7 24.9 42.6
36 58.4 20.7 20.9 41.6
48 36.8 22.4 33.1 55.5
52 33.4 26.0 20.5 46.5
56 37.9 23.8 12.7 36.5
72 60.7 14.8 24.4 39.3
96 61.6 19.9 16.5 36.4
168 43.8 24.5 26.6 51.2
Table D34b. VFA concentrations (%) in caecal liquor following intravenous administration 
of oxytetracycline to pony III
Time (h) L A P IB B IV V Total
0 0.0 25.6 7.6 0.0 14.0 0.0 0.0 47.2
0.25 0.0 17.9 4.6 0.0 11.8 0.0 0.0 34.3
0.5 0.0 19.9 6.9 0.0 9.3 0.0 0.0 36.1
0.75 0.0 9.4 3.7 0.0 6.8 0.0 1.0 20.9
1 0.0 17.5 3.0 0.0 7.2 2.6 0.0 30.3
1.5 0.0 20.2 6.9 0.0 10.8 0.0 0.0 37.9
2 0.0 19.9 5.5 0.0 9.7 0.0 0.0 35.1
4 0.0 31.1 7.7 0.0 16.8 0.0 0.0 55.6
8 0.0 31.1 8.9 1.0 22.5 0.0 0.0 63.5
12 0.0 25.8 7.6 0.0 11.5 0.0 0.0 44.9
24 0.1 11.7 6.0 0.0 4.5 0.0 0.0 22.2
28 2.3 16.6 1.8 0.0 7.5 1.0 0.0 26.9
32 2.3 18.8 7.3 0.0 10.1 0.0 0.0 36.2
36 0.0 20.9 10.6 0.0 12.9 0.0 0.0 44.4
48 0.0 20.9 7.1 0.0 6.2 0.0 0.0 34.2
52 0.0 20.5 6.0 0.0 9.2 0.0 0.0 35.7
56 0.0 28.6 10.8 0.0 22.3 0.0 0.0 61.7
72 4.5 14.7 5.9 0.0 5.3 1.2 0.0 27.1
96 2.2 17.4 6.6 0.0 18.9 1.0 0.0 43.9
168 0.0 17.6 5.3 0.0 9.4 0.0 0.0 32.3
administration of oxytetracycline to pony 112
in caeca liquor following intravenous
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Time (h) A P B P+B
0 54.2 16.1 29.7 45.8
0.25 52.2 13.4 34.4 47.8
0.5 55.1 19.1 25.8 44.9
0.75 45.0 17.7 32.5 50.2
1 57.8 9.9 23.8 33.7
1.5 53.3 18.2 28.5 46.7
2 56.7 15.7 27.6 43.3
4 55.9 13.8 30.2 44.1
8 49.0 14.0 35.4 49.4
12 57.5 16.9 25.6 42.5
24 52.7 27.0 20.3 47.3
28 61.7 6.7 27.9 34.6
32 51.9 20.2 27.9 48.1
36 47.1 23.9 29.1 52.9
48 61.1 20.8 18.1 38.9
52 57.4 16.8 25.8 42.6
56 46.4 17.5 36.1 53.6
72 54.2 21.8 19.6 41.3
96 39.6 15.0 43.1 58.1
168 54.5 16.4 29.1 45.5
Table D35b. VFA concentrations (%) in caecal liquor following intravenous administration 
of oxytetracycline to pony 112
Time (h) L A P IB B IV V Total
0.25 1.5 28.9 16.4 0.0 6.5 1.4 0.0 47.2
0.5 0.8 29.8 9.9 0.0 5.5 0.0 0.0 45.2
0.75 0.5 33.2 11.8 0.0 6.3 0.0 0.0 51.3
1 0.0 13.7 4.9 0.0 0.8 0.0 0.0 19.4
1.5 1.1 32.0 12.4 0.0 7.1 0.0 0.0 51.5
2 0.0 27.9 6.4 1.0 5.1 1.0 0.0 41.4
4 11.8 15.2 9.8 0.0 4.5 0.0 0.0 29.5
6 3.2 16.8 3.9 0.0 4.8 0.0 0.0 25.5
8 7.3 7.2 21.9 0.0 4.1 0.0 0.0 33.2
12 6.8 13.6 23.6 0.0 3.8 0.0 0.0 41.0
24 5.3 14.6 3.1 0.0 3.0 0.0 0.0 20.7
28 9.5 13.8 20.1 0.0 2.3 0.0 0.0 36.2
32 7.7 23.5 26.7 0.0 4.8 0.0 0.0 55.0
36 8.8 31.6 5.4 0.0 6.8 0.0 0.0 43.8
48 4.6 16.2 2.6 0.0 4.4 0.0 0.0 23.2
52 13.8 26.5 5.7 0.0 2.4 0.0 0.0 34.6
56 12.1 25.1 4.8 0.0 8.1 0.0 0.0 38.0
72 6.3 12.4 3.0 0.0 2.9 0.0 0.0 18.3
144 1.8 32.8 7.1 2.1 2.5 0.0 0.0 44.5
Table D36a. SCFA concentrations (mmol/1) in caeca liquor following intravenous
administration of oxytetracycline to pony III 1
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Time (h) A P B P+B
0.25 61.2 22.0 13.8 35.8
0.5 65.9 21.9 12.2 34.1
0.75 64.7 23.0 12.3 35.3
1 70.6 25.3 4.1 29.4
1.5 62.1 24.1 13.8 37.9
2 67.4 15.5 12.3 27.8
4 51.5 33.2 15.3 48.5
6 65.9 15.3 18.8 34.1
8 21.7 66.0 12.3 78.3
12 33.2 57.6 9.3 66.8
24 70.5 15.0 14.5 29.5
28 38.1 55.5 6.4 61.9
32 42.7 48.5 8.7 57.3
36 72.1 12.3 15.5 27.9
48 69.8 11.2 19.0 30.2
52 76.6 16.5 6.9 23.4
56 66.1 12.6 21.3 33.9
72 67.8 16.4 15.8 32.2
144 73.7 16.0 5.6 21.6
i t tu ic i^ ju u . v r r t  cu iiccu u iu n
of oxytetracycline to pony III1
(%) in caecal liquor following intravenous administration
Time (h) L A P IB B IV V Total
7 13.5 10.1 11.3 0.0 12.0 0.0 0.0 33.4
24 4.4 18.1 4.9 0.0 12.1 0.0 0.0 35.1
31 14.8 24.7 14.3 0.0 10.1 1.8 0.0 50.9
72 20.3 13.4 11.6 0.0 4.1 0.0 0.0 29.1
administration of oxytetracycline to pony III2
liquor following intravenous
Time (h) A P B P+B
7 30.2 33.8 35.9 69.8
24 51.6 14.0 34.5 48.4
31 48.5 28.1 19.8 47.9
72 46.0 39.9 14.1 54.0
Table D37b. VFA concentrations (%) in caecal liquor following intravenous administration 
of oxytetracycline to pony III2
Time (h) L A P IB B IV V Total
0.083 3.9 19.6 11.1 0.0 10.4 0.0 0.0 41.1
0.25 3.9 27.6 16.8 0.0 5.1 0.0 0.0 49.5
0.75 7.5 25.4 21.1 0.0 16.1 2.8 0.0 65.4
1 5.1 26.6 19.3 0.0 11.3 0.0 0.0 57.2
1.5 13.2 29.8 20.0 0.0 10.6 0.0 0.0 60.4
4 29.7 25.8 8.5 0.0 6.2 0.0 0.0 40.5
8 32.6 24.2 7.0 0.0 3.8 0.0 0.0 35.0
12 12.8 17.5 14.2 0.0 12.5 0.0 0.0 44.2
24 3.9 14.1 9.3 0.0 9.7 0.0 0.0 33.1
36 11.0 25.1 5.9 0.0 10.9 0.0 0.0 41.9
48 2.4 14.5 11.1 0.0 9.0 0.0 0.0 34.6
Table D38a. SCFA concentrations (mmol/1) in caeca
administration of oxytetracycline to pony III3
liquor following intravenous
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Time (h) A P B P+B
0.083 47.7 27.0 25.3 52.3
0.25 55.8 33.9 10.3 44.2
0.75 38.8 32.3 24.6 56.9
1 46.5 33.7 19.8 53.5
1.5 49.3 33.1 17.5 50.7
4 63.7 21.0 15.3 36.3
8 69.1 20.0 10.9 30.9
12 39.6 32.1 28.3 60.4
24 42.6 28.1 29.3 57.4
36 59.9 14.1 26.0 40.1
48 41.9 32.1 26.0 58.1
Table D38b. VFA concentrations (%) in caecal lie 
of oxytetracycline to pony III3
uor following intravenous administration
Time (h) L A P IB B IV V Total
0 0.6 0.0 0.0 0.0 14.3 4.2 0.0 18.3
24 0.0 0.0 0.0 0.0 6.7 0.0 0.0 6.7
48 0.0 0.0 8.0 0.0 5.0 0.0 0.0 13.0
72 0.0 0.0 0.0 0.0 8.4 0.0 0.0 8.4
96 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
168 0.0 0.0 0.0 3.1 15.8 0.0 0.0 18.9
of oxytetracycline to pony II
Time (h) L A P IB B IV V Total
0 3.1 15.9 6.4 0.0 67.5 0.0 0.0 92.9
24 2.7 19.5 9.6 0.0 57.4 0.0 0.0 89.2
48 4.5 25.3 13.0 0.0 97.7 0.0 0.0 140.5
72 4.6 22.6 14.6 0.0 112.5 0.0 0.0 154.3
96 3.2 22.6 9.9 0.0 84.3 0.0 0.0 120.0
168 3.1 24.3 5.6 0.0 42.8 0.0 0.0 75.8
Table D40. SCFA concentrations (mmol/kg) in faeces following intravenous administration 
of oxytetracycline to pony 12
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 26.9 0.0 0.0 26.9
24 4.2 3.1 0.0 0.0 65.7 0.0 0.0 68.8
48 25.7 13.8 8.9 0.0 102.0 0.0 0.0 124.7
72 0.0 0.0 9.1 0.0 2.3 0.0 0.0 11.4
96 0.0 0.0 5.9 0.0 36.1 0.0 0.0 42.0
168 0.0 0.0 0.0 3.7 15.7 0.0 0.0 19.4
of oxytetracycline to pony III
Time (h) L A P IB B IV V Total
0 4.0 17.1 10.2 0.0 117.1 0.0 0.0 144.4
24 9.0 36.7 17.8 0.0 154.0 0.0 0.0 208.5
48 3.6 20.4 9.4 0.0 109.7 0.0 0.0 139.5
72 2.6 19.1 11.2 0.0 94.5 0.0 0.0 124.8
96 4.5 20.4 10.2 0.0 107.7 0.0 0.0 138.3
168 3.9 24.7 6.4 0.0 55.0 0.0 0.0 86.1
Table D42. SCFA concentrations (mmol/kg) in faeces following intravenous administration
of oxytetracycline to pony 112
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Table D43. 
oxytetracycline to ponies
Time (h) 11 12 III 112
0 23.85 20.20 22.03 20.38
24 24.49 20.31 24.13 23.27
48 22.04 19.17 24.10 21.09
72 18.59 22.13 19.19 21.78
96 18.93 21.08 20.62 21.89
168 19.44 21.16 19.38 20.35
matter content (%) fo lowing intravenous administration of
Time (h) 0 24 48 72 96 168
urea (mmol/1) 1.4 3.0 4.0 3.0 4.1 3.7
sodium (mmol/1) 139 134 132 134 139 137
potassium (mmol/1) 3.6 4.1 3.9 4.3 3.0 2.8
chloride (mmol/1) 102 102 104 104 103 98
calcium (mmol/1) 3.19 3.11 2.84 3.00 2.91 2.98
magnesium (mmol/1) 0.63 0.68 0.62 0.59 0.58 6.63
phosphate (mmol/1) 1.06 1.01 1.20 1.28 1.00 0.76
creatinine (pmol/1) 127 134 144 140 139 154
bilirubin (pmol/1) 9 12 14 10 10 16
SAP (UA) 345 350 354 333 $36 $78
AST (UA) 248 254 254 255 252 273
total protein (g/1) 65 66 66 67 67 71
albumin (gA) 27 28 28 28 28 $6
globulin (gA) 38 38 38 39 39 41
Table D44. Plasma biochemistry following intravenous administration of oxytetracycline to 
pony II
Time (h) 0 24 48 72 96 168
urea (mmolA) 1.4 2.6 1.7 2.4 3.1 3.7
sodium (mmolA) 143 141 141 140 141 139
potassium (mmolA) 4.3 4.8 3.9 4.3 4.1 3.7
chloride (mmolA) 101 101 107 99 101 98
calcium (mmolA) 2.66 2.82 2.98 3.04 2.88 2.87
magnesium (mmolA) 0.62 0.64 0.72 0.66 0.73 0.57
phosphate (mmolA) 0.95 0.85 1.11 0.81 0.76 0.90
creatinine (pmolA) 142 150 106 130 148 149
bilirubin (jimolA) 6 5 8 6 6 5
SAP (UA) 381 356 457 348 334 354
AST (UA) 269 278 314 274 279 265
GGT (UA) 13 17 47 18 13 17
total protein (gA) 65 69 69 68 66 67
albumin (gA) 27 28 30 27 27 27
globulin (gA) 38 41 39 39 39 40
Table D45. Plasma biochemistry following intravenous administration of oxytetracycline to
pony 12
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Time (h) 0 24 48 72 96 168
urea (mmol/1) 1.8 2.3 3.1 2.7 2.8 2.5
sodium (mmol/1) 133 129 130 Ii6 133 129
potassium (mmol/1) 2.6 2.5 3.6 3.4 3.6 2.4
chloride (mmol/1) 99 102 103 103 104 99
calcium (mmol/1) 2.91 2.94 2.95 3.05 3.13 2.90
magnesium (mmol/1) 0.50 0.60 0.50 0.63 0.61 0.71
phosphate (mmol/1) 0.23 0.25 0.56 1.16 0.94 1.41
creatinine (|imol/l) 89 92 83 86 88 108
bilirubin (fimol/1) 32 26 21 15 11 12
SAP (U/l) 486 550 597 669 629 627
AST (U/l) 427 552 641 666 563 443
total protein (g/1) 65 67 72 75 71 77
albumin (g/1) 31 31 31 32 31 32
globulin (g/1) 34 36 41 43 40 45
pony III
Time (h) 0 24 48 72 96 168
urea (mmol/1) 0.8 0.9 1.6 2.3 1.8 1.6
sodium (mmol/1) 141 142 140 141 142 141
potassium (mmol/1) 4.2 3.7 4.3 4.7 3.6 3.1
chloride (mmol/1) 105 106 106 102 106 101
calcium (mmol/1) 2.82 2.86 3.12 2.96 2.88 2.79
magnesium (mmol/1) 0.63 0.62 0.72 0.71 0.84 0.73
phosphate (mmol/1) 1.11 0.97 0.99 1.02 0.94 0.93
creatinine (p.mol/1) 113 117 102 140 114 132
bilirubin (p.mol/1) 8 7 8 6 8 7
SAP (U/l) 480 464 451 325 417 444
AST (U/l) 330 328 314 256 311 327
GGT (U/l) 50 50 47 14 41 48
total protein (g/1) 73 71 71 64 70 74
albumin (g/1) 42 30 31 25 29 32
globulin (g/1) 50 41 40 39 41 42
Table D47. Plasma biochemistry following intravenous administration of oxytetracycline to 
pony 112
Time (h) 0 24 48 72 144
urea (mmol/1) 3.6 5.8 5.4 6.6 5.7
sodium (mmol/1) 133 130 131 131 125
potassium (mmol/1) 4.8 5.2 3.6 3.4 5.7
chloride (mmol/1) 105 99 102 103 96
calcium (mmol/l) 3.16 2.89 2.68 2.61 2.88
magnesium (mmol/l) 0.74 0.65 0.76 0.56 0.71
phosphate (mmol/l) 1.06 1.26 1.87 1.64 1.31
creatinine (p.mol/1) 143 137 153 149 140
bilirubin (pmol/l) 7 10 11 10 10
SAP (U/l) 233 272 273 241 319
AST (U/l) 486 545 548 565 575
ALT (U/l) 26 59 77 58 38
total protein (g/1) 70 74 71 69 70
albumin (g/1) 34 36 36 33 35
globulin (g/1) 36 36 35 36 35
pony III1
420
Time (h) 0 24 48 72 96 168
WCC (x 109/1) 9.4 8.8 8.5 9.2 9.1 7.5
RCC (x 1012/1) 6.22 6.32 6.29 6.10 6.47 6.75
Hb (g/dl) 10.6 11.0 10.8 10.5 11.3 11.6
Hct (1/1) 0.301 0.298 0.301 0.295 0.313 0.316
MCV (fl) 48.0 47.0 48.0 48.0 48.0 47.0
MCH (pg) 17.0 17.4 17.1 17.2 17.4 17.1
MCHC (g/dl) 35.2 36.9 35.8 35.5 36.1 36.7
PLTS (109/1) - 116 132 125 88 120
MPV (fl) - 6.1 6.2 6.4 6.4 6.1
PCT (%) - 0.070 0.081 0.080 0.056 0.073
PDW - 16.3 16.1 17.1 18.7 19.6
Neu (%) 44.5 54.5 47.0 51.5 43.0 41.9
Lym (%) 54.0 45.0 46.4 43.0 55.5 54.4
Mon (%) 0.5 0.0 3.5 3.5 1.0 2.5
Eos (%) 0.5 0.5 2.0 1.5 0.0 1.1
Bas (%) 0.5 0.0 1.0 0.5 0.5 0.0
Table D49. Haematology parameters following intravenous administration of oxytetracycline 
to pony II
Time (h) 0 24 48 72 96 168
WCC (x 109/1) 7.5 8.3 8.2 8.9 8.7 7.5
RCC (x 1012/1) 6.22 6.04 5.80 6.29 6.17 5.95
Hb (g/dl) 10.5 10.4 10.2 10.9 10.7 10.1
Hct (1/1) 0.312 0.303 0.291 0.315 0.309 0.294
MCV (fl) 50.0 50.0 50.0 50.0 50.0 49.0
MCH (pg) 16.8 17.2 17.5 17.3 17.3 16.9
MCHC (g/dl) 33.6 34.3 35.0 34.6 34.6 34.3
PLTS (109/1) 56 117 119 126 133 12
MPV (fl) 6.4 6.4 6.3 6.1 5.9 6.2
PCT (%) 0.035 0.074 0.074 0.078 0.078 0.075
PDW 18.7 15.6 15.8 16.3 18.6 16.1
Neu (%) 26.9 41.5 37.4 32.0 37.0 32.0
Lym (%) 70.0 55.0 58.3 65.9 58.5 64.5
Mon (%) 2.0 0.5 3.0 2.0 2.5 1.5
Eos (%) 1.1 3.0 1.0 0.0 1.9 2.0
Bas (%) 0.0 0.0 0.0 0.0 0.0 0.0
Table D50. Haematology parameters following intravenous administration of oxytetracycline
to pony 12
421
Time (h) 0 24 48 72 96 168
WCC (x 10^/1) 6.5 8.2 7.9 9.7 10.8 7.5
RCC (xl012/l) 7.15 7.43 7.03 7.61 6.99 6.99
Hb (g/dl) 11.3 11.5 11.0 11.6 11.0 11.5
Hct (1/1) 0.313 0.327 0.304 0.336 0.310 0.295
MCV (fl) 44.0 44.0 43.0 44.0 44.0 42.0
MCH (pg) 15.8 15.4 15.6 15.5 15.7 16.1
MCHC (g/dl) 36.1 35.1 36.1 35.1 35.4 38.3
PLTS (109/1) 71 88 96 107 101 119
MPV (fl) 6.2 6.5 6.6 6.5 7.0 6.8
PCT (%) 0.044 0.057 0.063 0.069 0.070 0.080
PDW 19.3 16.9 18.1 16.9 15.7 17.6
Neu (%) 76.0 76.0 52.0 58.0 71.0 54.5
Lym (%) 22.0 19.0 37.0 32.5 25.0 38.5
Mon (%) 2.0 4.0 10.0 7.0 4.0 5.5
Eos (%) 0.0 0.0 0.5 2.0 0.0 1.1
Bas (%) 0.0 1.0 0.5 0.5 0.0 0.5
Table D51. Haematology parameters following intravenous administration of oxytetracycline 
to pony III
Time (h) 0 24 48 72 96 168
WCC (x 109/1) 5.5 5.7 5.6 5.9 6.5 5.7
RCC (x 1012/1) 7.55 7.18 7.18 7.21 7.06 7.30
Hb (g/dl) 11.5 10.8 11.1 10.9 10.8 11.2
Hct (1/1) 0.342 0.324 0.324 0.327 0.318 0.321
MCV (fl) 45.0 45.0 45.0 45.0 45.0 44.0
MCH (pg) 15.2 15.0 15.4 15.1 15.2 15.3
MCHC (g/dl) 33.6 33.3 34.2 33.3 33.9 34.8
PLTS (109/1) 110 127 133 120 117 100
MPV (fl) 7.1 7.1 6.7 6.8 6.8 7.0
PCT (%) 0.078 0.090 0.089 0.081 0.079 0.070
PDW 15.4 15.4 14.9 16.1 16.1 15.7
Neu (%) 17.9 23.0 39.5 31.0 39.5 40.0
Lym (%) 69.5 73.0 62.9 65.9 53.5 57.0
Mon (%) 1.0 0.0 6.1 3.0 6.0 3.0
Eos (%) 3.2 1.0 2.0 0.0 0.5 0.0
Bas (%) 8.4 3.0 1.1 0.0 0.5 0.0
Table D52. Haematology parameters following intravenous administration of oxytetracycline 
to pony H2
Time (h) 0 24 48 72 144
WCC (x 109/1) 9.6 10.3 10.2 12.5 10.4
RBC (x 1012/1) 6.3 6.9 6.9 6.7 7.7
Hb (g/dl) 9.9 10.8 10.7 10.0 12.3
Hct (1/1) 0.292 0.318 0.324 0.319 0.367
MCV(fl) 46.4 46.1 47.0 47.0 48.0
Neu (%) 68.0 64.0 65.0 70.5 63.0
Lym (%) 31.0 30.0 33.0 27.0 34.0
Mon (%) 0.5 4.0 2.0 1.0 2.0
Eos (%) 0.5 1.0 0.0 1.5 1.0
Bas (%) 0.0 1.0 0.0 0.0 0.0
Table D53. Haematology parameters following intravenous administration of oxytetracycline
to pony III1
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Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.15 0.18 0.00 0.00
0.5 0.50 0.41 0.19 0.38
0.75 0.53 0.47 0.49 0.24
1 0.53 0.42 0.29 0.24
1.5 0.41 0.84 0.19 0.19
2 0.55 0.27 0.11 0.11
4 0.10 0.15 0.00 0.00
6 0.00 0.00 0.00 0.00
Table D54. Plasma concentrations (fig/ml) of oxytetracycline following oral administration 
to ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
0.25 0.00 0.00 0.00 0.00
0.5 0.00 0.00 0.00 0.00
0.75 0.00 0.00 0.00 0.00
1 13.69 0.00 0.00 0.00
1.5 80.50 48.52 0.00 0.00
2 64.28 61.74 0.00 0.00
4 27.50 21.96 0.00 0.00
6 16.49 11.77 15.69 10.24
8 10.90 9.87 34.11 12.94
12 5.71 7.71 29.75 18.40
24 0.48 0.31 9.71 8.45
28 0.00 0.00 10.87 7.41
32 0.00 0.00 5.50 7.20
48 0.00 0.00 0.00 0.82
52 0.00 0.00 0.00 0.77
56 0.00 0.00 0.00 0.47
72 0.00 0.00 0.00 0.00
Table D55. Caecal concentrations (|ig/ml) of oxytetracycline following oral administration to 
ponies
Time (h) 11 12 III 112
0 0.00 0.00 0.00 0.00
24 38.01 58.37 45.81 48.27
48 4.01 23.60 8.64 31.55
72 0.00 1.32 0.00 2.03
96 0.00 0.00 0.00 0.00
ponies
owing oral administration to
423
Time (h) '" I ! 12 13 III 112 113
coliform s
0 2.00E+03 3.00E+05 1.40E+05 3.00E+03 1.00E+06 1.00E+04
24 3.40E+11 5.10E+11 1.00E+09 9.00E+10 1.00E+09 1.00E+07
48 4.00E+10 6.00E+05 2.00E+05 1.00E+07 2.00E+07 2.00E+05
72 1.30E+05 4.00E+04 1.00E+05 1.00E+05 1.00E+05 3.00E+03
96 2.00E+09 2.00E+06 7.00E+03 2.00E+04 1.00E+05 1.00E+05
168 1.00E+07 1.00E+09 4.00E+05 3.00E+03 3.00E+04 1.00E+04
336 3.00E+05 1.00E+08 NS 1.00E+06 2.00E+04 NS
streptococci
0 4.00E+04 4.00E+07 9.00E+05 3.00E+06 5.00E+05 3.00E+04
24 2.10E+11 1.10E+11 1.00E+09 4.80E+11 1.00E+07 2.00E+06
48 1.80E+11 1.00E+08 4.00E+07 4.10E+11 1.00E+06 5.00E+04
72 3.00E+08 5.00E+05 1.60E+06 2.00E+08 1.00E+05 1.00E+04
96 2.00E+05 2.00E+05 8.00E+04 9.00E+05 2.00E+05 1.80E+04
168 4.00E+06 2.00E+05 5.00E+04 3.00E+05 1.00E+05 5.00E+03
336 4.00E+07 8.00E+04 NS 5.00E+05 1.00E+05 NS
lactobacil i
0 5.00E+07 1.00E+08 NS 1.00E+05 2.00E+09 NS
24 6.00E+10 3.10E+07 NS 2.00E+09 1.00E+06 NS
48 2.00E+10 2.00E+10 NS 8.00E+10 1.00E+08 NS
72 2.00E+10 9.00E+05 NS 1.00E+09 1.50E+06 NS
96 4.00E+06 3.00E+05 NS 3.00E+05 2.00E+05 NS
168 1.00E+08 1.00E+07 NS 3.00E+05 1.00E+06 NS
336 1.00E+08 4.00E+07 NS 2.00E+09 1.00E+06 NS
Bacteroides spp.
0 8.10E+10 2.30E+12 NS 2.60E+11 9.00E+10 NS
24 1.10E+11 1.00E+11 NS 4.00E+10 1.20E+10 NS
48 4.20E+11 4.00E+10 NS 4.00E+11 1.30E+08 NS
72 1.50E+11 2.10E+10 NS 7.20E+10 4.00E+09 NS
96 3.40E+11 1.20E+10 NS 1.30E+11 1.20E+10 NS
168 2.50E+11 1.00E+11 NS 1.20E+11 6.00E+10 NS
336 2.30E+12 1.40E+11 NS 9.00E+10 6.30E+10 NS
Clostridium spp.
0 - - NS - 1.00E+04 NS
24 4.00E+06 2.00E+07 NS 1.20E+06 3.00E+04 NS
48 2.30E+06 1.10E+04 NS 1.00E+06 2.10E+04 NS
72 1.00E+06 1.00E+04 NS 1.00E+07 4.00E+03 NS
96 2.00E+04 3.00E+03 NS 3.00E+03 2.00E+03 NS
168 1.00E+05 - NS - - NS
336 - - NS 1.00E+04 - NS
Table D57. Counts of viable bacteria per ml caecal liquor fol
oxytetracycline to ponies
owing oral administration of
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Time (h) 11 12 13 III 112 113
0 7.0 6.9 7.0 6.9 6.9 6.9
0.25 7.0 6.9 NS 6.8 6.9 NS
0.5 7.1 7.0 NS 6.8 6.9 NS
0.75 7.1 6.9 NS 6.8 6.9 NS
1 7.0 7.0 NS 6.9 7.0 NS
1.5 7.1 7.0 NS 6.8 6.9 NS
2 7.3 7.1 NS 6.8 6.9 NS
4 7.2 7.3 NS 6.8 7.0 NS
8 7.7 7.2 NS 7.0 7.0 NS
12 7.6 7.3 NS 6.9 7.0 NS
24 7.3 7.1 7.1 7.0 7.1 7.0
28 7.2 7.4 NS 7.0 7.2 NS
32 6.6 6.9 NS 7.0 7.1 NS
36 6.6 7.0 NS 7.0 6.9 NS
48 7.3 7.1 7.0 6.7 6.8 7.0
52 6.6 6.8 NS 6.5 6.9 NS
56 6.5 6.5 NS 6.5 6.6 NS
72 7.2 6.8 7.0 6.7 6.9 6.8
96 6.7 6.7 6.7 6.7 6.7 6.8
168 7.0 7.2 6.7 7.0 7.2 6.8
336 6.9 6.9 NS 6.9 6.9 NS
Table D58. Caecal liquor pH following oral administration of oxytetracycline to ponies
Time (h) L A P IB B IV V Total
0 2.8 21.0 9.3 1.2 8.5 1.1 0.9 42.0
0.25 0.8 25.5 11.4 0.0 17.9 0.0 0.0 54.8
0.5 0.7 15.8 6.8 0.0 12.2 0.0 0.0 34.8
0.75 1.0 13.5 6.4 0.2 11.1 0.0 0.0 31.2
1 1.0 16.5 7.8 0.0 10.3 0.0 0.0 34.6
1.5 0.7 14.8 5.5 0.2 8.2 0.0 0.0 28.7
2 0.4 11.3 4.2 0.0 8.1 0.0 0.0 23.6
4 14.6 18.2 9.3 0.6 18.0 2.3 2.6 51.0
6 22.6 12.8 16.8 0.0 21.1 0.0 0.0 50.7
8 53.9 20.4 33.5 1.9 23.7 1.8 0.0 81.3
12 50.6 11.6 37.7 0.0 17.6 0.0 0.0 66.9
24 32.9 16.5 2.8 0.0 23.8 0.0 0.0 43.1
28 16.8 9.4 2.5 0.0 20.3 0.0 0.0 32.2
32 43.8 23.5 10.5 0.0 20.6 0.0 3.5 58.1
48 4.1 21.9 18.9 0.0 58.1 0.0 0.0 98.9
52 4.3 26.2 8.0 0.0 29.6 1.3 0.0 65.1
56 5.5 29.7 6.2 0.0 33.8 0.0 0.0 69.7
' 72 0.8 15.1 5.4 0.0 14.0 0.0 0.0 34.5
96 3.1 29.6 9.9 0.0 9.9 0.4 0.0 49.8
168 0.8 24.8 12.2 0.0 14.6 0.0 0.0 51.6
336 0.4 26.3 13.0 0.0 29.0 0.0 0.0 68.3
'O x y te t r a c y c l in e  to  p o n y  I I
in  c a e c a l  l i q u o r  f o l l o w i n g  o r a administration of
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Time (h) A P B P+B
0 50.0 22.1 20.2 42.4
0.25 46.5 20.8 32.7 53.5
0.5 45.4 19.5 35.1 54.6
0.75 43.3 20.5 35.6 56.1
1 47.7 22.5 29.8 52.3
1.5 51.6 19.2 28.6 47.7
2 47.9 17.8 34.3 52.1
4 35.7 18.2 35.3 53.5
6 25.2 33.1 41.6 74.8
8 25.1 41.2 29.2 70.4
12 17.3 56.4 26.3 82.7
24 38.3 6.5 55.2 61.7
28 29.2 7.8 63.0 70.8
32 40.4 18.1 35.5 53.5
48 22.1 19.1 58.7 77.9
52 40.2 12.3 45.5 57.8
56 42.6 8.9 48.5 57.4
72 43.8 15.7 40.6 56.2
96 59.4 19.9 19.9 39.8
168 48.1 23.6 28.3 51.9
336 38.5 19.0 42.5 61.5
Table D59b. VFA concentrations (%) in caecal liquor following oral administration of 
oxytetracycline to pony II
Time (h) L A P IB B IV V Total
0 0.4 26.3 13.0 0.0 29.0 0.0 0.0 68.3
0.25 0.0 19.2 6.8 0.0 30.4 0.0 0.0 56.4
0.5 1.3 17.9 6.2 0.0 23.2 0.0 0.0 47.3
0.75 0.0 19.0 6.8 0.0 24.4 0.0 0.0 50.2
1 0.0 20.5 7.9 0.0 26.5 0.0 0.0 54.9
1.5 0.9 19.2 6.5 0.0 13.3 0.0 0.0 39.0
2 1.7 16.2 5.6 0.0 13.1 0.0 0.0 34.9
4 20.3 5.3 23.1 0.0 10.6 0.0 0.0 39.0
6 15.3 6.0 15.7 0.0 4.7 0.0 0.0 26.4
8 24.9 5.0 19.1 0.0 6.0 0.0 0.0 30.1
12 12.2 7.0 15.3 0.0 3.4 0.0 0.0 25.7
24 7.0 19.3 3.3 0.0 19.6 0.0 0.0 42.2
28 3.9 18.7 2.3 0.0 18.5 0.5 0.0 40.0
32 3.6 20.7 2.7 0.0 15.6 0.0 0.0 39.0
48 9.7 18.4 3.9 0.0 7.1 0.4 0.0 29.8
52 10.8 20.2 3.6 0.0 8.4 0.0 0.0 32.2
56 18.4 35.3 7.8 0.0 32.6 0.0 0.0 75.7
72 7.7 19.5 11.4 0.9 12.4 1.8 0.0 46.0
96 0.0 26.4 8.8 0.0 30.0 0.0 0.0 65.2
168 2.5 25.7 10.2 0.0 26.9 1.1 0.0 63.9
336 1.3 13.8 4.3 0.0 14.1 0.0 0.0 32.2
oxytetracycline to pony 12
in caecal liquor following ora administration of
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Time (h) A P B P+B
0 38.5 19.0 42.5 61.5
0.25 34.0 12.1 53.9 66.0
0.5 37.8 13.1 49.0 62.2
0.75 37.8 13.5 48.6 62.2
1 37.3 14.4 48.3 62.7
1.5 49.2 16.7 34.1 50.8
2 46.4 16.0 37.5 53.6
4 13.6 59.2 27.2 86.4
6 22.7 59.5 17.8 77.3
8 16.6 63.5 19.9 83.4
12 27.2 59.5 13.2 72.8
24 45.7 7.8 46.4 54.3
28 46.8 5.8 46.3 52.0
32 53.1 6.9 40.0 46.9
48 61.7 13.1 23.8 36.9
52 62.7 11.2 26.1 37.3
56 46.6 10.3 43.1 53.4
72 42.4 24.8 27.0 51.7
96 40.5 13.5 46.0 59.5
168 40.2 16.0 42.1 58.1
336 42.9 13.4 43.8 57.1
l a u i i /  i v u v u .  Y i n
oxytetracycline to pony 12
( % )  in  c a e c a l  l i q u o r ollowing oral administration of
Time (h) L A P IB B IV V Total
0 1.5 32.0 17.5 0.0 71.2 0.0 0.0 120.7
24 4.5 19.0 6.3 0.0 55.5 0.0 2.5 83.3
48 2.3 20.0 13.9 0.0 43.1 0.0 0.0 77.0
72 2.4 22.6 13.6 0.0 58.1 0.0 0.0 94.3
96 1.7 24.0 16.1 0.0 18.3 9.3 0.0 67.7
168 5.4 46.9 32.3 0.0 29.1 0.0 0.0 108.3
oxytetracycline to pony 13
Time (h) A P B P+B
0 26.5 14.5 59.0 73.5
24 22.8 7.6 66.6 74.2
48 26.0 18.1 56.0 74.0
72 24.0 14.4 61.6 76.0
96 35.5 23.8 27.0 50.8
168 43.3 29.8 26.9 56.7
oxytetracycline to pony 13
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Time (h) L A P IB B IV V Total
0 0.4 28.8 8.5 0.5 5.4 0.6 0.0 43.8
0.25 0.0 38.8 12.4 0.3 7.2 0.8 0.0 59.5
0.5 1.2 24.4 8.8 0.9 5.1 1.4 1.1 41.7
0.75 2.4 36.6 10.7 1.1 7.1 1.6 0.0 57.1
1 2.0 30.0 10.4 1.1 5.5 0.0 0.0 47.0
1.5 1.5 38.6 11.5 0.0 9.3 0.0 0.0 59.4
2 0.0 46.9 13.2 0.0 7.6 0.0 0.0 67.7
4 0.8 28.9 8.9 0.0 5.3 0.0 0.0 43.1
6 1.8 19.1 5.9 1.1 5.3 0.0 2.2 33.6
8 3.6 21.0 4.5 0.0 6.2 0.0 0.0 31.7
12 16.4 16.9 4.1 0.0 4.8 0.0 0.0 25.8
24 46.4 9.0 9.3 0.0 4.5 0.0 0.0 22.8
28 37.9 12.9 6.3 0.0 7.7 0.0 0.0 26.9
32 14.4 10.8 6.7 0.0 22.8 0.0 0.0 40.3
48 9.6 20.4 16.0 0.0 7.8 0.0 0.0 44.2
52 13.6 21.4 14.2 0.0 7.1 0.0 0.0 42.7
56 22.4 30.2 18.3 0.0 10.0 0.0 0.0 58.5
72 11.8 21.4 19.2 0.0 8.1 0.0 0.0 48.7
96 5.6 25.0 13.7 0.6 8.1 0.0 0.0 47.4
168 0.4 30.8 14.4 0.0 7.6 0.0 0.0 52.8
336 0.0 34.6 8.6 0.0 11.4 3.5 0.0 58.1
oxytetracycline to pony III
in caecal liquor following ora! administration of
Time (h) A P B P+B
0 65.8 19.4 12.3 31.7
0.25 65.2 20.8 12.1 32.9
0.5 58.5 21.1 12.2 33.3
0.75 64.1 18.7 12.4 31.2
1 63.8 22.1 11.7 33.8
1.5 65.0 19.4 15.7 35.0
2 69.3 19.5 11.2 30.7
4 67.1 20.6 12.3 32.9
6 56.8 17.6 15.8 33.3
8 66.2 14.2 19.6 33.8
12 65.5 15.9 18.6 34.5
24 39.5 40.8 19.7 60.5
28 48.0 23.4 28.6 52.0
32 26.8 16.6 56.6 73.2
48 46.2 36.2 17.6 53.8
52 50.1 33.3 16.6 49.9
56 51.6 31.3 17.1 48.4
72 43.9 39.4 16.6 56.1
96 52.7 28.9 17.1 46.0
168 58.3 27.3 14.4 41.7
336 59.6 14.8 19.6 34.4
oxytetracycline to pony III
(%) in caecal liquor ollowing oral administration of
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Time (h) L A P IB B IV V Total
0 0.0 34.6 8.6 0.0 11.4 3.5 0.0 58.1
0.25 0.6 29.6 6.7 0.0 8.3 1.1 0.0 45.7
0.5 0.0 33.3 8.0 0.0 11.2 0.0 0.0 52.5
0.75 1.1 32.0 8.1 1.6 8.3 0.0 0.0 50.0
1 0.0 33.4 9.1 0.0 9.4 0.0 0.0 51.9
1.5 0.0 31.2 8.2 0.7 10.4 0.0 0.0 50.5
2 0.0 41.3 10.7 0.0 9.6 0.0 0.0 61.6
4 0.0 34.7 10.7 0.0 12.0 3.1 0.0 60.5
6 0.0 24.5 5.2 0.0 8.8 0.0 0.0 38.5
8 1.1 23.5 5.5 0.0 10.8 0.0 0.0 39.8
12 4.9 24.8 6.2 0.8 8.8 1.9 0.0 42.5
24 7.0 25.8 6.7 0.0 9.8 1.1 0.0 43.4
28 10.3 22.0 4.1 0.0 10.4 0.0 0.0 36.5
32 12.5 19.6 3.8 0.0 4.4 0.9 0.0 28.7
48 21.5 32.8 10.2 0.0 7.9 0.0 0.0 50.9
52 23.0 26.5 8.8 0.0 4.5 1.3 0.0 41.1
56 32.0 33.5 12.1 0.0 11.6 2.2 0.0 59.4
72 7.8 25.8 25.5 0.9 13.1 4.0 0.0 69.3
96 0.8 26.8 10.8 0.0 11.5 0.0 0.0 49.1
168 0.6 36.8 14.2 0.0 17.2 0.0 0.0 68.2
336 0.6 28.0 10.8 0.0 29.2 0.0 0.0 68.0
oxytetracycline to pony 112
mmol/l) in caecal liquor following ora! administration of
Time (h) A P B P+B
0 59.6 14.8 19.6 34.4
0.25 64.8 14.7 18.2 32.8
0.5 63.4 15.2 21.3 36.6
0.75 64.0 16.2 16.6 32.8
1 64.4 17.5 18.1 35.6
1.5 61.8 16.2 20.6 36.8
2 67.0 17.4 15.6 33.0
4 57.4 17.7 19.8 37.5
6 63.6 13.5 22.9 36.4
8 59.0 13.8 27.1 41.0
12 58.4 14.6 20.7 35.3
24 59.4 15.4 22.6 38.0
28 60.3 11.2 28.5 39.7
32 68.3 13.2 15.3 28.6
48 64.4 20.0 15.5 35.6
52 64.5 21.4 10.9 32.4
56 56.4 20.4 19.5 39.9
72 37.2 36.8 18.9 55.7
96 54.6 22.0 23.4 45.4
168 54.0 20.8 25.2 46.0
336 41.2 15.9 42.9 58.8
Table D63b. VFA concentrations (%) in caecal liquor following oral administration of
oxytetracycline to pony 112
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Time (h) L A P IB B IV V Total
0 1.8 35.1 11.8 1.9 14.5 2.9 0.0 66.2
24 3.0 21.4 7.5 0.0 12.6 0.0 0.0 41.5
48 1.3 23.0 12.8 0.0 9.4 0.0 0.0 45.2
72 0.0 36.0 20.8 0.0 10.6 0.0 0.0 67.4
96 0.0 32.2 18.9 0.0 11.5 0.0 0.0 62.6
168 
a C P C A
0.0 40.7 14.9 0.0 11.9 0.0 0.0 67.5
oxytetracycline to pony 113
Time (h) A P B P+B
0 53.0 17.8 21.9 39.7
24 51.6 18.1 30.4 48.4
48 50.9 28.3 20.8 49.1
72 53.4 30.9 15.7 46.6
96 51.4 30.2 18.4 48.6
168 60.3 22.1 17.6 39.7
oxytetracycline to pony 113
'ollowing oral administration of
Time (h) L A P IB B IV V Total
0 2.2 0.0 5.9 0.0 14.1 0.0 0.0 20.0
24 15.4 5.0 6.3 0.0 23.9 0.0 0.0 35.2
48 17.4 2.9 43.7 0.0 18.8 0.0 0.0 65.4
72 1.2 2.9 9.7 0.0 12.0 1.4 0.0 26.0
96 2.2 14.6 7.4 0.0 11.8 4.2 0.0 38.0
168 3.1 26.0 14.5 0.0 12.9 0.0 0.0 53.4
336 1.9 0.0 5.2 0.0 14.4 0.0 0.0 19.6
Table D65. SCFA
oxytetracycline to pony II
concentrations (mmol/kg) in faeces ollowing oral administration of
Time (h) L A P IB B IV V Total
0 1.9 0.0 5.2 0.0 14.4 0.0 0.0 19.6
24 3.7 16.7 5.4 0.0 16.3 0.0 0.0 38.4
48 27.7 13.0 36.4 0.0 4.3 0.0 0.0 53.7
72 58.6 10.7 38.8 0.0 5.7 0.0 0.0 55.2
96 3.2 27.7 14.8 0.0 19.1 0.0 0.0 61.6
168 2.3 0.0 4.2 0.0 33.1 0.0 0.0 37.3
336 2.7 15.3 10.2 0.0 37.6 0.0 0.0 63.1
oxytetracycline to pony 12
ollowing oral administration of
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 32.2 0.0 0.0 32.2
24 16.9 3.5 35.6 0.0 52.0 0.0 0.0 91.1
48 2.1 0.0 15.8 0.0 60.9 0.0 0.0 76.7
72 3.5 23.4 16.9 0.0 37.9 0.0 0.0 78.2
96 0.0 5.4 8.3 0.0 27.7 0.0 0.0 41.4
168 0.0 20.3 5.2 0.0 38.6 0.0 0.0 64.1
oxytetracycline to pony 13
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Time (h) L A P IB B IV V Total
0 2.5 5.3 8.1 0.0 40.6 0.0 0.0 54.0
24 55.3 1.3 34.9 0.0 44.5 0.0 0.0 80.7
48 31.1 0.0 24.2 0.0 20.4 0.0 0.0 44.6
72 57.3 5.8 16.5 0.0 13.0 0.0 0.0 35.3
96 1.8 25.7 9.5 0.0 28.7 0.0 0.0 63.9
168 5.0 10.9 8.5 0.0 32.2 0.0 0.0 51.6
336 0.0 0.0 0.0 0.0 27.5 0.0 0.0 27.5
oxytetracycline to pony III
ollowing oral administration of
Time (h) L A P IB B IV V Total
0 0.0 0.0 0.0 0.0 27.5 0.0 0.0 27.5
24 14.3 17.7 7.0 0.0 20.8 0.0 0.0 45.5
48 65.4 11.1 19.3 0.0 29.4 0.0 0.0 59.8
72 63.8 9.8 20.2 0.0 28.2 0.0 0.0 58.2
96 6.6 20.8 9.1 0.0 61.2 0.0 0.0 91.1
168 0.0 0.0 3.3 0.0 87.3 0.0 0.0 90.6
336 4.1 23.0 8.3 0.0 82.9 0.0 0.0 114.2
oxytetracycline to pony 112
ollowing oral administration of
Time (h) L A P IB B IV V Total
0 0.0 2.0 0.0 0.0 27.9 0.0 0.0 29.9
24 3.6 0.0 30.8 0.0 16.0 0.0 0.0 46.8
48 4.3 0.0 12.6 0.0 70.6 0.0 0.0 83.2
72 3.0 27.0 10.3 0.0 33.1 0.0 0.0 70.4
96 0.0 16.4 10.9 0.0 36.4 0.0 0.0 63.7
168 2.2 14.1 11.3 0.0 43.2 0.0 0.0 68.6
oxytetracycline to pony 113
Time (h) 11 12 13 III 112 113
0 20.21 21.90 16.55 20.11 19.68 18.33
24 18.99 23.96 20.95 16.93 23.94 18.39
48 17.88 19.40 18.55 17.78 18.61 19.53
72 20.97 17.41 20.71 18.32 17.67 22.87
96 19.68 18.98 20.00 19.68 23.96 19.93
168 18.72 20.94 19.07 18.98 20.54 19.77
336 21.90 24.16 NS 19.68 22.99 NS
Table D71. Faecal dry matter content (%) following oral administration of oxytetracycline to
ponies
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Time (h) 0 24 48 168 336
urea (mmol/l) 2.4 5.3 4.3 1.7 4.3
sodium (mmol/l) 135 133 134 133 136
potassium (mmol/l) 4.0 4.1 3.9 3.1 4.1
chloride (mmol/l) 95 103 106 99 94
calcium (mmol/l) 2.89 3.0 2.67 3.10 3.05
magnesium (mmol/l) 0.63 0.60 0.66 0.72 0.55
phosphate (mmol/l) 1.11 1.47 1.45 0.95 0.97
creatinine (jimol/1) 133 136 139 139 161
bilirubin (jimol/1) 6 9 9 6 12
SAP (U/l) 276 285 301 289 317
AST (U/l) 289 300 293 306 315
GGT (U/l) 20 19 17 26 18
total protein (g/1) 62 68 70 61 68
albumin (g/1) 25 29 30 27 27
globulin (g/1) 37 39 40 34 41
Table D72. Plasma biochemistry fol owing oral administration of oxytetracycline to pony II
Time (h) 0 24 48 168 336
urea (mmol/l) 4.3 7.5 5.5 3.7 3.5
sodium (mmol/l) 136 132 134 134 133
potassium (mmol/l) 4.1 4.6 3.5 2.5 3.3
chloride (mmol/l) 94 96 100 98 98
calcium (mmol/l) 3.05 3.04 2.79 2.98 2.98
magnesium (mmol/l) 0.55 0.63 0.56 0.80 0.75
phosphate (mmol/l) 0.97 0.69 1.01 0.63 1.16
creatinine (jimol/1) 161 161 160 133 122
bilirubin (pmol/l) 12 18 19 9 11
SAP (UA) 317 314 288 288 271
AST (UA) 315 304 296 302 307
GGT (UA) 18 29 13 15 17
totaljjrotein (gA) 68 69 66 67 68
albumin (gA) 27 27 27 27 27
globulin (gA) 41 42 39 40 41
Table D73. Plasma biochemistry following oral administration of oxytetracycline to pony 12
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Time (h) 0 24 48 168
urea (mmol/l) 1.9 4.9 2.3 3.1
sodium (mmol/l) 136 136 138 136
potassium (mmol/l) 4.2 3.9 2.4 2.9
chloride (mmol/l) 98 97 98 101
calcium (mmol/l) 2.78 2.78 2.63 3.07
magnesium (mmol/l) 0.62 0.70 0.66 0.71
phosphate (mmol/l) 1.02 1.11 0.91 0.72
creatinine (pmol/1) 123 103 126 131
bilirubin (|imol/l) 4 16 7 4
SAP (U/l) 276 299 311 280
AST (U/l) 276 335 309 301
GGT (U/l) 26 29 29 26
total protein (g/1) 64 69 72 71
albumin (g/1) 26 29 27 25
globulin (g/1) 38 40 45 46
Table D74. Plasma biochemistry following oral administration of oxytetracycline to pony 13
Time (h) 0 24 48 168 336
urea (mmol/l) 0.6 1.9 1.2 0.5 2.3
sodium (mmol/l) 134 135 134 132 137
potassium (mmol/l) 3.2 3.9 3.1 3.9 3.5
chloride (mmol/l) 100 107 107 100 98
calcium (mmol/l) 2.99 2.92 2.86 3.28 2.96
magnesium (mmol/l) 0.65 0.69 0.64 0.74 0.62
jjhosphate (mmol/l) 0.97 1.49 2.06 1.02 0.98
creatinine (fimol/1) 116 115 112 116 147
bilirubin (pmol/l) 8 11 6 4 15
SAP (U/l) 321 312 318 441 379
AST (U/l) 353 350 348 357 375
GGT (U/l) 28 24 26 26 21
total protein (g/1) 68 68 71 66 71
albumin (g/1) 28 28 31 27 30
globulin (g/1) 40 40 40 39 41
Table D75. Plasma biochemistry fol owing oral administration of oxytetracycline to pony III
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Time (h) 0 24 48 168 336
urea (mmol/1) 2.3 3.9 3.3 1.8 2.3
sodium (mmol/1) 137 136 134 135 136
potassium (mmol/1) 3.5 3.3 3.7 5.0 3.7
chloride (mmol/1) 98 99 105 100 101
calcium (mmol/1) 2.96 3.18 2 M 2.99 2.90
magnesium (mmol/1) 0.62 0.70 0.63 0.82 0.70
^phosphate (mmol/1) 0.98 0.49 0.96 0.94 0.92
creatinine (pmol/1) 147 142 135 109 104
bilirubin ((j.mol/1) 15 20 11 6 10
SAP (U/l) 379 761 317 312 309
AST (U/l) 375 364 334 359 360
GGT (U/l) 21 31 15 8 21
total protein (g/1) 71 70 65 73 75
albumin (g/1) 30 30 27 31 30
globulin (g/1) 41 40 38 42 45
Table D76. Plasma biochemistry fol owing oral administration of oxytetracycline to pony 112
Time (h) 0 24 48 168
urea (mmol/1) 0.5 4.9 3.4 1.8
sodium (mmol/1) 136 135 140 134
potassium (mmol/1) 4.3 4.4 2.8 3.1
chloride (mmol/1) 101 99 101 100
calcium (mmol/1) 2.88 2.98 2.65 3.04
magnesium (mmol/1) 0.70 0.64 0.70 0.75
phosphate (mmol/1) 1.02 0.93 0.90 0.51
creatinine (pmol/l) 108 113 120 106
bilirubin (jimol/1) 5 7 15 13
SAP (U/l) 293 284 323 287
AST (U/l) 325 291 379 354
GGT (U/l) 24 17 37 27
total protein (g/1) 69 68 78 73
albumin (g/1) 30 26 31 26
globulin (g/1) 39 42 47 47
Table D77. Plasma biochemistry following oral administration of oxytetracycline to pony 113
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Table D78. h 
pony II
Time (h) 0 24 48 72 168 336
WCC (x 10^/1) 6.9 5.& 5.9 6.4 5.7 7.0
RCC (xl012/l) 5.74 5.18 5.57 5.59 5.49 5.52
Hb (g/dl) 9.8 9.2 9.6 9.8 9.4 9.6
Hct (1/1) 0.291 0.259 0.281 0.275 0.273 0.278
MCV (fl) 51 50 50 49 50 50
MCH(pg) 17.0 17.7 17.2 17.5 17.1 17.3
MCHC (g/dl) 33.6 35.5 34.1 35.6 34.4 34.5
PLTS (109/1) 80 99 127 110 116 102
MPV (fl) 5.8 6.0 5.5 5.7 5.3 5.8
PCT (%) 0.046 0.059 0.069 0.062 0.061 0.059
PDW 18.9 16.6 18.1 15.7 16.9 17.2
Neu (%) 33.0 46.0 40.4 38.0 38.0 29.0
Lym (%) 63.0 51.0 55.0 60.0 56.9 67.5
Mon (%) 2.5 2.0 1.5 0.0 1.6 2.5
Eos (%) 1.0 1.0 3.0 2.0 3.0 1.0
Bas (%) 0.4 0.0 0.0 0.0 0.5 0.0
aematology parameters following oral administration of oxytetracycline to
Time (h) 0 24 48 72 168 336
WCC (x 109/1) 7.0 5.6 6.4 6.5 6.3 5.0
RCC (X1012/1) 5.52 5.26 5.17 5.61 5.23 5.03
Hb (g/dl) 9.6 9.0 8.9 9.3 8.9 8.3
Hct (1/1) 0.278 0.260 0.257 0.280 0.260 0.250
MCV (fl) 50 49 50 50 50 50
MCH (pg) 17.3 17.1 17.2 16.5 17.0 16.5
MCHC (g/dl) 34.5 34.6 34.6 33.2 34.2 33.2
PLTS (109/1) 102 95 105 119 115 124
MPV (fl) 5.8 , 5.8 5.8 5.7 5.9 6.0
PCT (%) 0.059 0.055 0.060 0.067 0.067 0.074
PDW 17.2 15.5 15.5 15.7 16.9 16.6
Neu (%) 29.0 44.5 37.0 34.0 46.0 40.5
Lym (%) 67.5 54.5 62.0 59.0 53.0 58.9
Mon (%) 2.5 0.5 0.0 4.0 0.5 0.0
Eos (%) 1.0 0.5 1.0 3.0 0.5 0.6
Bas (%) 0.0 0.0 0.0 0.0 0.0 0.0
Table D79. Haematology parameters following oral administration of oxytetracycline to
pony 12
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Time (h) 0 24 48 72 168
WCC (x 109/1) 5.9 6.7 6.4 7.2 7.0
RCC (xl012/l) 5.11 5.35 5.70 5.78 5.73
Hb (g/dl) 8.9 9.4 9.9 10.2 10.0
Hct (1/1) 0.264 0.276 0.294 0.297 0.293
MCV (fl) 52.0 52.0 52.0 51.0 51.0
MCH(pg) 17.4 17.5 17.3 17.6 17.4
MCHC (g/dl) 33.7 34.0 33.6 34.3 34.1
PLTS (109/1) 113 120 124 118 127
MPV (fl) 5.9 5.7 5.6 6.0 5.6
PCT (%) 0.066 0.068 0.069 0.070 0.071
PDW 16.9 15.7 17.8 16.6 16.0
Neu (%) 36.0 50.0 32.0 30.5 36.0
Lym (%) 61.0 48.0 66.5 66.5 61.5
Mon (%) 2.0 1.5 0.5 2.0 1.0
Eos (%) 1.0 0.5 0.5 1.0 1.5
Bas (%) 0.0 0.0 0.5 0.0 0.0
Table D80. Haematology parameters following oral administration of oxytetracycline to 
pony 13
Time (h) 0 24 48 72 168 336
WCC (x 109/1) 6.2 6.1 6.5 6.6 5.8 6.8
RCC (x 10*2/1) 6.37 6.04 6.04 6.52 6.31 6.52
Hb (g/dl) 10.0 9.4 9.2 10.4 9.fc 10.1
Hct (1/1) 0.297 0.278 (5.278 0.294 0.287 0.297
MCV (fl) 47 46 46 45 45 46
MCH (pg) 15.6 15.5 15.2 15.9 15.5 15.4
MCHC (g/dl) 33.6 33.8 33.0 35.3 34.1 34.0
PLTS (109/1) 90 103 125 105 99 84
MPV (fl) 6.2 6.2 6.2 6.3 6.1 6.6
PCT (%) 0.055 0.063 0.077 0.066 0.060 0.055
PDW 16.1 17.7 17.7 15.8 16.3 15.1
Neu (%) 32.6 46.0 36.0 37.0 40.4 48.5
Lym (%) 61.9 51.0 59.9 58.5 57.5 46.0
Mon (%) 5.0 2.0 3.1 3.0 0.5 1.5
Eos (%) 0.5 1.0 1.0 1.5 1.6 4.0
Bas (%) 0.0 0.0 0.0 0.0 0.0 0.0
Table D81. Haematology parameters following oral administration of oxytetracycline to
pony III
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Time (h) 0 24 48 72 168 336
WCC (x 109/1) 6.8 6.0 6.2 7.0 5.8 6.2
RCC (x 1012/1) 6.52 6.28 6.05 6.31 6.87 6.40
Hb (g/dl) 10.1 9.9 9.5 9.7 10.7 9.8
Hct (1/1) 0.297 0.287 0.277 0.287 0.316 0.293
MCV (fl) 46 46 46 45 46 46
MCH (pg) 15.4 15.7 15.7 15.3 15.5 15.3
MCHC (g/dl) 34.0 34.4 34.2 33.7 33.8 33.4
PLTS (109/1) 84 88 83 106 79 95
MPV(fl) 6.6 6.8 6.5 6.4 6.7 6.8
PCT (%) 0.055 0.059 0.053 0.067 0.052 0.064
PDW 15.1 14.7 15.3 17.1 16.4 16.1
Neu (%) 48.5 56.5 31.9 34.5 38.3 46.0
Lym (%) 46.0 39.5 63.1 60.5 59.6 53.0
Mon (%) 1.5 3.5 1.9 2.0 2.1 0.0
Eos (%) 4.0 0.5 3.1 2.0 0.0 1.0
Bas (%) 0.0 0.0 0.0 1.0 0.0 0.0
pony 112
Time (h) 0 24 48 72 168
WCC (x 109/1) 6.3 5.9 6.6 7.2 6.6
RCC (x 1012/1) 6.84 6.90 7.14 7.50 7.14
Hb (g/dl) - 10.7 10.9 11.2 11.9 11.6
Hct (1/1) 0.323 0.322 0.334 0.349 0.336
MCV (fl) 47.0 47.0 47.0 47.0 47.0
MCH (pg) 15.6 15.7 15.6 15.8 16.2
MCHC (g/dl) 33.1 33.8 33.5 34.0 34.5
PLTS (109/1) 103 99 103 118 96
MPV(fl) 6.4 6.5 6.3 6.4 6.4
PCT (%) 0.065 0.064 0.064 0.075 0.061
PDW 17.1 16.9 17.4 15.6 17.1
Neu (%) 39.5 41.0 34.5 46.0 56.5
Lym (%) 56.0 54.5 61.5 52.0 40.5
Mon (%) 2.5 2.0 2.0 2.0 1.5
Eos (%) 1.5 2.0 2.0 0.0 1.5
Bas (%) 0.5 0.5 0.0 0.0 0.0
Table D83. Haematology parameters following oral administration of oxytetracycline to 
pony 113
Cone. (p.g/ml) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0 .00±0.00
0.25 0.00 0.00 0.00 0.00 0.00±0.00
1 0.00 0.59 0.37 0.30 0.32±0.12
5 3.02 6.03 3.42 4.74 4.3010.68
10 7.54 9.36 8.69 8.57 8.5410.38
20 17.51 17.31 18.2 16.80 17.4610.29
40 34.61 42.94 28.65 30.87 34.2713.14
80 54.93 81.05 54.19 50.37 60.1417.04
Table D84a. Concentrations (pg/ml) of oxytetracycline in caecal liquor following incubation
in vitro for 3 h
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Cone. (|ig/ml) 1 2 3 4 meaniSEM
0 0.00 0.00 0.00 0.00 0.00±0.00
0.25 0.00 0.00 0.00 0.00 0.00±0.00
1 0.32 0.45 1.31 0.00 0.5210.28
5 4.49 4.43 5.76 4.32 4.7510.34
10 8.79 11.29 12.17 6.69 9.7411.24
20 15.73 7.66 23.45 15.73 15.6413.22
40 29.17 29.63 35.73 26.59 30.2811.94
80 46.02 48.88 65.87 63.46 56.0615.03
Table D84b. Concentrations (|ig/ml) of oxytetracycline in caecal liquor following incubation 
in vitro for 24 h
Time (h) 1 2 3 4 meaniSEM
coliform s
0
3
24
1.00E+04
1.80E+04
1.00E+05
1.00E+04 
3.00E+04 
1.00E+05
2.00E+06
1.00E+05
1.00E+04
4.00E+05
5.00E+05
2.00E+03
6.05E+0514.74E+05
1.62E+0511.14E+05
5.30E+0412.72E+04
streptococci
0 3.00E+05 7.00E+04 1.00E+05 1.00E+05 1.43E+0515.30E+04
3 4.00E+05 2.00E+05 2.00E+05 8.00E+03 2.02E+0518.00E+04
24 3.00E+06 2.00E+06 2.00E+04 3.00E+04 1.26E+0617.43E+05
lactobacil i
0 1.00E+06 4.00E+07 4.00E+04 2.00E+05 1.03E+0719.90E+06
3 1.00E+06 1.00E+08 3.00E+05 3.00E+05 2.54E+0712.49E+07
24 1.00E+06 1.00E+06 1.00E+05 1.00E+04 5.28E+0512.73E+05
Bacteroides spp.
0 7.l()E+10 1.90E+11 2.50E+07 1.40E+08 6.53E+1014.48E+10
3 5.00E+10 1.40E+11 7.20E+07 1.30E+08 4.76E+1013.30E+10
24 6.10E+10 1.20E+11 8.50E+07 4.90E+07 4.53E+1012.87E+10
Clostridium spp.
0 3.00E+03 - 1.00E+03 1.00E+03 1.67E+0316.67E+02
3 2.00E+03 1.00E+06 - - 5.01 E+0514.99E+05
24 1.00E+06 - - - 1.00E+06
Table D85a. Counts of viable bacteria per ml caecal liquor following in vitro incubation of 
caecal liquor
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Time (h)
. . .  T
2 3 4 mean±SEM
coliform s
0
3
24
1.00E+04
4.00E+04
7.00E+10
1.00E+04
6.00E+03
1.00E+05
2.00E+06
4.00E+03
7.00E+04
4.00E+05
3.00E+04
1.00E+03
6.05E+05±4.74E+05 
2.00E+04±8.91E+03 
1.75E+10±1.75E+10
streptococci
0 3.00E+05 7.00E+04 1.00E+05 1.00E+05 1.43E+05±5.30E+04
3 2.00E+05 2.00E+04 1.00E+05 6.00E+04 9.50E+04±3.86E+04
24 1.00E+06 2.00E+06 1.00E+06 6.00E+03 1.00E+O6±4.07E+O5
lactobacil i
0 1.00E+06 4.00E+07 4.00E+04 2.00E+05 1.03E+07±9.90E+06
3 2.00E+06 1.00E+07 5.00E+05 1.00E+05 3.15E+06±2.32E+06
24 1.00E+07 1.00E+06 4.00E+05 1.00E+06 3.10E-K)6±2.30E+06
Bacteroides spp.
0 7.10E+10 1.90E+11 2.50E+07 1.40E+08 6.53E+10±4.48E+10
3 4.10E+10 4.10E+10 1.00E+07 1.20E+08 2.05E+10±1.18E+10
24 1.20E+10 5.00E+10 6.00E+06 6.40E+07 1.55E+10±1.18E+10
Clostridium spp.
0 3.00E+03 - 1.00E+03 1.00E+03 1.67E+03±6.67E+02
3 1.00E+03 - 1.00E+03 - 1.00E+03
24 4.00E+06 - 2.00E+03 - 2.00E+06±2.00E+06
e D85b. Counts of viable bacteria per ml caeca liquor following in vitro incubation
80 |ig/ml oxytetracycline
Cone (M-g/ml) L A P IB B IV V Total
0 0.7 37.1 14.2 0.0 13.5 0.3 0.0 65.1
0.25 0.1 39.3 12.2 0.0 15.2 0.0 0.0 66.7
1 0.6 35.8 13.2 0.0 16.1 0.3 0.0 65.4
5 0.0 37.1 12.1 0.0 21.4 0.0 0.0 70.6
10 0.4 34.0 12.4 0.0 19.4 0.0 0.7 66.5
20 0.0 39.7 10.9 0.0 21.4 0.0 0.0 72.0
40 0.5 29.6 9.8 0.0 15.5 0.0 0.0 54.9
80 0.0 34.7 13.0 0.0 21.2 0.0 0.0 68.9
Table D86a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 3 h (replicate 1)
Cone (M-g/ml) L A P IB B IV V Total
0 1.3 46.8 21.0 0.5 11.2 0.0 0.0 79.5
0.25 0.0 38.7 16.8 0.0 9.1 0.6 0.0 65.2
1 0.0 42.7 17.7 0.0 9.3 0.0 0.0 69.7
5 0.0 41.6 15.8 0.2 9.9 0.0 0.0 67.5
10 0.0 44.1 16.0 0.0 9.3 0.0 0.0 69.4
20 0.0 38.3 14.2 0.6 8.9 0.0 0.0 62.0
40 0.0 35.4 12.4 0.0 18.5 0.0 0.0 66.3
80 0.2 35.3 15.0 0.0 21.2 0.0 0.0 71.5
Table D86b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with oxytetracycline for 24 h (replicate 1)
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Cone (M -g/m l) L A P IB B IV V Total
0 0.0 40.3 12.1 0.0 9.7 0.0 0.0 62.1
0.25 2.3 32.5 9.9 2.2 9.5 2.3 0.0 56.4
1 0.5 37.6 10.5 1.1 9.8 0.0 2.3 61.3
5 2.2 36.9 12.8 1.6 11.4 3.3 2.4 68.4
10 1.3 34.2 9.1 0.0 9.1 0.0 0.0 52.4
20 3.2 34.3 10.3 2.9 10.7 3.6 5.4 67.2
40 0.5 35.4 11.5 0.0 10.9 1.6 0.0 59.4
80 2.8 33.8 10.2 0.0 15.5 0.0 0.0 59.5
Table D87a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 3 h (replicate 2)
Cone (Mg/ml) L A P IB B IV V Total
0 0.0 39.5 11.7 0.8 8.6 0.0 0.0 60.6
0.25 1.2 47.8 15.0 1.4 10.9 2.4 2.6 80.1
1 0.0 47.6 15.4 0.0 10.2 0.0 0.0 73.2
5 0.6 40.7 13.4 1.0 10.7 2.6 0.0 68.4
10 0.0 38.3 10.6 0.0 7.8 0.0 0.0 56.7
20 1.3 39.8 11.0 1.8 9.4 3.6 0.0 65.6
40 0.0 37.8 10.3 0.8 7.6 0.0 0.0 56.5
80 1.8 42.2 15.0 2.7 9.2 3.2 0.0 72.3
Table D87b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 24 h (replicate 2)
Cone (M g/ml) L A P IB B IV V Total
0 1.6 28.3 12.2 1.5 7.1 0.0 2.3 51.4
0.25 2.2 18.7 10.2 1.9 7.1 2.6 0.0 40.5
1 0.3 31.0 10.8 0.0 6.0 0.5 0.0 48.3
5 2.3 28.1 11.3 2.3 8.6 3.0 2.4 55.7
10 0.5 29.4 11.4 0.4 7.5 1.2 0.0 49.9
20 2.2 31.9 12.9 2.0 9.6 2.4 3.0 61.8
40 0.5 30.4 10.9 0.0 7.5 1.0 0.0 49.8
80 2.3 26.3 10.5 2.3 14.5 4.3 2.3 60.2
Table D88a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 3 h (replicate 3)
Cone (M g/ml) L A P IB B IV V Total
0 0.3 31.0 12.1 0.8 6.0 1.3 0.0 51.2
0.25 3.1 27.4 11.9 3.1 7.1 4.2 3.7 57.4
1 0.3 26.9 12.8 0.0 5.3 0.0 0.0 45.0
5 1.8 31.4 13.2 1.4 7.2 2.2 0.0 55.4
10 0.4 28.7 11.4 0.0 5.7 1.6 0.0 47.4
20 1.8 30.1 13.0 1.7 8.2 1.9 1.3 56.2
40 0.9 30.5 10.5 0.0 6.1 2.4 0.0 49.5
80 3.8 31.2 16.5 2.0 11.7 4.2 4.3 69.9
Table D88b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation
with oxytetracycline for 24 h (replicate 3)
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Cone (jig/ml) L A P IB B IV V Total
0 1.3 38.3 11.9 1.0 7.4 1.3 0.0 59.9
0.25 0.0 26.1 12.6 0.0 7.8 1.2 0.0 47.7
1 0.9 33.3 10.5 1.0 7.5 1.4 0.0 53.7
5 0.0 41.6 14.7 0.0 11.1 0.0 0.0 67.4
10 1.3 38.1 12.8 1.1 10.9 2.3 0.0 65.2
20 0.0 41.8 14.1 0.0 12.2 0.0 0.0 68.1
40 3.5 51.6 17.4 0.0 12.9 0.0 0.0 81.9
80 0.0 42.7 12.5 0.0 14.0 0.0 0.0 69.2
Table D89a. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 3 h (replicate 4)
Cone. (M ^g/ml) L A P IB B IV V Total
0 0.0 42.8 11.1 0.0 8.8 0.0 0.0 62.7
0.25 1.0 40.7 11.3 1.6 8.2 2.5 2.0 66.3
1 0.3 37.8 10.5 0.1 6.3 0.8 0.8 56.3
5 0.7 47.7 13.6 0.6 8.3 1.9 0.0 72.1
10 0.0 51.8 14.5 0.0 11.8 0.0 0.0 78.1
20 1.3 52.2 13.1 1.1 11.2 3.1 1.9 82.6
40 1.4 46.9 14.1 1.5 10.5 2.3 0.0 75.3
80 0.0 44.7 15.0 0.0 13.8 0.0 0.0 73.5
Table D89b. SCFA concentrations (mmol/1) in caecal liquor following in vitro incubation 
with oxytetracycline for 24 h (replicate 4)
3 h 24 h
Cone (M -g/m l) L Total L Total
0 0.9±0.4 59.6±2.9 0.4±0.3 63.5±5.9
0.25 1.2±0.6 52.9±5.7 1.3±0.6 70.9±5.7
1 0.6±0.1 57.1 ±3.8 0 .2±0.1 61.1±6.5
5 1.1±0.6 65.5±3.4 0.8±0.4 70.0±6.9
10 0.9±0.2 58.5±4.3 0.1 ±0.1 62.9±6.8
20 1.4±0.8 67.3±2.1 1.1 ±0.4 66.6±5.7
40 1.3±0.8 61.5±7.1 0.6±0.3 61.8±5.6
80 1.3±0.8 64.5±2.6 1.5±0.9 71.8±0.8
incubation with oxytetracycline
owing in vitro
Cone. (M -g/m l) 1 2 3 4 mean±SEM
0 0.00 0.00 0.00 0.00 0.00±0.00
1 1.05 1.09 0.95 0.63 0.93±0.10
2 2.07 2.17 2.62 1.82 2.17±0.17
5 4.91 4.60 3.33 5.04 4.47±0.39
10 8.64 11.05 8.01 8.97 9.17±0.66
Table D91. Concentrations (M-g/ml) (mean±SEM) of oxytetracycline following incubation in 
vitro at pH 1.9 for 1 h
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